[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDY0d17A5mbP6YXKP8_TfLypoCZed4WymBnx7IFqdr4o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Brigham and Women's Hospital",[4],1233,false,297,76,12899802,146,724,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Hypertension",48,{"name":18,"count":19},"Asthma",36,{"name":21,"count":22},"Obesity",32,{"name":24,"count":25},"Heart Failure",27,{"name":27,"count":28},"Diabetes",26,{"name":30,"count":31},"Cardiovascular Diseases",21,{"name":33,"count":34},"Healthy",20,{"name":36,"count":34},"Obstructive Sleep Apnea",[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT01169259","Vitamin D and Omega-3 Trial (VITAL)","2018-11-10","omega-3 fatty acids",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03858751","Pharmacological Activation of HMN for OSA Aim 2","2022-11-30","LTM1201AZ",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04573946","VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL)","2023-07-21","Omega-3 fatty acids",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03522961","Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery","2023-09-30","Nitrofurantoin Prophylaxis\u002FPlacebo",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03216525","Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol","2023-12-01","Alvimopan",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05467397","Feasibility of [11C]Acetate-PET in LAM and TSC","2024-06-04","[11C]acetate",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04018053","18Fluorine-Fluciclovine PET\u002FCT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy","2024-06-30","18F-fluciclovine",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04633889","Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury","2024-08-26","Deferoxamine",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05852574","CP101 for the Treatment of Ulcerative Colitis","2024-11-21","CP-101",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT03935971","The Effects of Dupilumab on Allergic Contact Dermatitis","2024-12-31","Dupilumab",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,232,279,319,368,411,453,501,537,561,587,615,633,659,686,704,727,753,771,798,823,841,859,900,941,1083,1110,1132,1159,1177,1195,1219,1329,1401,1445,1490,1539,1575,1609,1682,1736,1761,1795,1832,1854,1887,1905,1923,1941,1959,1977,1995,2017,2040,2065,2091,2115,2133,2155,2173,2198,2221,2239,2257,2275,2297,2322,2348,2366,2384,2407,2425,2449,2490,2508,2533,2551,2579,2597,2622,2646,2669,2716,2749,2779,2821,2841,2859,2887,2905,2929,2952,2979,2997,3045,3075,3101,3156,3178,3203,3231,3255,3273,3291,3309,3327,3345,3363,3381,3399,3417,3435,3453,3471,3489,3507,3525,3543,3561,3582,3633,3731,3769,3799,3890,3939,3981,4013,4045,4067,4094,4122,4140,4168,4186,4204,4222,4250,4268,4292,4310,4338,4361,4379,4405,4423,4441,4494,4532,4565,4599,4625,4652,4677,4711,4748,4784,4818,4847,4872,4890,4916,4934,4958,4983,5001,5024,5049,5067,5093,5111,5135,5158,5176,5199,5225,5249,5272,5294,5318,5336,5360,5384,5402,5426,5444,5468,5492,5510,5528,5554,5578,5602,5620,5644,5662,5686,5704,5727,5751,5769,5798,5816,5840,5864,5886,5910,5934,5957,5983,6001,6019,6037,6060,6084,6109,6127,6150,6173,6195,6219,6243,6291,6324,6368,6400,6430,6456,6489,6522,6544,6567,6595,6620,6638,6660,6684,6711,6729,6756,6774,6801,6827,6845,6869,6891,6914,6932,6955,6978,7000,7025,7046,7071,7089,7112,7135,7160,7183,7201,7222,7245,7269,7290,7315,7333,7359,7377,7395,7418,7443,7466,7519,7557,7590,7612,7636,7665,7698,7734,7765,7787,7811,7829,7852,7875,7897,7921,7945,7969,7992,8016,8041,8065,8083,8101,8119,8141,8165,8183,8210,8228,8246,8264,8287,8305,8338,8361,8384,8408,8434,8458,8481,8506,8530,8554,8577,8598,8622,8643,8668,8691,8713,8735,8759,8784,8806,8831,8857,8880,8901,8926,8948,8972,8990,9015,9033,9051,9075,9098,9116,9134,9159,9177,9195,9220,9238,9256,9280,9304,9322,9344,9377,9395,9418,9436,9454,9477,9495,9516,9541,9559,9584,9608,9631,9654,9672,9696,9720,9744,9768,9799,9821,9842,9870,9896,9919,9937,9961,9986,10012,10034,10058,10084,10108,10173,10213,10247,10288,10334,10384,10433,10467,10502,10543,10581,10609,10647,10682,10708,10738,10763,10791,10817,10839,10861,10896,10921,10948,10970,10999,11032,11054,11082,11104,11126,11153,11188,11217,11241,11269,11303,11334,11360,11382,11409,11435,11462,11485,11503,11525,11550,11568,11586,11604,11629,11647,11671,11689,11715,11738,11756,11781,11799,11822,11840,11861,11879,11897,11915,11933,11957,11975,11998,12020,12038,12066,12088,12106,12129,12154,12177,12195,12213,12236,12254,12278,12296,12317,12339,12357,12381,12407,12431,12449,12474,12496,12521,12539,12563,12581,12604,12622,12640,12658,12676,12700,12718,12736,12758,12776,12794,12817,12840,12858,12876,12902,12920,12938,12960,12982,13008,13026,13050,13068,13092,13110,13138,13156,13174,13192,13210,13228,13254,13277,13301,13319,13341,13367,13385,13403,13425,13443,13461,13484,13502,13524,13548,13566,13589,13607,13625,13643,13668,13686,13708,13726,13748,13766],{"intervention":97,"totalTrials":98,"cells":99},"Eplerenone",10,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":118,"PHASE3":120,"PHASE4":135,"NA":198},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT02871648","The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production","COMPLETED",[90],"2019-10","2019-12","2016-01",23,[115],"Healthy Volunteers",[117,97],"Fludrocortisone",{"trials":119,"activeCount":102},[],{"trials":121,"activeCount":102},[122],{"nctId":123,"briefTitle":124,"status":108,"phases":125,"primaryCompletion":126,"completion":127,"start":112,"enrollment":128,"conditions":129,"interventions":131},"NCT02525796","Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism",[91,92],"2021-10-01","2021-10-02",69,[130],"Primary Hyperparathyroidism",[132,133,134],"eplerenone","amiloride","Cinacalcet",{"trials":136,"activeCount":197,"soonestReadout":176},[137,149,159,171,184],{"nctId":138,"briefTitle":139,"status":108,"phases":140,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":147},"NCT04519164","Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity",[93],"2025-09-17","2020-12-01",79,[145,15,146],"Metabolic Syndrome","Overweight and Obesity",[97,148],"Chlorthalidone with potassium chloride",{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":102,"conditions":156,"interventions":158},"NCT01794091","Detection of Diffuse Scar in Patients With Diabetes","WITHDRAWN",[93],"2017-08","2013-08",[157],"Diabetes Mellitus, Type II",[97],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT05030545","Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study","RECRUITING",[93],"2026-10-31","2027-02-28","2022-12-15",40,[169,15],"Primary Aldosteronism",[97],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT04840342","MR Antagonist and LSD1","ACTIVE_NOT_RECRUITING",[93],"2025-09-15","2026-06","2022-02-03",300,[15,181],"Mineralocorticoid Excess",[97,183],"Amlodipine",{"nctId":185,"briefTitle":186,"status":162,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT05593055","Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension",[93],"2027-04-01","2027-12-31","2023-08-25",75,[15,193],"Left Ventricular Hypertrophy",[97,195,196],"Chlorthalidone","Potassium",3,{"trials":199,"activeCount":102},[200,210,223],{"nctId":201,"briefTitle":202,"status":108,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT01786551","Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults",[94],"2013-01","2010-03",16,[208],"Systemic Proinflammatory State",[97],{"nctId":211,"briefTitle":212,"status":108,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":221},"NCT00214825","Aldosterone and Vascular Disease in Diabetes Mellitus",[94],"2006-03","2003-08",46,[218,219,220],"Diabetes Mellitus","Endothelial Dysfunction","Albuminuria",[132,222],"Hydrochlorothiazide",{"nctId":224,"briefTitle":225,"status":108,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":31,"conditions":229,"interventions":231},"NCT01394627","Hypoglycemia and the Mineralocorticoid Receptor",[94],"2016-08","2011-01",[230],"Hypoglycemia",[97],{"intervention":87,"totalTrials":197,"cells":233},{"EARLY_PHASE1":234,"PHASE1":248,"PHASE2":250,"PHASE3":266,"PHASE4":268,"NA":277},{"trials":235,"activeCount":102},[236],{"nctId":237,"briefTitle":238,"status":239,"phases":240,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":247},"NCT03675022","Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis","TERMINATED",[89],"2022-07-01","2018-08-15",9,[245,246],"Sleep Apnea","Rhinosinusitis Chronic",[87],{"trials":249,"activeCount":102},[],{"trials":251,"activeCount":265,"soonestReadout":256},[252],{"nctId":253,"briefTitle":254,"status":174,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":264},"NCT05575037","Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease",[91],"2026-04-30","2023-08-01",17,[260,261,262,263],"Nasal Polyps","Asthma, Aspirin-Induced","Aspirin-Exacerbated Respiratory Disease","Aspirin-Sensitive Asthma With Nasal Polyps",[87],1,{"trials":267,"activeCount":102},[],{"trials":269,"activeCount":265,"soonestReadout":86},[270],{"nctId":84,"briefTitle":85,"status":174,"phases":271,"primaryCompletion":86,"completion":272,"start":273,"enrollment":258,"conditions":274,"interventions":276},[93],"2026-07-31","2019-12-18",[275],"Allergic Contact Dermatitis",[87],{"trials":278,"activeCount":102},[],{"intervention":280,"totalTrials":281,"cells":282},"Sacubitril-valsartan",2,{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":300,"PHASE4":302,"NA":317},{"trials":284,"activeCount":102},[],{"trials":286,"activeCount":102},[],{"trials":288,"activeCount":265,"soonestReadout":293},[289],{"nctId":290,"briefTitle":291,"status":162,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":299},"NCT05498181","Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation",[91],"2026-03-31","2026-07-30","2022-10-11",100,[298],"Hemodialysis",[280],{"trials":301,"activeCount":102},[],{"trials":303,"activeCount":265,"soonestReadout":309},[304],{"nctId":305,"briefTitle":306,"status":307,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":19,"conditions":312,"interventions":315},"NCT06536309","Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction","NOT_YET_RECRUITING",[93],"2028-12","2029-09","2026-07",[313,314],"Heart Failure With Preserved Ejection Fraction","Myocardial Fibrosis",[280,316],"Valsartan",{"trials":318,"activeCount":102},[],{"intervention":320,"totalTrials":197,"cells":321},"Trazodone",{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":339,"PHASE4":341,"NA":355},{"trials":323,"activeCount":102},[],{"trials":325,"activeCount":102},[],{"trials":327,"activeCount":265,"soonestReadout":332},[328],{"nctId":329,"briefTitle":330,"status":162,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT05293600","Rescue Pharmacotherapy for OSA",[90,91],"2026-10-30","2023-07-01",70,[36],[337,320,338],"Acetazolamide","Atomoxetine and eszopiclone",{"trials":340,"activeCount":102},[],{"trials":342,"activeCount":265,"soonestReadout":347},[343],{"nctId":344,"briefTitle":345,"status":162,"phases":346,"primaryCompletion":347,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":353},"NCT07136415","Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms",[93],"2031-02","2026-02-13",1000,[351,352],"Menopausal Women","Insomnia",[320,354],"Daridorexant",{"trials":356,"activeCount":102},[357],{"nctId":358,"briefTitle":359,"status":108,"phases":360,"primaryCompletion":361,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":367},"NCT01817907","The Effects of Trazodone on Sleep Apnea Severity",[94],"2014-04","2014-12","2013-03",15,[366],"Sleep Apnea, Obstructive",[320],{"intervention":369,"totalTrials":281,"cells":370},"SGLT2 inhibitor",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":393},{"trials":372,"activeCount":102},[],{"trials":374,"activeCount":102},[],{"trials":376,"activeCount":102},[],{"trials":378,"activeCount":102},[],{"trials":380,"activeCount":265,"soonestReadout":385},[381],{"nctId":382,"briefTitle":383,"status":162,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":391},"NCT05390892","PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes",[93],"2029-03-01","2022-09-26",6000,[389,390],"Type2Diabetes","ASCVD",[369,392],"GLP-1 receptor agonist",{"trials":394,"activeCount":265,"soonestReadout":399},[395],{"nctId":396,"briefTitle":397,"status":174,"phases":398,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":407},"NCT05220917","Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study",[],"2026-05-31","2027-09-30","2021-08-01",781430,[404,405,406],"Cardiovascular Events","Type2 Diabetes","Renal Disease",[369,408,409,410],"DPP-4 inhibitor","GLP-1RA","2nd generation SU",{"intervention":412,"totalTrials":197,"cells":413},"Bupivacaine Hydrochloride",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":451},{"trials":415,"activeCount":102},[],{"trials":417,"activeCount":102},[],{"trials":419,"activeCount":102},[],{"trials":421,"activeCount":102},[],{"trials":423,"activeCount":265,"soonestReadout":428},[424,433,443],{"nctId":425,"briefTitle":426,"status":162,"phases":427,"primaryCompletion":428,"completion":428,"start":61,"enrollment":429,"conditions":430,"interventions":432},"NCT06146842","ED90 of Bupivacaine After Lidocaine Test Dose with DPE and EPL",[93],"2026-01-31",120,[431],"Labor Pain",[412],{"nctId":434,"briefTitle":435,"status":436,"phases":437,"primaryCompletion":438,"completion":438,"start":439,"enrollment":429,"conditions":440,"interventions":442},"NCT05543694","ED90 of Epidural Bupivacaine With Lidocaine for the Initiation of Labor Analgesia","UNKNOWN",[93],"2024-10-01","2022-10-01",[431,441],"Analgesia",[412],{"nctId":444,"briefTitle":445,"status":108,"phases":446,"primaryCompletion":447,"completion":447,"start":448,"enrollment":296,"conditions":449,"interventions":450},"NCT04814537","Optimal Bupivacaine Dose for Initiation of Labor Epidural Techniques",[93],"2022-03-23","2021-02-25",[431,441],[412],{"trials":452,"activeCount":102},[],{"intervention":454,"totalTrials":197,"cells":455},"Rosuvastatin",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":474,"NA":499},{"trials":457,"activeCount":102},[],{"trials":459,"activeCount":102},[],{"trials":461,"activeCount":102},[],{"trials":463,"activeCount":102},[464],{"nctId":465,"briefTitle":466,"status":108,"phases":467,"completion":468,"start":469,"enrollment":167,"conditions":470,"interventions":472},"NCT00115830","Rho Kinase in Patients With Atherosclerosis",[92],"2007-02","2004-12",[471],"Atherosclerosis",[473,454],"Atorvastatin",{"trials":475,"activeCount":265,"soonestReadout":480},[476,488],{"nctId":477,"briefTitle":478,"status":307,"phases":479,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":487},"NCT07303816","Statins to Prevent Cancer Associated Blood Clots",[93],"2031-03-31","2032-03-31","2026-06-30",4000,[485,486,404],"Venous Thromboembolism","Cancer",[454],{"nctId":489,"briefTitle":490,"status":152,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":102,"conditions":494,"interventions":498},"NCT04417114","SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE",[93],"2025-03-31","2021-04-01",[495,496,497],"Psoriasis","Psoriatic Arthritis","Cardiovascular Risk Factor",[454],{"trials":500,"activeCount":102},[],{"intervention":502,"totalTrials":281,"cells":503},"Evolocumab",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":535},{"trials":505,"activeCount":102},[],{"trials":507,"activeCount":102},[],{"trials":509,"activeCount":102},[],{"trials":511,"activeCount":102},[],{"trials":513,"activeCount":265,"soonestReadout":529},[514,525],{"nctId":515,"briefTitle":516,"status":108,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":524},"NCT04608474","Lipid Management in Renal Transplant Recipients Using Evolocumab.",[93],"2024-01-11","2025-05-14","2021-02-17",81,[523],"Hyperlipidemias",[502],{"nctId":526,"briefTitle":527,"status":162,"phases":528,"primaryCompletion":529,"completion":189,"start":530,"enrollment":531,"conditions":532,"interventions":534},"NCT05152888","The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk",[93],"2027-03-31","2022-03-03",50,[533],"Stable Coronary Disease",[502],{"trials":536,"activeCount":102},[],{"intervention":538,"totalTrials":265,"cells":539},"Sonotherapy",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":559},{"trials":541,"activeCount":102},[],{"trials":543,"activeCount":102},[],{"trials":545,"activeCount":102},[],{"trials":547,"activeCount":102},[],{"trials":549,"activeCount":265,"soonestReadout":256},[550],{"nctId":551,"briefTitle":552,"status":162,"phases":553,"primaryCompletion":256,"completion":554,"start":555,"enrollment":334,"conditions":556,"interventions":558},"NCT04667494","Ultrasound Therapy In Cardiac Amyloidosis",[93],"2027-04-30","2023-08-31",[557],"Amyloidosis Cardiac",[538],{"trials":560,"activeCount":102},[],{"intervention":562,"totalTrials":265,"cells":563},"Dapagliflozin (10Mg Tab) along with standard medical therapy",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":572,"NA":585},{"trials":565,"activeCount":102},[],{"trials":567,"activeCount":102},[],{"trials":569,"activeCount":102},[],{"trials":571,"activeCount":102},[],{"trials":573,"activeCount":265,"soonestReadout":578},[574],{"nctId":575,"briefTitle":576,"status":162,"phases":577,"primaryCompletion":578,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":584},"NCT07323524","Dapagliflozin in Active Lupus Nephritis",[93],"2029-07","2030-01","2026-05-19",33,[583],"Lupus Nephritis (LN)",[562],{"trials":586,"activeCount":102},[],{"intervention":588,"totalTrials":265,"cells":589},"Vancomycin",{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":598,"NA":613},{"trials":591,"activeCount":102},[],{"trials":593,"activeCount":102},[],{"trials":595,"activeCount":102},[],{"trials":597,"activeCount":102},[],{"trials":599,"activeCount":265,"soonestReadout":604},[600],{"nctId":601,"briefTitle":602,"status":307,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":611},"NCT06794944","Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease",[93],"2030-09-01","2031-09","2026-09",60,[609,610],"Inflammatory Bowel Disease (IBD)","Clostridioides Difficile Infection",[588,612],"Fidaxomicin",{"trials":614,"activeCount":102},[],{"intervention":612,"totalTrials":265,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":631},{"trials":618,"activeCount":102},[],{"trials":620,"activeCount":102},[],{"trials":622,"activeCount":102},[],{"trials":624,"activeCount":102},[],{"trials":626,"activeCount":265,"soonestReadout":604},[627],{"nctId":601,"briefTitle":602,"status":307,"phases":628,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":629,"interventions":630},[93],[609,610],[588,612],{"trials":632,"activeCount":102},[],{"intervention":634,"totalTrials":265,"cells":635},"Fremanezumab",{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":644,"NA":657},{"trials":637,"activeCount":102},[],{"trials":639,"activeCount":102},[],{"trials":641,"activeCount":102},[],{"trials":643,"activeCount":102},[],{"trials":645,"activeCount":265,"soonestReadout":311},[646],{"nctId":647,"briefTitle":648,"status":174,"phases":649,"primaryCompletion":311,"completion":311,"start":650,"enrollment":651,"conditions":652,"interventions":656},"NCT06173661","Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45",[93],"2024-03-01",72,[653,654,655],"Migraine","Menstrual Migraine","Menstrually Related Migraine",[634],{"trials":658,"activeCount":102},[],{"intervention":660,"totalTrials":265,"cells":661},"Oral treprostinil (UT-15C) sustained release",{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":666,"PHASE3":668,"PHASE4":670,"NA":684},{"trials":663,"activeCount":102},[],{"trials":665,"activeCount":102},[],{"trials":667,"activeCount":102},[],{"trials":669,"activeCount":102},[],{"trials":671,"activeCount":265,"soonestReadout":676},[672],{"nctId":673,"briefTitle":674,"status":162,"phases":675,"primaryCompletion":676,"completion":385,"start":677,"enrollment":678,"conditions":679,"interventions":683},"NCT07112183","Open Label Treprostinil Raynaud's Study",[93],"2028-09-30","2025-10-15",30,[680,681,682],"Raynaud's Disease","Raynaud Phenomena","Raynauds",[660],{"trials":685,"activeCount":102},[],{"intervention":354,"totalTrials":265,"cells":687},{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":702},{"trials":689,"activeCount":102},[],{"trials":691,"activeCount":102},[],{"trials":693,"activeCount":102},[],{"trials":695,"activeCount":102},[],{"trials":697,"activeCount":265,"soonestReadout":347},[698],{"nctId":344,"briefTitle":345,"status":162,"phases":699,"primaryCompletion":347,"completion":347,"start":348,"enrollment":349,"conditions":700,"interventions":701},[93],[351,352],[320,354],{"trials":703,"activeCount":102},[],{"intervention":705,"totalTrials":265,"cells":706},"[F-18]FDG",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":715,"NA":725},{"trials":708,"activeCount":102},[],{"trials":710,"activeCount":102},[],{"trials":712,"activeCount":102},[],{"trials":714,"activeCount":102},[],{"trials":716,"activeCount":265,"soonestReadout":189},[717],{"nctId":718,"briefTitle":719,"status":162,"phases":720,"primaryCompletion":189,"completion":189,"start":721,"enrollment":531,"conditions":722,"interventions":724},"NCT07087106","Glucose Consumption in MS Using [F-18]FDG-PET",[93],"2025-05-31",[723],"Multiple Sclerosis",[705],{"trials":726,"activeCount":102},[],{"intervention":728,"totalTrials":265,"cells":729},"18F-DCFPyl",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":751},{"trials":731,"activeCount":102},[],{"trials":733,"activeCount":102},[],{"trials":735,"activeCount":102},[],{"trials":737,"activeCount":102},[],{"trials":739,"activeCount":265,"soonestReadout":744},[740],{"nctId":741,"briefTitle":742,"status":162,"phases":743,"primaryCompletion":744,"completion":744,"start":745,"enrollment":678,"conditions":746,"interventions":750},"NCT06099093","Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan",[93],"2026-12-01","2024-04-01",[747,748,749],"Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Metastatic Castration-resistant Prostate Carcinoma",[728],{"trials":752,"activeCount":102},[],{"intervention":316,"totalTrials":265,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":769},{"trials":756,"activeCount":102},[],{"trials":758,"activeCount":102},[],{"trials":760,"activeCount":102},[],{"trials":762,"activeCount":102},[],{"trials":764,"activeCount":265,"soonestReadout":309},[765],{"nctId":305,"briefTitle":306,"status":307,"phases":766,"primaryCompletion":309,"completion":310,"start":311,"enrollment":19,"conditions":767,"interventions":768},[93],[313,314],[280,316],{"trials":770,"activeCount":102},[],{"intervention":772,"totalTrials":265,"cells":773},"Subanesthetic dose intravenous ketamine",{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":780,"PHASE4":782,"NA":796},{"trials":775,"activeCount":102},[],{"trials":777,"activeCount":102},[],{"trials":779,"activeCount":102},[],{"trials":781,"activeCount":102},[],{"trials":783,"activeCount":265,"soonestReadout":789},[784],{"nctId":785,"briefTitle":786,"status":787,"phases":788,"primaryCompletion":789,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT06034821","Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","ENROLLING_BY_INVITATION",[93],"2030-10-01","2030-12-01","2023-10-01",1500,[794],"Acute Suicidal Depression (ASD)",[772],{"trials":797,"activeCount":102},[],{"intervention":799,"totalTrials":265,"cells":800},"18F-rhPSMA-7.3",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":821},{"trials":802,"activeCount":102},[],{"trials":804,"activeCount":102},[],{"trials":806,"activeCount":102},[],{"trials":808,"activeCount":102},[],{"trials":810,"activeCount":265,"soonestReadout":482},[811],{"nctId":812,"briefTitle":813,"status":174,"phases":814,"primaryCompletion":482,"completion":815,"start":71,"enrollment":34,"conditions":816,"interventions":820},"NCT06479187","PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer",[93],"2027-06-20",[817,818,819],"Metastatic Prostate Cancer","Hormone Sensitive Prostate Cancer","Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",[799],{"trials":822,"activeCount":102},[],{"intervention":195,"totalTrials":265,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":839},{"trials":826,"activeCount":102},[],{"trials":828,"activeCount":102},[],{"trials":830,"activeCount":102},[],{"trials":832,"activeCount":102},[],{"trials":834,"activeCount":265,"soonestReadout":188},[835],{"nctId":185,"briefTitle":186,"status":162,"phases":836,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":837,"interventions":838},[93],[15,193],[97,195,196],{"trials":840,"activeCount":102},[],{"intervention":196,"totalTrials":265,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":851,"NA":857},{"trials":844,"activeCount":102},[],{"trials":846,"activeCount":102},[],{"trials":848,"activeCount":102},[],{"trials":850,"activeCount":102},[],{"trials":852,"activeCount":265,"soonestReadout":188},[853],{"nctId":185,"briefTitle":186,"status":162,"phases":854,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":855,"interventions":856},[93],[15,193],[97,195,196],{"trials":858,"activeCount":102},[],{"intervention":392,"totalTrials":197,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":869,"NA":875},{"trials":862,"activeCount":102},[],{"trials":864,"activeCount":102},[],{"trials":866,"activeCount":102},[],{"trials":868,"activeCount":102},[],{"trials":870,"activeCount":265,"soonestReadout":385},[871],{"nctId":382,"briefTitle":383,"status":162,"phases":872,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":873,"interventions":874},[93],[389,390],[369,392],{"trials":876,"activeCount":102},[877,888],{"nctId":878,"briefTitle":879,"status":436,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":886},"NCT04034524","Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin",[],"2020-12-31","2019-05-01",20000,[885],"Diabetes Mellitus, Type 2",[392,887],"Insulin",{"nctId":889,"briefTitle":890,"status":436,"phases":891,"primaryCompletion":71,"completion":71,"start":892,"enrollment":893,"conditions":894,"interventions":895},"NCT05161429","BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes",[],"2021-07-01",550000,[885],[896,392,897,898,899],"DPP4","Basal Insulin","SLGT2","SU",{"intervention":183,"totalTrials":197,"cells":901},{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":917,"PHASE4":919,"NA":925},{"trials":903,"activeCount":102},[],{"trials":905,"activeCount":102},[],{"trials":907,"activeCount":102},[908],{"nctId":909,"briefTitle":910,"status":108,"phases":911,"primaryCompletion":912,"completion":912,"start":913,"enrollment":364,"conditions":914,"interventions":916},"NCT04179019","Calcium Channel Blockade in Primary Aldosteronism",[91],"2023-12-30","2020-09-01",[169,915],"Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)",[183],{"trials":918,"activeCount":102},[],{"trials":920,"activeCount":265,"soonestReadout":176},[921],{"nctId":172,"briefTitle":173,"status":174,"phases":922,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":923,"interventions":924},[93],[15,181],[97,183],{"trials":926,"activeCount":102},[927],{"nctId":928,"briefTitle":929,"status":239,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":938},"NCT01252238","Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance",[94],"2012-12","2010-06",24,[935,936,937],"Insulin Sensitivity","Aortic Compliance","Diastolic Function",[939,940,183],"Aliskiren","Valsartan and Aliskiren",{"intervention":42,"totalTrials":942,"cells":943},13,{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":982,"NA":984},{"trials":945,"activeCount":102},[],{"trials":947,"activeCount":102},[],{"trials":949,"activeCount":102},[],{"trials":951,"activeCount":281,"soonestReadout":41},[952,960,969],{"nctId":39,"briefTitle":40,"status":174,"phases":953,"primaryCompletion":41,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":959},[92],"2026-05","2010-07",25871,[486,958],"Cardiovascular Disease",[42],{"nctId":961,"briefTitle":962,"status":174,"phases":963,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":968},"NCT02178410","VITAL Rhythm Study",[92],"2026-10","2012-10",25119,[958],[52],{"nctId":970,"briefTitle":971,"status":108,"phases":972,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":977,"interventions":980},"NCT00729430","Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging",[92],"2013-10","2014-07","2008-08",358,[978,979],"Myocardial Infarction","Death, Sudden, Cardiac",[981],"Omega-3 Fatty Acids",{"trials":983,"activeCount":102},[],{"trials":985,"activeCount":1082,"soonestReadout":51},[986,997,1007,1017,1027,1035,1043,1054,1064,1074],{"nctId":987,"briefTitle":988,"status":108,"phases":989,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":994,"interventions":996},"NCT01669915","A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline",[94],"2016-06-08","2021-12-31","2011-09-14",3424,[995],"Cognitive Decline",[42],{"nctId":998,"briefTitle":999,"status":174,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1006},"NCT01632761","Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia",[94],"2025-12-28","2012-11",2000,[1005],"Anemia",[42],{"nctId":1008,"briefTitle":1009,"status":174,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":955,"enrollment":1012,"conditions":1013,"interventions":1016},"NCT01758081","Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)",[94],"2026-12",25874,[1014,1015],"Infections","Human Cathelicidin Antimicrobial Peptide (hCAP-18)",[42],{"nctId":1018,"briefTitle":1019,"status":108,"phases":1020,"primaryCompletion":1021,"completion":1022,"start":1023,"enrollment":956,"conditions":1024,"interventions":1026},"NCT01704859","VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers",[94],"2022-03-31","2022-11-23","2018-06-01",[1025],"Fractures",[42],{"nctId":1028,"briefTitle":1029,"status":436,"phases":1030,"primaryCompletion":111,"completion":1031,"start":955,"enrollment":956,"conditions":1032,"interventions":1034},"NCT01782352","Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)",[94],"2024-09",[1033],"Age-related Macular Degeneration",[52],{"nctId":49,"briefTitle":50,"status":174,"phases":1036,"primaryCompletion":51,"completion":1037,"start":1038,"enrollment":956,"conditions":1039,"interventions":1042},[94],"2026-12-31","2019-07-01",[1040,1041,1025],"Bone Density","Bone Health",[52],{"nctId":1044,"briefTitle":1045,"status":436,"phases":1046,"primaryCompletion":1047,"completion":1048,"start":955,"enrollment":1049,"conditions":1050,"interventions":1052},"NCT01880463","Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)",[94],"2020-12","2021-12",25875,[1051],"Dry Eye Disease",[52,1053],"Fish oil placebo",{"nctId":1055,"briefTitle":1056,"status":108,"phases":1057,"primaryCompletion":991,"completion":492,"start":955,"enrollment":1058,"conditions":1059,"interventions":1063},"NCT01696435","VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL",[94],18353,[1060,1061,1062],"Depression","Depressive Symptoms","Mood",[42],{"nctId":1065,"briefTitle":1066,"status":436,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1073},"NCT01785004","Vitamin D and Omega-3 Adiposity Trial (VITAL Adiposity)",[94],"2022-07","2012-07",600,[1072],"Adiposity",[42],{"nctId":1075,"briefTitle":1076,"status":174,"phases":1077,"primaryCompletion":1078,"completion":177,"start":1079,"enrollment":1049,"conditions":1080,"interventions":1081},"NCT01653678","Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)",[94],"2025-11","2011-11",[15],[52,1053],4,{"intervention":1084,"totalTrials":265,"cells":1085},"Cessation of antibiotics",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1106,"NA":1108},{"trials":1087,"activeCount":102},[],{"trials":1089,"activeCount":102},[],{"trials":1091,"activeCount":102},[],{"trials":1093,"activeCount":265,"soonestReadout":1098},[1094],{"nctId":1095,"briefTitle":1096,"status":307,"phases":1097,"primaryCompletion":1098,"completion":1099,"start":650,"enrollment":1100,"conditions":1101,"interventions":1105},"NCT06278896","Early Neutropenic Fever De-escalation of Antibiotics Study",[92],"2026-03-01","2028-03-01",260,[1102,1103,1104],"Hematologic Malignancy","Febrile Neutropenia","Antibiotic Stewardship",[1084],{"trials":1107,"activeCount":102},[],{"trials":1109,"activeCount":102},[],{"intervention":62,"totalTrials":265,"cells":1111},{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1128,"NA":1130},{"trials":1113,"activeCount":102},[],{"trials":1115,"activeCount":102},[],{"trials":1117,"activeCount":102},[],{"trials":1119,"activeCount":265,"soonestReadout":61},[1120],{"nctId":59,"briefTitle":60,"status":162,"phases":1121,"primaryCompletion":61,"completion":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1127},[92],"2024-06-01","2018-10-01",136,[1126],"Bladder Cancer",[62],{"trials":1129,"activeCount":102},[],{"trials":1131,"activeCount":102},[],{"intervention":1133,"totalTrials":265,"cells":1134},"multimodal analgesia pathway with up-front small opioid prescription",{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1141,"PHASE4":1155,"NA":1157},{"trials":1136,"activeCount":102},[],{"trials":1138,"activeCount":102},[],{"trials":1140,"activeCount":102},[],{"trials":1142,"activeCount":265,"soonestReadout":1037},[1143],{"nctId":1144,"briefTitle":1145,"status":162,"phases":1146,"primaryCompletion":1037,"completion":554,"start":1098,"enrollment":179,"conditions":1147,"interventions":1152},"NCT07427043","Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)",[92],[1148,1149,1150,1151,747],"Opioid Consumption, Postoperative","Multimodal Analgesia","Robotic Assisted Laparoscopic Surgery","Robotic Assisted Laparoscopic Radical Prostatectomy",[1133,1153,1154],"multimodal analgesia pathway without up-front small opioid prescription","pre-implementation baseline including opioid",{"trials":1156,"activeCount":102},[],{"trials":1158,"activeCount":102},[],{"intervention":1153,"totalTrials":265,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1167,"PHASE4":1173,"NA":1175},{"trials":1162,"activeCount":102},[],{"trials":1164,"activeCount":102},[],{"trials":1166,"activeCount":102},[],{"trials":1168,"activeCount":265,"soonestReadout":1037},[1169],{"nctId":1144,"briefTitle":1145,"status":162,"phases":1170,"primaryCompletion":1037,"completion":554,"start":1098,"enrollment":179,"conditions":1171,"interventions":1172},[92],[1148,1149,1150,1151,747],[1133,1153,1154],{"trials":1174,"activeCount":102},[],{"trials":1176,"activeCount":102},[],{"intervention":1154,"totalTrials":265,"cells":1178},{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1191,"NA":1193},{"trials":1180,"activeCount":102},[],{"trials":1182,"activeCount":102},[],{"trials":1184,"activeCount":102},[],{"trials":1186,"activeCount":265,"soonestReadout":1037},[1187],{"nctId":1144,"briefTitle":1145,"status":162,"phases":1188,"primaryCompletion":1037,"completion":554,"start":1098,"enrollment":179,"conditions":1189,"interventions":1190},[92],[1148,1149,1150,1151,747],[1133,1153,1154],{"trials":1192,"activeCount":102},[],{"trials":1194,"activeCount":102},[],{"intervention":1196,"totalTrials":265,"cells":1197},"[64Cu]FBP8 PET\u002FMR",{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1215,"NA":1217},{"trials":1199,"activeCount":102},[],{"trials":1201,"activeCount":102},[],{"trials":1203,"activeCount":102},[],{"trials":1205,"activeCount":265,"soonestReadout":1210},[1206],{"nctId":1207,"briefTitle":1208,"status":162,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":34,"conditions":1212,"interventions":1214},"NCT07560306","[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy",[92],"2027-03-30","2026-05-01",[1213],"Cardiac Amyloidosis",[1196],{"trials":1216,"activeCount":102},[],{"trials":1218,"activeCount":102},[],{"intervention":1220,"totalTrials":98,"cells":1221},"Tirzepatide",{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1245,"PHASE4":1247,"NA":1249},{"trials":1223,"activeCount":102},[],{"trials":1225,"activeCount":102},[],{"trials":1227,"activeCount":281,"soonestReadout":954},[1228,1238],{"nctId":1229,"briefTitle":1230,"status":307,"phases":1231,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1237},"NCT07265752","Tirzepatide for the Treatment of Cannabis Use Disorder",[91],"2028-06-30","2026-07-01",6,[1236],"Cannabis Use Disorder",[1220],{"nctId":1239,"briefTitle":1240,"status":162,"phases":1241,"primaryCompletion":954,"completion":311,"start":176,"enrollment":34,"conditions":1242,"interventions":1244},"NCT06727331","Study of Tirzepatide for Recovery and Alcohol Use Management",[91],[1243],"Alcohol Use Disorder (AUD)",[1220],{"trials":1246,"activeCount":102},[],{"trials":1248,"activeCount":102},[],{"trials":1250,"activeCount":197,"soonestReadout":1306},[1251,1263,1273,1284,1293,1302,1312,1321],{"nctId":1252,"briefTitle":1253,"status":108,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":438,"enrollment":1256,"conditions":1257,"interventions":1261},"NCT07088718","Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data",[],"2025-07-30",44671,[1258,1259,1260],"Type 2 Diabetes","Major Adverse Cardiac Events","Cardiovascular (CV) Risk",[1220,1262],"Dulaglutide",{"nctId":1264,"briefTitle":1265,"status":108,"phases":1266,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1272},"NCT06914154","Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data",[],"2025-06-01","2025-01-14",11265,[885,1271],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[1220],{"nctId":1274,"briefTitle":1275,"status":108,"phases":1276,"primaryCompletion":1277,"completion":1277,"start":438,"enrollment":1278,"conditions":1279,"interventions":1281},"NCT07096063","Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk",[],"2025-07-15",887132,[1258,1280,1260],"Overweight",[1220,1262,1282,1283],"Semaglutide","Sitagliptin",{"nctId":1285,"briefTitle":1286,"status":108,"phases":1287,"primaryCompletion":1288,"completion":1098,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1292},"NCT06779929","Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes",[],"2025-12-01","2024-11-01",70000,[1258],[1220,1262,1282],{"nctId":1294,"briefTitle":1295,"status":174,"phases":1296,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1301},"NCT07619508","Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.",[],"2026-06-01","2026-02-10",100000,[21,1280],[1220,1282],{"nctId":1303,"briefTitle":1304,"status":174,"phases":1305,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT06980623","Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction",[],"2025-11-30","2026-10-01","2025-01-01",26000,[1258,24],[1220,1282],{"nctId":1313,"briefTitle":1314,"status":174,"phases":1315,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":1319,"interventions":1320},"NCT07417618","INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)",[],"2026-05-22","2026-01-27",60000,[1258,1280,390],[1262,1282,1220,1283],{"nctId":1322,"briefTitle":1323,"status":108,"phases":1324,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":1325,"conditions":1326,"interventions":1328},"NCT06914141","Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction",[],28118,[885,1327],"HFpEF - Heart Failure With Preserved Ejection Fraction",[1220,1282],{"intervention":1282,"totalTrials":98,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1332,"activeCount":102},[],{"trials":1334,"activeCount":102},[],{"trials":1336,"activeCount":265,"soonestReadout":1341},[1337],{"nctId":1338,"briefTitle":1339,"status":162,"phases":1340,"primaryCompletion":1341,"completion":1341,"start":1342,"enrollment":216,"conditions":1343,"interventions":1345},"NCT06639464","Semaglutide for Helping Opioid Recovery",[91],"2026-08-31","2025-06-02",[1344],"Opioid Use Disorder",[1282],{"trials":1347,"activeCount":102},[],{"trials":1349,"activeCount":102},[],{"trials":1351,"activeCount":1082,"soonestReadout":1306},[1352,1361,1370,1374,1378,1382,1386,1390,1397],{"nctId":1353,"briefTitle":1354,"status":108,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":46,"enrollment":1358,"conditions":1359,"interventions":1360},"NCT05768945","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors",[],"2023-07-07","2023-12-31",742670,[27],[1282,408],{"nctId":1362,"briefTitle":1363,"status":174,"phases":1364,"primaryCompletion":1297,"completion":1297,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1369},"NCT07619495","Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk",[],"2026-01-20",120000,[1368,21,1280],"Type 2 Diabetes Mellitus",[1282,1262],{"nctId":1274,"briefTitle":1275,"status":108,"phases":1371,"primaryCompletion":1277,"completion":1277,"start":438,"enrollment":1278,"conditions":1372,"interventions":1373},[],[1258,1280,1260],[1220,1262,1282,1283],{"nctId":1285,"briefTitle":1286,"status":108,"phases":1375,"primaryCompletion":1288,"completion":1098,"start":1289,"enrollment":1290,"conditions":1376,"interventions":1377},[],[1258],[1220,1262,1282],{"nctId":1294,"briefTitle":1295,"status":174,"phases":1379,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":1380,"interventions":1381},[],[21,1280],[1220,1282],{"nctId":1303,"briefTitle":1304,"status":174,"phases":1383,"primaryCompletion":1306,"completion":1307,"start":1308,"enrollment":1309,"conditions":1384,"interventions":1385},[],[1258,24],[1220,1282],{"nctId":1313,"briefTitle":1314,"status":174,"phases":1387,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":1388,"interventions":1389},[],[1258,1280,390],[1262,1282,1220,1283],{"nctId":1391,"briefTitle":1392,"status":108,"phases":1393,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":1394,"conditions":1395,"interventions":1396},"NCT06914102","Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data",[],58387,[885,1327],[1282],{"nctId":1322,"briefTitle":1323,"status":108,"phases":1398,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":1325,"conditions":1399,"interventions":1400},[],[885,1327],[1220,1282],{"intervention":1402,"totalTrials":197,"cells":1403},"BRS201",{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1405,"activeCount":102},[],{"trials":1407,"activeCount":102},[],{"trials":1409,"activeCount":197,"soonestReadout":1297},[1410,1419,1429],{"nctId":1411,"briefTitle":1412,"status":162,"phases":1413,"primaryCompletion":1297,"completion":744,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1418},"NCT05835505","Detoxification of the Liver In PSC (Dolphin)",[91],"2023-12-12",28,[1417],"Primary Sclerosing Cholangitis",[1402],{"nctId":1420,"briefTitle":1421,"status":162,"phases":1422,"primaryCompletion":744,"completion":1423,"start":1424,"enrollment":34,"conditions":1425,"interventions":1428},"NCT06420375","Treatment of UC With Novel Therapeutics",[91],"2027-07-31","2025-05-27",[1426,1427],"Ulcerative Colitis Mild","Ulcerative Colitis",[1402],{"nctId":1430,"briefTitle":1431,"status":162,"phases":1432,"primaryCompletion":744,"completion":1433,"start":1434,"enrollment":34,"conditions":1435,"interventions":1438},"NCT06420492","Study of Novel Therapeutics for Acute Remedy of Colitis",[91],"2027-06-01","2025-09-30",[1427,1436,1437],"Ulcerative Colitis Chronic Moderate","Ulcerative Colitis Chronic Severe",[1402],{"trials":1440,"activeCount":102},[],{"trials":1442,"activeCount":102},[],{"trials":1444,"activeCount":102},[],{"intervention":1446,"totalTrials":197,"cells":1447},"MIB-626",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1461,"PHASE3":1484,"PHASE4":1486,"NA":1488},{"trials":1449,"activeCount":102},[],{"trials":1451,"activeCount":265,"soonestReadout":1456},[1452],{"nctId":1453,"briefTitle":1454,"status":307,"phases":1455,"primaryCompletion":1456,"completion":1232,"start":1457,"enrollment":933,"conditions":1458,"interventions":1460},"NCT07278492","NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome",[90],"2028-03-31","2026-04-01",[1459],"Down Syndrome (DS)",[1446],{"trials":1462,"activeCount":281,"soonestReadout":1467},[1463,1474],{"nctId":1464,"briefTitle":1465,"status":174,"phases":1466,"primaryCompletion":1467,"completion":256,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1473},"NCT05040321","Sirtuin-NAD Activator in Alzheimer's Disease",[90,91],"2025-12-15","2021-12-01",22,[1471,1472],"Alzheimer's Disease (Incl Subtypes)","Dementia",[1446],{"nctId":1475,"briefTitle":1476,"status":307,"phases":1477,"primaryCompletion":1478,"completion":1479,"start":293,"enrollment":1480,"conditions":1481,"interventions":1483},"NCT07013591","Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery",[91],"2028-10-01","2029-01-01",90,[1482],"Coronary Artery Bypass Graft",[1446],{"trials":1485,"activeCount":102},[],{"trials":1487,"activeCount":102},[],{"trials":1489,"activeCount":102},[],{"intervention":1491,"totalTrials":197,"cells":1492},"normal saline",{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1533,"PHASE4":1535,"NA":1537},{"trials":1494,"activeCount":102},[],{"trials":1496,"activeCount":102},[],{"trials":1498,"activeCount":281,"soonestReadout":76},[1499,1511,1524],{"nctId":1500,"briefTitle":1501,"status":239,"phases":1502,"primaryCompletion":1503,"completion":1504,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1509},"NCT00719914","A Safety\u002FEfficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks",[91],"2008-11","2009-01","2007-11",31,[1508],"ST-Elevation Myocardial Infarction",[1510,1510,1491],"eptifibatide",{"nctId":1512,"briefTitle":1513,"status":162,"phases":1514,"primaryCompletion":1515,"completion":1516,"start":1517,"enrollment":1518,"conditions":1519,"interventions":1521},"NCT05730816","MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI",[91],"2027-04-03","2028-01-01","2023-04-04",130,[1520],"Mesothelioma",[1522,1523],"Magnesium sulfate","Normal Saline",{"nctId":74,"briefTitle":75,"status":174,"phases":1525,"primaryCompletion":76,"completion":1526,"start":1527,"enrollment":1528,"conditions":1529,"interventions":1531},[91],"2026-08-01","2021-04-13",320,[1530],"Acute Kidney Injury",[77,1532],"Normal saline",{"trials":1534,"activeCount":102},[],{"trials":1536,"activeCount":102},[],{"trials":1538,"activeCount":102},[],{"intervention":337,"totalTrials":197,"cells":1540},{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1569,"PHASE4":1571,"NA":1573},{"trials":1542,"activeCount":102},[],{"trials":1544,"activeCount":102},[],{"trials":1546,"activeCount":281,"soonestReadout":332},[1547,1556,1560],{"nctId":1548,"briefTitle":1549,"status":108,"phases":1550,"primaryCompletion":1288,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1555},"NCT05589792","Acetazolamide on REM OSA",[90,91],"2025-12-31","2023-01-30",11,[36],[337],{"nctId":329,"briefTitle":330,"status":162,"phases":1557,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":1558,"interventions":1559},[90,91],[36],[337,320,338],{"nctId":1561,"briefTitle":1562,"status":162,"phases":1563,"primaryCompletion":1564,"completion":189,"start":1565,"enrollment":19,"conditions":1566,"interventions":1568},"NCT06091085","Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA",[90,91],"2027-12-01","2024-01-31",[1567],"OSA",[337],{"trials":1570,"activeCount":102},[],{"trials":1572,"activeCount":102},[],{"trials":1574,"activeCount":102},[],{"intervention":1576,"totalTrials":281,"cells":1577},"Oxytocin",{"EARLY_PHASE1":1578,"PHASE1":1580,"PHASE2":1582,"PHASE3":1592,"PHASE4":1594,"NA":1607},{"trials":1579,"activeCount":102},[],{"trials":1581,"activeCount":102},[],{"trials":1583,"activeCount":265,"soonestReadout":1233},[1584],{"nctId":1585,"briefTitle":1586,"status":162,"phases":1587,"primaryCompletion":1233,"completion":744,"start":1267,"enrollment":1588,"conditions":1589,"interventions":1591},"NCT06483659","Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy",[91],152,[1590],"Postoperative Pain",[1576],{"trials":1593,"activeCount":102},[],{"trials":1595,"activeCount":102},[1596],{"nctId":1597,"briefTitle":1598,"status":108,"phases":1599,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":607,"conditions":1602,"interventions":1605},"NCT01549223","Oxytocin And Uterotonic Agent Use For Cesarean Delivery",[93],"2012-01","2011-04",[1603,1604],"Uterine Atony","Hypotension",[1576,1606],"Oxytocin Bolus",{"trials":1608,"activeCount":102},[],{"intervention":1610,"totalTrials":1234,"cells":1611},"[F-18]PBR06",{"EARLY_PHASE1":1612,"PHASE1":1628,"PHASE2":1630,"PHASE3":1666,"PHASE4":1678,"NA":1680},{"trials":1613,"activeCount":102},[1614],{"nctId":1615,"briefTitle":1616,"status":108,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1626},"NCT04616456","Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients",[89],"2022-01-30","2020-12-30",19,[1622,1623,1624,1625],"Multiple System Atrophy","Multiple System Atrophy, Cerebellar Variant","Multiple System Atrophy, Parkinson Variant (Disorder)","Multiple System Atrophy (MSA) With Orthostatic Hypotension",[1610,1627],"Verdiperstat",{"trials":1629,"activeCount":102},[],{"trials":1631,"activeCount":265,"soonestReadout":189},[1632,1641,1649,1659],{"nctId":1633,"briefTitle":1634,"status":108,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":258,"conditions":1638,"interventions":1640},"NCT03033680","Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA",[90,91],"2021-01-15","2017-03-24",[1639],"MSA",[1610],{"nctId":1642,"briefTitle":1643,"status":108,"phases":1644,"primaryCompletion":1527,"completion":1527,"start":1645,"enrollment":98,"conditions":1646,"interventions":1647},"NCT04144257","Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue",[90,91],"2020-03-12",[723],[1610,1648],"[C-11]Methylreboxetine",{"nctId":1650,"briefTitle":1651,"status":162,"phases":1652,"primaryCompletion":189,"completion":189,"start":1653,"enrollment":1654,"conditions":1655,"interventions":1657},"NCT02649985","PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases",[90,91],"2016-05-02",250,[723,1656],"Alzheimer's Disease",[1610,1658],"[C-11]PBR28",{"nctId":1660,"briefTitle":1661,"status":152,"phases":1662,"primaryCompletion":1663,"completion":1663,"start":1048,"enrollment":102,"conditions":1664,"interventions":1665},"NCT03983252","Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis",[90,91],"2024-05-01",[723],[1610],{"trials":1667,"activeCount":102},[1668],{"nctId":1669,"briefTitle":1670,"status":108,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":98,"conditions":1674,"interventions":1676},"NCT04510220","9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis",[92],"2022-12-28","2020-09-21",[1675],"Relapsing Multiple Sclerosis",[1677,1610],"Ofatumumab",{"trials":1679,"activeCount":102},[],{"trials":1681,"activeCount":102},[],{"intervention":1683,"totalTrials":1082,"cells":1684},"Oxygen",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1720,"PHASE4":1732,"NA":1734},{"trials":1686,"activeCount":102},[],{"trials":1688,"activeCount":102},[],{"trials":1690,"activeCount":265,"soonestReadout":1695},[1691,1702,1711],{"nctId":1692,"briefTitle":1693,"status":162,"phases":1694,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1699,"interventions":1701},"NCT06043440","Down Syndrome Obstructive Sleep Apnea",[91],"2027-11-30","2027-12-30","2023-10-24",230,[1700,36],"Down Syndrome",[1683],{"nctId":1703,"briefTitle":1704,"status":108,"phases":1705,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1709,"interventions":1710},"NCT03189173","Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea",[91],"2023-05-01","2017-09-06",41,[36],[1683],{"nctId":1712,"briefTitle":1713,"status":152,"phases":1714,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":102,"conditions":1717,"interventions":1719},"NCT01261377","Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)",[90,91],"2011-09","2010-11",[1718],"Chronic Obstructive Airway Disease",[1683],{"trials":1721,"activeCount":102},[1722],{"nctId":1723,"briefTitle":1724,"status":239,"phases":1725,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":1728,"conditions":1729,"interventions":1731},"NCT03745898","The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea",[92],"2022-06-17","2019-04-15",98,[24,1730],"Central Sleep Apnea",[1683],{"trials":1733,"activeCount":102},[],{"trials":1735,"activeCount":102},[],{"intervention":1648,"totalTrials":281,"cells":1737},{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1739,"activeCount":102},[],{"trials":1741,"activeCount":102},[],{"trials":1743,"activeCount":265,"soonestReadout":1037},[1744,1748],{"nctId":1642,"briefTitle":1643,"status":108,"phases":1745,"primaryCompletion":1527,"completion":1527,"start":1645,"enrollment":98,"conditions":1746,"interventions":1747},[90,91],[723],[1610,1648],{"nctId":1749,"briefTitle":1750,"status":162,"phases":1751,"primaryCompletion":1037,"completion":1037,"start":1752,"enrollment":1620,"conditions":1753,"interventions":1754},"NCT03207464","Molecular Imaging of NET Using [C-11]MRB-PET in MS",[90,91],"2017-10-10",[723],[1648],{"trials":1756,"activeCount":102},[],{"trials":1758,"activeCount":102},[],{"trials":1760,"activeCount":102},[],{"intervention":1762,"totalTrials":281,"cells":1763},"Colchicine",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1778,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1765,"activeCount":102},[],{"trials":1767,"activeCount":102},[1768],{"nctId":1769,"briefTitle":1770,"status":436,"phases":1771,"primaryCompletion":1772,"completion":1772,"start":1773,"enrollment":1774,"conditions":1775,"interventions":1777},"NCT04355585","Revisiting the Mechanism of the Anti-inflammatory Effect of Colchicine",[90],"2023-04","2020-05-06",18,[1776],"Colchicine Mechanism of Action",[1762],{"trials":1779,"activeCount":265,"soonestReadout":272},[1780],{"nctId":1781,"briefTitle":1782,"status":162,"phases":1783,"primaryCompletion":272,"completion":1784,"start":1785,"enrollment":34,"conditions":1786,"interventions":1788},"NCT04500665","Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine",[91],"2026-11-11","2021-11-01",[1787],"Chronic Kidney Diseases",[1762],{"trials":1790,"activeCount":102},[],{"trials":1792,"activeCount":102},[],{"trials":1794,"activeCount":102},[],{"intervention":1796,"totalTrials":281,"cells":1797},"Testosterone Cypionate",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1799,"activeCount":102},[],{"trials":1801,"activeCount":102},[],{"trials":1803,"activeCount":265,"soonestReadout":293},[1804,1816],{"nctId":1805,"briefTitle":1806,"status":108,"phases":1807,"primaryCompletion":1808,"completion":1808,"start":1809,"enrollment":19,"conditions":1810,"interventions":1815},"NCT04895306","Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)",[91],"2026-03-27","2022-11-15",[1811,1812,1813,1814],"Pain","Opioid Use","Androgen Deficiency","Back Pain",[1796],{"nctId":1817,"briefTitle":1818,"status":162,"phases":1819,"primaryCompletion":293,"completion":399,"start":1820,"enrollment":678,"conditions":1821,"interventions":1824},"NCT06111209","The Anabolic Effect of Testosterone on Pelvic Floor Muscles",[91],"2025-02-15",[1822,1823],"Stress Urinary Incontinence","Menopause",[1825],"Testosterone cypionate",{"trials":1827,"activeCount":102},[],{"trials":1829,"activeCount":102},[],{"trials":1831,"activeCount":102},[],{"intervention":1833,"totalTrials":265,"cells":1834},"Extended-release Buprenorphine",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1839,"PHASE3":1848,"PHASE4":1850,"NA":1852},{"trials":1836,"activeCount":102},[],{"trials":1838,"activeCount":102},[],{"trials":1840,"activeCount":265,"soonestReadout":272},[1841],{"nctId":1842,"briefTitle":1843,"status":162,"phases":1844,"primaryCompletion":272,"completion":272,"start":1845,"enrollment":678,"conditions":1846,"interventions":1847},"NCT06441604","Extended-release Buprenorphine as a Novel Low-dose Induction Strategy",[91],"2025-10-27",[1344],[1833],{"trials":1849,"activeCount":102},[],{"trials":1851,"activeCount":102},[],{"trials":1853,"activeCount":102},[],{"intervention":1855,"totalTrials":265,"cells":1856},"Bedaquiline",{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1858,"activeCount":102},[],{"trials":1860,"activeCount":102},[],{"trials":1862,"activeCount":265,"soonestReadout":1867},[1863],{"nctId":1864,"briefTitle":1865,"status":174,"phases":1866,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1871,"interventions":1874},"NCT05556746","Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB",[91],"2025-06-12","2027-01","2023-11-24",94,[1872,1873],"Tuberculosis, Pulmonary","HIV",[1855,1875,1876,1877,1878,1879,1880,1876],"Clofazimine","Pyrazinamide","Delamanid","Rifampin","Isoniazid","Ethambutol",{"trials":1882,"activeCount":102},[],{"trials":1884,"activeCount":102},[],{"trials":1886,"activeCount":102},[],{"intervention":1875,"totalTrials":265,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1899,"PHASE4":1901,"NA":1903},{"trials":1890,"activeCount":102},[],{"trials":1892,"activeCount":102},[],{"trials":1894,"activeCount":265,"soonestReadout":1867},[1895],{"nctId":1864,"briefTitle":1865,"status":174,"phases":1896,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1897,"interventions":1898},[91],[1872,1873],[1855,1875,1876,1877,1878,1879,1880,1876],{"trials":1900,"activeCount":102},[],{"trials":1902,"activeCount":102},[],{"trials":1904,"activeCount":102},[],{"intervention":1876,"totalTrials":265,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1917,"PHASE4":1919,"NA":1921},{"trials":1908,"activeCount":102},[],{"trials":1910,"activeCount":102},[],{"trials":1912,"activeCount":265,"soonestReadout":1867},[1913],{"nctId":1864,"briefTitle":1865,"status":174,"phases":1914,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1915,"interventions":1916},[91],[1872,1873],[1855,1875,1876,1877,1878,1879,1880,1876],{"trials":1918,"activeCount":102},[],{"trials":1920,"activeCount":102},[],{"trials":1922,"activeCount":102},[],{"intervention":1877,"totalTrials":265,"cells":1924},{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1926,"activeCount":102},[],{"trials":1928,"activeCount":102},[],{"trials":1930,"activeCount":265,"soonestReadout":1867},[1931],{"nctId":1864,"briefTitle":1865,"status":174,"phases":1932,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1933,"interventions":1934},[91],[1872,1873],[1855,1875,1876,1877,1878,1879,1880,1876],{"trials":1936,"activeCount":102},[],{"trials":1938,"activeCount":102},[],{"trials":1940,"activeCount":102},[],{"intervention":1878,"totalTrials":265,"cells":1942},{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1944,"activeCount":102},[],{"trials":1946,"activeCount":102},[],{"trials":1948,"activeCount":265,"soonestReadout":1867},[1949],{"nctId":1864,"briefTitle":1865,"status":174,"phases":1950,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1951,"interventions":1952},[91],[1872,1873],[1855,1875,1876,1877,1878,1879,1880,1876],{"trials":1954,"activeCount":102},[],{"trials":1956,"activeCount":102},[],{"trials":1958,"activeCount":102},[],{"intervention":1879,"totalTrials":265,"cells":1960},{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1971,"PHASE4":1973,"NA":1975},{"trials":1962,"activeCount":102},[],{"trials":1964,"activeCount":102},[],{"trials":1966,"activeCount":265,"soonestReadout":1867},[1967],{"nctId":1864,"briefTitle":1865,"status":174,"phases":1968,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1969,"interventions":1970},[91],[1872,1873],[1855,1875,1876,1877,1878,1879,1880,1876],{"trials":1972,"activeCount":102},[],{"trials":1974,"activeCount":102},[],{"trials":1976,"activeCount":102},[],{"intervention":1880,"totalTrials":265,"cells":1978},{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1983,"PHASE3":1989,"PHASE4":1991,"NA":1993},{"trials":1980,"activeCount":102},[],{"trials":1982,"activeCount":102},[],{"trials":1984,"activeCount":265,"soonestReadout":1867},[1985],{"nctId":1864,"briefTitle":1865,"status":174,"phases":1986,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1987,"interventions":1988},[91],[1872,1873],[1855,1875,1876,1877,1878,1879,1880,1876],{"trials":1990,"activeCount":102},[],{"trials":1992,"activeCount":102},[],{"trials":1994,"activeCount":102},[],{"intervention":1996,"totalTrials":265,"cells":1997},"Atomoxetine-plus-oxybutynin (80\u002F5 mg) (AtoOxy), active comparator condition",{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":1999,"activeCount":102},[],{"trials":2001,"activeCount":102},[],{"trials":2003,"activeCount":265,"soonestReadout":1564},[2004],{"nctId":2005,"briefTitle":2006,"status":307,"phases":2007,"primaryCompletion":1564,"completion":1564,"start":1297,"enrollment":933,"conditions":2008,"interventions":2010},"NCT07577661","Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea",[90,91],[36,2009],"Sleep-disordered Breathing",[1996],{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[],{"trials":2016,"activeCount":102},[],{"intervention":2018,"totalTrials":265,"cells":2019},"Trazodone Hydrochloride",{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2034,"PHASE4":2036,"NA":2038},{"trials":2021,"activeCount":102},[],{"trials":2023,"activeCount":102},[],{"trials":2025,"activeCount":265,"soonestReadout":2030},[2026],{"nctId":2027,"briefTitle":2028,"status":162,"phases":2029,"primaryCompletion":2030,"completion":1297,"start":2031,"enrollment":1774,"conditions":2032,"interventions":2033},"NCT06286189","Trazodone on OSA Endotypes",[90,91],"2026-01-01","2024-01-01",[36],[2018],{"trials":2035,"activeCount":102},[],{"trials":2037,"activeCount":102},[],{"trials":2039,"activeCount":102},[],{"intervention":2041,"totalTrials":265,"cells":2042},"Colchicine Pill",{"EARLY_PHASE1":2043,"PHASE1":2045,"PHASE2":2047,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2044,"activeCount":102},[],{"trials":2046,"activeCount":102},[],{"trials":2048,"activeCount":265,"soonestReadout":2053},[2049],{"nctId":2050,"briefTitle":2051,"status":307,"phases":2052,"primaryCompletion":2053,"completion":2054,"start":1233,"enrollment":2055,"conditions":2056,"interventions":2058},"NCT06855433","Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment",[91],"2030-04-30","2030-09-30",150,[2057],"CPPD - Calcium Pyrophosphate Deposition Disease",[2041],{"trials":2060,"activeCount":102},[],{"trials":2062,"activeCount":102},[],{"trials":2064,"activeCount":102},[],{"intervention":2066,"totalTrials":265,"cells":2067},"Investigational Product - MIB 626",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2085,"PHASE4":2087,"NA":2089},{"trials":2069,"activeCount":102},[],{"trials":2071,"activeCount":102},[],{"trials":2073,"activeCount":265,"soonestReadout":2078},[2074],{"nctId":2075,"briefTitle":2076,"status":162,"phases":2077,"primaryCompletion":2078,"completion":529,"start":2079,"enrollment":2080,"conditions":2081,"interventions":2084},"NCT05759468","NAD Augmentation in Diabetes Kidney Disease",[91],"2026-11-30","2023-04-13",156,[2082,2083],"Type2diabetes","Diabetic Kidney Disease",[2066],{"trials":2086,"activeCount":102},[],{"trials":2088,"activeCount":102},[],{"trials":2090,"activeCount":102},[],{"intervention":2092,"totalTrials":265,"cells":2093},"Medication for opioid use disorder",{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2109,"PHASE4":2111,"NA":2113},{"trials":2095,"activeCount":102},[],{"trials":2097,"activeCount":102},[],{"trials":2099,"activeCount":265,"soonestReadout":2104},[2100],{"nctId":2101,"briefTitle":2102,"status":307,"phases":2103,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":191,"conditions":2107,"interventions":2108},"NCT07011758","Dynamic Treatment Regimes for Opioid Use Disorder",[91],"2029-06-01","2030-06-01","2028-07-01",[1344],[2092],{"trials":2110,"activeCount":102},[],{"trials":2112,"activeCount":102},[],{"trials":2114,"activeCount":102},[],{"intervention":1522,"totalTrials":265,"cells":2116},{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2127,"PHASE4":2129,"NA":2131},{"trials":2118,"activeCount":102},[],{"trials":2120,"activeCount":102},[],{"trials":2122,"activeCount":265,"soonestReadout":1515},[2123],{"nctId":1512,"briefTitle":1513,"status":162,"phases":2124,"primaryCompletion":1515,"completion":1516,"start":1517,"enrollment":1518,"conditions":2125,"interventions":2126},[91],[1520],[1522,1523],{"trials":2128,"activeCount":102},[],{"trials":2130,"activeCount":102},[],{"trials":2132,"activeCount":102},[],{"intervention":67,"totalTrials":265,"cells":2134},{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2149,"PHASE4":2151,"NA":2153},{"trials":2136,"activeCount":102},[],{"trials":2138,"activeCount":102},[],{"trials":2140,"activeCount":265,"soonestReadout":66},[2141],{"nctId":64,"briefTitle":65,"status":174,"phases":2142,"primaryCompletion":66,"completion":482,"start":2143,"enrollment":2144,"conditions":2145,"interventions":2148},[90,91],"2021-08-30",7,[2146,2147],"Lymphangioleiomyomatosis","Tuberous Sclerosis Complex",[67],{"trials":2150,"activeCount":102},[],{"trials":2152,"activeCount":102},[],{"trials":2154,"activeCount":102},[],{"intervention":1658,"totalTrials":265,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2158,"activeCount":102},[],{"trials":2160,"activeCount":102},[],{"trials":2162,"activeCount":265,"soonestReadout":189},[2163],{"nctId":1650,"briefTitle":1651,"status":162,"phases":2164,"primaryCompletion":189,"completion":189,"start":1653,"enrollment":1654,"conditions":2165,"interventions":2166},[90,91],[723,1656],[1610,1658],{"trials":2168,"activeCount":102},[],{"trials":2170,"activeCount":102},[],{"trials":2172,"activeCount":102},[],{"intervention":2174,"totalTrials":265,"cells":2175},"Elranatamab",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2177,"activeCount":102},[],{"trials":2179,"activeCount":102},[],{"trials":2181,"activeCount":265,"soonestReadout":2186},[2182],{"nctId":2183,"briefTitle":2184,"status":162,"phases":2185,"primaryCompletion":2186,"completion":2187,"start":1289,"enrollment":2188,"conditions":2189,"interventions":2191},"NCT06569147","Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis",[90,91],"2027-09-01","2029-09-01",49,[2190],"AL Amyloidosis",[2174],{"trials":2193,"activeCount":102},[],{"trials":2195,"activeCount":102},[],{"trials":2197,"activeCount":102},[],{"intervention":47,"totalTrials":265,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2215,"PHASE4":2217,"NA":2219},{"trials":2201,"activeCount":102},[],{"trials":2203,"activeCount":102},[],{"trials":2205,"activeCount":265,"soonestReadout":46},[2206],{"nctId":44,"briefTitle":45,"status":162,"phases":2207,"primaryCompletion":46,"completion":2208,"start":2209,"enrollment":206,"conditions":2210,"interventions":2211},[90,91],"2022-12-31","2019-03-01",[36],[47,2212,2213,2214],"LTM1201AT","LTM1201AG","LTM1201AD",{"trials":2216,"activeCount":102},[],{"trials":2218,"activeCount":102},[],{"trials":2220,"activeCount":102},[],{"intervention":2212,"totalTrials":265,"cells":2222},{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2224,"activeCount":102},[],{"trials":2226,"activeCount":102},[],{"trials":2228,"activeCount":265,"soonestReadout":46},[2229],{"nctId":44,"briefTitle":45,"status":162,"phases":2230,"primaryCompletion":46,"completion":2208,"start":2209,"enrollment":206,"conditions":2231,"interventions":2232},[90,91],[36],[47,2212,2213,2214],{"trials":2234,"activeCount":102},[],{"trials":2236,"activeCount":102},[],{"trials":2238,"activeCount":102},[],{"intervention":2213,"totalTrials":265,"cells":2240},{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2242,"activeCount":102},[],{"trials":2244,"activeCount":102},[],{"trials":2246,"activeCount":265,"soonestReadout":46},[2247],{"nctId":44,"briefTitle":45,"status":162,"phases":2248,"primaryCompletion":46,"completion":2208,"start":2209,"enrollment":206,"conditions":2249,"interventions":2250},[90,91],[36],[47,2212,2213,2214],{"trials":2252,"activeCount":102},[],{"trials":2254,"activeCount":102},[],{"trials":2256,"activeCount":102},[],{"intervention":2214,"totalTrials":265,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2260,"activeCount":102},[],{"trials":2262,"activeCount":102},[],{"trials":2264,"activeCount":265,"soonestReadout":46},[2265],{"nctId":44,"briefTitle":45,"status":162,"phases":2266,"primaryCompletion":46,"completion":2208,"start":2209,"enrollment":206,"conditions":2267,"interventions":2268},[90,91],[36],[47,2212,2213,2214],{"trials":2270,"activeCount":102},[],{"trials":2272,"activeCount":102},[],{"trials":2274,"activeCount":102},[],{"intervention":2276,"totalTrials":265,"cells":2277},"Atomoxetine Oral Capsule [Strattera]",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2279,"activeCount":102},[],{"trials":2281,"activeCount":102},[],{"trials":2283,"activeCount":265,"soonestReadout":1297},[2284],{"nctId":2285,"briefTitle":2286,"status":162,"phases":2287,"primaryCompletion":1297,"completion":1297,"start":2288,"enrollment":1774,"conditions":2289,"interventions":2290},"NCT05350215","Atomoxetine and DAW2022 on OSA Severity",[90,91],"2022-06-01",[36],[2276],{"trials":2292,"activeCount":102},[],{"trials":2294,"activeCount":102},[],{"trials":2296,"activeCount":102},[],{"intervention":2298,"totalTrials":265,"cells":2299},"Defibrotide",{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2316,"PHASE4":2318,"NA":2320},{"trials":2301,"activeCount":102},[],{"trials":2303,"activeCount":102},[],{"trials":2305,"activeCount":265,"soonestReadout":1297},[2306],{"nctId":2307,"briefTitle":2308,"status":162,"phases":2309,"primaryCompletion":1297,"completion":2310,"start":2311,"enrollment":2312,"conditions":2313,"interventions":2315},"NCT04652115","Defibrotide for the Treatment of Severe COVID-19",[91],"2027-01-01","2021-01-01",42,[2314],"Covid19",[2298],{"trials":2317,"activeCount":102},[],{"trials":2319,"activeCount":102},[],{"trials":2321,"activeCount":102},[],{"intervention":2323,"totalTrials":265,"cells":2324},"Bicalutamide",{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2326,"activeCount":102},[],{"trials":2328,"activeCount":102},[],{"trials":2330,"activeCount":265,"soonestReadout":2335},[2331],{"nctId":2332,"briefTitle":2333,"status":174,"phases":2334,"primaryCompletion":2335,"completion":1099,"start":2336,"enrollment":2337,"conditions":2338,"interventions":2339},"NCT04025372","INTREPId (INTermediate Risk Erection PreservatIon Trial)",[91],"2027-10-01","2020-06-01",234,[747],[2323,2340,2341],"GnRH Agonist","Darolutamide",{"trials":2343,"activeCount":102},[],{"trials":2345,"activeCount":102},[],{"trials":2347,"activeCount":102},[],{"intervention":2340,"totalTrials":265,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2351,"activeCount":102},[],{"trials":2353,"activeCount":102},[],{"trials":2355,"activeCount":265,"soonestReadout":2335},[2356],{"nctId":2332,"briefTitle":2333,"status":174,"phases":2357,"primaryCompletion":2335,"completion":1099,"start":2336,"enrollment":2337,"conditions":2358,"interventions":2359},[91],[747],[2323,2340,2341],{"trials":2361,"activeCount":102},[],{"trials":2363,"activeCount":102},[],{"trials":2365,"activeCount":102},[],{"intervention":2341,"totalTrials":265,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2378,"PHASE4":2380,"NA":2382},{"trials":2369,"activeCount":102},[],{"trials":2371,"activeCount":102},[],{"trials":2373,"activeCount":265,"soonestReadout":2335},[2374],{"nctId":2332,"briefTitle":2333,"status":174,"phases":2375,"primaryCompletion":2335,"completion":1099,"start":2336,"enrollment":2337,"conditions":2376,"interventions":2377},[91],[747],[2323,2340,2341],{"trials":2379,"activeCount":102},[],{"trials":2381,"activeCount":102},[],{"trials":2383,"activeCount":102},[],{"intervention":2385,"totalTrials":265,"cells":2386},"Inhaled Carbon Monoxide at 200 ppm",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2401,"PHASE4":2403,"NA":2405},{"trials":2388,"activeCount":102},[],{"trials":2390,"activeCount":102},[],{"trials":2392,"activeCount":265,"soonestReadout":2397},[2393],{"nctId":2394,"briefTitle":2395,"status":174,"phases":2396,"primaryCompletion":2397,"completion":2397,"start":1038,"enrollment":22,"conditions":2398,"interventions":2400},"NCT03799874","Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)",[91],"2026-01",[2399],"Acute Respiratory Distress Syndrome",[2385],{"trials":2402,"activeCount":102},[],{"trials":2404,"activeCount":102},[],{"trials":2406,"activeCount":102},[],{"intervention":338,"totalTrials":265,"cells":2408},{"EARLY_PHASE1":2409,"PHASE1":2411,"PHASE2":2413,"PHASE3":2419,"PHASE4":2421,"NA":2423},{"trials":2410,"activeCount":102},[],{"trials":2412,"activeCount":102},[],{"trials":2414,"activeCount":265,"soonestReadout":332},[2415],{"nctId":329,"briefTitle":330,"status":162,"phases":2416,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":2417,"interventions":2418},[90,91],[36],[337,320,338],{"trials":2420,"activeCount":102},[],{"trials":2422,"activeCount":102},[],{"trials":2424,"activeCount":102},[],{"intervention":2426,"totalTrials":265,"cells":2427},"losartan 25 mg",{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2429,"activeCount":102},[],{"trials":2431,"activeCount":102},[],{"trials":2433,"activeCount":265,"soonestReadout":2438},[2434],{"nctId":2435,"briefTitle":2436,"status":162,"phases":2437,"primaryCompletion":2438,"completion":2438,"start":2439,"enrollment":1480,"conditions":2440,"interventions":2442},"NCT06933706","Losartan to Improve Outcomes After Multi-ligament Knee Injury",[91],"2029-09-30","2025-10-01",[2441],"Multi-ligament Knee Injury",[2426],{"trials":2444,"activeCount":102},[],{"trials":2446,"activeCount":102},[],{"trials":2448,"activeCount":102},[],{"intervention":2450,"totalTrials":265,"cells":2451},"AGuIX gadolinium-based nanoparticles",{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2456,"PHASE3":2484,"PHASE4":2486,"NA":2488},{"trials":2453,"activeCount":102},[],{"trials":2455,"activeCount":102},[],{"trials":2457,"activeCount":265,"soonestReadout":2462},[2458],{"nctId":2459,"briefTitle":2460,"status":174,"phases":2461,"primaryCompletion":2462,"completion":2463,"start":2464,"enrollment":2465,"conditions":2466,"interventions":2483},"NCT04899908","Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases",[91],"2028-04","2029-05","2021-09-15",134,[2467,2468,2469,2470,2471,2472,2473,2474,2475,2476,2477,2478,2479,2480,2481,2482],"Brain Cancer","Brain Metastases","Melanoma","Lung Cancer","Breast Cancer","HER2-positive Breast Cancer","Colorectal Cancer","Gastrointestinal Cancer","SRS","SRT","Whole Brain Radiation","Stereotactic Radiation","AGuIX","Nanoparticle","Cystic","Brain Tumor",[2450],{"trials":2485,"activeCount":102},[],{"trials":2487,"activeCount":102},[],{"trials":2489,"activeCount":102},[],{"intervention":77,"totalTrials":265,"cells":2491},{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2496,"PHASE3":2502,"PHASE4":2504,"NA":2506},{"trials":2493,"activeCount":102},[],{"trials":2495,"activeCount":102},[],{"trials":2497,"activeCount":265,"soonestReadout":76},[2498],{"nctId":74,"briefTitle":75,"status":174,"phases":2499,"primaryCompletion":76,"completion":1526,"start":1527,"enrollment":1528,"conditions":2500,"interventions":2501},[91],[1530],[77,1532],{"trials":2503,"activeCount":102},[],{"trials":2505,"activeCount":102},[],{"trials":2507,"activeCount":102},[],{"intervention":2509,"totalTrials":265,"cells":2510},"Foralumab TZLS-401 50 µg",{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2527,"PHASE4":2529,"NA":2531},{"trials":2512,"activeCount":102},[],{"trials":2514,"activeCount":102},[],{"trials":2516,"activeCount":265,"soonestReadout":177},[2517],{"nctId":2518,"briefTitle":2519,"status":162,"phases":2520,"primaryCompletion":177,"completion":1011,"start":2521,"enrollment":206,"conditions":2522,"interventions":2525},"NCT06489548","Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease",[91],"2025-09-16",[1472,2523,2524],"Alzheimers Disease","Mild Cognitive Impairment Due to Alzheimer's Disease",[2509,2526],"Foralumab TZLS-401 100 µg",{"trials":2528,"activeCount":102},[],{"trials":2530,"activeCount":102},[],{"trials":2532,"activeCount":102},[],{"intervention":2526,"totalTrials":265,"cells":2534},{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2545,"PHASE4":2547,"NA":2549},{"trials":2536,"activeCount":102},[],{"trials":2538,"activeCount":102},[],{"trials":2540,"activeCount":265,"soonestReadout":177},[2541],{"nctId":2518,"briefTitle":2519,"status":162,"phases":2542,"primaryCompletion":177,"completion":1011,"start":2521,"enrollment":206,"conditions":2543,"interventions":2544},[91],[1472,2523,2524],[2509,2526],{"trials":2546,"activeCount":102},[],{"trials":2548,"activeCount":102},[],{"trials":2550,"activeCount":102},[],{"intervention":2552,"totalTrials":265,"cells":2553},"Pyridostigmine",{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2555,"activeCount":102},[],{"trials":2557,"activeCount":102},[],{"trials":2559,"activeCount":265,"soonestReadout":606},[2560],{"nctId":2561,"briefTitle":2562,"status":162,"phases":2563,"primaryCompletion":606,"completion":2564,"start":2565,"enrollment":2566,"conditions":2567,"interventions":2571},"NCT06366724","LIFT: Life Improvement Trial",[91],"2026-11","2024-09-10",160,[2568,2569,2570],"ME\u002FCFS","Long COVID","PASC",[2552,2572],"Low-Dose Naltrexone",{"trials":2574,"activeCount":102},[],{"trials":2576,"activeCount":102},[],{"trials":2578,"activeCount":102},[],{"intervention":2572,"totalTrials":265,"cells":2580},{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2585,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2582,"activeCount":102},[],{"trials":2584,"activeCount":102},[],{"trials":2586,"activeCount":265,"soonestReadout":606},[2587],{"nctId":2561,"briefTitle":2562,"status":162,"phases":2588,"primaryCompletion":606,"completion":2564,"start":2565,"enrollment":2566,"conditions":2589,"interventions":2590},[91],[2568,2569,2570],[2552,2572],{"trials":2592,"activeCount":102},[],{"trials":2594,"activeCount":102},[],{"trials":2596,"activeCount":102},[],{"intervention":2598,"totalTrials":265,"cells":2599},"Methylprednisone",{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2604,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2601,"activeCount":102},[],{"trials":2603,"activeCount":102},[],{"trials":2605,"activeCount":265,"soonestReadout":2610},[2606],{"nctId":2607,"briefTitle":2608,"status":307,"phases":2609,"primaryCompletion":2610,"completion":2611,"start":1233,"enrollment":678,"conditions":2612,"interventions":2615},"NCT07461961","CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock",[91],"2028-02-01","2029-02-01",[2613,24,2614],"Cardiogenic Shock","Inflammation",[2598],{"trials":2617,"activeCount":102},[],{"trials":2619,"activeCount":102},[],{"trials":2621,"activeCount":102},[],{"intervention":2623,"totalTrials":265,"cells":2624},"Psilocybin",{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2640,"PHASE4":2642,"NA":2644},{"trials":2626,"activeCount":102},[],{"trials":2628,"activeCount":102},[],{"trials":2630,"activeCount":265,"soonestReadout":2635},[2631],{"nctId":2632,"briefTitle":2633,"status":307,"phases":2634,"primaryCompletion":2635,"completion":2636,"start":1211,"enrollment":19,"conditions":2637,"interventions":2639},"NCT07296094","Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder",[91],"2029-12-01","2030-02",[2638],"Alcohol Use Disorder",[2623],{"trials":2641,"activeCount":102},[],{"trials":2643,"activeCount":102},[],{"trials":2645,"activeCount":102},[],{"intervention":2647,"totalTrials":265,"cells":2648},"Testosterone Undecanoate 250 MG\u002FML",{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2663,"PHASE4":2665,"NA":2667},{"trials":2650,"activeCount":102},[],{"trials":2652,"activeCount":102},[],{"trials":2654,"activeCount":265,"soonestReadout":400},[2655],{"nctId":2656,"briefTitle":2657,"status":162,"phases":2658,"primaryCompletion":400,"completion":1696,"start":2659,"enrollment":2055,"conditions":2660,"interventions":2662},"NCT04798469","Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism",[91],"2022-01-10",[1812,1811,2661],"Hypogonadism, Male",[2647],{"trials":2664,"activeCount":102},[],{"trials":2666,"activeCount":102},[],{"trials":2668,"activeCount":102},[],{"intervention":2670,"totalTrials":197,"cells":2671},"Metformin",{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2676,"PHASE3":2690,"PHASE4":2692,"NA":2705},{"trials":2673,"activeCount":102},[],{"trials":2675,"activeCount":102},[],{"trials":2677,"activeCount":265,"soonestReadout":309},[2678],{"nctId":2679,"briefTitle":2680,"status":162,"phases":2681,"primaryCompletion":309,"completion":2682,"start":2683,"enrollment":2684,"conditions":2685,"interventions":2689},"NCT06096259","Preventing Injured Knees From osteoArthritis: Severity Outcomes",[91],"2029-12","2024-05-06",512,[2686,2687,2688],"Osteoarthritis, Knee","Post-traumatic Osteoarthritis","ACL Tear",[2670],{"trials":2691,"activeCount":102},[],{"trials":2693,"activeCount":102},[2694],{"nctId":2695,"briefTitle":2696,"status":239,"phases":2697,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":2701,"interventions":2702},"NCT00366301","The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes",[93],"2009-04","2006-08",500,[1258],[2703,2704],"Insulin glargine","metformin",{"trials":2706,"activeCount":102},[2707],{"nctId":2708,"briefTitle":2709,"status":436,"phases":2710,"primaryCompletion":2711,"completion":2711,"start":2712,"enrollment":883,"conditions":2713,"interventions":2714},"NCT03627039","Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)",[],"2020-08-01","2018-09-01",[885],[2715,2670],"SGLT2",{"intervention":2717,"totalTrials":281,"cells":2718},"Xylitol",{"EARLY_PHASE1":2719,"PHASE1":2729,"PHASE2":2741,"PHASE3":2743,"PHASE4":2745,"NA":2747},{"trials":2720,"activeCount":265,"soonestReadout":604},[2721],{"nctId":2722,"briefTitle":2723,"status":307,"phases":2724,"primaryCompletion":604,"completion":2725,"start":2726,"enrollment":128,"conditions":2727,"interventions":2728},"NCT06799039","Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease",[89],"2031-09-01","2026-09-01",[609,610],[2717],{"trials":2730,"activeCount":265,"soonestReadout":2735},[2731],{"nctId":2732,"briefTitle":2733,"status":307,"phases":2734,"primaryCompletion":2735,"completion":2736,"start":1526,"enrollment":2737,"conditions":2738,"interventions":2740},"NCT05852587","Xylitol Use for Decolonization of C. Difficile in Patients With IBD",[90],"2032-01-01","2033-01-01",99,[2739,610],"Inflammatory Bowel Diseases",[2717],{"trials":2742,"activeCount":102},[],{"trials":2744,"activeCount":102},[],{"trials":2746,"activeCount":102},[],{"trials":2748,"activeCount":102},[],{"intervention":72,"totalTrials":281,"cells":2750},{"EARLY_PHASE1":2751,"PHASE1":2759,"PHASE2":2771,"PHASE3":2773,"PHASE4":2775,"NA":2777},{"trials":2752,"activeCount":265,"soonestReadout":71},[2753],{"nctId":69,"briefTitle":70,"status":174,"phases":2754,"primaryCompletion":71,"completion":1233,"start":2755,"enrollment":206,"conditions":2756,"interventions":2758},[89],"2020-02-26",[1126,2757],"Urothelial Carcinoma",[72],{"trials":2760,"activeCount":265,"soonestReadout":2726},[2761],{"nctId":2762,"briefTitle":2763,"status":162,"phases":2764,"primaryCompletion":2726,"completion":2765,"start":2766,"enrollment":678,"conditions":2767,"interventions":2770},"NCT06062745","Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET\u002FCT",[90],"2028-09-01","2024-02-01",[2768,817,2769],"Advanced Prostate Cancer","Metastatic Prostate Neuroendocrine Carcinoma",[72],{"trials":2772,"activeCount":102},[],{"trials":2774,"activeCount":102},[],{"trials":2776,"activeCount":102},[],{"trials":2778,"activeCount":102},[],{"intervention":2780,"totalTrials":281,"cells":2781},"Microdevice",{"EARLY_PHASE1":2782,"PHASE1":2784,"PHASE2":2813,"PHASE3":2815,"PHASE4":2817,"NA":2819},{"trials":2783,"activeCount":102},[],{"trials":2785,"activeCount":281,"soonestReadout":2801},[2786,2797],{"nctId":2787,"briefTitle":2788,"status":787,"phases":2789,"primaryCompletion":2790,"completion":2791,"start":2792,"enrollment":2793,"conditions":2794,"interventions":2796},"NCT04399876","Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer",[90],"2027-08-01","2027-11-01","2020-06-22",35,[747,2795],"Radical Prostatectomy",[2780],{"nctId":2798,"briefTitle":2799,"status":162,"phases":2800,"primaryCompletion":2801,"completion":2802,"start":2803,"enrollment":34,"conditions":2804,"interventions":2812},"NCT04701645","Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer",[90],"2027-06-05","2027-06-30","2022-11-01",[2805,2806,2807,2808,2809,2810,2811],"Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer","Ovarian Cancer Stage III","Ovarian Cancer Stage IV","Fallopian Tube Cancer Stage IV","Fallopian Tube Cancer Stage III",[2780],{"trials":2814,"activeCount":102},[],{"trials":2816,"activeCount":102},[],{"trials":2818,"activeCount":102},[],{"trials":2820,"activeCount":102},[],{"intervention":82,"totalTrials":265,"cells":2822},{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2833,"PHASE3":2835,"PHASE4":2837,"NA":2839},{"trials":2824,"activeCount":102},[],{"trials":2826,"activeCount":265,"soonestReadout":81},[2827],{"nctId":79,"briefTitle":80,"status":174,"phases":2828,"primaryCompletion":81,"completion":1288,"start":2829,"enrollment":678,"conditions":2830,"interventions":2831},[90],"2023-09-01",[1427],[82,2832],"CP-101 + Placebo",{"trials":2834,"activeCount":102},[],{"trials":2836,"activeCount":102},[],{"trials":2838,"activeCount":102},[],{"trials":2840,"activeCount":102},[],{"intervention":2832,"totalTrials":265,"cells":2842},{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2851,"PHASE3":2853,"PHASE4":2855,"NA":2857},{"trials":2844,"activeCount":102},[],{"trials":2846,"activeCount":265,"soonestReadout":81},[2847],{"nctId":79,"briefTitle":80,"status":174,"phases":2848,"primaryCompletion":81,"completion":1288,"start":2829,"enrollment":678,"conditions":2849,"interventions":2850},[90],[1427],[82,2832],{"trials":2852,"activeCount":102},[],{"trials":2854,"activeCount":102},[],{"trials":2856,"activeCount":102},[],{"trials":2858,"activeCount":102},[],{"intervention":2860,"totalTrials":265,"cells":2861},"sparsentan",{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2879,"PHASE3":2881,"PHASE4":2883,"NA":2885},{"trials":2863,"activeCount":102},[],{"trials":2865,"activeCount":265,"soonestReadout":744},[2866],{"nctId":2867,"briefTitle":2868,"status":307,"phases":2869,"primaryCompletion":744,"completion":2870,"start":2871,"enrollment":34,"conditions":2872,"interventions":2877},"NCT07224776","Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria",[90],"2028-12-01","2026-06-10",[2873,2874,2875,2876],"Proteinuric Renal Disease","Proteinuric Kidney Disease","Proteinuria","Proteinuria in Nephrotic Range",[2860,2878],"No sparsentan",{"trials":2880,"activeCount":102},[],{"trials":2882,"activeCount":102},[],{"trials":2884,"activeCount":102},[],{"trials":2886,"activeCount":102},[],{"intervention":2878,"totalTrials":265,"cells":2888},{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2897,"PHASE3":2899,"PHASE4":2901,"NA":2903},{"trials":2890,"activeCount":102},[],{"trials":2892,"activeCount":265,"soonestReadout":744},[2893],{"nctId":2867,"briefTitle":2868,"status":307,"phases":2894,"primaryCompletion":744,"completion":2870,"start":2871,"enrollment":34,"conditions":2895,"interventions":2896},[90],[2873,2874,2875,2876],[2860,2878],{"trials":2898,"activeCount":102},[],{"trials":2900,"activeCount":102},[],{"trials":2902,"activeCount":102},[],{"trials":2904,"activeCount":102},[],{"intervention":2906,"totalTrials":265,"cells":2907},"Ropeginterferon",{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2921,"PHASE3":2923,"PHASE4":2925,"NA":2927},{"trials":2909,"activeCount":102},[],{"trials":2911,"activeCount":265,"soonestReadout":2916},[2912],{"nctId":2913,"briefTitle":2914,"status":307,"phases":2915,"primaryCompletion":2916,"completion":2916,"start":177,"enrollment":2917,"conditions":2918,"interventions":2920},"NCT07249840","Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis",[90],"2030-06",12,[2919],"JAK2 Mutation",[2906],{"trials":2922,"activeCount":102},[],{"trials":2924,"activeCount":102},[],{"trials":2926,"activeCount":102},[],{"trials":2928,"activeCount":102},[],{"intervention":2930,"totalTrials":265,"cells":2931},"rifampicin",{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2944,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2933,"activeCount":102},[],{"trials":2935,"activeCount":265,"soonestReadout":1011},[2936],{"nctId":2937,"briefTitle":2938,"status":162,"phases":2939,"primaryCompletion":1011,"completion":1011,"start":1356,"enrollment":34,"conditions":2940,"interventions":2943},"NCT05069688","Dolutegravir Pharmacokinetics Among HIV\u002FTB Coinfected Children Receiving Standard and High-dose Rifampicin",[90],[2941,2942],"Pediatric HIV Infection","Tuberculosis Infection",[2930],{"trials":2945,"activeCount":102},[],{"trials":2947,"activeCount":102},[],{"trials":2949,"activeCount":102},[],{"trials":2951,"activeCount":102},[],{"intervention":2953,"totalTrials":265,"cells":2954},"Rifapentine",{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2971,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2956,"activeCount":102},[],{"trials":2958,"activeCount":265,"soonestReadout":2963},[2959],{"nctId":2960,"briefTitle":2961,"status":162,"phases":2962,"primaryCompletion":2963,"completion":2964,"start":2965,"enrollment":2966,"conditions":2967,"interventions":2969},"NCT06281834","Dolutegravir Pharmacokinetics During Weekly Rifapentine\u002FIsoniazid for TB Prevention",[90],"2027-02","2027-06","2024-11-15",25,[2941,2968],"Latent Tuberculosis",[2953,2970],"Dolutegravir",{"trials":2972,"activeCount":102},[],{"trials":2974,"activeCount":102},[],{"trials":2976,"activeCount":102},[],{"trials":2978,"activeCount":102},[],{"intervention":2970,"totalTrials":265,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2989,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2982,"activeCount":102},[],{"trials":2984,"activeCount":265,"soonestReadout":2963},[2985],{"nctId":2960,"briefTitle":2961,"status":162,"phases":2986,"primaryCompletion":2963,"completion":2964,"start":2965,"enrollment":2966,"conditions":2987,"interventions":2988},[90],[2941,2968],[2953,2970],{"trials":2990,"activeCount":102},[],{"trials":2992,"activeCount":102},[],{"trials":2994,"activeCount":102},[],{"trials":2996,"activeCount":102},[],{"intervention":2998,"totalTrials":1082,"cells":2999},"Para-aminohippuric Acid",{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3015,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":3001,"activeCount":102},[],{"trials":3003,"activeCount":265,"soonestReadout":3008},[3004],{"nctId":3005,"briefTitle":3006,"status":174,"phases":3007,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":429,"conditions":3010,"interventions":3012},"NCT01426529","Caveolin-1 and Vascular Dysfunction",[90],"2026-10-15","2010-10-01",[15,3011],"Insulin Resistance",[2998,3013,3014],"Angiotensin II","Norepinephrine",{"trials":3016,"activeCount":102},[],{"trials":3018,"activeCount":102},[],{"trials":3020,"activeCount":102},[],{"trials":3022,"activeCount":102},[3023,3029,3037],{"nctId":3024,"briefTitle":3025,"status":152,"phases":3026,"start":1069,"enrollment":102,"conditions":3027,"interventions":3028},"NCT01702688","Evaluation of Lysine-Specific Demethylase 1",[94],[15],[2998,3013],{"nctId":3030,"briefTitle":3031,"status":239,"phases":3032,"primaryCompletion":3033,"completion":3033,"start":3034,"enrollment":2055,"conditions":3035,"interventions":3036},"NCT01456208","Genetic Mechanisms in Human Hypertension",[],"2020-06","1999-10",[15],[2998,3013,3014],{"nctId":3038,"briefTitle":3039,"status":239,"phases":3040,"primaryCompletion":3041,"completion":3033,"start":3042,"enrollment":296,"conditions":3043,"interventions":3044},"NCT01511042","Vascular Dysfunction in Diabetes: Genes and Hormones",[],"2020-01","1999-12",[218],[2998,3013,3014],{"intervention":3013,"totalTrials":1082,"cells":3046},{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3055,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3048,"activeCount":102},[],{"trials":3050,"activeCount":265,"soonestReadout":3008},[3051],{"nctId":3005,"briefTitle":3006,"status":174,"phases":3052,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":429,"conditions":3053,"interventions":3054},[90],[15,3011],[2998,3013,3014],{"trials":3056,"activeCount":102},[],{"trials":3058,"activeCount":102},[],{"trials":3060,"activeCount":102},[],{"trials":3062,"activeCount":102},[3063,3067,3071],{"nctId":3024,"briefTitle":3025,"status":152,"phases":3064,"start":1069,"enrollment":102,"conditions":3065,"interventions":3066},[94],[15],[2998,3013],{"nctId":3030,"briefTitle":3031,"status":239,"phases":3068,"primaryCompletion":3033,"completion":3033,"start":3034,"enrollment":2055,"conditions":3069,"interventions":3070},[],[15],[2998,3013,3014],{"nctId":3038,"briefTitle":3039,"status":239,"phases":3072,"primaryCompletion":3041,"completion":3033,"start":3042,"enrollment":296,"conditions":3073,"interventions":3074},[],[218],[2998,3013,3014],{"intervention":3014,"totalTrials":197,"cells":3076},{"EARLY_PHASE1":3077,"PHASE1":3079,"PHASE2":3085,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3078,"activeCount":102},[],{"trials":3080,"activeCount":265,"soonestReadout":3008},[3081],{"nctId":3005,"briefTitle":3006,"status":174,"phases":3082,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":429,"conditions":3083,"interventions":3084},[90],[15,3011],[2998,3013,3014],{"trials":3086,"activeCount":102},[],{"trials":3088,"activeCount":102},[],{"trials":3090,"activeCount":102},[],{"trials":3092,"activeCount":102},[3093,3097],{"nctId":3030,"briefTitle":3031,"status":239,"phases":3094,"primaryCompletion":3033,"completion":3033,"start":3034,"enrollment":2055,"conditions":3095,"interventions":3096},[],[15],[2998,3013,3014],{"nctId":3038,"briefTitle":3039,"status":239,"phases":3098,"primaryCompletion":3041,"completion":3033,"start":3042,"enrollment":296,"conditions":3099,"interventions":3100},[],[218],[2998,3013,3014],{"intervention":3102,"totalTrials":281,"cells":3103},"Cisplatin",{"EARLY_PHASE1":3104,"PHASE1":3134,"PHASE2":3148,"PHASE3":3150,"PHASE4":3152,"NA":3154},{"trials":3105,"activeCount":265,"soonestReadout":2106},[3106],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3109,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3112,"interventions":3114},"NCT06204614","Drug Screening Using IMD in Bladder Cancer",[89],"2028-08-01","2024-06-14",[3113],"Muscle Invasive Bladder Urothelial Carcinoma",[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],"Methotrexate","Carboplatin","Avelumab","Paclitaxel","Vinblastine","Gemcitabine\u002FCisplatin I","Methotrexate\u002FVinblastine\u002FDoxorubicin\u002FCisplatin\u002FAvelumab","Gemcitabine\u002FCisplatin II","Nivolumab","Pembrolizumab","Gemcitabine\u002FCarboplatin","Methotrexate\u002FVinblastine\u002FDoxorubicin\u002FCisplatin","Gemcitabine\u002FCisplatin\u002FNivolumab","Erdafitinib","Paclitaxel\u002FDocetaxel\u002FIfosfamide","Gemcitabine","Gemcitabine\u002FCarboplatin\u002FNivolumab","Enfortumab","Sacituzumab",{"trials":3135,"activeCount":102},[3136],{"nctId":3137,"briefTitle":3138,"status":108,"phases":3139,"primaryCompletion":1079,"completion":3140,"start":1505,"enrollment":3141,"conditions":3142,"interventions":3144},"NCT00571298","Extrapleural Pneumonectomy \u002FPleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma",[90],"2015-06",141,[3143],"Malignant Pleural Mesothelioma",[3102,3145,3146,3147],"gemcitabine","amifostine","sodium thiosulfate",{"trials":3149,"activeCount":102},[],{"trials":3151,"activeCount":102},[],{"trials":3153,"activeCount":102},[],{"trials":3155,"activeCount":102},[],{"intervention":3145,"totalTrials":281,"cells":3157},{"EARLY_PHASE1":3158,"PHASE1":3164,"PHASE2":3170,"PHASE3":3172,"PHASE4":3174,"NA":3176},{"trials":3159,"activeCount":265,"soonestReadout":2106},[3160],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3161,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3162,"interventions":3163},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3165,"activeCount":102},[3166],{"nctId":3137,"briefTitle":3138,"status":108,"phases":3167,"primaryCompletion":1079,"completion":3140,"start":1505,"enrollment":3141,"conditions":3168,"interventions":3169},[90],[3143],[3102,3145,3146,3147],{"trials":3171,"activeCount":102},[],{"trials":3173,"activeCount":102},[],{"trials":3175,"activeCount":102},[],{"trials":3177,"activeCount":102},[],{"intervention":3179,"totalTrials":265,"cells":3180},"Cenobamate",{"EARLY_PHASE1":3181,"PHASE1":3193,"PHASE2":3195,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3182,"activeCount":265,"soonestReadout":3187},[3183],{"nctId":3184,"briefTitle":3185,"status":307,"phases":3186,"primaryCompletion":3187,"completion":3188,"start":177,"enrollment":98,"conditions":3189,"interventions":3192},"NCT06352723","Cenobamate in the Intensive Care Unit",[89],"2028-06","2029-06",[3190,3191],"Epilepsy","Neurologic Disorder",[3179],{"trials":3194,"activeCount":102},[],{"trials":3196,"activeCount":102},[],{"trials":3198,"activeCount":102},[],{"trials":3200,"activeCount":102},[],{"trials":3202,"activeCount":102},[],{"intervention":3204,"totalTrials":265,"cells":3205},"Implantable Microdevice",{"EARLY_PHASE1":3206,"PHASE1":3221,"PHASE2":3223,"PHASE3":3225,"PHASE4":3227,"NA":3229},{"trials":3207,"activeCount":265,"soonestReadout":3212},[3208],{"nctId":3209,"briefTitle":3210,"status":162,"phases":3211,"primaryCompletion":3212,"completion":3213,"start":3214,"enrollment":678,"conditions":3215,"interventions":3220},"NCT05553782","Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers",[89],"2029-04-01","2029-08-01","2023-11-01",[3216,3217,3218,3219],"Salivary Gland Cancer","Adenoid Cystic Carcinoma of the Salivary Gland","Squamous Cell Carcinoma of Head and Neck","Head and Neck Cancer",[3204],{"trials":3222,"activeCount":102},[],{"trials":3224,"activeCount":102},[],{"trials":3226,"activeCount":102},[],{"trials":3228,"activeCount":102},[],{"trials":3230,"activeCount":102},[],{"intervention":3232,"totalTrials":265,"cells":3233},"Morphine p.o.",{"EARLY_PHASE1":3234,"PHASE1":3245,"PHASE2":3247,"PHASE3":3249,"PHASE4":3251,"NA":3253},{"trials":3235,"activeCount":265,"soonestReadout":2310},[3236],{"nctId":3237,"briefTitle":3238,"status":307,"phases":3239,"primaryCompletion":2310,"completion":3240,"start":1233,"enrollment":28,"conditions":3241,"interventions":3244},"NCT06854211","Impacts of Opioids on Respiratory Drive During Sleep",[89],"2027-01-31",[3242,3243],"Opioids","Obstructive Sleep Apnea (OSA)",[3232],{"trials":3246,"activeCount":102},[],{"trials":3248,"activeCount":102},[],{"trials":3250,"activeCount":102},[],{"trials":3252,"activeCount":102},[],{"trials":3254,"activeCount":102},[],{"intervention":3116,"totalTrials":265,"cells":3256},{"EARLY_PHASE1":3257,"PHASE1":3263,"PHASE2":3265,"PHASE3":3267,"PHASE4":3269,"NA":3271},{"trials":3258,"activeCount":265,"soonestReadout":2106},[3259],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3260,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3261,"interventions":3262},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3264,"activeCount":102},[],{"trials":3266,"activeCount":102},[],{"trials":3268,"activeCount":102},[],{"trials":3270,"activeCount":102},[],{"trials":3272,"activeCount":102},[],{"intervention":3117,"totalTrials":265,"cells":3274},{"EARLY_PHASE1":3275,"PHASE1":3281,"PHASE2":3283,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3276,"activeCount":265,"soonestReadout":2106},[3277],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3278,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3279,"interventions":3280},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3282,"activeCount":102},[],{"trials":3284,"activeCount":102},[],{"trials":3286,"activeCount":102},[],{"trials":3288,"activeCount":102},[],{"trials":3290,"activeCount":102},[],{"intervention":3118,"totalTrials":265,"cells":3292},{"EARLY_PHASE1":3293,"PHASE1":3299,"PHASE2":3301,"PHASE3":3303,"PHASE4":3305,"NA":3307},{"trials":3294,"activeCount":265,"soonestReadout":2106},[3295],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3296,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3297,"interventions":3298},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3300,"activeCount":102},[],{"trials":3302,"activeCount":102},[],{"trials":3304,"activeCount":102},[],{"trials":3306,"activeCount":102},[],{"trials":3308,"activeCount":102},[],{"intervention":3119,"totalTrials":265,"cells":3310},{"EARLY_PHASE1":3311,"PHASE1":3317,"PHASE2":3319,"PHASE3":3321,"PHASE4":3323,"NA":3325},{"trials":3312,"activeCount":265,"soonestReadout":2106},[3313],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3314,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3315,"interventions":3316},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3318,"activeCount":102},[],{"trials":3320,"activeCount":102},[],{"trials":3322,"activeCount":102},[],{"trials":3324,"activeCount":102},[],{"trials":3326,"activeCount":102},[],{"intervention":3120,"totalTrials":265,"cells":3328},{"EARLY_PHASE1":3329,"PHASE1":3335,"PHASE2":3337,"PHASE3":3339,"PHASE4":3341,"NA":3343},{"trials":3330,"activeCount":265,"soonestReadout":2106},[3331],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3332,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3333,"interventions":3334},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3336,"activeCount":102},[],{"trials":3338,"activeCount":102},[],{"trials":3340,"activeCount":102},[],{"trials":3342,"activeCount":102},[],{"trials":3344,"activeCount":102},[],{"intervention":3121,"totalTrials":265,"cells":3346},{"EARLY_PHASE1":3347,"PHASE1":3353,"PHASE2":3355,"PHASE3":3357,"PHASE4":3359,"NA":3361},{"trials":3348,"activeCount":265,"soonestReadout":2106},[3349],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3350,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3351,"interventions":3352},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3354,"activeCount":102},[],{"trials":3356,"activeCount":102},[],{"trials":3358,"activeCount":102},[],{"trials":3360,"activeCount":102},[],{"trials":3362,"activeCount":102},[],{"intervention":3122,"totalTrials":265,"cells":3364},{"EARLY_PHASE1":3365,"PHASE1":3371,"PHASE2":3373,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3366,"activeCount":265,"soonestReadout":2106},[3367],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3368,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3369,"interventions":3370},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3372,"activeCount":102},[],{"trials":3374,"activeCount":102},[],{"trials":3376,"activeCount":102},[],{"trials":3378,"activeCount":102},[],{"trials":3380,"activeCount":102},[],{"intervention":3123,"totalTrials":265,"cells":3382},{"EARLY_PHASE1":3383,"PHASE1":3389,"PHASE2":3391,"PHASE3":3393,"PHASE4":3395,"NA":3397},{"trials":3384,"activeCount":265,"soonestReadout":2106},[3385],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3386,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3387,"interventions":3388},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3390,"activeCount":102},[],{"trials":3392,"activeCount":102},[],{"trials":3394,"activeCount":102},[],{"trials":3396,"activeCount":102},[],{"trials":3398,"activeCount":102},[],{"intervention":3124,"totalTrials":265,"cells":3400},{"EARLY_PHASE1":3401,"PHASE1":3407,"PHASE2":3409,"PHASE3":3411,"PHASE4":3413,"NA":3415},{"trials":3402,"activeCount":265,"soonestReadout":2106},[3403],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3404,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3405,"interventions":3406},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3408,"activeCount":102},[],{"trials":3410,"activeCount":102},[],{"trials":3412,"activeCount":102},[],{"trials":3414,"activeCount":102},[],{"trials":3416,"activeCount":102},[],{"intervention":3125,"totalTrials":265,"cells":3418},{"EARLY_PHASE1":3419,"PHASE1":3425,"PHASE2":3427,"PHASE3":3429,"PHASE4":3431,"NA":3433},{"trials":3420,"activeCount":265,"soonestReadout":2106},[3421],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3422,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3423,"interventions":3424},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3426,"activeCount":102},[],{"trials":3428,"activeCount":102},[],{"trials":3430,"activeCount":102},[],{"trials":3432,"activeCount":102},[],{"trials":3434,"activeCount":102},[],{"intervention":3126,"totalTrials":265,"cells":3436},{"EARLY_PHASE1":3437,"PHASE1":3443,"PHASE2":3445,"PHASE3":3447,"PHASE4":3449,"NA":3451},{"trials":3438,"activeCount":265,"soonestReadout":2106},[3439],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3440,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3441,"interventions":3442},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3444,"activeCount":102},[],{"trials":3446,"activeCount":102},[],{"trials":3448,"activeCount":102},[],{"trials":3450,"activeCount":102},[],{"trials":3452,"activeCount":102},[],{"intervention":3127,"totalTrials":265,"cells":3454},{"EARLY_PHASE1":3455,"PHASE1":3461,"PHASE2":3463,"PHASE3":3465,"PHASE4":3467,"NA":3469},{"trials":3456,"activeCount":265,"soonestReadout":2106},[3457],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3458,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3459,"interventions":3460},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3462,"activeCount":102},[],{"trials":3464,"activeCount":102},[],{"trials":3466,"activeCount":102},[],{"trials":3468,"activeCount":102},[],{"trials":3470,"activeCount":102},[],{"intervention":3128,"totalTrials":265,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3479,"PHASE2":3481,"PHASE3":3483,"PHASE4":3485,"NA":3487},{"trials":3474,"activeCount":265,"soonestReadout":2106},[3475],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3476,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3477,"interventions":3478},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3480,"activeCount":102},[],{"trials":3482,"activeCount":102},[],{"trials":3484,"activeCount":102},[],{"trials":3486,"activeCount":102},[],{"trials":3488,"activeCount":102},[],{"intervention":3129,"totalTrials":265,"cells":3490},{"EARLY_PHASE1":3491,"PHASE1":3497,"PHASE2":3499,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3492,"activeCount":265,"soonestReadout":2106},[3493],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3494,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3495,"interventions":3496},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3498,"activeCount":102},[],{"trials":3500,"activeCount":102},[],{"trials":3502,"activeCount":102},[],{"trials":3504,"activeCount":102},[],{"trials":3506,"activeCount":102},[],{"intervention":3131,"totalTrials":265,"cells":3508},{"EARLY_PHASE1":3509,"PHASE1":3515,"PHASE2":3517,"PHASE3":3519,"PHASE4":3521,"NA":3523},{"trials":3510,"activeCount":265,"soonestReadout":2106},[3511],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3512,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3513,"interventions":3514},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3516,"activeCount":102},[],{"trials":3518,"activeCount":102},[],{"trials":3520,"activeCount":102},[],{"trials":3522,"activeCount":102},[],{"trials":3524,"activeCount":102},[],{"intervention":3132,"totalTrials":265,"cells":3526},{"EARLY_PHASE1":3527,"PHASE1":3533,"PHASE2":3535,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3528,"activeCount":265,"soonestReadout":2106},[3529],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3530,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3531,"interventions":3532},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":102},[],{"trials":3538,"activeCount":102},[],{"trials":3540,"activeCount":102},[],{"trials":3542,"activeCount":102},[],{"intervention":3133,"totalTrials":265,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3551,"PHASE2":3553,"PHASE3":3555,"PHASE4":3557,"NA":3559},{"trials":3546,"activeCount":265,"soonestReadout":2106},[3547],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3548,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3549,"interventions":3550},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3552,"activeCount":102},[],{"trials":3554,"activeCount":102},[],{"trials":3556,"activeCount":102},[],{"trials":3558,"activeCount":102},[],{"trials":3560,"activeCount":102},[],{"intervention":3562,"totalTrials":265,"cells":3563},"[F-18]SDM-8",{"EARLY_PHASE1":3564,"PHASE1":3572,"PHASE2":3574,"PHASE3":3576,"PHASE4":3578,"NA":3580},{"trials":3565,"activeCount":265,"soonestReadout":1037},[3566],{"nctId":3567,"briefTitle":3568,"status":162,"phases":3569,"primaryCompletion":1037,"completion":1037,"start":519,"enrollment":678,"conditions":3570,"interventions":3571},"NCT04634994","Assessment of Synaptic Density in MS",[89],[723],[3562],{"trials":3573,"activeCount":102},[],{"trials":3575,"activeCount":102},[],{"trials":3577,"activeCount":102},[],{"trials":3579,"activeCount":102},[],{"trials":3581,"activeCount":102},[],{"intervention":3115,"totalTrials":1082,"cells":3583},{"EARLY_PHASE1":3584,"PHASE1":3590,"PHASE2":3592,"PHASE3":3594,"PHASE4":3605,"NA":3621},{"trials":3585,"activeCount":265,"soonestReadout":2106},[3586],{"nctId":3107,"briefTitle":3108,"status":787,"phases":3587,"primaryCompletion":2106,"completion":3110,"start":3111,"enrollment":1774,"conditions":3588,"interventions":3589},[89],[3113],[3115,3116,3117,3118,3119,3120,3121,3122,3102,3123,3124,3125,3126,3127,3128,3129,3130,3131,3132,3133],{"trials":3591,"activeCount":102},[],{"trials":3593,"activeCount":102},[],{"trials":3595,"activeCount":102},[3596],{"nctId":3597,"briefTitle":3598,"status":108,"phases":3599,"primaryCompletion":1727,"completion":3600,"start":3601,"enrollment":3602,"conditions":3603,"interventions":3604},"NCT01594333","Cardiovascular Inflammation Reduction Trial",[92],"2019-10-30","2013-04",4786,[958],[3115],{"trials":3606,"activeCount":102},[3607],{"nctId":3608,"briefTitle":3609,"status":108,"phases":3610,"primaryCompletion":3611,"completion":3611,"start":3612,"enrollment":3613,"conditions":3614,"interventions":3616},"NCT02374021","Treatments Against RA and Effect on FDG-PET\u002FCT",[93],"2021-05","2016-07",159,[3615],"Arthritis, Rheumatoid",[3115,3617,3618,3619,3620],"Sulfasalazine","Hydroxychloroquine","Etanercept","Adalimumab",{"trials":3622,"activeCount":102},[3623],{"nctId":3624,"briefTitle":3625,"status":108,"phases":3626,"primaryCompletion":3627,"completion":3627,"start":3628,"enrollment":3629,"conditions":3630,"interventions":3632},"NCT04691505","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine",[],"2021-08-31","2020-12-23",133553,[3631],"Rheumatoid Arthritis",[3115,3618],{"intervention":1283,"totalTrials":98,"cells":3634},{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3639,"PHASE3":3641,"PHASE4":3643,"NA":3645},{"trials":3636,"activeCount":102},[],{"trials":3638,"activeCount":102},[],{"trials":3640,"activeCount":102},[],{"trials":3642,"activeCount":102},[],{"trials":3644,"activeCount":102},[],{"trials":3646,"activeCount":3730,"soonestReadout":3721},[3647,3657,3666,3674,3685,3689,3700,3707,3717,3726],{"nctId":3648,"briefTitle":3649,"status":108,"phases":3650,"primaryCompletion":3651,"completion":3651,"start":3652,"enrollment":3653,"conditions":3654,"interventions":3655},"NCT06659718","Emulation of the SOUL Diabetes Trial in Healthcare Claims",[],"2025-02-13","2024-10-24",43650,[885],[3656,1283],"Oral semaglutide",{"nctId":3658,"briefTitle":3659,"status":174,"phases":3660,"primaryCompletion":3661,"completion":3661,"start":3662,"enrollment":3663,"conditions":3664,"interventions":3665},"NCT07390110","Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)",[],"2026-05-30","2026-01-24",25664,[1258,24],[3656,1283],{"nctId":3667,"briefTitle":3668,"status":108,"phases":3669,"primaryCompletion":401,"completion":401,"start":2712,"enrollment":3670,"conditions":3671,"interventions":3672},"NCT05099198","Replication of the GRADE Diabetes Trial in Healthcare Claims Data",[],6403,[27],[1283,3673],"Glimepiride",{"nctId":3675,"briefTitle":3676,"status":174,"phases":3677,"primaryCompletion":1297,"completion":1297,"start":3678,"enrollment":3679,"conditions":3680,"interventions":3683},"NCT07599345","Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data",[],"2024-10-13",23955,[3681,3682],"Heart Failure With Reduced Ejection Fraction","Chronic Heart Failure",[3684,1283],"Empagliflozin",{"nctId":1274,"briefTitle":1275,"status":108,"phases":3686,"primaryCompletion":1277,"completion":1277,"start":438,"enrollment":1278,"conditions":3687,"interventions":3688},[],[1258,1280,1260],[1220,1262,1282,1283],{"nctId":3690,"briefTitle":3691,"status":108,"phases":3692,"primaryCompletion":3693,"completion":3693,"start":3694,"enrollment":3695,"conditions":3696,"interventions":3698},"NCT04882813","Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data",[],"2021-06-11","2020-12-13",87727,[3697],"Chronic Kidney Disease",[3699,1283],"Dapagliflozin",{"nctId":3701,"briefTitle":3702,"status":174,"phases":3703,"primaryCompletion":1297,"completion":1297,"start":3678,"enrollment":3704,"conditions":3705,"interventions":3706},"NCT07599293","Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data",[],39614,[313,3682,1368],[3684,1283],{"nctId":3708,"briefTitle":3709,"status":108,"phases":3710,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3713,"conditions":3714,"interventions":3715},"NCT03936062","Replication of the TECOS Diabetes Trial in Healthcare Claims",[],"2021-02-18","2017-09-22",349476,[27],[1283,3716],"Sulfonylurea",{"nctId":3718,"briefTitle":3719,"status":174,"phases":3720,"primaryCompletion":3721,"completion":3721,"start":3722,"enrollment":3723,"conditions":3724,"interventions":3725},"NCT07417631","Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.",[],"2026-03","2026-02-03",30000,[1258],[1262,1283],{"nctId":1313,"briefTitle":1314,"status":174,"phases":3727,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":3728,"interventions":3729},[],[1258,1280,390],[1262,1282,1220,1283],5,{"intervention":1262,"totalTrials":1234,"cells":3732},{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3734,"activeCount":102},[],{"trials":3736,"activeCount":102},[],{"trials":3738,"activeCount":102},[],{"trials":3740,"activeCount":102},[],{"trials":3742,"activeCount":102},[],{"trials":3744,"activeCount":197,"soonestReadout":3721},[3745,3749,3753,3757,3761,3765],{"nctId":1252,"briefTitle":1253,"status":108,"phases":3746,"primaryCompletion":1255,"completion":1255,"start":438,"enrollment":1256,"conditions":3747,"interventions":3748},[],[1258,1259,1260],[1220,1262],{"nctId":1362,"briefTitle":1363,"status":174,"phases":3750,"primaryCompletion":1297,"completion":1297,"start":1365,"enrollment":1366,"conditions":3751,"interventions":3752},[],[1368,21,1280],[1282,1262],{"nctId":1274,"briefTitle":1275,"status":108,"phases":3754,"primaryCompletion":1277,"completion":1277,"start":438,"enrollment":1278,"conditions":3755,"interventions":3756},[],[1258,1280,1260],[1220,1262,1282,1283],{"nctId":1285,"briefTitle":1286,"status":108,"phases":3758,"primaryCompletion":1288,"completion":1098,"start":1289,"enrollment":1290,"conditions":3759,"interventions":3760},[],[1258],[1220,1262,1282],{"nctId":3718,"briefTitle":3719,"status":174,"phases":3762,"primaryCompletion":3721,"completion":3721,"start":3722,"enrollment":3723,"conditions":3763,"interventions":3764},[],[1258],[1262,1283],{"nctId":1313,"briefTitle":1314,"status":174,"phases":3766,"primaryCompletion":1316,"completion":1316,"start":1317,"enrollment":1318,"conditions":3767,"interventions":3768},[],[1258,1280,390],[1262,1282,1220,1283],{"intervention":3684,"totalTrials":197,"cells":3770},{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3775,"PHASE3":3777,"PHASE4":3779,"NA":3781},{"trials":3772,"activeCount":102},[],{"trials":3774,"activeCount":102},[],{"trials":3776,"activeCount":102},[],{"trials":3778,"activeCount":102},[],{"trials":3780,"activeCount":102},[],{"trials":3782,"activeCount":281,"soonestReadout":1297},[3783,3787,3795],{"nctId":3675,"briefTitle":3676,"status":174,"phases":3784,"primaryCompletion":1297,"completion":1297,"start":3678,"enrollment":3679,"conditions":3785,"interventions":3786},[],[3681,3682],[3684,1283],{"nctId":3788,"briefTitle":3789,"status":108,"phases":3790,"primaryCompletion":3711,"completion":3711,"start":3791,"enrollment":3792,"conditions":3793,"interventions":3794},"NCT04215536","Replication of the EMPAREG Diabetes Trial in Healthcare Claims",[],"2019-07-08",103752,[27],[3684,408],{"nctId":3701,"briefTitle":3702,"status":174,"phases":3796,"primaryCompletion":1297,"completion":1297,"start":3678,"enrollment":3704,"conditions":3797,"interventions":3798},[],[313,3682,1368],[3684,1283],{"intervention":3800,"totalTrials":3801,"cells":3802},"Rivaroxaban",8,{"EARLY_PHASE1":3803,"PHASE1":3805,"PHASE2":3807,"PHASE3":3809,"PHASE4":3811,"NA":3813},{"trials":3804,"activeCount":102},[],{"trials":3806,"activeCount":102},[],{"trials":3808,"activeCount":102},[],{"trials":3810,"activeCount":102},[],{"trials":3812,"activeCount":102},[],{"trials":3814,"activeCount":265,"soonestReadout":1297},[3815,3824,3832,3841,3855,3864,3873,3882],{"nctId":3816,"briefTitle":3817,"status":108,"phases":3818,"primaryCompletion":3711,"completion":3711,"start":913,"enrollment":3819,"conditions":3820,"interventions":3822},"NCT04593056","Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data",[],102636,[3821],"Atrial Fibrillation",[3823,3800],"Warfarin",{"nctId":3825,"briefTitle":3826,"status":108,"phases":3827,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":3829,"conditions":3830,"interventions":3831},"NCT04736420","Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data",[],"2020-09-22",78605,[485],[3800,3823],{"nctId":3833,"briefTitle":3834,"status":174,"phases":3835,"primaryCompletion":1297,"completion":1297,"start":3678,"enrollment":3836,"conditions":3837,"interventions":3839},"NCT07599384","Emulation of the RECORD3 Trial Using Healthcare Claims Data",[],149248,[3838],"Deep Vein Thrombosis, Pulmonary Embolus",[3800,3840],"Enoxaparin",{"nctId":3842,"briefTitle":3843,"status":436,"phases":3844,"primaryCompletion":2208,"completion":2208,"start":3845,"enrollment":3846,"conditions":3847,"interventions":3851},"NCT04878497","Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty",[],"2021-03-30",1000000,[3821,3848,3849,3850],"Frailty","Anticoagulant-induced Bleeding","Stroke",[3823,3852,3800,3853,3854],"Dabigatran","Apixaban","Edoxaban",{"nctId":3856,"briefTitle":3857,"status":108,"phases":3858,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":3861,"conditions":3862,"interventions":3863},"NCT05256797","Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data",[],"2022-06-15","2021-05-03",353980,[3821],[3800,3853],{"nctId":3865,"briefTitle":3866,"status":108,"phases":3867,"primaryCompletion":3693,"completion":3693,"start":3868,"enrollment":3869,"conditions":3870,"interventions":3872},"NCT04879407","Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data",[],"2020-10-10",98947,[3871],"Pulmonary Embolism",[3800,3823],{"nctId":3874,"briefTitle":3875,"status":108,"phases":3876,"primaryCompletion":3877,"completion":3878,"start":3828,"enrollment":3879,"conditions":3880,"interventions":3881},"NCT05083455","Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data",[],"2021-07-21","2021-07-22",89215,[3838],[3800,3840],{"nctId":3883,"briefTitle":3884,"status":108,"phases":3885,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":3886,"conditions":3887,"interventions":3889},"NCT05264168","Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data",[],41875,[485,3871,3888],"DVT",[3800,3853],{"intervention":408,"totalTrials":1234,"cells":3891},{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3896,"PHASE3":3898,"PHASE4":3900,"NA":3902},{"trials":3893,"activeCount":102},[],{"trials":3895,"activeCount":102},[],{"trials":3897,"activeCount":102},[],{"trials":3899,"activeCount":102},[],{"trials":3901,"activeCount":102},[],{"trials":3903,"activeCount":265,"soonestReadout":399},[3904,3911,3919,3923,3927,3931],{"nctId":3905,"briefTitle":3906,"status":108,"phases":3907,"primaryCompletion":3711,"completion":3711,"start":3791,"enrollment":3908,"conditions":3909,"interventions":3910},"NCT04215523","Replication of the DECLARE Diabetes Trial in Healthcare Claims",[],49790,[27],[3699,408],{"nctId":3912,"briefTitle":3913,"status":108,"phases":3914,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3915,"conditions":3916,"interventions":3917},"NCT03936010","Replication of the CANVAS Diabetes Trial in Healthcare Claims",[],152202,[27],[3918,408],"Canagliflozin",{"nctId":1353,"briefTitle":1354,"status":108,"phases":3920,"primaryCompletion":1356,"completion":1357,"start":46,"enrollment":1358,"conditions":3921,"interventions":3922},[],[27],[1282,408],{"nctId":396,"briefTitle":397,"status":174,"phases":3924,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":3925,"interventions":3926},[],[404,405,406],[369,408,409,410],{"nctId":3788,"briefTitle":3789,"status":108,"phases":3928,"primaryCompletion":3711,"completion":3711,"start":3791,"enrollment":3792,"conditions":3929,"interventions":3930},[],[27],[3684,408],{"nctId":3932,"briefTitle":3933,"status":108,"phases":3934,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3935,"conditions":3936,"interventions":3937},"NCT03936049","Replication of the LEADER Diabetes Trial in Healthcare Claims",[],168690,[27],[3938,408],"Liraglutide",{"intervention":1053,"totalTrials":1082,"cells":3940},{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3945,"PHASE3":3947,"PHASE4":3958,"NA":3960},{"trials":3942,"activeCount":102},[],{"trials":3944,"activeCount":102},[],{"trials":3946,"activeCount":102},[],{"trials":3948,"activeCount":102},[3949],{"nctId":3950,"briefTitle":3951,"status":108,"phases":3952,"primaryCompletion":3953,"completion":3953,"start":1079,"enrollment":3954,"conditions":3955,"interventions":3956},"NCT01633177","Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes",[92],"2024-05-30",22220,[1258],[3957,1053],"Omega-3 fatty acid",{"trials":3959,"activeCount":102},[],{"trials":3961,"activeCount":265,"soonestReadout":1078},[3962,3973,3977],{"nctId":3963,"briefTitle":3964,"status":108,"phases":3965,"primaryCompletion":3966,"completion":3966,"start":3967,"enrollment":3968,"conditions":3969,"interventions":3971},"NCT04070833","Effects of Vitamin D and Omega-3 on Cerebrovascular Disease",[94],"2018-09-17","2016-08-01",290,[3850,3970],"Vitamin D",[3972,1053],"Fish oil",{"nctId":1044,"briefTitle":1045,"status":436,"phases":3974,"primaryCompletion":1047,"completion":1048,"start":955,"enrollment":1049,"conditions":3975,"interventions":3976},[94],[1051],[52,1053],{"nctId":1075,"briefTitle":1076,"status":174,"phases":3978,"primaryCompletion":1078,"completion":177,"start":1079,"enrollment":1049,"conditions":3979,"interventions":3980},[94],[15],[52,1053],{"intervention":3840,"totalTrials":197,"cells":3982},{"EARLY_PHASE1":3983,"PHASE1":3985,"PHASE2":3987,"PHASE3":3989,"PHASE4":3991,"NA":3993},{"trials":3984,"activeCount":102},[],{"trials":3986,"activeCount":102},[],{"trials":3988,"activeCount":102},[],{"trials":3990,"activeCount":102},[],{"trials":3992,"activeCount":102},[],{"trials":3994,"activeCount":265,"soonestReadout":1297},[3995,3999,4009],{"nctId":3833,"briefTitle":3834,"status":174,"phases":3996,"primaryCompletion":1297,"completion":1297,"start":3678,"enrollment":3836,"conditions":3997,"interventions":3998},[],[3838],[3800,3840],{"nctId":4000,"briefTitle":4001,"status":108,"phases":4002,"primaryCompletion":4003,"completion":4004,"start":4005,"enrollment":167,"conditions":4006,"interventions":4008},"NCT00413374","Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and\u002For Pulmonary Embolism",[94],"2008-04","2008-12","2006-05",[4007,3871],"Deep Vein Thrombosis",[3840],{"nctId":3874,"briefTitle":3875,"status":108,"phases":4010,"primaryCompletion":3877,"completion":3878,"start":3828,"enrollment":3879,"conditions":4011,"interventions":4012},[],[3838],[3800,3840],{"intervention":4014,"totalTrials":281,"cells":4015},"Daratumumab",{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4022,"PHASE4":4024,"NA":4026},{"trials":4017,"activeCount":102},[],{"trials":4019,"activeCount":102},[],{"trials":4021,"activeCount":102},[],{"trials":4023,"activeCount":102},[],{"trials":4025,"activeCount":102},[],{"trials":4027,"activeCount":265,"soonestReadout":1297},[4028,4037],{"nctId":4029,"briefTitle":4030,"status":162,"phases":4031,"primaryCompletion":1297,"completion":1297,"start":1122,"enrollment":4032,"conditions":4033,"interventions":4036},"NCT06483139","Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy",[],450,[4034,4035,1530],"Multiple Myeloma","Light Chain Nephropathy",[4014],{"nctId":4038,"briefTitle":4039,"status":108,"phases":4040,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":34,"conditions":4043,"interventions":4044},"NCT06549634","Biomarkers of AKI in Patients Receiving Daratumumab",[],"2026-01-15","2024-09-01",[1530,4034,4035],[4014],{"intervention":3656,"totalTrials":281,"cells":4046},{"EARLY_PHASE1":4047,"PHASE1":4049,"PHASE2":4051,"PHASE3":4053,"PHASE4":4055,"NA":4057},{"trials":4048,"activeCount":102},[],{"trials":4050,"activeCount":102},[],{"trials":4052,"activeCount":102},[],{"trials":4054,"activeCount":102},[],{"trials":4056,"activeCount":102},[],{"trials":4058,"activeCount":265,"soonestReadout":3661},[4059,4063],{"nctId":3648,"briefTitle":3649,"status":108,"phases":4060,"primaryCompletion":3651,"completion":3651,"start":3652,"enrollment":3653,"conditions":4061,"interventions":4062},[],[885],[3656,1283],{"nctId":3658,"briefTitle":3659,"status":174,"phases":4064,"primaryCompletion":3661,"completion":3661,"start":3662,"enrollment":3663,"conditions":4065,"interventions":4066},[],[1258,24],[3656,1283],{"intervention":4068,"totalTrials":265,"cells":4069},"Dialysate bicarbonate concentration",{"EARLY_PHASE1":4070,"PHASE1":4072,"PHASE2":4074,"PHASE3":4076,"PHASE4":4078,"NA":4080},{"trials":4071,"activeCount":102},[],{"trials":4073,"activeCount":102},[],{"trials":4075,"activeCount":102},[],{"trials":4077,"activeCount":102},[],{"trials":4079,"activeCount":102},[],{"trials":4081,"activeCount":265,"soonestReadout":2726},[4082],{"nctId":4083,"briefTitle":4084,"status":162,"phases":4085,"primaryCompletion":2726,"completion":1307,"start":4086,"enrollment":3141,"conditions":4087,"interventions":4093},"NCT05814146","Trial of Variable Dialysate Bicarbonate",[94],"2023-08-24",[4088,4089,4090,4091,4092],"Peri-dialytic Cardiac Rhythms","Intradialytic Hypotension","Electrolyte Changes","pH Changes","Adverse Symptoms",[4068],{"intervention":4095,"totalTrials":265,"cells":4096},"Gadavist",{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4101,"PHASE3":4103,"PHASE4":4105,"NA":4107},{"trials":4098,"activeCount":102},[],{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[],{"trials":4104,"activeCount":102},[],{"trials":4106,"activeCount":102},[],{"trials":4108,"activeCount":265,"soonestReadout":4113},[4109],{"nctId":4110,"briefTitle":4111,"status":162,"phases":4112,"primaryCompletion":4113,"completion":4114,"start":4115,"enrollment":349,"conditions":4116,"interventions":4120},"NCT06854458","The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study",[94],"2029-01","2029-03","2025-06-27",[4117,4118,4119],"Ischemic Heart Disease (IHD)","Cardiac Magnetic Resonance Imaging","Myocardial Blood Flow",[4095,4121],"Vasodilator",{"intervention":4121,"totalTrials":265,"cells":4123},{"EARLY_PHASE1":4124,"PHASE1":4126,"PHASE2":4128,"PHASE3":4130,"PHASE4":4132,"NA":4134},{"trials":4125,"activeCount":102},[],{"trials":4127,"activeCount":102},[],{"trials":4129,"activeCount":102},[],{"trials":4131,"activeCount":102},[],{"trials":4133,"activeCount":102},[],{"trials":4135,"activeCount":265,"soonestReadout":4113},[4136],{"nctId":4110,"briefTitle":4111,"status":162,"phases":4137,"primaryCompletion":4113,"completion":4114,"start":4115,"enrollment":349,"conditions":4138,"interventions":4139},[94],[4117,4118,4119],[4095,4121],{"intervention":4141,"totalTrials":265,"cells":4142},"PARTICS using a single ICS add on",{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4147,"PHASE3":4149,"PHASE4":4151,"NA":4153},{"trials":4144,"activeCount":102},[],{"trials":4146,"activeCount":102},[],{"trials":4148,"activeCount":102},[],{"trials":4150,"activeCount":102},[],{"trials":4152,"activeCount":102},[],{"trials":4154,"activeCount":265,"soonestReadout":4159},[4155],{"nctId":4156,"briefTitle":4157,"status":307,"phases":4158,"primaryCompletion":4159,"completion":4160,"start":311,"enrollment":4161,"conditions":4162,"interventions":4166},"NCT06596512","Improving the Quality of Care for Asthma Patients at Risk of Exacerbations",[94],"2030-05","2030-12",4100,[18,4163,4164,4165],"Asthma Chronic","Asthma Severe Persistent With Exacerbation","Asthma Moderate Persistent With Exacerbation",[4141,4167],"MART",{"intervention":4167,"totalTrials":265,"cells":4169},{"EARLY_PHASE1":4170,"PHASE1":4172,"PHASE2":4174,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4171,"activeCount":102},[],{"trials":4173,"activeCount":102},[],{"trials":4175,"activeCount":102},[],{"trials":4177,"activeCount":102},[],{"trials":4179,"activeCount":102},[],{"trials":4181,"activeCount":265,"soonestReadout":4159},[4182],{"nctId":4156,"briefTitle":4157,"status":307,"phases":4183,"primaryCompletion":4159,"completion":4160,"start":311,"enrollment":4161,"conditions":4184,"interventions":4185},[94],[18,4163,4164,4165],[4141,4167],{"intervention":409,"totalTrials":265,"cells":4187},{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4192,"PHASE3":4194,"PHASE4":4196,"NA":4198},{"trials":4189,"activeCount":102},[],{"trials":4191,"activeCount":102},[],{"trials":4193,"activeCount":102},[],{"trials":4195,"activeCount":102},[],{"trials":4197,"activeCount":102},[],{"trials":4199,"activeCount":265,"soonestReadout":399},[4200],{"nctId":396,"briefTitle":397,"status":174,"phases":4201,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":4202,"interventions":4203},[],[404,405,406],[369,408,409,410],{"intervention":410,"totalTrials":265,"cells":4205},{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4212,"PHASE4":4214,"NA":4216},{"trials":4207,"activeCount":102},[],{"trials":4209,"activeCount":102},[],{"trials":4211,"activeCount":102},[],{"trials":4213,"activeCount":102},[],{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":265,"soonestReadout":399},[4218],{"nctId":396,"briefTitle":397,"status":174,"phases":4219,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":4220,"interventions":4221},[],[404,405,406],[369,408,409,410],{"intervention":4223,"totalTrials":265,"cells":4224},"Initiation of nivolumab",{"EARLY_PHASE1":4225,"PHASE1":4227,"PHASE2":4229,"PHASE3":4231,"PHASE4":4233,"NA":4235},{"trials":4226,"activeCount":102},[],{"trials":4228,"activeCount":102},[],{"trials":4230,"activeCount":102},[],{"trials":4232,"activeCount":102},[],{"trials":4234,"activeCount":102},[],{"trials":4236,"activeCount":265,"soonestReadout":4241},[4237],{"nctId":4238,"briefTitle":4239,"status":174,"phases":4240,"primaryCompletion":4241,"completion":4242,"start":4243,"enrollment":4244,"conditions":4245,"interventions":4248},"NCT07485166","Emulation of the CheckMate 017\u002F057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases",[],"2026-09-12","2027-03-12","2026-03-12",810,[4246,4247],"Advanced Non-squamous Non-small-cell Lung Cancer","Advanced Squamous Non Small Cell Lung Cancer",[4223,4249],"Initiation of docetaxel",{"intervention":4249,"totalTrials":265,"cells":4251},{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4258,"PHASE4":4260,"NA":4262},{"trials":4253,"activeCount":102},[],{"trials":4255,"activeCount":102},[],{"trials":4257,"activeCount":102},[],{"trials":4259,"activeCount":102},[],{"trials":4261,"activeCount":102},[],{"trials":4263,"activeCount":265,"soonestReadout":4241},[4264],{"nctId":4238,"briefTitle":4239,"status":174,"phases":4265,"primaryCompletion":4241,"completion":4242,"start":4243,"enrollment":4244,"conditions":4266,"interventions":4267},[],[4246,4247],[4223,4249],{"intervention":4269,"totalTrials":265,"cells":4270},"Initiation of pembrolizumab",{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4275,"PHASE3":4277,"PHASE4":4279,"NA":4281},{"trials":4272,"activeCount":102},[],{"trials":4274,"activeCount":102},[],{"trials":4276,"activeCount":102},[],{"trials":4278,"activeCount":102},[],{"trials":4280,"activeCount":102},[],{"trials":4282,"activeCount":265,"soonestReadout":4241},[4283],{"nctId":4284,"briefTitle":4285,"status":174,"phases":4286,"primaryCompletion":4241,"completion":4242,"start":4243,"enrollment":4287,"conditions":4288,"interventions":4290},"NCT07485179","Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases",[],770,[4289],"Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[4269,4291],"Initiation of chemotherapy",{"intervention":4291,"totalTrials":265,"cells":4293},{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4300,"PHASE4":4302,"NA":4304},{"trials":4295,"activeCount":102},[],{"trials":4297,"activeCount":102},[],{"trials":4299,"activeCount":102},[],{"trials":4301,"activeCount":102},[],{"trials":4303,"activeCount":102},[],{"trials":4305,"activeCount":265,"soonestReadout":4241},[4306],{"nctId":4284,"briefTitle":4285,"status":174,"phases":4307,"primaryCompletion":4241,"completion":4242,"start":4243,"enrollment":4287,"conditions":4308,"interventions":4309},[],[4289],[4269,4291],{"intervention":4311,"totalTrials":265,"cells":4312},"Lithium",{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4317,"PHASE3":4319,"PHASE4":4321,"NA":4323},{"trials":4314,"activeCount":102},[],{"trials":4316,"activeCount":102},[],{"trials":4318,"activeCount":102},[],{"trials":4320,"activeCount":102},[],{"trials":4322,"activeCount":102},[],{"trials":4324,"activeCount":265,"soonestReadout":4329},[4325],{"nctId":4326,"briefTitle":4327,"status":174,"phases":4328,"primaryCompletion":4329,"completion":1297,"start":4330,"enrollment":429,"conditions":4331,"interventions":4337},"NCT03336918","Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder",[],"2025-06-30","2017-12-07",[4332,4333,4334,4335,1060,4336],"Bipolar Disorder","Bipolar I Depression","Bipolar II Depression","Bipolar Depression","Major Depressive Episode",[4311],{"intervention":57,"totalTrials":265,"cells":4339},{"EARLY_PHASE1":4340,"PHASE1":4342,"PHASE2":4344,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4341,"activeCount":102},[],{"trials":4343,"activeCount":102},[],{"trials":4345,"activeCount":102},[],{"trials":4347,"activeCount":102},[],{"trials":4349,"activeCount":102},[],{"trials":4351,"activeCount":265,"soonestReadout":56},[4352],{"nctId":54,"briefTitle":55,"status":174,"phases":4353,"primaryCompletion":56,"completion":1037,"start":242,"enrollment":4354,"conditions":4355,"interventions":4359},[94],142,[4356,4357,4358],"Urinary Tract Infections","Pelvic Organ Prolapse","Urinary Incontinence",[57,4360],"Cranberry",{"intervention":4360,"totalTrials":265,"cells":4362},{"EARLY_PHASE1":4363,"PHASE1":4365,"PHASE2":4367,"PHASE3":4369,"PHASE4":4371,"NA":4373},{"trials":4364,"activeCount":102},[],{"trials":4366,"activeCount":102},[],{"trials":4368,"activeCount":102},[],{"trials":4370,"activeCount":102},[],{"trials":4372,"activeCount":102},[],{"trials":4374,"activeCount":265,"soonestReadout":56},[4375],{"nctId":54,"briefTitle":55,"status":174,"phases":4376,"primaryCompletion":56,"completion":1037,"start":242,"enrollment":4354,"conditions":4377,"interventions":4378},[94],[4356,4357,4358],[57,4360],{"intervention":4380,"totalTrials":265,"cells":4381},"Clopidogrel",{"EARLY_PHASE1":4382,"PHASE1":4384,"PHASE2":4386,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4383,"activeCount":102},[],{"trials":4385,"activeCount":102},[],{"trials":4387,"activeCount":102},[],{"trials":4389,"activeCount":102},[],{"trials":4391,"activeCount":102},[],{"trials":4393,"activeCount":265,"soonestReadout":399},[4394],{"nctId":4395,"briefTitle":4396,"status":174,"phases":4397,"primaryCompletion":399,"completion":399,"start":4398,"enrollment":4399,"conditions":4400,"interventions":4402},"NCT07610577","Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction",[],"2025-11-01",377753,[4401],"Acute Myocardial Infarction (AMI)",[4380,4403,4404],"Prasugrel","Ticagrelor",{"intervention":4403,"totalTrials":265,"cells":4406},{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4411,"PHASE3":4413,"PHASE4":4415,"NA":4417},{"trials":4408,"activeCount":102},[],{"trials":4410,"activeCount":102},[],{"trials":4412,"activeCount":102},[],{"trials":4414,"activeCount":102},[],{"trials":4416,"activeCount":102},[],{"trials":4418,"activeCount":265,"soonestReadout":399},[4419],{"nctId":4395,"briefTitle":4396,"status":174,"phases":4420,"primaryCompletion":399,"completion":399,"start":4398,"enrollment":4399,"conditions":4421,"interventions":4422},[],[4401],[4380,4403,4404],{"intervention":4404,"totalTrials":265,"cells":4424},{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4426,"activeCount":102},[],{"trials":4428,"activeCount":102},[],{"trials":4430,"activeCount":102},[],{"trials":4432,"activeCount":102},[],{"trials":4434,"activeCount":102},[],{"trials":4436,"activeCount":265,"soonestReadout":399},[4437],{"nctId":4395,"briefTitle":4396,"status":174,"phases":4438,"primaryCompletion":399,"completion":399,"start":4398,"enrollment":4399,"conditions":4439,"interventions":4440},[],[4401],[4380,4403,4404],{"intervention":4442,"totalTrials":1082,"cells":4443},"Ketamine",{"EARLY_PHASE1":4444,"PHASE1":4457,"PHASE2":4459,"PHASE3":4477,"PHASE4":4479,"NA":4492},{"trials":4445,"activeCount":102},[4446],{"nctId":4447,"briefTitle":4448,"status":436,"phases":4449,"primaryCompletion":4450,"completion":1288,"start":4451,"enrollment":4452,"conditions":4453,"interventions":4456},"NCT03090776","Prevention of Post Mastectomy With Intraoperative Ketamine",[89],"2025-10-16","2017-07-01",200,[4454,4455],"Pain, Postoperative","Post-Mastectomy Chronic Pain Syndrome",[4442],{"trials":4458,"activeCount":102},[],{"trials":4460,"activeCount":102},[4461,4469],{"nctId":4462,"briefTitle":4463,"status":239,"phases":4464,"primaryCompletion":4465,"completion":492,"start":3111,"enrollment":1082,"conditions":4466,"interventions":4468},"NCT06111339","Ketamine for OUD and Suicidal Ideation in the ED",[91],"2025-03-11",[1344,4467],"Suicidal Ideation",[4442],{"nctId":4470,"briefTitle":4471,"status":152,"phases":4472,"primaryCompletion":4473,"completion":4473,"start":2829,"enrollment":102,"conditions":4474,"interventions":4475},"NCT05661669","Ketamine for the Treatment for Alcohol Use Disorder in the ED",[91],"2024-08-19",[2638],[4442,4476],"Saline",{"trials":4478,"activeCount":102},[],{"trials":4480,"activeCount":102},[4481],{"nctId":4482,"briefTitle":4483,"status":108,"phases":4484,"primaryCompletion":4485,"completion":4486,"start":4487,"enrollment":4488,"conditions":4489,"interventions":4490},"NCT01591382","Efficacy Study of Ketamine for Postoperative Pain in Opioid Dependent Patients",[93],"2011-06","2012-06","2008-09",64,[1590],[4442,4491],"Hydromorphone PCA",{"trials":4493,"activeCount":102},[],{"intervention":4495,"totalTrials":281,"cells":4496},"Enalapril",{"EARLY_PHASE1":4497,"PHASE1":4499,"PHASE2":4501,"PHASE3":4503,"PHASE4":4505,"NA":4530},{"trials":4498,"activeCount":102},[],{"trials":4500,"activeCount":102},[],{"trials":4502,"activeCount":102},[],{"trials":4504,"activeCount":102},[],{"trials":4506,"activeCount":102},[4507,4516],{"nctId":4508,"briefTitle":4509,"status":152,"phases":4510,"primaryCompletion":4511,"completion":4511,"start":4512,"enrollment":102,"conditions":4513,"interventions":4514},"NCT03119623","Comparing ARNI With ACE Inhibitor on Endothelial Function",[93],"2019-08","2017-06-01",[3681],[4515,4495],"sacubitril\u002Fvalsartan",{"nctId":4517,"briefTitle":4518,"status":108,"phases":4519,"primaryCompletion":4520,"completion":4520,"start":4521,"enrollment":1870,"conditions":4522,"interventions":4528},"NCT04236258","Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period",[93],"2021-06-30","2020-01-24",[4523,4524,4525,4526,4527],"Hypertension in Pregnancy","Preeclampsia Severe","Gestational Hypertension","Postpartum Preeclampsia","Postpartum",[4529,4495],"NIFEdipine ER",{"trials":4531,"activeCount":102},[],{"intervention":4533,"totalTrials":281,"cells":4534},"Suvorexant",{"EARLY_PHASE1":4535,"PHASE1":4537,"PHASE2":4539,"PHASE3":4541,"PHASE4":4543,"NA":4563},{"trials":4536,"activeCount":102},[],{"trials":4538,"activeCount":102},[],{"trials":4540,"activeCount":102},[],{"trials":4542,"activeCount":102},[],{"trials":4544,"activeCount":102},[4545,4554],{"nctId":4546,"briefTitle":4547,"status":108,"phases":4548,"primaryCompletion":4549,"completion":4549,"start":4550,"enrollment":1506,"conditions":4551,"interventions":4553},"NCT05593653","Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia",[93],"2025-10-24","2023-01-06",[352,4552,1823],"Metabolic Health",[4533],{"nctId":4555,"briefTitle":4556,"status":108,"phases":4557,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":607,"conditions":4560,"interventions":4561},"NCT03034018","Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia",[93],"2020-04-03","2017-05-25",[352],[4562],"suvorexant",{"trials":4564,"activeCount":102},[],{"intervention":4566,"totalTrials":281,"cells":4567},"Intramuscular Progesterone",{"EARLY_PHASE1":4568,"PHASE1":4570,"PHASE2":4572,"PHASE3":4574,"PHASE4":4576,"NA":4597},{"trials":4569,"activeCount":102},[],{"trials":4571,"activeCount":102},[],{"trials":4573,"activeCount":102},[],{"trials":4575,"activeCount":102},[],{"trials":4577,"activeCount":102},[4578,4589],{"nctId":4579,"briefTitle":4580,"status":108,"phases":4581,"primaryCompletion":1503,"completion":4582,"start":4583,"enrollment":4584,"conditions":4585,"interventions":4587},"NCT00656201","Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)",[93],"2009-07","2003-07",468,[4586],"Infertility",[4588,4566],"Crinone 8% Vaginal Gel",{"nctId":4590,"briefTitle":4591,"status":152,"phases":4592,"primaryCompletion":4593,"enrollment":102,"conditions":4594,"interventions":4595},"NCT02772120","Comparison of Vaginal and Intramuscular Progesterone in Vitrified-warmed Blastocyst Transfer Cycles",[93],"2019-09",[4586],[4596,4566],"Vaginal progesterone gel",{"trials":4598,"activeCount":102},[],{"intervention":3617,"totalTrials":281,"cells":4600},{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4605,"PHASE3":4615,"PHASE4":4617,"NA":4623},{"trials":4602,"activeCount":102},[],{"trials":4604,"activeCount":102},[],{"trials":4606,"activeCount":102},[4607],{"nctId":4608,"briefTitle":4609,"status":108,"phases":4610,"primaryCompletion":4611,"completion":4611,"start":4612,"enrollment":22,"conditions":4613,"interventions":4614},"NCT03561584","Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis",[91],"2026-03-03","2018-07-01",[1417],[3617],{"trials":4616,"activeCount":102},[],{"trials":4618,"activeCount":102},[4619],{"nctId":3608,"briefTitle":3609,"status":108,"phases":4620,"primaryCompletion":3611,"completion":3611,"start":3612,"enrollment":3613,"conditions":4621,"interventions":4622},[93],[3615],[3115,3617,3618,3619,3620],{"trials":4624,"activeCount":102},[],{"intervention":1510,"totalTrials":281,"cells":4626},{"EARLY_PHASE1":4627,"PHASE1":4629,"PHASE2":4631,"PHASE3":4637,"PHASE4":4639,"NA":4650},{"trials":4628,"activeCount":102},[],{"trials":4630,"activeCount":102},[],{"trials":4632,"activeCount":102},[4633],{"nctId":1500,"briefTitle":1501,"status":239,"phases":4634,"primaryCompletion":1503,"completion":1504,"start":1505,"enrollment":1506,"conditions":4635,"interventions":4636},[91],[1508],[1510,1510,1491],{"trials":4638,"activeCount":102},[],{"trials":4640,"activeCount":102},[4641],{"nctId":4642,"briefTitle":4643,"status":239,"phases":4644,"completion":4645,"start":214,"enrollment":4646,"conditions":4647,"interventions":4649},"NCT00289601","Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty",[93],"2007-12",1200,[4648],"Angioplasty",[1510],{"trials":4651,"activeCount":102},[],{"intervention":3619,"totalTrials":281,"cells":4653},{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4665,"PHASE3":4667,"PHASE4":4669,"NA":4675},{"trials":4655,"activeCount":102},[],{"trials":4657,"activeCount":102},[4658],{"nctId":4659,"briefTitle":4660,"status":108,"phases":4661,"primaryCompletion":932,"completion":932,"start":214,"enrollment":206,"conditions":4662,"interventions":4664},"NCT00112385","A Pilot Study of Etanercept in Dermatomyositis",[90],[4663],"Dermatomyositis",[3619],{"trials":4666,"activeCount":102},[],{"trials":4668,"activeCount":102},[],{"trials":4670,"activeCount":102},[4671],{"nctId":3608,"briefTitle":3609,"status":108,"phases":4672,"primaryCompletion":3611,"completion":3611,"start":3612,"enrollment":3613,"conditions":4673,"interventions":4674},[93],[3615],[3115,3617,3618,3619,3620],{"trials":4676,"activeCount":102},[],{"intervention":4678,"totalTrials":281,"cells":4679},"Truvada",{"EARLY_PHASE1":4680,"PHASE1":4682,"PHASE2":4684,"PHASE3":4686,"PHASE4":4698,"NA":4709},{"trials":4681,"activeCount":102},[],{"trials":4683,"activeCount":102},[],{"trials":4685,"activeCount":102},[],{"trials":4687,"activeCount":102},[4688],{"nctId":4689,"briefTitle":4690,"status":108,"phases":4691,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":678,"conditions":4694,"interventions":4697},"NCT03512418","Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)",[92],"2024-04-10","2019-06-20",[4695,4696],"HIV Infections","Substance Use Disorders",[4678],{"trials":4699,"activeCount":102},[4700],{"nctId":4701,"briefTitle":4702,"status":108,"phases":4703,"primaryCompletion":4704,"completion":4704,"start":1123,"enrollment":206,"conditions":4705,"interventions":4708},"NCT03842436","Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use",[93],"2020-04-22",[4706,4696,4707],"HIV\u002FAIDS","Adherence, Medication",[4678],{"trials":4710,"activeCount":102},[],{"intervention":4712,"totalTrials":281,"cells":4713},"Oxycodone",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4718,"PHASE3":4720,"PHASE4":4722,"NA":4746},{"trials":4715,"activeCount":102},[],{"trials":4717,"activeCount":102},[],{"trials":4719,"activeCount":102},[],{"trials":4721,"activeCount":102},[],{"trials":4723,"activeCount":102},[4724,4735],{"nctId":4725,"briefTitle":4726,"status":108,"phases":4727,"primaryCompletion":204,"completion":204,"start":4728,"enrollment":521,"conditions":4729,"interventions":4733},"NCT01502644","Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms",[93],"2009-02",[4730,4731,1060,4732],"Chronic Low Back Pain","Degenerative Disc Disease","Anxiety",[4712,4734],"Morphine",{"nctId":4736,"briefTitle":4737,"status":436,"phases":4738,"primaryCompletion":4739,"completion":4739,"start":4740,"enrollment":296,"conditions":4741,"interventions":4743},"NCT03105518","Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction",[93],"2023-06-30","2011-03-01",[4742,1590],"Oocyte Retrieval",[4744,4745,4712],"Fentanyl","Acetaminophen",{"trials":4747,"activeCount":102},[],{"intervention":3970,"totalTrials":281,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4768,"NA":4782},{"trials":4751,"activeCount":102},[],{"trials":4753,"activeCount":102},[],{"trials":4755,"activeCount":102},[],{"trials":4757,"activeCount":102},[4758],{"nctId":4759,"briefTitle":4760,"status":152,"phases":4761,"primaryCompletion":932,"completion":932,"start":4762,"enrollment":102,"conditions":4763,"interventions":4766},"NCT00948740","The Effect of Vitamin D on Urinary Calcium Excretion in Kidney Stone Formers With High Urinary Calcium",[91,92],"2009-08",[4764,4765],"Vitamin D Deficiency","Nephrolithiasis",[4767],"vitamin D",{"trials":4769,"activeCount":102},[4770],{"nctId":4771,"briefTitle":4772,"status":108,"phases":4773,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":28,"conditions":4777,"interventions":4778},"NCT01400516","Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial",[93],"2015-07-30","2016-07-28","2011-08",[3631],[4779,4780,3970,4781],"Teriparatide","calcium citrate","TNF antagonist",{"trials":4783,"activeCount":102},[],{"intervention":4785,"totalTrials":281,"cells":4786},"losartan",{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4793,"PHASE4":4805,"NA":4816},{"trials":4788,"activeCount":102},[],{"trials":4790,"activeCount":102},[],{"trials":4792,"activeCount":102},[],{"trials":4794,"activeCount":102},[4795],{"nctId":4796,"briefTitle":4797,"status":108,"phases":4798,"primaryCompletion":931,"completion":931,"start":4799,"enrollment":167,"conditions":4800,"interventions":4802},"NCT00723801","Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome",[92],"2007-10",[4801],"Marfan Syndrome",[4803,4804],"Atenolol","Losartan",{"trials":4806,"activeCount":102},[4807],{"nctId":4808,"briefTitle":4809,"status":108,"phases":4810,"primaryCompletion":4004,"completion":4004,"start":4811,"enrollment":4812,"conditions":4813,"interventions":4815},"NCT00675987","A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients",[93],"2007-05",53,[21,15,4814],"Hyperglycemia",[4785],{"trials":4817,"activeCount":102},[],{"intervention":4745,"totalTrials":281,"cells":4819},{"EARLY_PHASE1":4820,"PHASE1":4822,"PHASE2":4824,"PHASE3":4826,"PHASE4":4828,"NA":4845},{"trials":4821,"activeCount":102},[],{"trials":4823,"activeCount":102},[],{"trials":4825,"activeCount":102},[],{"trials":4827,"activeCount":102},[],{"trials":4829,"activeCount":102},[4830,4841],{"nctId":4831,"briefTitle":4832,"status":108,"phases":4833,"primaryCompletion":4834,"completion":4835,"start":4836,"enrollment":4837,"conditions":4838,"interventions":4840},"NCT02369211","Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV)",[93],"2018-01","2018-03","2015-09",86,[4839,1811],"Prostatectomy",[4745],{"nctId":4736,"briefTitle":4737,"status":436,"phases":4842,"primaryCompletion":4739,"completion":4739,"start":4740,"enrollment":296,"conditions":4843,"interventions":4844},[93],[4742,1590],[4744,4745,4712],{"trials":4846,"activeCount":102},[],{"intervention":4848,"totalTrials":265,"cells":4849},"Sublingual film containing dexmedetomidine",{"EARLY_PHASE1":4850,"PHASE1":4852,"PHASE2":4854,"PHASE3":4856,"PHASE4":4858,"NA":4870},{"trials":4851,"activeCount":102},[],{"trials":4853,"activeCount":102},[],{"trials":4855,"activeCount":102},[],{"trials":4857,"activeCount":102},[],{"trials":4859,"activeCount":102},[4860],{"nctId":4861,"briefTitle":4862,"status":152,"phases":4863,"primaryCompletion":1434,"completion":482,"start":2829,"enrollment":102,"conditions":4864,"interventions":4869},"NCT05974527","Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department",[93],[4865,4866,4867,4868,4332],"Agitation","Schizophrenia","Schizoaffective Disorder","Schizophreniform Disorders",[4848],{"trials":4871,"activeCount":102},[],{"intervention":148,"totalTrials":265,"cells":4873},{"EARLY_PHASE1":4874,"PHASE1":4876,"PHASE2":4878,"PHASE3":4880,"PHASE4":4882,"NA":4888},{"trials":4875,"activeCount":102},[],{"trials":4877,"activeCount":102},[],{"trials":4879,"activeCount":102},[],{"trials":4881,"activeCount":102},[],{"trials":4883,"activeCount":102},[4884],{"nctId":138,"briefTitle":139,"status":108,"phases":4885,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":4886,"interventions":4887},[93],[145,15,146],[97,148],{"trials":4889,"activeCount":102},[],{"intervention":4891,"totalTrials":265,"cells":4892},"Testosterone Gel",{"EARLY_PHASE1":4893,"PHASE1":4895,"PHASE2":4897,"PHASE3":4899,"PHASE4":4901,"NA":4914},{"trials":4894,"activeCount":102},[],{"trials":4896,"activeCount":102},[],{"trials":4898,"activeCount":102},[],{"trials":4900,"activeCount":102},[],{"trials":4902,"activeCount":102},[4903],{"nctId":4904,"briefTitle":4905,"status":108,"phases":4906,"primaryCompletion":4907,"completion":4908,"start":4909,"enrollment":4910,"conditions":4911,"interventions":4913},"NCT00287586","Testosterone Replacement in Older Men and Atherosclerosis Progression",[93],"2012-02-07","2012-05-12","2004-09",308,[4912,471],"Hypogonadism",[4891],{"trials":4915,"activeCount":102},[],{"intervention":1606,"totalTrials":265,"cells":4917},{"EARLY_PHASE1":4918,"PHASE1":4920,"PHASE2":4922,"PHASE3":4924,"PHASE4":4926,"NA":4932},{"trials":4919,"activeCount":102},[],{"trials":4921,"activeCount":102},[],{"trials":4923,"activeCount":102},[],{"trials":4925,"activeCount":102},[],{"trials":4927,"activeCount":102},[4928],{"nctId":1597,"briefTitle":1598,"status":108,"phases":4929,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":607,"conditions":4930,"interventions":4931},[93],[1603,1604],[1576,1606],{"trials":4933,"activeCount":102},[],{"intervention":4935,"totalTrials":265,"cells":4936},"Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine",{"EARLY_PHASE1":4937,"PHASE1":4939,"PHASE2":4941,"PHASE3":4943,"PHASE4":4945,"NA":4956},{"trials":4938,"activeCount":102},[],{"trials":4940,"activeCount":102},[],{"trials":4942,"activeCount":102},[],{"trials":4944,"activeCount":102},[],{"trials":4946,"activeCount":102},[4947],{"nctId":4948,"briefTitle":4949,"status":108,"phases":4950,"primaryCompletion":4951,"completion":4952,"start":3600,"enrollment":34,"conditions":4953,"interventions":4955},"NCT04090190","Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics",[93],"2021-05-30","2021-10-31",[4358,4954],"Urgency Urinary",[4935],{"trials":4957,"activeCount":102},[],{"intervention":4959,"totalTrials":265,"cells":4960},"SGLT2i, beta blocker, ARNI, MRA, MTD",{"EARLY_PHASE1":4961,"PHASE1":4963,"PHASE2":4965,"PHASE3":4967,"PHASE4":4969,"NA":4981},{"trials":4962,"activeCount":102},[],{"trials":4964,"activeCount":102},[],{"trials":4966,"activeCount":102},[],{"trials":4968,"activeCount":102},[],{"trials":4970,"activeCount":102},[4971],{"nctId":4972,"briefTitle":4973,"status":108,"phases":4974,"primaryCompletion":4975,"completion":4976,"start":4977,"enrollment":4978,"conditions":4979,"interventions":4980},"NCT05734690","COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure",[93],"2025-05-19","2025-06-09","2023-05-05",503,[24],[4959],{"trials":4982,"activeCount":102},[],{"intervention":4588,"totalTrials":265,"cells":4984},{"EARLY_PHASE1":4985,"PHASE1":4987,"PHASE2":4989,"PHASE3":4991,"PHASE4":4993,"NA":4999},{"trials":4986,"activeCount":102},[],{"trials":4988,"activeCount":102},[],{"trials":4990,"activeCount":102},[],{"trials":4992,"activeCount":102},[],{"trials":4994,"activeCount":102},[4995],{"nctId":4579,"briefTitle":4580,"status":108,"phases":4996,"primaryCompletion":1503,"completion":4582,"start":4583,"enrollment":4584,"conditions":4997,"interventions":4998},[93],[4586],[4588,4566],{"trials":5000,"activeCount":102},[],{"intervention":5002,"totalTrials":265,"cells":5003},"SGLT2 inhibitor, GLP-1 RA",{"EARLY_PHASE1":5004,"PHASE1":5006,"PHASE2":5008,"PHASE3":5010,"PHASE4":5012,"NA":5022},{"trials":5005,"activeCount":102},[],{"trials":5007,"activeCount":102},[],{"trials":5009,"activeCount":102},[],{"trials":5011,"activeCount":102},[],{"trials":5013,"activeCount":102},[5014],{"nctId":5015,"briefTitle":5016,"status":108,"phases":5017,"primaryCompletion":5018,"completion":5018,"start":5019,"enrollment":4452,"conditions":5020,"interventions":5021},"NCT06046560","Diabetes Remote Intervention to improVe Use of Evidence-based Medications",[93],"2023-07-25","2021-03-22",[30,27],[5002],{"trials":5023,"activeCount":102},[],{"intervention":5025,"totalTrials":265,"cells":5026},"Angiotensin-Converting Enzyme Inhibitor",{"EARLY_PHASE1":5027,"PHASE1":5029,"PHASE2":5031,"PHASE3":5033,"PHASE4":5035,"NA":5047},{"trials":5028,"activeCount":102},[],{"trials":5030,"activeCount":102},[],{"trials":5032,"activeCount":102},[],{"trials":5034,"activeCount":102},[],{"trials":5036,"activeCount":102},[5037],{"nctId":5038,"briefTitle":5039,"status":239,"phases":5040,"primaryCompletion":5041,"completion":5041,"start":5042,"enrollment":1082,"conditions":5043,"interventions":5045},"NCT02788656","Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril\u002FValsartan)",[93],"2018-11-09","2016-09",[5044],"Congestive Heart Failure",[5025,5046,4515],"Angiotensin II Type 1 Receptor Blocker",{"trials":5048,"activeCount":102},[],{"intervention":5046,"totalTrials":265,"cells":5050},{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5055,"PHASE3":5057,"PHASE4":5059,"NA":5065},{"trials":5052,"activeCount":102},[],{"trials":5054,"activeCount":102},[],{"trials":5056,"activeCount":102},[],{"trials":5058,"activeCount":102},[],{"trials":5060,"activeCount":102},[5061],{"nctId":5038,"briefTitle":5039,"status":239,"phases":5062,"primaryCompletion":5041,"completion":5041,"start":5042,"enrollment":1082,"conditions":5063,"interventions":5064},[93],[5044],[5025,5046,4515],{"trials":5066,"activeCount":102},[],{"intervention":5068,"totalTrials":265,"cells":5069},"soy isoflavones",{"EARLY_PHASE1":5070,"PHASE1":5072,"PHASE2":5074,"PHASE3":5076,"PHASE4":5078,"NA":5091},{"trials":5071,"activeCount":102},[],{"trials":5073,"activeCount":102},[],{"trials":5075,"activeCount":102},[],{"trials":5077,"activeCount":102},[],{"trials":5079,"activeCount":102},[5080],{"nctId":5081,"briefTitle":5082,"status":108,"phases":5083,"primaryCompletion":5084,"completion":5085,"start":5086,"enrollment":5087,"conditions":5088,"interventions":5090},"NCT01401946","Soy Isoflavone Tablets: Effects on Sleep, Quality of Life, Symptoms and Cognitive Function in Menopausal Women",[93],"2000-10","2001-01","2000-05",88,[5089],"Hot Flashes",[5068],{"trials":5092,"activeCount":102},[],{"intervention":3620,"totalTrials":265,"cells":5094},{"EARLY_PHASE1":5095,"PHASE1":5097,"PHASE2":5099,"PHASE3":5101,"PHASE4":5103,"NA":5109},{"trials":5096,"activeCount":102},[],{"trials":5098,"activeCount":102},[],{"trials":5100,"activeCount":102},[],{"trials":5102,"activeCount":102},[],{"trials":5104,"activeCount":102},[5105],{"nctId":3608,"briefTitle":3609,"status":108,"phases":5106,"primaryCompletion":3611,"completion":3611,"start":3612,"enrollment":3613,"conditions":5107,"interventions":5108},[93],[3615],[3115,3617,3618,3619,3620],{"trials":5110,"activeCount":102},[],{"intervention":5112,"totalTrials":265,"cells":5113},"Brisement",{"EARLY_PHASE1":5114,"PHASE1":5116,"PHASE2":5118,"PHASE3":5120,"PHASE4":5122,"NA":5133},{"trials":5115,"activeCount":102},[],{"trials":5117,"activeCount":102},[],{"trials":5119,"activeCount":102},[],{"trials":5121,"activeCount":102},[],{"trials":5123,"activeCount":102},[5124],{"nctId":5125,"briefTitle":5126,"status":152,"phases":5127,"primaryCompletion":1038,"completion":5128,"start":5129,"enrollment":102,"conditions":5130,"interventions":5132},"NCT03363789","The Efficacy of Brisement Compared to Physical Therapy for the Treatment of Achilles Tendinosis",[93],"2019-07-02","2018-02-01",[5131],"Achilles Tendinopathy",[5112],{"trials":5134,"activeCount":102},[],{"intervention":5136,"totalTrials":265,"cells":5137},"Monoferric",{"EARLY_PHASE1":5138,"PHASE1":5140,"PHASE2":5142,"PHASE3":5144,"PHASE4":5146,"NA":5156},{"trials":5139,"activeCount":102},[],{"trials":5141,"activeCount":102},[],{"trials":5143,"activeCount":102},[],{"trials":5145,"activeCount":102},[],{"trials":5147,"activeCount":102},[5148],{"nctId":5149,"briefTitle":5150,"status":436,"phases":5151,"primaryCompletion":5152,"completion":1772,"start":2803,"enrollment":22,"conditions":5153,"interventions":5155},"NCT05258825","Preoperative Monoferric for Abdominal Surgery",[93],"2023-03",[1005,5154],"Surgery",[5136],{"trials":5157,"activeCount":102},[],{"intervention":4596,"totalTrials":265,"cells":5159},{"EARLY_PHASE1":5160,"PHASE1":5162,"PHASE2":5164,"PHASE3":5166,"PHASE4":5168,"NA":5174},{"trials":5161,"activeCount":102},[],{"trials":5163,"activeCount":102},[],{"trials":5165,"activeCount":102},[],{"trials":5167,"activeCount":102},[],{"trials":5169,"activeCount":102},[5170],{"nctId":4590,"briefTitle":4591,"status":152,"phases":5171,"primaryCompletion":4593,"enrollment":102,"conditions":5172,"interventions":5173},[93],[4586],[4596,4566],{"trials":5175,"activeCount":102},[],{"intervention":5177,"totalTrials":265,"cells":5178},"Metformin 1000 mg",{"EARLY_PHASE1":5179,"PHASE1":5181,"PHASE2":5183,"PHASE3":5185,"PHASE4":5187,"NA":5197},{"trials":5180,"activeCount":102},[],{"trials":5182,"activeCount":102},[],{"trials":5184,"activeCount":102},[],{"trials":5186,"activeCount":102},[],{"trials":5188,"activeCount":102},[5189],{"nctId":5190,"briefTitle":5191,"status":239,"phases":5192,"primaryCompletion":3140,"completion":3140,"start":5193,"enrollment":281,"conditions":5194,"interventions":5196},"NCT01901224","Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease",[93],"2013-07",[5195],"Peripheral Artery Disease",[5177],{"trials":5198,"activeCount":102},[],{"intervention":5200,"totalTrials":265,"cells":5201},"Sofosbuvir\u002Fvelpatasvir",{"EARLY_PHASE1":5202,"PHASE1":5204,"PHASE2":5206,"PHASE3":5208,"PHASE4":5210,"NA":5223},{"trials":5203,"activeCount":102},[],{"trials":5205,"activeCount":102},[],{"trials":5207,"activeCount":102},[],{"trials":5209,"activeCount":102},[],{"trials":5211,"activeCount":102},[5212],{"nctId":5213,"briefTitle":5214,"status":436,"phases":5215,"primaryCompletion":5216,"completion":5216,"start":5217,"enrollment":5218,"conditions":5219,"interventions":5222},"NCT03086044","Transplanting Hepatitis C Positive Organs",[93],"2023-12","2017-03-01",148,[5220,5221],"Hepatitis C","Awaiting Organ Transplant",[5200],{"trials":5224,"activeCount":102},[],{"intervention":5226,"totalTrials":265,"cells":5227},"Apixaban 2.5 MG",{"EARLY_PHASE1":5228,"PHASE1":5230,"PHASE2":5232,"PHASE3":5234,"PHASE4":5236,"NA":5247},{"trials":5229,"activeCount":102},[],{"trials":5231,"activeCount":102},[],{"trials":5233,"activeCount":102},[],{"trials":5235,"activeCount":102},[],{"trials":5237,"activeCount":102},[5238],{"nctId":5239,"briefTitle":5240,"status":108,"phases":5241,"primaryCompletion":5242,"completion":5243,"start":5244,"enrollment":1070,"conditions":5245,"interventions":5246},"NCT04168203","Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism",[93],"2023-11-30","2025-04-08","2021-03-01",[4007,3871,485],[5226],{"trials":5248,"activeCount":102},[],{"intervention":5250,"totalTrials":265,"cells":5251},"tolterodine",{"EARLY_PHASE1":5252,"PHASE1":5254,"PHASE2":5256,"PHASE3":5258,"PHASE4":5260,"NA":5270},{"trials":5253,"activeCount":102},[],{"trials":5255,"activeCount":102},[],{"trials":5257,"activeCount":102},[],{"trials":5259,"activeCount":102},[],{"trials":5261,"activeCount":102},[5262],{"nctId":5263,"briefTitle":5264,"status":239,"phases":5265,"primaryCompletion":5266,"completion":228,"start":5267,"enrollment":1620,"conditions":5268,"interventions":5269},"NCT00323635","A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.",[93],"2010-01","2006-04",[4358],[5250],{"trials":5271,"activeCount":102},[],{"intervention":5273,"totalTrials":265,"cells":5274},"Budesonide \u002F Formoterol",{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5281,"PHASE4":5283,"NA":5292},{"trials":5276,"activeCount":102},[],{"trials":5278,"activeCount":102},[],{"trials":5280,"activeCount":102},[],{"trials":5282,"activeCount":102},[],{"trials":5284,"activeCount":102},[5285],{"nctId":5286,"briefTitle":5287,"status":239,"phases":5288,"primaryCompletion":1069,"completion":965,"start":1600,"enrollment":3730,"conditions":5289,"interventions":5291},"NCT01760304","Changes in Cardiac Function in COPD Patients After Administration of Budesonide\u002FFormoterol (Symbicort®) Versus Placebo",[93],[5290],"Chronic Obstructive Pulmonary Disease (COPD)",[5273],{"trials":5293,"activeCount":102},[],{"intervention":5295,"totalTrials":265,"cells":5296},"Vasopressin",{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5301,"PHASE3":5303,"PHASE4":5305,"NA":5316},{"trials":5298,"activeCount":102},[],{"trials":5300,"activeCount":102},[],{"trials":5302,"activeCount":102},[],{"trials":5304,"activeCount":102},[],{"trials":5306,"activeCount":102},[5307],{"nctId":5308,"briefTitle":5309,"status":108,"phases":5310,"primaryCompletion":5311,"completion":3140,"start":5312,"enrollment":1588,"conditions":5313,"interventions":5315},"NCT01393704","Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial",[93],"2015-04","2011-07",[5314],"Blood Loss, Surgical",[5295],{"trials":5317,"activeCount":102},[],{"intervention":4734,"totalTrials":265,"cells":5319},{"EARLY_PHASE1":5320,"PHASE1":5322,"PHASE2":5324,"PHASE3":5326,"PHASE4":5328,"NA":5334},{"trials":5321,"activeCount":102},[],{"trials":5323,"activeCount":102},[],{"trials":5325,"activeCount":102},[],{"trials":5327,"activeCount":102},[],{"trials":5329,"activeCount":102},[5330],{"nctId":4725,"briefTitle":4726,"status":108,"phases":5331,"primaryCompletion":204,"completion":204,"start":4728,"enrollment":521,"conditions":5332,"interventions":5333},[93],[4730,4731,1060,4732],[4712,4734],{"trials":5335,"activeCount":102},[],{"intervention":5337,"totalTrials":265,"cells":5338},"Vasodilator testing",{"EARLY_PHASE1":5339,"PHASE1":5341,"PHASE2":5343,"PHASE3":5345,"PHASE4":5347,"NA":5358},{"trials":5340,"activeCount":102},[],{"trials":5342,"activeCount":102},[],{"trials":5344,"activeCount":102},[],{"trials":5346,"activeCount":102},[],{"trials":5348,"activeCount":102},[5349],{"nctId":5350,"briefTitle":5351,"status":108,"phases":5352,"primaryCompletion":5353,"completion":5353,"start":1636,"enrollment":5354,"conditions":5355,"interventions":5357},"NCT04231084","Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide",[93],"2024-08-01",115,[5356],"Pulmonary Hypertension",[5337,5337],{"trials":5359,"activeCount":102},[],{"intervention":5361,"totalTrials":265,"cells":5362},"Pramipexole",{"EARLY_PHASE1":5363,"PHASE1":5365,"PHASE2":5367,"PHASE3":5369,"PHASE4":5371,"NA":5382},{"trials":5364,"activeCount":102},[],{"trials":5366,"activeCount":102},[],{"trials":5368,"activeCount":102},[],{"trials":5370,"activeCount":102},[],{"trials":5372,"activeCount":102},[5373],{"nctId":5374,"briefTitle":5375,"status":108,"phases":5376,"primaryCompletion":5377,"completion":5377,"start":5378,"enrollment":5379,"conditions":5380,"interventions":5381},"NCT02397837","Targeting Cognition in Bipolar Disorder With Pramipexole",[93],"2018-07-26","2014-10",103,[4332],[5361],{"trials":5383,"activeCount":102},[],{"intervention":4491,"totalTrials":265,"cells":5385},{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5400},{"trials":5387,"activeCount":102},[],{"trials":5389,"activeCount":102},[],{"trials":5391,"activeCount":102},[],{"trials":5393,"activeCount":102},[],{"trials":5395,"activeCount":102},[5396],{"nctId":4482,"briefTitle":4483,"status":108,"phases":5397,"primaryCompletion":4485,"completion":4486,"start":4487,"enrollment":4488,"conditions":5398,"interventions":5399},[93],[1590],[4442,4491],{"trials":5401,"activeCount":102},[],{"intervention":5403,"totalTrials":265,"cells":5404},"Aspirin 81 mg",{"EARLY_PHASE1":5405,"PHASE1":5407,"PHASE2":5409,"PHASE3":5411,"PHASE4":5413,"NA":5424},{"trials":5406,"activeCount":102},[],{"trials":5408,"activeCount":102},[],{"trials":5410,"activeCount":102},[],{"trials":5412,"activeCount":102},[],{"trials":5414,"activeCount":102},[5415],{"nctId":5416,"briefTitle":5417,"status":436,"phases":5418,"primaryCompletion":1618,"completion":5419,"start":5420,"enrollment":5421,"conditions":5422,"interventions":5423},"NCT03433586","COMT on Aspirin Platelets Effects (CAPE)",[93],"2022-04-30","2020-07-10",45,[30],[5403],{"trials":5425,"activeCount":102},[],{"intervention":2703,"totalTrials":265,"cells":5427},{"EARLY_PHASE1":5428,"PHASE1":5430,"PHASE2":5432,"PHASE3":5434,"PHASE4":5436,"NA":5442},{"trials":5429,"activeCount":102},[],{"trials":5431,"activeCount":102},[],{"trials":5433,"activeCount":102},[],{"trials":5435,"activeCount":102},[],{"trials":5437,"activeCount":102},[5438],{"nctId":2695,"briefTitle":2696,"status":239,"phases":5439,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":5440,"interventions":5441},[93],[1258],[2703,2704],{"trials":5443,"activeCount":102},[],{"intervention":5445,"totalTrials":265,"cells":5446},"Ambrisentan",{"EARLY_PHASE1":5447,"PHASE1":5449,"PHASE2":5451,"PHASE3":5453,"PHASE4":5455,"NA":5466},{"trials":5448,"activeCount":102},[],{"trials":5450,"activeCount":102},[],{"trials":5452,"activeCount":102},[],{"trials":5454,"activeCount":102},[],{"trials":5456,"activeCount":102},[5457],{"nctId":5458,"briefTitle":5459,"status":108,"phases":5460,"primaryCompletion":5461,"completion":5462,"start":4487,"enrollment":678,"conditions":5463,"interventions":5465},"NCT01338636","An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)",[93],"2016-02","2016-05",[5464],"Exercise-induced Pulmonary Arterial Hypertension",[5445],{"trials":5467,"activeCount":102},[],{"intervention":5469,"totalTrials":265,"cells":5470},"Diclofenac Gel",{"EARLY_PHASE1":5471,"PHASE1":5473,"PHASE2":5475,"PHASE3":5477,"PHASE4":5479,"NA":5490},{"trials":5472,"activeCount":102},[],{"trials":5474,"activeCount":102},[],{"trials":5476,"activeCount":102},[],{"trials":5478,"activeCount":102},[],{"trials":5480,"activeCount":102},[5481],{"nctId":5482,"briefTitle":5483,"status":108,"phases":5484,"primaryCompletion":5485,"completion":931,"start":4485,"enrollment":5486,"conditions":5487,"interventions":5489},"NCT01383954","The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis",[93],"2012-08",52,[5488],"Knee Osteoarthritis",[5469],{"trials":5491,"activeCount":102},[],{"intervention":4780,"totalTrials":265,"cells":5493},{"EARLY_PHASE1":5494,"PHASE1":5496,"PHASE2":5498,"PHASE3":5500,"PHASE4":5502,"NA":5508},{"trials":5495,"activeCount":102},[],{"trials":5497,"activeCount":102},[],{"trials":5499,"activeCount":102},[],{"trials":5501,"activeCount":102},[],{"trials":5503,"activeCount":102},[5504],{"nctId":4771,"briefTitle":4772,"status":108,"phases":5505,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":28,"conditions":5506,"interventions":5507},[93],[3631],[4779,4780,3970,4781],{"trials":5509,"activeCount":102},[],{"intervention":4781,"totalTrials":265,"cells":5511},{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5516,"PHASE3":5518,"PHASE4":5520,"NA":5526},{"trials":5513,"activeCount":102},[],{"trials":5515,"activeCount":102},[],{"trials":5517,"activeCount":102},[],{"trials":5519,"activeCount":102},[],{"trials":5521,"activeCount":102},[5522],{"nctId":4771,"briefTitle":4772,"status":108,"phases":5523,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":28,"conditions":5524,"interventions":5525},[93],[3631],[4779,4780,3970,4781],{"trials":5527,"activeCount":102},[],{"intervention":5529,"totalTrials":265,"cells":5530},"Gabapentin",{"EARLY_PHASE1":5531,"PHASE1":5533,"PHASE2":5535,"PHASE3":5537,"PHASE4":5539,"NA":5552},{"trials":5532,"activeCount":102},[],{"trials":5534,"activeCount":102},[],{"trials":5536,"activeCount":102},[],{"trials":5538,"activeCount":102},[],{"trials":5540,"activeCount":102},[5541],{"nctId":5542,"briefTitle":5543,"status":108,"phases":5544,"primaryCompletion":5545,"completion":5545,"start":5546,"enrollment":5547,"conditions":5548,"interventions":5551},"NCT03334903","Gabapentin Regimens and Their Effects on Opioid Consumption",[93],"2019-04-24","2018-05-15",77,[5488,5549,1812,5550],"Knee Pain Chronic","Opioid Dependence",[5529],{"trials":5553,"activeCount":102},[],{"intervention":5555,"totalTrials":265,"cells":5556},"Sublingual",{"EARLY_PHASE1":5557,"PHASE1":5559,"PHASE2":5561,"PHASE3":5563,"PHASE4":5565,"NA":5576},{"trials":5558,"activeCount":102},[],{"trials":5560,"activeCount":102},[],{"trials":5562,"activeCount":102},[],{"trials":5564,"activeCount":102},[],{"trials":5566,"activeCount":102},[5567],{"nctId":5568,"briefTitle":5569,"status":108,"phases":5570,"primaryCompletion":5571,"completion":912,"start":142,"enrollment":5572,"conditions":5573,"interventions":5575},"NCT04263909","The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients",[93],"2022-04-01",199,[5574,4454,1812],"Spine Fusion",[5555],{"trials":5577,"activeCount":102},[],{"intervention":5579,"totalTrials":265,"cells":5580},"High Dose Trivalent Influenza Vaccine",{"EARLY_PHASE1":5581,"PHASE1":5583,"PHASE2":5585,"PHASE3":5587,"PHASE4":5589,"NA":5600},{"trials":5582,"activeCount":102},[],{"trials":5584,"activeCount":102},[],{"trials":5586,"activeCount":102},[],{"trials":5588,"activeCount":102},[],{"trials":5590,"activeCount":102},[5591],{"nctId":5592,"briefTitle":5593,"status":108,"phases":5594,"primaryCompletion":5595,"completion":5595,"start":3967,"enrollment":5596,"conditions":5597,"interventions":5598},"NCT02787044","INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure",[93],"2020-05-31",5388,[24,978],[5579,5599],"Standard Dose Quadrivalent Influenza Vaccine",{"trials":5601,"activeCount":102},[],{"intervention":5599,"totalTrials":265,"cells":5603},{"EARLY_PHASE1":5604,"PHASE1":5606,"PHASE2":5608,"PHASE3":5610,"PHASE4":5612,"NA":5618},{"trials":5605,"activeCount":102},[],{"trials":5607,"activeCount":102},[],{"trials":5609,"activeCount":102},[],{"trials":5611,"activeCount":102},[],{"trials":5613,"activeCount":102},[5614],{"nctId":5592,"briefTitle":5593,"status":108,"phases":5615,"primaryCompletion":5595,"completion":5595,"start":3967,"enrollment":5596,"conditions":5616,"interventions":5617},[93],[24,978],[5579,5599],{"trials":5619,"activeCount":102},[],{"intervention":5621,"totalTrials":265,"cells":5622},"15-methyl prostaglandin F2α",{"EARLY_PHASE1":5623,"PHASE1":5625,"PHASE2":5627,"PHASE3":5629,"PHASE4":5631,"NA":5642},{"trials":5624,"activeCount":102},[],{"trials":5626,"activeCount":102},[],{"trials":5628,"activeCount":102},[],{"trials":5630,"activeCount":102},[],{"trials":5632,"activeCount":102},[5633],{"nctId":5634,"briefTitle":5635,"status":108,"phases":5636,"primaryCompletion":5637,"completion":3859,"start":2209,"enrollment":296,"conditions":5638,"interventions":5640},"NCT03584854","Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial",[93],"2022-05-22",[5639,1603],"Postpartum Hemorrhage",[5621,5641],"Methylergonovine Maleate",{"trials":5643,"activeCount":102},[],{"intervention":5641,"totalTrials":265,"cells":5645},{"EARLY_PHASE1":5646,"PHASE1":5648,"PHASE2":5650,"PHASE3":5652,"PHASE4":5654,"NA":5660},{"trials":5647,"activeCount":102},[],{"trials":5649,"activeCount":102},[],{"trials":5651,"activeCount":102},[],{"trials":5653,"activeCount":102},[],{"trials":5655,"activeCount":102},[5656],{"nctId":5634,"briefTitle":5635,"status":108,"phases":5657,"primaryCompletion":5637,"completion":3859,"start":2209,"enrollment":296,"conditions":5658,"interventions":5659},[93],[5639,1603],[5621,5641],{"trials":5661,"activeCount":102},[],{"intervention":5663,"totalTrials":265,"cells":5664},"Ambrisentan plus Spironolactone",{"EARLY_PHASE1":5665,"PHASE1":5667,"PHASE2":5669,"PHASE3":5671,"PHASE4":5673,"NA":5684},{"trials":5666,"activeCount":102},[],{"trials":5668,"activeCount":102},[],{"trials":5670,"activeCount":102},[],{"trials":5672,"activeCount":102},[],{"trials":5674,"activeCount":102},[5675],{"nctId":5676,"briefTitle":5677,"status":239,"phases":5678,"primaryCompletion":5679,"completion":5679,"start":4836,"enrollment":281,"conditions":5680,"interventions":5682},"NCT02253394","The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study",[93],"2018-02",[5681],"Pulmonary Arterial Hypertension",[5663,5683],"Ambrisentan plus Placebo",{"trials":5685,"activeCount":102},[],{"intervention":5683,"totalTrials":265,"cells":5687},{"EARLY_PHASE1":5688,"PHASE1":5690,"PHASE2":5692,"PHASE3":5694,"PHASE4":5696,"NA":5702},{"trials":5689,"activeCount":102},[],{"trials":5691,"activeCount":102},[],{"trials":5693,"activeCount":102},[],{"trials":5695,"activeCount":102},[],{"trials":5697,"activeCount":102},[5698],{"nctId":5676,"briefTitle":5677,"status":239,"phases":5699,"primaryCompletion":5679,"completion":5679,"start":4836,"enrollment":281,"conditions":5700,"interventions":5701},[93],[5681],[5663,5683],{"trials":5703,"activeCount":102},[],{"intervention":5705,"totalTrials":265,"cells":5706},"Estradiol withdrawal",{"EARLY_PHASE1":5707,"PHASE1":5709,"PHASE2":5711,"PHASE3":5713,"PHASE4":5715,"NA":5725},{"trials":5708,"activeCount":102},[],{"trials":5710,"activeCount":102},[],{"trials":5712,"activeCount":102},[],{"trials":5714,"activeCount":102},[],{"trials":5716,"activeCount":102},[5717],{"nctId":5718,"briefTitle":5719,"status":108,"phases":5720,"primaryCompletion":5721,"completion":5721,"start":5722,"enrollment":1708,"conditions":5723,"interventions":5724},"NCT03047330","Menopausal Sleep Fragmentation and Body Fat Gain",[93],"2022-08-01","2017-07-15",[1823],[5705],{"trials":5726,"activeCount":102},[],{"intervention":5728,"totalTrials":265,"cells":5729},"Estradiol+MPA",{"EARLY_PHASE1":5730,"PHASE1":5732,"PHASE2":5734,"PHASE3":5736,"PHASE4":5738,"NA":5749},{"trials":5731,"activeCount":102},[],{"trials":5733,"activeCount":102},[],{"trials":5735,"activeCount":102},[],{"trials":5737,"activeCount":102},[],{"trials":5739,"activeCount":102},[5740],{"nctId":5741,"briefTitle":5742,"status":108,"phases":5743,"primaryCompletion":1600,"completion":5744,"start":5745,"enrollment":933,"conditions":5746,"interventions":5747},"NCT01109979","Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function",[93],"2016-06","2009-12",[30],[5728,5748],"Estradiol+Drospirenone",{"trials":5750,"activeCount":102},[],{"intervention":5748,"totalTrials":265,"cells":5752},{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5757,"PHASE3":5759,"PHASE4":5761,"NA":5767},{"trials":5754,"activeCount":102},[],{"trials":5756,"activeCount":102},[],{"trials":5758,"activeCount":102},[],{"trials":5760,"activeCount":102},[],{"trials":5762,"activeCount":102},[5763],{"nctId":5741,"briefTitle":5742,"status":108,"phases":5764,"primaryCompletion":1600,"completion":5744,"start":5745,"enrollment":933,"conditions":5765,"interventions":5766},[93],[30],[5728,5748],{"trials":5768,"activeCount":102},[],{"intervention":5770,"totalTrials":265,"cells":5771},"Azithromycin 500 mg",{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5778,"PHASE4":5780,"NA":5796},{"trials":5773,"activeCount":102},[],{"trials":5775,"activeCount":102},[],{"trials":5777,"activeCount":102},[],{"trials":5779,"activeCount":102},[],{"trials":5781,"activeCount":102},[5782],{"nctId":5783,"briefTitle":5784,"status":152,"phases":5785,"primaryCompletion":5786,"completion":5787,"start":5788,"enrollment":102,"conditions":5789,"interventions":5795},"NCT04171388","Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Ethiopia",[93],"2021-05-28","2021-11-30","2020-03-01",[5790,5791,5792,5793,4356,5794],"Low Birthweight","Preterm Birth","Maternal; Malnutrition, Affecting Fetus","Sexually Transmitted Diseases","Pregnancy and Infectious Disease",[5770],{"trials":5797,"activeCount":102},[],{"intervention":4529,"totalTrials":265,"cells":5799},{"EARLY_PHASE1":5800,"PHASE1":5802,"PHASE2":5804,"PHASE3":5806,"PHASE4":5808,"NA":5814},{"trials":5801,"activeCount":102},[],{"trials":5803,"activeCount":102},[],{"trials":5805,"activeCount":102},[],{"trials":5807,"activeCount":102},[],{"trials":5809,"activeCount":102},[5810],{"nctId":4517,"briefTitle":4518,"status":108,"phases":5811,"primaryCompletion":4520,"completion":4520,"start":4521,"enrollment":1870,"conditions":5812,"interventions":5813},[93],[4523,4524,4525,4526,4527],[4529,4495],{"trials":5815,"activeCount":102},[],{"intervention":5817,"totalTrials":265,"cells":5818},"Menactra",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5825,"PHASE4":5827,"NA":5838},{"trials":5820,"activeCount":102},[],{"trials":5822,"activeCount":102},[],{"trials":5824,"activeCount":102},[],{"trials":5826,"activeCount":102},[],{"trials":5828,"activeCount":102},[5829],{"nctId":5830,"briefTitle":5831,"status":436,"phases":5832,"primaryCompletion":791,"completion":5833,"start":1645,"enrollment":5834,"conditions":5835,"interventions":5837},"NCT04224311","Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors",[93],"2024-04-15",102,[5836],"Preventive Immunization; Meningitis",[5817],{"trials":5839,"activeCount":102},[],{"intervention":5841,"totalTrials":265,"cells":5842},"F-18 florbetapir PET",{"EARLY_PHASE1":5843,"PHASE1":5845,"PHASE2":5847,"PHASE3":5849,"PHASE4":5851,"NA":5862},{"trials":5844,"activeCount":102},[],{"trials":5846,"activeCount":102},[],{"trials":5848,"activeCount":102},[],{"trials":5850,"activeCount":102},[],{"trials":5852,"activeCount":102},[5853],{"nctId":5854,"briefTitle":5855,"status":108,"phases":5856,"primaryCompletion":5857,"completion":5858,"start":5859,"enrollment":113,"conditions":5860,"interventions":5861},"NCT01683825","Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography",[93],"2018-10-04","2018-10-10","2013-03-23",[1213],[5841],{"trials":5863,"activeCount":102},[],{"intervention":5865,"totalTrials":265,"cells":5866},"Improved Opioid-Tapering Instructions",{"EARLY_PHASE1":5867,"PHASE1":5869,"PHASE2":5871,"PHASE3":5873,"PHASE4":5875,"NA":5884},{"trials":5868,"activeCount":102},[],{"trials":5870,"activeCount":102},[],{"trials":5872,"activeCount":102},[],{"trials":5874,"activeCount":102},[],{"trials":5876,"activeCount":102},[5877],{"nctId":5878,"briefTitle":5879,"status":152,"phases":5880,"primaryCompletion":2829,"completion":4042,"start":5881,"enrollment":102,"conditions":5882,"interventions":5883},"NCT03534102","Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption",[93],"2022-06-06",[1812,5550,5549,5488],[5865],{"trials":5885,"activeCount":102},[],{"intervention":5887,"totalTrials":265,"cells":5888},"PARTICS using QVAR",{"EARLY_PHASE1":5889,"PHASE1":5891,"PHASE2":5893,"PHASE3":5895,"PHASE4":5897,"NA":5908},{"trials":5890,"activeCount":102},[],{"trials":5892,"activeCount":102},[],{"trials":5894,"activeCount":102},[],{"trials":5896,"activeCount":102},[],{"trials":5898,"activeCount":102},[5899],{"nctId":5900,"briefTitle":5901,"status":108,"phases":5902,"primaryCompletion":5903,"completion":5903,"start":5904,"enrollment":5905,"conditions":5906,"interventions":5907},"NCT02995733","Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief",[93],"2021-04-30","2017-11-27",1220,[18],[5887],{"trials":5909,"activeCount":102},[],{"intervention":5911,"totalTrials":265,"cells":5912},"Deucravacitinib",{"EARLY_PHASE1":5913,"PHASE1":5915,"PHASE2":5917,"PHASE3":5919,"PHASE4":5921,"NA":5932},{"trials":5914,"activeCount":102},[],{"trials":5916,"activeCount":102},[],{"trials":5918,"activeCount":102},[],{"trials":5920,"activeCount":102},[],{"trials":5922,"activeCount":102},[5923],{"nctId":5924,"briefTitle":5925,"status":239,"phases":5926,"primaryCompletion":5927,"completion":5928,"start":333,"enrollment":197,"conditions":5929,"interventions":5931},"NCT05710185","Deucravacitinib for the Treatment of Palmoplantar Pustulosis",[93],"2024-12-01","2025-01-31",[5930],"Palmoplantar Pustulosis",[5911],{"trials":5933,"activeCount":102},[],{"intervention":5935,"totalTrials":265,"cells":5936},"levofloxacin",{"EARLY_PHASE1":5937,"PHASE1":5939,"PHASE2":5941,"PHASE3":5943,"PHASE4":5945,"NA":5955},{"trials":5938,"activeCount":102},[],{"trials":5940,"activeCount":102},[],{"trials":5942,"activeCount":102},[],{"trials":5944,"activeCount":102},[],{"trials":5946,"activeCount":102},[5947],{"nctId":5948,"briefTitle":5949,"status":108,"phases":5950,"primaryCompletion":4486,"completion":965,"start":4728,"enrollment":5951,"conditions":5952,"interventions":5954},"NCT01034176","BK Treatment Study",[93],43,[5953],"BK Viremia",[5935],{"trials":5956,"activeCount":102},[],{"intervention":5958,"totalTrials":265,"cells":5959},"Hydromorphone 25mcg",{"EARLY_PHASE1":5960,"PHASE1":5962,"PHASE2":5964,"PHASE3":5966,"PHASE4":5968,"NA":5981},{"trials":5961,"activeCount":102},[],{"trials":5963,"activeCount":102},[],{"trials":5965,"activeCount":102},[],{"trials":5967,"activeCount":102},[],{"trials":5969,"activeCount":102},[5970],{"nctId":5971,"briefTitle":5972,"status":239,"phases":5973,"primaryCompletion":3612,"completion":227,"start":362,"enrollment":5974,"conditions":5975,"interventions":5977},"NCT01943565","Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study",[93],29,[33,1811,5976],"Pregnancy",[5958,5978,5979,5980],"Hydromorphone 50mcg","Hydromorphone 100mcg","spinal anesthesia",{"trials":5982,"activeCount":102},[],{"intervention":5978,"totalTrials":265,"cells":5984},{"EARLY_PHASE1":5985,"PHASE1":5987,"PHASE2":5989,"PHASE3":5991,"PHASE4":5993,"NA":5999},{"trials":5986,"activeCount":102},[],{"trials":5988,"activeCount":102},[],{"trials":5990,"activeCount":102},[],{"trials":5992,"activeCount":102},[],{"trials":5994,"activeCount":102},[5995],{"nctId":5971,"briefTitle":5972,"status":239,"phases":5996,"primaryCompletion":3612,"completion":227,"start":362,"enrollment":5974,"conditions":5997,"interventions":5998},[93],[33,1811,5976],[5958,5978,5979,5980],{"trials":6000,"activeCount":102},[],{"intervention":5979,"totalTrials":265,"cells":6002},{"EARLY_PHASE1":6003,"PHASE1":6005,"PHASE2":6007,"PHASE3":6009,"PHASE4":6011,"NA":6017},{"trials":6004,"activeCount":102},[],{"trials":6006,"activeCount":102},[],{"trials":6008,"activeCount":102},[],{"trials":6010,"activeCount":102},[],{"trials":6012,"activeCount":102},[6013],{"nctId":5971,"briefTitle":5972,"status":239,"phases":6014,"primaryCompletion":3612,"completion":227,"start":362,"enrollment":5974,"conditions":6015,"interventions":6016},[93],[33,1811,5976],[5958,5978,5979,5980],{"trials":6018,"activeCount":102},[],{"intervention":5980,"totalTrials":265,"cells":6020},{"EARLY_PHASE1":6021,"PHASE1":6023,"PHASE2":6025,"PHASE3":6027,"PHASE4":6029,"NA":6035},{"trials":6022,"activeCount":102},[],{"trials":6024,"activeCount":102},[],{"trials":6026,"activeCount":102},[],{"trials":6028,"activeCount":102},[],{"trials":6030,"activeCount":102},[6031],{"nctId":5971,"briefTitle":5972,"status":239,"phases":6032,"primaryCompletion":3612,"completion":227,"start":362,"enrollment":5974,"conditions":6033,"interventions":6034},[93],[33,1811,5976],[5958,5978,5979,5980],{"trials":6036,"activeCount":102},[],{"intervention":6038,"totalTrials":265,"cells":6039},"erythropoeitin",{"EARLY_PHASE1":6040,"PHASE1":6042,"PHASE2":6044,"PHASE3":6046,"PHASE4":6048,"NA":6058},{"trials":6041,"activeCount":102},[],{"trials":6043,"activeCount":102},[],{"trials":6045,"activeCount":102},[],{"trials":6047,"activeCount":102},[],{"trials":6049,"activeCount":102},[6050],{"nctId":6051,"briefTitle":6052,"status":239,"phases":6053,"primaryCompletion":1505,"completion":6054,"start":4909,"enrollment":258,"conditions":6055,"interventions":6057},"NCT00476619","Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial",[93],"2008-06",[6056],"Contrast Induced Nephropathy",[6038],{"trials":6059,"activeCount":102},[],{"intervention":6061,"totalTrials":265,"cells":6062},"Hydralazine\u002FIsorsorbide Dinitrate",{"EARLY_PHASE1":6063,"PHASE1":6065,"PHASE2":6067,"PHASE3":6069,"PHASE4":6071,"NA":6082},{"trials":6064,"activeCount":102},[],{"trials":6066,"activeCount":102},[],{"trials":6068,"activeCount":102},[],{"trials":6070,"activeCount":102},[],{"trials":6072,"activeCount":102},[6073],{"nctId":6074,"briefTitle":6075,"status":108,"phases":6076,"primaryCompletion":6077,"completion":6077,"start":6078,"enrollment":258,"conditions":6079,"interventions":6081},"NCT02228408","Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD",[93],"2019-05-07","2017-08-28",[6080],"Chronic Hemodialysis (ESRD)",[6061],{"trials":6083,"activeCount":102},[],{"intervention":6085,"totalTrials":265,"cells":6086},"Exercise plus Regadenoson",{"EARLY_PHASE1":6087,"PHASE1":6089,"PHASE2":6091,"PHASE3":6093,"PHASE4":6095,"NA":6107},{"trials":6088,"activeCount":102},[],{"trials":6090,"activeCount":102},[],{"trials":6092,"activeCount":102},[],{"trials":6094,"activeCount":102},[],{"trials":6096,"activeCount":102},[6097],{"nctId":6098,"briefTitle":6099,"status":108,"phases":6100,"primaryCompletion":6101,"completion":6101,"start":6102,"enrollment":5951,"conditions":6103,"interventions":6105},"NCT01109992","Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET",[93],"2017-06-06","2011-02",[6104],"Coronary Artery Disease",[6085,6106],"Regadenoson",{"trials":6108,"activeCount":102},[],{"intervention":6106,"totalTrials":265,"cells":6110},{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6117,"PHASE4":6119,"NA":6125},{"trials":6112,"activeCount":102},[],{"trials":6114,"activeCount":102},[],{"trials":6116,"activeCount":102},[],{"trials":6118,"activeCount":102},[],{"trials":6120,"activeCount":102},[6121],{"nctId":6098,"briefTitle":6099,"status":108,"phases":6122,"primaryCompletion":6101,"completion":6101,"start":6102,"enrollment":5951,"conditions":6123,"interventions":6124},[93],[6104],[6085,6106],{"trials":6126,"activeCount":102},[],{"intervention":6128,"totalTrials":265,"cells":6129},"brexanolone",{"EARLY_PHASE1":6130,"PHASE1":6132,"PHASE2":6134,"PHASE3":6136,"PHASE4":6138,"NA":6148},{"trials":6131,"activeCount":102},[],{"trials":6133,"activeCount":102},[],{"trials":6135,"activeCount":102},[],{"trials":6137,"activeCount":102},[],{"trials":6139,"activeCount":102},[6140],{"nctId":6141,"briefTitle":6142,"status":239,"phases":6143,"primaryCompletion":6144,"completion":6144,"start":6145,"enrollment":281,"conditions":6146,"interventions":6147},"NCT05329779","Study on Allopregnanolone and Depression in Perimenopausal Women",[93],"2023-07-18","2022-11-04",[1060],[6128],{"trials":6149,"activeCount":102},[],{"intervention":6151,"totalTrials":265,"cells":6152},"Calcium Chloride",{"EARLY_PHASE1":6153,"PHASE1":6155,"PHASE2":6157,"PHASE3":6159,"PHASE4":6161,"NA":6171},{"trials":6154,"activeCount":102},[],{"trials":6156,"activeCount":102},[],{"trials":6158,"activeCount":102},[],{"trials":6160,"activeCount":102},[],{"trials":6162,"activeCount":102},[6163],{"nctId":6164,"briefTitle":6165,"status":239,"phases":6166,"primaryCompletion":6167,"completion":6167,"start":4582,"enrollment":3801,"conditions":6168,"interventions":6170},"NCT00955266","A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass",[93],"2010-02",[6169],"Diastolic Dysfunction",[6151],{"trials":6172,"activeCount":102},[],{"intervention":6174,"totalTrials":265,"cells":6175},"Milnacipran",{"EARLY_PHASE1":6176,"PHASE1":6178,"PHASE2":6180,"PHASE3":6182,"PHASE4":6184,"NA":6193},{"trials":6177,"activeCount":102},[],{"trials":6179,"activeCount":102},[],{"trials":6181,"activeCount":102},[],{"trials":6183,"activeCount":102},[],{"trials":6185,"activeCount":102},[6186],{"nctId":6187,"briefTitle":6188,"status":108,"phases":6189,"primaryCompletion":6190,"completion":6190,"start":228,"enrollment":2188,"conditions":6191,"interventions":6192},"NCT01207453","Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis",[93],"2013-11",[3615],[6174],{"trials":6194,"activeCount":102},[],{"intervention":6196,"totalTrials":265,"cells":6197},"four factor prothrombin complex concentrate",{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6202,"PHASE3":6204,"PHASE4":6206,"NA":6217},{"trials":6199,"activeCount":102},[],{"trials":6201,"activeCount":102},[],{"trials":6203,"activeCount":102},[],{"trials":6205,"activeCount":102},[],{"trials":6207,"activeCount":102},[6208],{"nctId":6209,"briefTitle":6210,"status":436,"phases":6211,"primaryCompletion":991,"completion":1021,"start":6212,"enrollment":531,"conditions":6213,"interventions":6216},"NCT03473132","Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)",[93],"2018-03-15",[6214,6215],"Anticoagulation","Anticoagulation Reversal",[6196],{"trials":6218,"activeCount":102},[],{"intervention":6220,"totalTrials":265,"cells":6221},"Eplerenone vs Amlodipine",{"EARLY_PHASE1":6222,"PHASE1":6224,"PHASE2":6226,"PHASE3":6228,"PHASE4":6230,"NA":6241},{"trials":6223,"activeCount":102},[],{"trials":6225,"activeCount":102},[],{"trials":6227,"activeCount":102},[],{"trials":6229,"activeCount":102},[],{"trials":6231,"activeCount":102},[6232],{"nctId":6233,"briefTitle":6234,"status":108,"phases":6235,"primaryCompletion":6236,"completion":1565,"start":6237,"enrollment":1480,"conditions":6238,"interventions":6240},"NCT03683069","Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN",[93],"2023-08-28","2019-01-15",[15,6239],"Genetics Hypertension",[6220],{"trials":6242,"activeCount":102},[],{"intervention":6244,"totalTrials":1082,"cells":6245},"Melatonin",{"EARLY_PHASE1":6246,"PHASE1":6248,"PHASE2":6250,"PHASE3":6278,"PHASE4":6287,"NA":6289},{"trials":6247,"activeCount":102},[],{"trials":6249,"activeCount":102},[],{"trials":6251,"activeCount":102},[6252,6262,6270],{"nctId":6253,"briefTitle":6254,"status":152,"phases":6255,"primaryCompletion":205,"completion":6256,"start":6257,"enrollment":102,"conditions":6258,"interventions":6260},"NCT00869869","Melatonin Supplementation to Improve Sleep in Patients With Heart Failure",[91],"2011-03","2009-03",[24,6259],"Sleep Disorders",[6261],"melatonin",{"nctId":6263,"briefTitle":6264,"status":108,"phases":6265,"primaryCompletion":6266,"completion":6266,"start":6267,"enrollment":206,"conditions":6268,"interventions":6269},"NCT00238108","Melatonin Supplements for Improving Sleep in Individuals With Hypertension",[91],"2010-08","2005-10",[6259,15],[6244],{"nctId":6271,"briefTitle":6272,"status":239,"phases":6273,"primaryCompletion":6274,"completion":6274,"start":112,"enrollment":2917,"conditions":6275,"interventions":6277},"NCT02631148","Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.",[91],"2017-12-31",[21,6276],"Prediabetic State",[6244],{"trials":6279,"activeCount":102},[6280],{"nctId":6281,"briefTitle":6282,"status":436,"phases":6283,"primaryCompletion":6284,"completion":1048,"start":5042,"enrollment":429,"conditions":6285,"interventions":6286},"NCT02681887","Effect of Melatonin on Cardiometabolic Risk- FULL",[92],"2021-06",[21,6276],[6244],{"trials":6288,"activeCount":102},[],{"trials":6290,"activeCount":102},[],{"intervention":6292,"totalTrials":281,"cells":6293},"Testosterone enanthate",{"EARLY_PHASE1":6294,"PHASE1":6296,"PHASE2":6298,"PHASE3":6300,"PHASE4":6320,"NA":6322},{"trials":6295,"activeCount":102},[],{"trials":6297,"activeCount":102},[],{"trials":6299,"activeCount":102},[],{"trials":6301,"activeCount":102},[6302,6312],{"nctId":6303,"briefTitle":6304,"status":108,"phases":6305,"primaryCompletion":6306,"completion":6306,"start":6307,"enrollment":6308,"conditions":6309,"interventions":6311},"NCT01275365","Optimizing Protein Intake in Older Americans With Mobility Limitations",[92],"2017-01-19","2011-05",92,[6310],"Mobility Limitation",[6292,6292],{"nctId":6313,"briefTitle":6314,"status":152,"phases":6315,"primaryCompletion":6316,"completion":2288,"start":2311,"enrollment":102,"conditions":6317,"interventions":6318},"NCT04026880","Testosterone Effects on Pelvic Floor Muscles",[92],"2022-01-01",[4358,1823],[6319],"Testosterone Enanthate",{"trials":6321,"activeCount":102},[],{"trials":6323,"activeCount":102},[],{"intervention":6325,"totalTrials":281,"cells":6326},"Vitamin E",{"EARLY_PHASE1":6327,"PHASE1":6329,"PHASE2":6331,"PHASE3":6349,"PHASE4":6364,"NA":6366},{"trials":6328,"activeCount":102},[],{"trials":6330,"activeCount":102},[],{"trials":6332,"activeCount":102},[6333],{"nctId":6334,"briefTitle":6335,"status":108,"phases":6336,"primaryCompletion":6337,"completion":6337,"start":6338,"conditions":6339,"interventions":6344},"NCT00000541","Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)",[91],"2005-07","1993-05",[30,6340,6341,6342,978,6343],"Coronary Arteriosclerosis","Coronary Disease","Heart Diseases","Myocardial Ischemia",[6345,6346,6347,6348],"vitamin C","vitamin E","beta-carotene","folic acid\u002FVitamin B6\u002FVitamin B12",{"trials":6350,"activeCount":102},[6351],{"nctId":6352,"briefTitle":6353,"status":108,"phases":6354,"primaryCompletion":6355,"completion":6356,"start":6357,"enrollment":6358,"conditions":6359,"interventions":6362},"NCT00000479","Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer",[92],"2004-03","2005-02","1992-09",39876,[30,6360,6341,6342,978,6343,6361],"Cerebrovascular Disorders","Vascular Diseases",[6363,6325],"Aspirin",{"trials":6365,"activeCount":102},[],{"trials":6367,"activeCount":102},[],{"intervention":6369,"totalTrials":281,"cells":6370},"acipimox",{"EARLY_PHASE1":6371,"PHASE1":6373,"PHASE2":6375,"PHASE3":6385,"PHASE4":6396,"NA":6398},{"trials":6372,"activeCount":102},[],{"trials":6374,"activeCount":102},[],{"trials":6376,"activeCount":102},[6377],{"nctId":6378,"briefTitle":6379,"status":108,"phases":6380,"primaryCompletion":6381,"completion":363,"start":6382,"enrollment":167,"conditions":6383,"interventions":6384},"NCT00153179","Free Fatty Acids and Vascular Function in Subjects With Diabetes",[90,91],"2011-12","2005-09",[1368],[6369],{"trials":6386,"activeCount":102},[6387],{"nctId":6388,"briefTitle":6389,"status":108,"phases":6390,"primaryCompletion":6391,"completion":6392,"start":6393,"enrollment":167,"conditions":6394,"interventions":6395},"NCT00759291","The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome",[91,92],"2017-12-01","2017-12-30","2006-04-01",[145],[6369],{"trials":6397,"activeCount":102},[],{"trials":6399,"activeCount":102},[],{"intervention":6401,"totalTrials":281,"cells":6402},"Atazanavir",{"EARLY_PHASE1":6403,"PHASE1":6405,"PHASE2":6416,"PHASE3":6418,"PHASE4":6426,"NA":6428},{"trials":6404,"activeCount":102},[],{"trials":6406,"activeCount":102},[6407],{"nctId":6408,"briefTitle":6409,"status":108,"phases":6410,"primaryCompletion":6411,"completion":6411,"start":6412,"enrollment":364,"conditions":6413,"interventions":6415},"NCT01421355","A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus",[90],"2014-02","2012-05",[6414],"Type 1 Diabetes Mellitus",[6401],{"trials":6417,"activeCount":102},[],{"trials":6419,"activeCount":102},[6420],{"nctId":6421,"briefTitle":6422,"status":108,"phases":6423,"primaryCompletion":3140,"completion":5744,"start":6381,"enrollment":607,"conditions":6424,"interventions":6425},"NCT03019783","Atazanavir and Endothelial Function in Older HIV Patients",[91,92],[1873],[6401],{"trials":6427,"activeCount":102},[],{"trials":6429,"activeCount":102},[],{"intervention":473,"totalTrials":281,"cells":6431},{"EARLY_PHASE1":6432,"PHASE1":6434,"PHASE2":6436,"PHASE3":6438,"PHASE4":6452,"NA":6454},{"trials":6433,"activeCount":102},[],{"trials":6435,"activeCount":102},[],{"trials":6437,"activeCount":102},[],{"trials":6439,"activeCount":102},[6440,6444],{"nctId":465,"briefTitle":466,"status":108,"phases":6441,"completion":468,"start":469,"enrollment":167,"conditions":6442,"interventions":6443},[92],[471],[473,454],{"nctId":6445,"briefTitle":6446,"status":108,"phases":6447,"completion":6448,"start":6449,"enrollment":19,"conditions":6450,"interventions":6451},"NCT00115817","The Effects of Atorvastatin in Patients With Atherosclerosis",[92],"2007-03","2005-06",[471],[473],{"trials":6453,"activeCount":102},[],{"trials":6455,"activeCount":102},[],{"intervention":6457,"totalTrials":281,"cells":6458},"Ferumoxytol",{"EARLY_PHASE1":6459,"PHASE1":6461,"PHASE2":6471,"PHASE3":6473,"PHASE4":6485,"NA":6487},{"trials":6460,"activeCount":102},[],{"trials":6462,"activeCount":102},[6463],{"nctId":6464,"briefTitle":6465,"status":108,"phases":6466,"primaryCompletion":6467,"completion":6467,"start":6468,"enrollment":265,"conditions":6469,"interventions":6470},"NCT03173066","Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography",[90],"2022-05-31","2018-09-21",[3871],[6457],{"trials":6472,"activeCount":102},[],{"trials":6474,"activeCount":102},[6475],{"nctId":6476,"briefTitle":6477,"status":436,"phases":6478,"primaryCompletion":3214,"completion":6479,"start":6480,"enrollment":6481,"conditions":6482,"interventions":6483},"NCT02954510","Ferumoxytol-enhanced Magnetic Resonance Imaging",[92],"2024-02-27","2017-02-01",185,[6104],[6484],"ferumoxytol",{"trials":6486,"activeCount":102},[],{"trials":6488,"activeCount":102},[],{"intervention":6490,"totalTrials":281,"cells":6491},"Mannitol",{"EARLY_PHASE1":6492,"PHASE1":6494,"PHASE2":6496,"PHASE3":6507,"PHASE4":6518,"NA":6520},{"trials":6493,"activeCount":102},[],{"trials":6495,"activeCount":102},[],{"trials":6497,"activeCount":102},[6498],{"nctId":6499,"briefTitle":6500,"status":108,"phases":6501,"primaryCompletion":3612,"completion":6502,"start":6412,"enrollment":5486,"conditions":6503,"interventions":6505},"NCT01520207","Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension",[91],"2018-12",[6504],"Intra-dialytic Hypotension",[6490,6506],"0.9% saline",{"trials":6508,"activeCount":102},[6509],{"nctId":6510,"briefTitle":6511,"status":108,"phases":6512,"primaryCompletion":86,"completion":86,"start":6513,"enrollment":1506,"conditions":6514,"interventions":6517},"NCT04428372","MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)",[91,92],"2021-04-06",[6515,6516],"Hemodialysis Complication","Hemodynamic Instability",[6490,6506],{"trials":6519,"activeCount":102},[],{"trials":6521,"activeCount":102},[],{"intervention":6506,"totalTrials":281,"cells":6523},{"EARLY_PHASE1":6524,"PHASE1":6526,"PHASE2":6528,"PHASE3":6534,"PHASE4":6540,"NA":6542},{"trials":6525,"activeCount":102},[],{"trials":6527,"activeCount":102},[],{"trials":6529,"activeCount":102},[6530],{"nctId":6499,"briefTitle":6500,"status":108,"phases":6531,"primaryCompletion":3612,"completion":6502,"start":6412,"enrollment":5486,"conditions":6532,"interventions":6533},[91],[6504],[6490,6506],{"trials":6535,"activeCount":102},[6536],{"nctId":6510,"briefTitle":6511,"status":108,"phases":6537,"primaryCompletion":86,"completion":86,"start":6513,"enrollment":1506,"conditions":6538,"interventions":6539},[91,92],[6515,6516],[6490,6506],{"trials":6541,"activeCount":102},[],{"trials":6543,"activeCount":102},[],{"intervention":6545,"totalTrials":265,"cells":6546},"thiopental\u002Fpentobarbital",{"EARLY_PHASE1":6547,"PHASE1":6549,"PHASE2":6551,"PHASE3":6553,"PHASE4":6563,"NA":6565},{"trials":6548,"activeCount":102},[],{"trials":6550,"activeCount":102},[],{"trials":6552,"activeCount":102},[],{"trials":6554,"activeCount":102},[6555],{"nctId":6556,"briefTitle":6557,"status":239,"phases":6558,"primaryCompletion":205,"completion":205,"start":4005,"enrollment":113,"conditions":6559,"interventions":6561},"NCT00265616","Treatment of Refractory Status Epilepticus",[92],[6560],"Status Epilepticus",[6562,6545],"propofol",{"trials":6564,"activeCount":102},[],{"trials":6566,"activeCount":102},[],{"intervention":6568,"totalTrials":265,"cells":6569},"0.25% Timolol gel with paraffin gauze dressings",{"EARLY_PHASE1":6570,"PHASE1":6572,"PHASE2":6574,"PHASE3":6576,"PHASE4":6591,"NA":6593},{"trials":6571,"activeCount":102},[],{"trials":6573,"activeCount":102},[],{"trials":6575,"activeCount":102},[],{"trials":6577,"activeCount":102},[6578],{"nctId":6579,"briefTitle":6580,"status":108,"phases":6581,"primaryCompletion":6582,"completion":4520,"start":6583,"enrollment":6584,"conditions":6585,"interventions":6590},"NCT03452072","Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds",[91,92],"2020-12-29","2018-08-20",87,[6586,6587,6588,6589],"Wound of Skin","Wound Heal","Wound Open","Surgical Wound",[6568],{"trials":6592,"activeCount":102},[],{"trials":6594,"activeCount":102},[],{"intervention":6596,"totalTrials":265,"cells":6597},"Descovy or Truvada",{"EARLY_PHASE1":6598,"PHASE1":6600,"PHASE2":6602,"PHASE3":6604,"PHASE4":6616,"NA":6618},{"trials":6599,"activeCount":102},[],{"trials":6601,"activeCount":102},[],{"trials":6603,"activeCount":102},[],{"trials":6605,"activeCount":102},[6606],{"nctId":6607,"briefTitle":6608,"status":108,"phases":6609,"primaryCompletion":6610,"completion":6610,"start":6611,"enrollment":167,"conditions":6612,"interventions":6615},"NCT05378399","SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder",[92],"2026-02-27","2022-12-20",[4695,6613,4707,6614],"Substance Use","Adherence, Treatment",[6596],{"trials":6617,"activeCount":102},[],{"trials":6619,"activeCount":102},[],{"intervention":3957,"totalTrials":265,"cells":6621},{"EARLY_PHASE1":6622,"PHASE1":6624,"PHASE2":6626,"PHASE3":6628,"PHASE4":6634,"NA":6636},{"trials":6623,"activeCount":102},[],{"trials":6625,"activeCount":102},[],{"trials":6627,"activeCount":102},[],{"trials":6629,"activeCount":102},[6630],{"nctId":3950,"briefTitle":3951,"status":108,"phases":6631,"primaryCompletion":3953,"completion":3953,"start":1079,"enrollment":3954,"conditions":6632,"interventions":6633},[92],[1258],[3957,1053],{"trials":6635,"activeCount":102},[],{"trials":6637,"activeCount":102},[],{"intervention":6639,"totalTrials":265,"cells":6640},"Biktarvy",{"EARLY_PHASE1":6641,"PHASE1":6643,"PHASE2":6645,"PHASE3":6647,"PHASE4":6656,"NA":6658},{"trials":6642,"activeCount":102},[],{"trials":6644,"activeCount":102},[],{"trials":6646,"activeCount":102},[],{"trials":6648,"activeCount":102},[6649],{"nctId":6650,"briefTitle":6651,"status":108,"phases":6652,"primaryCompletion":2464,"completion":2464,"start":6653,"enrollment":2966,"conditions":6654,"interventions":6655},"NCT03656783","Effects of Biktarvy on CFR in Stable HIV Patients",[92],"2018-09-14",[1873],[6639],{"trials":6657,"activeCount":102},[],{"trials":6659,"activeCount":102},[],{"intervention":6661,"totalTrials":265,"cells":6662},"Borage and Echium Seed Oils",{"EARLY_PHASE1":6663,"PHASE1":6665,"PHASE2":6667,"PHASE3":6669,"PHASE4":6680,"NA":6682},{"trials":6664,"activeCount":102},[],{"trials":6666,"activeCount":102},[],{"trials":6668,"activeCount":102},[],{"trials":6670,"activeCount":102},[6671],{"nctId":6672,"briefTitle":6673,"status":108,"phases":6674,"primaryCompletion":6675,"completion":6675,"start":6676,"enrollment":6677,"conditions":6678,"interventions":6679},"NCT01560988","Borage and Echium Seed Oils for Asthma",[92],"2015-05","2013-02",62,[18],[6661],{"trials":6681,"activeCount":102},[],{"trials":6683,"activeCount":102},[],{"intervention":6685,"totalTrials":265,"cells":6686},"Truvada for pre-exposure prophylaxis",{"EARLY_PHASE1":6687,"PHASE1":6689,"PHASE2":6691,"PHASE3":6693,"PHASE4":6707,"NA":6709},{"trials":6688,"activeCount":102},[],{"trials":6690,"activeCount":102},[],{"trials":6692,"activeCount":102},[],{"trials":6694,"activeCount":102},[6695],{"nctId":6696,"briefTitle":6697,"status":108,"phases":6698,"primaryCompletion":6699,"completion":6699,"start":6700,"enrollment":364,"conditions":6701,"interventions":6705},"NCT05592613","Next Generation Ingestible Sensors for Medication Adherence Measurement",[92],"2024-07-25","2023-02-06",[6702,4707,6614,6703,6704],"HIV Infection","Pre-Exposure Prophylaxis","Antiretroviral Therapy",[6685,6706],"Biktarvy for antiretroviral therapy",{"trials":6708,"activeCount":102},[],{"trials":6710,"activeCount":102},[],{"intervention":6706,"totalTrials":265,"cells":6712},{"EARLY_PHASE1":6713,"PHASE1":6715,"PHASE2":6717,"PHASE3":6719,"PHASE4":6725,"NA":6727},{"trials":6714,"activeCount":102},[],{"trials":6716,"activeCount":102},[],{"trials":6718,"activeCount":102},[],{"trials":6720,"activeCount":102},[6721],{"nctId":6696,"briefTitle":6697,"status":108,"phases":6722,"primaryCompletion":6699,"completion":6699,"start":6700,"enrollment":364,"conditions":6723,"interventions":6724},[92],[6702,4707,6614,6703,6704],[6685,6706],{"trials":6726,"activeCount":102},[],{"trials":6728,"activeCount":102},[],{"intervention":6730,"totalTrials":265,"cells":6731},"Vitamin D ergocalciferol",{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6736,"PHASE3":6738,"PHASE4":6752,"NA":6754},{"trials":6733,"activeCount":102},[],{"trials":6735,"activeCount":102},[],{"trials":6737,"activeCount":102},[],{"trials":6739,"activeCount":102},[6740],{"nctId":6741,"briefTitle":6742,"status":108,"phases":6743,"primaryCompletion":6675,"completion":3140,"start":6256,"enrollment":6744,"conditions":6745,"interventions":6749},"NCT01320722","Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function",[92],242,[6746,6747,6748,1280,21],"Renal Function","Endothelial Function","Blood Pressure",[6730,6750,6751],"Probenecid","Allopurinol",{"trials":6753,"activeCount":102},[],{"trials":6755,"activeCount":102},[],{"intervention":134,"totalTrials":265,"cells":6757},{"EARLY_PHASE1":6758,"PHASE1":6760,"PHASE2":6762,"PHASE3":6764,"PHASE4":6770,"NA":6772},{"trials":6759,"activeCount":102},[],{"trials":6761,"activeCount":102},[],{"trials":6763,"activeCount":102},[],{"trials":6765,"activeCount":102},[6766],{"nctId":123,"briefTitle":124,"status":108,"phases":6767,"primaryCompletion":126,"completion":127,"start":112,"enrollment":128,"conditions":6768,"interventions":6769},[91,92],[130],[132,133,134],{"trials":6771,"activeCount":102},[],{"trials":6773,"activeCount":102},[],{"intervention":6775,"totalTrials":265,"cells":6776},"Ranolazine",{"EARLY_PHASE1":6777,"PHASE1":6779,"PHASE2":6781,"PHASE3":6783,"PHASE4":6797,"NA":6799},{"trials":6778,"activeCount":102},[],{"trials":6780,"activeCount":102},[],{"trials":6782,"activeCount":102},[],{"trials":6784,"activeCount":102},[6785],{"nctId":6786,"briefTitle":6787,"status":108,"phases":6788,"primaryCompletion":6789,"completion":6790,"start":3601,"enrollment":6791,"conditions":6792,"interventions":6796},"NCT01754259","Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD",[92],"2015-10","2015-12",47,[6793,6794,6795,6104],"Diabetes, Type I","Diabetes, Type II","Angina",[6775],{"trials":6798,"activeCount":102},[],{"trials":6800,"activeCount":102},[],{"intervention":6802,"totalTrials":265,"cells":6803},"lacosamide",{"EARLY_PHASE1":6804,"PHASE1":6806,"PHASE2":6808,"PHASE3":6810,"PHASE4":6823,"NA":6825},{"trials":6805,"activeCount":102},[],{"trials":6807,"activeCount":102},[],{"trials":6809,"activeCount":102},[],{"trials":6811,"activeCount":102},[6812],{"nctId":6813,"briefTitle":6814,"status":108,"phases":6815,"primaryCompletion":6816,"completion":6817,"start":6818,"enrollment":6819,"conditions":6820,"interventions":6821},"NCT01345058","Add on Lacosamide Versus High Dose Monotherapy",[92],"2014-02-15","2014-10-21","2011-08-01",56,[3190],[6802,6822],"levetiracetam",{"trials":6824,"activeCount":102},[],{"trials":6826,"activeCount":102},[],{"intervention":6822,"totalTrials":265,"cells":6828},{"EARLY_PHASE1":6829,"PHASE1":6831,"PHASE2":6833,"PHASE3":6835,"PHASE4":6841,"NA":6843},{"trials":6830,"activeCount":102},[],{"trials":6832,"activeCount":102},[],{"trials":6834,"activeCount":102},[],{"trials":6836,"activeCount":102},[6837],{"nctId":6813,"briefTitle":6814,"status":108,"phases":6838,"primaryCompletion":6816,"completion":6817,"start":6818,"enrollment":6819,"conditions":6839,"interventions":6840},[92],[3190],[6802,6822],{"trials":6842,"activeCount":102},[],{"trials":6844,"activeCount":102},[],{"intervention":6846,"totalTrials":265,"cells":6847},"salsalate",{"EARLY_PHASE1":6848,"PHASE1":6850,"PHASE2":6852,"PHASE3":6854,"PHASE4":6865,"NA":6867},{"trials":6849,"activeCount":102},[],{"trials":6851,"activeCount":102},[],{"trials":6853,"activeCount":102},[],{"trials":6855,"activeCount":102},[6856],{"nctId":6857,"briefTitle":6858,"status":108,"phases":6859,"primaryCompletion":6860,"completion":6102,"start":6861,"enrollment":6862,"conditions":6863,"interventions":6864},"NCT00760019","Inflammation and Vascular Function in Atherosclerosis",[91,92],"2009-10","2005-08",58,[471],[6846],{"trials":6866,"activeCount":102},[],{"trials":6868,"activeCount":102},[],{"intervention":6870,"totalTrials":265,"cells":6871},"Ruboxistaurin",{"EARLY_PHASE1":6872,"PHASE1":6874,"PHASE2":6876,"PHASE3":6878,"PHASE4":6887,"NA":6889},{"trials":6873,"activeCount":102},[],{"trials":6875,"activeCount":102},[],{"trials":6877,"activeCount":102},[],{"trials":6879,"activeCount":102},[6880],{"nctId":6881,"briefTitle":6882,"status":108,"phases":6883,"primaryCompletion":4799,"completion":4799,"start":6884,"enrollment":678,"conditions":6885,"interventions":6886},"NCT00761852","Signaling Mechanisms and Vascular Function in Diabetes Mellitus",[91,92],"1999-05",[6414,1368],[6870],{"trials":6888,"activeCount":102},[],{"trials":6890,"activeCount":102},[],{"intervention":6892,"totalTrials":265,"cells":6893},"0.25% timolol gel with full-thickness skin grafts",{"EARLY_PHASE1":6894,"PHASE1":6896,"PHASE2":6898,"PHASE3":6900,"PHASE4":6910,"NA":6912},{"trials":6895,"activeCount":102},[],{"trials":6897,"activeCount":102},[],{"trials":6899,"activeCount":102},[],{"trials":6901,"activeCount":102},[6902],{"nctId":6903,"briefTitle":6904,"status":239,"phases":6905,"primaryCompletion":2659,"completion":2659,"start":6906,"enrollment":98,"conditions":6907,"interventions":6909},"NCT03579160","Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes",[91,92],"2019-01-02",[6586,6587,6589,6908],"Full Thickness Skin Graft Healing",[6892],{"trials":6911,"activeCount":102},[],{"trials":6913,"activeCount":102},[],{"intervention":1677,"totalTrials":265,"cells":6915},{"EARLY_PHASE1":6916,"PHASE1":6918,"PHASE2":6920,"PHASE3":6922,"PHASE4":6928,"NA":6930},{"trials":6917,"activeCount":102},[],{"trials":6919,"activeCount":102},[],{"trials":6921,"activeCount":102},[],{"trials":6923,"activeCount":102},[6924],{"nctId":1669,"briefTitle":1670,"status":108,"phases":6925,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":98,"conditions":6926,"interventions":6927},[92],[1675],[1677,1610],{"trials":6929,"activeCount":102},[],{"trials":6931,"activeCount":102},[],{"intervention":6933,"totalTrials":265,"cells":6934},"Colestipol",{"EARLY_PHASE1":6935,"PHASE1":6937,"PHASE2":6939,"PHASE3":6941,"PHASE4":6951,"NA":6953},{"trials":6936,"activeCount":102},[],{"trials":6938,"activeCount":102},[],{"trials":6940,"activeCount":102},[],{"trials":6942,"activeCount":102},[6943],{"nctId":6944,"briefTitle":6945,"status":108,"phases":6946,"primaryCompletion":6947,"completion":6947,"start":6307,"enrollment":1082,"conditions":6948,"interventions":6950},"NCT01422915","Sorbent Therapy of the Cutaneous Porphyrias",[91,92],"2012-03",[6949],"Erythropoietic Protoporphyria",[6933],{"trials":6952,"activeCount":102},[],{"trials":6954,"activeCount":102},[],{"intervention":6956,"totalTrials":265,"cells":6957},"Diclofenac and Atropine combination drug",{"EARLY_PHASE1":6958,"PHASE1":6960,"PHASE2":6962,"PHASE3":6964,"PHASE4":6974,"NA":6976},{"trials":6959,"activeCount":102},[],{"trials":6961,"activeCount":102},[],{"trials":6963,"activeCount":102},[],{"trials":6965,"activeCount":102},[6966],{"nctId":6967,"briefTitle":6968,"status":108,"phases":6969,"primaryCompletion":6970,"completion":6971,"start":361,"enrollment":296,"conditions":6972,"interventions":6973},"NCT02194088","Combined Medication for Improved Analgesia in Superficial Pain",[92],"2014-11","2017-06",[1811],[6956],{"trials":6975,"activeCount":102},[],{"trials":6977,"activeCount":102},[],{"intervention":6979,"totalTrials":265,"cells":6980},"Omega -3 fatty acids",{"EARLY_PHASE1":6981,"PHASE1":6983,"PHASE2":6985,"PHASE3":6987,"PHASE4":6996,"NA":6998},{"trials":6982,"activeCount":102},[],{"trials":6984,"activeCount":102},[],{"trials":6986,"activeCount":102},[],{"trials":6988,"activeCount":102},[6989],{"nctId":6990,"briefTitle":6991,"status":108,"phases":6992,"primaryCompletion":6412,"completion":4486,"start":6266,"enrollment":6993,"conditions":6994,"interventions":6995},"NCT00970489","Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation",[92],1516,[3821],[6979],{"trials":6997,"activeCount":102},[],{"trials":6999,"activeCount":102},[],{"intervention":7001,"totalTrials":265,"cells":7002},"Chemotherapy",{"EARLY_PHASE1":7003,"PHASE1":7005,"PHASE2":7007,"PHASE3":7009,"PHASE4":7021,"NA":7023},{"trials":7004,"activeCount":102},[],{"trials":7006,"activeCount":102},[],{"trials":7008,"activeCount":102},[],{"trials":7010,"activeCount":102},[7011],{"nctId":7012,"briefTitle":7013,"status":436,"phases":7014,"primaryCompletion":86,"completion":1551,"start":7015,"enrollment":2055,"conditions":7016,"interventions":7020},"NCT04756713","Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia",[92],"2021-02-11",[7017,7018,7019],"Gestational Trophoblastic Neoplasia","Molar Pregnancy","Gestational Trophoblastic Tumor, Non-Metastatic",[7001],{"trials":7022,"activeCount":102},[],{"trials":7024,"activeCount":102},[],{"intervention":7026,"totalTrials":265,"cells":7027},"Icosapent ethyl",{"EARLY_PHASE1":7028,"PHASE1":7030,"PHASE2":7032,"PHASE3":7034,"PHASE4":7042,"NA":7044},{"trials":7029,"activeCount":102},[],{"trials":7031,"activeCount":102},[],{"trials":7033,"activeCount":102},[],{"trials":7035,"activeCount":102},[7036],{"nctId":7037,"briefTitle":7038,"status":239,"phases":7039,"primaryCompletion":5217,"completion":5217,"start":5311,"enrollment":281,"conditions":7040,"interventions":7041},"NCT02422446","Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects",[92],[1258,6104],[7026],{"trials":7043,"activeCount":102},[],{"trials":7045,"activeCount":102},[],{"intervention":7047,"totalTrials":265,"cells":7048},"High-Titer COVID-19 Convalescent Plasma",{"EARLY_PHASE1":7049,"PHASE1":7051,"PHASE2":7053,"PHASE3":7055,"PHASE4":7067,"NA":7069},{"trials":7050,"activeCount":102},[],{"trials":7052,"activeCount":102},[],{"trials":7054,"activeCount":102},[],{"trials":7056,"activeCount":102},[7057],{"nctId":7058,"briefTitle":7059,"status":239,"phases":7060,"primaryCompletion":493,"completion":4520,"start":7061,"enrollment":5421,"conditions":7062,"interventions":7065},"NCT04361253","Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy",[92],"2020-04-30",[7063,7064],"COVID","Infectious Disease",[7047,7066],"Standard Plasma",{"trials":7068,"activeCount":102},[],{"trials":7070,"activeCount":102},[],{"intervention":7066,"totalTrials":265,"cells":7072},{"EARLY_PHASE1":7073,"PHASE1":7075,"PHASE2":7077,"PHASE3":7079,"PHASE4":7085,"NA":7087},{"trials":7074,"activeCount":102},[],{"trials":7076,"activeCount":102},[],{"trials":7078,"activeCount":102},[],{"trials":7080,"activeCount":102},[7081],{"nctId":7058,"briefTitle":7059,"status":239,"phases":7082,"primaryCompletion":493,"completion":4520,"start":7061,"enrollment":5421,"conditions":7083,"interventions":7084},[92],[7063,7064],[7047,7066],{"trials":7086,"activeCount":102},[],{"trials":7088,"activeCount":102},[],{"intervention":7090,"totalTrials":265,"cells":7091},"cysteine hydrochloride",{"EARLY_PHASE1":7092,"PHASE1":7094,"PHASE2":7096,"PHASE3":7098,"PHASE4":7108,"NA":7110},{"trials":7093,"activeCount":102},[],{"trials":7095,"activeCount":102},[],{"trials":7097,"activeCount":102},[],{"trials":7099,"activeCount":102},[7100],{"nctId":7101,"briefTitle":7102,"status":108,"phases":7103,"completion":7104,"start":7105,"enrollment":531,"conditions":7106,"interventions":7107},"NCT00004940","Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria",[92],"2001-09","1996-05",[6949],[7090],{"trials":7109,"activeCount":102},[],{"trials":7111,"activeCount":102},[],{"intervention":7113,"totalTrials":265,"cells":7114},"Ateronon",{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7119,"PHASE3":7121,"PHASE4":7131,"NA":7133},{"trials":7116,"activeCount":102},[],{"trials":7118,"activeCount":102},[],{"trials":7120,"activeCount":102},[],{"trials":7122,"activeCount":102},[7123],{"nctId":7124,"briefTitle":7125,"status":108,"phases":7126,"primaryCompletion":6307,"completion":6307,"start":4582,"enrollment":7127,"conditions":7128,"interventions":7130},"NCT00939237","Trial of Lycopene\u002FAteronon for Secondary Prevention of Coronary Heart Disease",[92],213,[7129],"Coronary Heart Disease",[7113],{"trials":7132,"activeCount":102},[],{"trials":7134,"activeCount":102},[],{"intervention":7136,"totalTrials":265,"cells":7137},"carotene",{"EARLY_PHASE1":7138,"PHASE1":7140,"PHASE2":7142,"PHASE3":7144,"PHASE4":7156,"NA":7158},{"trials":7139,"activeCount":102},[],{"trials":7141,"activeCount":102},[],{"trials":7143,"activeCount":102},[],{"trials":7145,"activeCount":102},[7146],{"nctId":7147,"briefTitle":7148,"status":108,"phases":7149,"primaryCompletion":7150,"completion":7151,"start":7152,"conditions":7153,"interventions":7154},"NCT00000500","Physicians' Health Study",[92],"1995-12","1996-12","1981-09",[30,6341,6342,6343],[7155,7136],"aspirin",{"trials":7157,"activeCount":102},[],{"trials":7159,"activeCount":102},[],{"intervention":7161,"totalTrials":265,"cells":7162},"Vitamin D and fish oil",{"EARLY_PHASE1":7163,"PHASE1":7165,"PHASE2":7167,"PHASE3":7169,"PHASE4":7179,"NA":7181},{"trials":7164,"activeCount":102},[],{"trials":7166,"activeCount":102},[],{"trials":7168,"activeCount":102},[],{"trials":7170,"activeCount":102},[7171],{"nctId":7172,"briefTitle":7173,"status":108,"phases":7174,"primaryCompletion":111,"completion":111,"start":7175,"enrollment":956,"conditions":7176,"interventions":7177},"NCT02271230","Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure",[92],"2014-08",[24],[7161,7178],"Vitamin D alone",{"trials":7180,"activeCount":102},[],{"trials":7182,"activeCount":102},[],{"intervention":7178,"totalTrials":265,"cells":7184},{"EARLY_PHASE1":7185,"PHASE1":7187,"PHASE2":7189,"PHASE3":7191,"PHASE4":7197,"NA":7199},{"trials":7186,"activeCount":102},[],{"trials":7188,"activeCount":102},[],{"trials":7190,"activeCount":102},[],{"trials":7192,"activeCount":102},[7193],{"nctId":7172,"briefTitle":7173,"status":108,"phases":7194,"primaryCompletion":111,"completion":111,"start":7175,"enrollment":956,"conditions":7195,"interventions":7196},[92],[24],[7161,7178],{"trials":7198,"activeCount":102},[],{"trials":7200,"activeCount":102},[],{"intervention":7202,"totalTrials":265,"cells":7203},"Savella",{"EARLY_PHASE1":7204,"PHASE1":7206,"PHASE2":7208,"PHASE3":7210,"PHASE4":7218,"NA":7220},{"trials":7205,"activeCount":102},[],{"trials":7207,"activeCount":102},[],{"trials":7209,"activeCount":102},[],{"trials":7211,"activeCount":102},[7212],{"nctId":7213,"briefTitle":7214,"status":152,"phases":7215,"primaryCompletion":4776,"completion":4776,"start":6266,"enrollment":102,"conditions":7216,"interventions":7217},"NCT01221740","Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran",[92],[1814],[7202],{"trials":7219,"activeCount":102},[],{"trials":7221,"activeCount":102},[],{"intervention":7223,"totalTrials":265,"cells":7224},"Marinol",{"EARLY_PHASE1":7225,"PHASE1":7227,"PHASE2":7229,"PHASE3":7231,"PHASE4":7241,"NA":7243},{"trials":7226,"activeCount":102},[],{"trials":7228,"activeCount":102},[],{"trials":7230,"activeCount":102},[],{"trials":7232,"activeCount":102},[7233],{"nctId":7234,"briefTitle":7235,"status":108,"phases":7236,"primaryCompletion":5267,"completion":5267,"start":7237,"enrollment":678,"conditions":7238,"interventions":7240},"NCT00153192","Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain",[91,92],"2001-04",[7239],"Chronic Pain",[7223],{"trials":7242,"activeCount":102},[],{"trials":7244,"activeCount":102},[],{"intervention":7246,"totalTrials":265,"cells":7247},"Glycyrrhetic Acid",{"EARLY_PHASE1":7248,"PHASE1":7250,"PHASE2":7252,"PHASE3":7254,"PHASE4":7265,"NA":7267},{"trials":7249,"activeCount":102},[],{"trials":7251,"activeCount":102},[],{"trials":7253,"activeCount":102},[],{"trials":7255,"activeCount":102},[7256],{"nctId":7257,"briefTitle":7258,"status":108,"phases":7259,"primaryCompletion":7260,"completion":7260,"start":7261,"enrollment":364,"conditions":7262,"interventions":7264},"NCT00759525","The Role of Mineralocorticoid Receptors in Vascular Function",[91,92],"2009-09","2002-02",[7263],"Apparent Mineralocorticoid Excess (AME)",[7246],{"trials":7266,"activeCount":102},[],{"trials":7268,"activeCount":102},[],{"intervention":7270,"totalTrials":265,"cells":7271},"Ebselen",{"EARLY_PHASE1":7272,"PHASE1":7274,"PHASE2":7276,"PHASE3":7278,"PHASE4":7286,"NA":7288},{"trials":7273,"activeCount":102},[],{"trials":7275,"activeCount":102},[],{"trials":7277,"activeCount":102},[],{"trials":7279,"activeCount":102},[7280],{"nctId":7281,"briefTitle":7282,"status":108,"phases":7283,"primaryCompletion":4799,"completion":4799,"start":6884,"enrollment":607,"conditions":7284,"interventions":7285},"NCT00762671","Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus",[91,92],[6414,1368],[7270],{"trials":7287,"activeCount":102},[],{"trials":7289,"activeCount":102},[],{"intervention":7291,"totalTrials":265,"cells":7292},"Diltiazem",{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7299,"PHASE4":7311,"NA":7313},{"trials":7294,"activeCount":102},[],{"trials":7296,"activeCount":102},[],{"trials":7298,"activeCount":102},[],{"trials":7300,"activeCount":102},[7301],{"nctId":7302,"briefTitle":7303,"status":108,"phases":7304,"primaryCompletion":931,"completion":7305,"start":7306,"enrollment":7307,"conditions":7308,"interventions":7310},"NCT00319982","Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem",[91,92],"2013-12","2006-01",39,[7309],"Hypertrophic Cardiomyopathy",[7291],{"trials":7312,"activeCount":102},[],{"trials":7314,"activeCount":102},[],{"intervention":4803,"totalTrials":265,"cells":7316},{"EARLY_PHASE1":7317,"PHASE1":7319,"PHASE2":7321,"PHASE3":7323,"PHASE4":7329,"NA":7331},{"trials":7318,"activeCount":102},[],{"trials":7320,"activeCount":102},[],{"trials":7322,"activeCount":102},[],{"trials":7324,"activeCount":102},[7325],{"nctId":4796,"briefTitle":4797,"status":108,"phases":7326,"primaryCompletion":931,"completion":931,"start":4799,"enrollment":167,"conditions":7327,"interventions":7328},[92],[4801],[4803,4804],{"trials":7330,"activeCount":102},[],{"trials":7332,"activeCount":102},[],{"intervention":7334,"totalTrials":265,"cells":7335},"atorvastatin and pioglitazone",{"EARLY_PHASE1":7336,"PHASE1":7338,"PHASE2":7340,"PHASE3":7342,"PHASE4":7355,"NA":7357},{"trials":7337,"activeCount":102},[],{"trials":7339,"activeCount":102},[],{"trials":7341,"activeCount":102},[],{"trials":7343,"activeCount":102},[7344],{"nctId":7345,"briefTitle":7346,"status":108,"phases":7347,"primaryCompletion":1716,"completion":6381,"start":7348,"enrollment":9,"conditions":7349,"interventions":7352},"NCT00153166","ARREST PAD (Peripheral Arterial Disease)",[91,92],"2004-01",[7350,7351,3011],"Arterial Occlusive Disease","Intermittent Claudication",[7334,7353,7354],"atorvastatin\u002Fplacebo","pioglitazone\u002Fplacebo",{"trials":7356,"activeCount":102},[],{"trials":7358,"activeCount":102},[],{"intervention":7353,"totalTrials":265,"cells":7360},{"EARLY_PHASE1":7361,"PHASE1":7363,"PHASE2":7365,"PHASE3":7367,"PHASE4":7373,"NA":7375},{"trials":7362,"activeCount":102},[],{"trials":7364,"activeCount":102},[],{"trials":7366,"activeCount":102},[],{"trials":7368,"activeCount":102},[7369],{"nctId":7345,"briefTitle":7346,"status":108,"phases":7370,"primaryCompletion":1716,"completion":6381,"start":7348,"enrollment":9,"conditions":7371,"interventions":7372},[91,92],[7350,7351,3011],[7334,7353,7354],{"trials":7374,"activeCount":102},[],{"trials":7376,"activeCount":102},[],{"intervention":7354,"totalTrials":265,"cells":7378},{"EARLY_PHASE1":7379,"PHASE1":7381,"PHASE2":7383,"PHASE3":7385,"PHASE4":7391,"NA":7393},{"trials":7380,"activeCount":102},[],{"trials":7382,"activeCount":102},[],{"trials":7384,"activeCount":102},[],{"trials":7386,"activeCount":102},[7387],{"nctId":7345,"briefTitle":7346,"status":108,"phases":7388,"primaryCompletion":1716,"completion":6381,"start":7348,"enrollment":9,"conditions":7389,"interventions":7390},[91,92],[7350,7351,3011],[7334,7353,7354],{"trials":7392,"activeCount":102},[],{"trials":7394,"activeCount":102},[],{"intervention":7396,"totalTrials":265,"cells":7397},"Fish oil (Super Omega-3, 4 caps\u002Fd) vs. placebo",{"EARLY_PHASE1":7398,"PHASE1":7400,"PHASE2":7402,"PHASE3":7404,"PHASE4":7414,"NA":7416},{"trials":7399,"activeCount":102},[],{"trials":7401,"activeCount":102},[],{"trials":7403,"activeCount":102},[],{"trials":7405,"activeCount":102},[7406],{"nctId":7407,"briefTitle":7408,"status":108,"phases":7409,"completion":7410,"start":7411,"enrollment":167,"conditions":7412,"interventions":7413},"NCT00299533","Polyunsaturated Fatty Acids for Adjunctive Treatment of Refractory Epilepsy",[92],"2006-09","2004-02",[3190],[7396],{"trials":7415,"activeCount":102},[],{"trials":7417,"activeCount":102},[],{"intervention":7419,"totalTrials":265,"cells":7420},"Ravulizumab",{"EARLY_PHASE1":7421,"PHASE1":7423,"PHASE2":7425,"PHASE3":7427,"PHASE4":7439,"NA":7441},{"trials":7422,"activeCount":102},[],{"trials":7424,"activeCount":102},[],{"trials":7426,"activeCount":102},[],{"trials":7428,"activeCount":102},[7429],{"nctId":7430,"briefTitle":7431,"status":436,"phases":7432,"primaryCompletion":7433,"completion":7434,"start":7435,"enrollment":22,"conditions":7436,"interventions":7438},"NCT04570397","Ravulizumab and COVID-19",[92],"2023-05","2023-11","2020-12-18",[2314,7437,1530],"Thrombotic Microangiopathies",[7419],{"trials":7440,"activeCount":102},[],{"trials":7442,"activeCount":102},[],{"intervention":7444,"totalTrials":265,"cells":7445},"[68Ga]CBP8 PET\u002FMRI",{"EARLY_PHASE1":7446,"PHASE1":7448,"PHASE2":7450,"PHASE3":7452,"PHASE4":7462,"NA":7464},{"trials":7447,"activeCount":102},[],{"trials":7449,"activeCount":102},[],{"trials":7451,"activeCount":102},[],{"trials":7453,"activeCount":102},[7454],{"nctId":7455,"briefTitle":7456,"status":108,"phases":7457,"primaryCompletion":7458,"completion":7458,"start":7459,"enrollment":1774,"conditions":7460,"interventions":7461},"NCT05619302","Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis",[92],"2025-07-31","2023-01-03",[1213],[7444],{"trials":7463,"activeCount":102},[],{"trials":7465,"activeCount":102},[],{"intervention":7467,"totalTrials":1082,"cells":7468},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":7469,"PHASE1":7471,"PHASE2":7473,"PHASE3":7513,"PHASE4":7515,"NA":7517},{"trials":7470,"activeCount":102},[],{"trials":7472,"activeCount":102},[],{"trials":7474,"activeCount":102},[7475,7485,7496,7504],{"nctId":7476,"briefTitle":7477,"status":108,"phases":7478,"primaryCompletion":7479,"completion":7480,"start":7481,"enrollment":98,"conditions":7482,"interventions":7484},"NCT02424175","Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.",[90,91],"2017-08-30","2018-05-08","2016-02-01",[7483],"Sclerosing Cholangitis",[7467],{"nctId":7486,"briefTitle":7487,"status":108,"phases":7488,"primaryCompletion":7489,"completion":1267,"start":7490,"enrollment":7491,"conditions":7492,"interventions":7494},"NCT03829475","ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI",[91],"2023-08-03","2020-01-01",61,[2739,7493],"Clostridium Difficile Infection",[7495,7467],"Bezlotoxumab",{"nctId":7497,"briefTitle":7498,"status":108,"phases":7499,"primaryCompletion":7500,"completion":881,"start":7501,"enrollment":531,"conditions":7502,"interventions":7503},"NCT03106844","The ICON Study: Outcomes After FMT for Patients With IBD and CDI",[90,91],"2020-04-07","2017-08-01",[2739,7493],[7467],{"nctId":7505,"briefTitle":7506,"status":108,"phases":7507,"primaryCompletion":7508,"completion":7509,"start":7510,"enrollment":1469,"conditions":7511,"interventions":7512},"NCT02741518","Fecal Microbiota Transplantation for the Treatment of Obesity",[90,91],"2018-10-18","2019-07-24","2017-04-01",[21],[7467],{"trials":7514,"activeCount":102},[],{"trials":7516,"activeCount":102},[],{"trials":7518,"activeCount":102},[],{"intervention":7520,"totalTrials":281,"cells":7521},"Lidocaine",{"EARLY_PHASE1":7522,"PHASE1":7524,"PHASE2":7537,"PHASE3":7551,"PHASE4":7553,"NA":7555},{"trials":7523,"activeCount":102},[],{"trials":7525,"activeCount":102},[7526],{"nctId":7527,"briefTitle":7528,"status":108,"phases":7529,"primaryCompletion":7530,"completion":7530,"start":7531,"enrollment":1774,"conditions":7532,"interventions":7535},"NCT02644421","Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 in Lumbar Radiculopathy (Sciatica)",[90],"2017-07","2015-11",[7533,7534],"Radiculopathy","Sciatica",[7536,7520],"VVZ-149",{"trials":7538,"activeCount":102},[7539],{"nctId":7540,"briefTitle":7541,"status":108,"phases":7542,"primaryCompletion":7543,"completion":7543,"start":7544,"enrollment":28,"conditions":7545,"interventions":7549},"NCT02218203","Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan\u002FLidocaine Combination Clinical Trial",[91],"2008-01","2003-04",[7546,7547,7548],"Central Neuropathic Pain","Allodynia","Spinal Cord Injury",[7550,7520],"Dextromethorphan",{"trials":7552,"activeCount":102},[],{"trials":7554,"activeCount":102},[],{"trials":7556,"activeCount":102},[],{"intervention":7558,"totalTrials":281,"cells":7559},"Atomoxetine",{"EARLY_PHASE1":7560,"PHASE1":7562,"PHASE2":7564,"PHASE3":7584,"PHASE4":7586,"NA":7588},{"trials":7561,"activeCount":102},[],{"trials":7563,"activeCount":102},[],{"trials":7565,"activeCount":102},[7566,7575],{"nctId":7567,"briefTitle":7568,"status":436,"phases":7569,"primaryCompletion":7570,"completion":7570,"start":7571,"enrollment":1469,"conditions":7572,"interventions":7573},"NCT05550246","Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy",[90,91],"2024-12","2022-05-05",[36],[7558,7574],"Oxybutynin",{"nctId":7576,"briefTitle":7577,"status":108,"phases":7578,"primaryCompletion":7579,"completion":7579,"start":7580,"enrollment":7581,"conditions":7582,"interventions":7583},"NCT03919955","A Novel Pharmacological Therapy for Obstructive Sleep Apnea",[91],"2023-09-07","2019-09-03",117,[245],[7558,7574],{"trials":7585,"activeCount":102},[],{"trials":7587,"activeCount":102},[],{"trials":7589,"activeCount":102},[],{"intervention":7574,"totalTrials":281,"cells":7591},{"EARLY_PHASE1":7592,"PHASE1":7594,"PHASE2":7596,"PHASE3":7606,"PHASE4":7608,"NA":7610},{"trials":7593,"activeCount":102},[],{"trials":7595,"activeCount":102},[],{"trials":7597,"activeCount":102},[7598,7602],{"nctId":7567,"briefTitle":7568,"status":436,"phases":7599,"primaryCompletion":7570,"completion":7570,"start":7571,"enrollment":1469,"conditions":7600,"interventions":7601},[90,91],[36],[7558,7574],{"nctId":7576,"briefTitle":7577,"status":108,"phases":7603,"primaryCompletion":7579,"completion":7579,"start":7580,"enrollment":7581,"conditions":7604,"interventions":7605},[91],[245],[7558,7574],{"trials":7607,"activeCount":102},[],{"trials":7609,"activeCount":102},[],{"trials":7611,"activeCount":102},[],{"intervention":7550,"totalTrials":281,"cells":7613},{"EARLY_PHASE1":7614,"PHASE1":7616,"PHASE2":7618,"PHASE3":7630,"PHASE4":7632,"NA":7634},{"trials":7615,"activeCount":102},[],{"trials":7617,"activeCount":102},[],{"trials":7619,"activeCount":102},[7620,7624],{"nctId":7540,"briefTitle":7541,"status":108,"phases":7621,"primaryCompletion":7543,"completion":7543,"start":7544,"enrollment":28,"conditions":7622,"interventions":7623},[91],[7546,7547,7548],[7550,7520],{"nctId":7625,"briefTitle":7626,"status":108,"phases":7627,"primaryCompletion":7543,"completion":7543,"start":7544,"enrollment":28,"conditions":7628,"interventions":7629},"NCT01435798","Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial",[91],[7546,7547,7548],[7550],{"trials":7631,"activeCount":102},[],{"trials":7633,"activeCount":102},[],{"trials":7635,"activeCount":102},[],{"intervention":7637,"totalTrials":281,"cells":7638},"Desipramine",{"EARLY_PHASE1":7639,"PHASE1":7641,"PHASE2":7643,"PHASE3":7659,"PHASE4":7661,"NA":7663},{"trials":7640,"activeCount":102},[],{"trials":7642,"activeCount":102},[],{"trials":7644,"activeCount":102},[7645,7653],{"nctId":7646,"briefTitle":7647,"status":108,"phases":7648,"primaryCompletion":7531,"completion":7649,"start":7650,"enrollment":258,"conditions":7651,"interventions":7652},"NCT02428478","Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A",[91],"2016-03","2015-03",[366],[7637],{"nctId":7654,"briefTitle":7655,"status":108,"phases":7656,"primaryCompletion":6790,"completion":7649,"start":5311,"enrollment":206,"conditions":7657,"interventions":7658},"NCT02436031","Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B",[91],[366],[7637],{"trials":7660,"activeCount":102},[],{"trials":7662,"activeCount":102},[],{"trials":7664,"activeCount":102},[],{"intervention":7666,"totalTrials":281,"cells":7667},"Dexamethasone",{"EARLY_PHASE1":7668,"PHASE1":7670,"PHASE2":7672,"PHASE3":7692,"PHASE4":7694,"NA":7696},{"trials":7669,"activeCount":102},[],{"trials":7671,"activeCount":102},[],{"trials":7673,"activeCount":102},[7674,7682],{"nctId":7675,"briefTitle":7676,"status":108,"phases":7677,"primaryCompletion":931,"completion":363,"start":975,"enrollment":216,"conditions":7678,"interventions":7680},"NCT00686855","Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease",[91],[7679],"Oral Chronic Graft-versus-host Disease",[7681,7666],"Tacrolimus",{"nctId":7683,"briefTitle":7684,"status":108,"phases":7685,"primaryCompletion":7686,"completion":7687,"start":7688,"enrollment":933,"conditions":7689,"interventions":7691},"NCT02850601","Dexamethasone Solution for the Treatment of Oral Lichen Planus",[91],"2019-12-19","2019-12-20","2017-02-07",[7690],"Lichen Planus",[7666],{"trials":7693,"activeCount":102},[],{"trials":7695,"activeCount":102},[],{"trials":7697,"activeCount":102},[],{"intervention":7699,"totalTrials":281,"cells":7700},"Simvastatin",{"EARLY_PHASE1":7701,"PHASE1":7703,"PHASE2":7715,"PHASE3":7728,"PHASE4":7730,"NA":7732},{"trials":7702,"activeCount":102},[],{"trials":7704,"activeCount":102},[7705],{"nctId":7706,"briefTitle":7707,"status":108,"phases":7708,"primaryCompletion":7709,"completion":7709,"start":7710,"enrollment":5379,"conditions":7711,"interventions":7713},"NCT02871687","Effect of Statin Use on Aldosterone Secretion",[90],"2021-03","2016-04",[7712],"Healthy Subjects",[7699,7714],"Pravastatin",{"trials":7716,"activeCount":102},[7717],{"nctId":7718,"briefTitle":7719,"status":108,"phases":7720,"primaryCompletion":7306,"completion":7721,"start":7722,"enrollment":7723,"conditions":7724,"interventions":7727},"NCT00235963","A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm",[90,91],"2006-02","2002-12",104,[7725,7726],"Subarachnoid Hemorrhage","Delayed Vasospasm",[7699],{"trials":7729,"activeCount":102},[],{"trials":7731,"activeCount":102},[],{"trials":7733,"activeCount":102},[],{"intervention":7714,"totalTrials":281,"cells":7735},{"EARLY_PHASE1":7736,"PHASE1":7738,"PHASE2":7744,"PHASE3":7759,"PHASE4":7761,"NA":7763},{"trials":7737,"activeCount":102},[],{"trials":7739,"activeCount":102},[7740],{"nctId":7706,"briefTitle":7707,"status":108,"phases":7741,"primaryCompletion":7709,"completion":7709,"start":7710,"enrollment":5379,"conditions":7742,"interventions":7743},[90],[7712],[7699,7714],{"trials":7745,"activeCount":102},[7746],{"nctId":7747,"briefTitle":7748,"status":108,"phases":7749,"primaryCompletion":7750,"completion":7750,"start":7751,"enrollment":2055,"conditions":7752,"interventions":7755},"NCT00054938","Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)",[91],"2005-12","2003-03",[7753,7754],"Systemic Lupus Erythematosus","Lupus",[7756,7155,7757,7758],"pravastatin","ramipril","Vitamins: B6, B12, and folate",{"trials":7760,"activeCount":102},[],{"trials":7762,"activeCount":102},[],{"trials":7764,"activeCount":102},[],{"intervention":7766,"totalTrials":265,"cells":7767},"Isis 420915\u002FGSK 299872",{"EARLY_PHASE1":7768,"PHASE1":7770,"PHASE2":7772,"PHASE3":7781,"PHASE4":7783,"NA":7785},{"trials":7769,"activeCount":102},[],{"trials":7771,"activeCount":102},[],{"trials":7773,"activeCount":102},[7774],{"nctId":7775,"briefTitle":7776,"status":152,"phases":7777,"primaryCompletion":6502,"completion":6502,"start":112,"enrollment":102,"conditions":7778,"interventions":7780},"NCT02627820","The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart",[91],[7779],"Amyloidosis",[7766],{"trials":7782,"activeCount":102},[],{"trials":7784,"activeCount":102},[],{"trials":7786,"activeCount":102},[],{"intervention":7788,"totalTrials":265,"cells":7789},"Oral OKT3",{"EARLY_PHASE1":7790,"PHASE1":7792,"PHASE2":7794,"PHASE3":7805,"PHASE4":7807,"NA":7809},{"trials":7791,"activeCount":102},[],{"trials":7793,"activeCount":102},[],{"trials":7795,"activeCount":102},[7796],{"nctId":7797,"briefTitle":7798,"status":108,"phases":7799,"primaryCompletion":7800,"completion":7800,"start":7801,"enrollment":1234,"conditions":7802,"interventions":7803},"NCT01287195","Oral OKT3 for the Treatment of Active Ulcerative Colitis",[90,91],"2013-05-02","2011-04-07",[1427],[7788,7804],"Omeprazole",{"trials":7806,"activeCount":102},[],{"trials":7808,"activeCount":102},[],{"trials":7810,"activeCount":102},[],{"intervention":7804,"totalTrials":265,"cells":7812},{"EARLY_PHASE1":7813,"PHASE1":7815,"PHASE2":7817,"PHASE3":7823,"PHASE4":7825,"NA":7827},{"trials":7814,"activeCount":102},[],{"trials":7816,"activeCount":102},[],{"trials":7818,"activeCount":102},[7819],{"nctId":7797,"briefTitle":7798,"status":108,"phases":7820,"primaryCompletion":7800,"completion":7800,"start":7801,"enrollment":1234,"conditions":7821,"interventions":7822},[90,91],[1427],[7788,7804],{"trials":7824,"activeCount":102},[],{"trials":7826,"activeCount":102},[],{"trials":7828,"activeCount":102},[],{"intervention":7830,"totalTrials":265,"cells":7831},"Hyperpolarized 129Xe gas",{"EARLY_PHASE1":7832,"PHASE1":7834,"PHASE2":7836,"PHASE3":7846,"PHASE4":7848,"NA":7850},{"trials":7833,"activeCount":102},[],{"trials":7835,"activeCount":102},[],{"trials":7837,"activeCount":102},[7838],{"nctId":7839,"briefTitle":7840,"status":239,"phases":7841,"primaryCompletion":7842,"completion":7842,"start":204,"enrollment":265,"conditions":7843,"interventions":7845},"NCT01697332","Functional Applications of Hyperpolarized 129Xe MRI",[90,91],"2016-12",[7844],"Chronic Obstructive Pulmonary Disease",[7830],{"trials":7847,"activeCount":102},[],{"trials":7849,"activeCount":102},[],{"trials":7851,"activeCount":102},[],{"intervention":7853,"totalTrials":265,"cells":7854},"Belatacept",{"EARLY_PHASE1":7855,"PHASE1":7857,"PHASE2":7859,"PHASE3":7869,"PHASE4":7871,"NA":7873},{"trials":7856,"activeCount":102},[],{"trials":7858,"activeCount":102},[],{"trials":7860,"activeCount":102},[7861],{"nctId":7862,"briefTitle":7863,"status":108,"phases":7864,"primaryCompletion":7865,"completion":7866,"start":6789,"enrollment":364,"conditions":7867,"interventions":7868},"NCT02327403","Belatacept Conversion in Proteinuric Kidney Transplant Recipients",[91],"2020-09","2020-10-01",[2875],[7853],{"trials":7870,"activeCount":102},[],{"trials":7872,"activeCount":102},[],{"trials":7874,"activeCount":102},[],{"intervention":7876,"totalTrials":265,"cells":7877},"Dexamethasone acetate",{"EARLY_PHASE1":7878,"PHASE1":7880,"PHASE2":7882,"PHASE3":7891,"PHASE4":7893,"NA":7895},{"trials":7879,"activeCount":102},[],{"trials":7881,"activeCount":102},[],{"trials":7883,"activeCount":102},[7884],{"nctId":7885,"briefTitle":7886,"status":152,"phases":7887,"primaryCompletion":4485,"completion":4485,"start":1716,"enrollment":102,"conditions":7888,"interventions":7890},"NCT01247961","Early Treatment With Dexamethasone in Mild Acute Pancreatitis",[91],[7889],"Patients With Acute Pancreatitis",[7876],{"trials":7892,"activeCount":102},[],{"trials":7894,"activeCount":102},[],{"trials":7896,"activeCount":102},[],{"intervention":7898,"totalTrials":265,"cells":7899},"Celecoxib",{"EARLY_PHASE1":7900,"PHASE1":7902,"PHASE2":7904,"PHASE3":7915,"PHASE4":7917,"NA":7919},{"trials":7901,"activeCount":102},[],{"trials":7903,"activeCount":102},[],{"trials":7905,"activeCount":102},[7906],{"nctId":7907,"briefTitle":7908,"status":108,"phases":7909,"primaryCompletion":7910,"completion":7910,"start":7911,"enrollment":2917,"conditions":7912,"interventions":7914},"NCT02484664","COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC",[91],"2018-11-19","2016-06-15",[7913],"Lymphangioleiomyomatosis (LAM)",[7898],{"trials":7916,"activeCount":102},[],{"trials":7918,"activeCount":102},[],{"trials":7920,"activeCount":102},[],{"intervention":7922,"totalTrials":265,"cells":7923},"ION 682884",{"EARLY_PHASE1":7924,"PHASE1":7926,"PHASE2":7928,"PHASE3":7939,"PHASE4":7941,"NA":7943},{"trials":7925,"activeCount":102},[],{"trials":7927,"activeCount":102},[],{"trials":7929,"activeCount":102},[7930],{"nctId":7931,"briefTitle":7932,"status":152,"phases":7933,"primaryCompletion":7934,"completion":1551,"start":7935,"enrollment":102,"conditions":7936,"interventions":7938},"NCT04843020","ION-682884 in Patients With TTR Amyloid Cardiomyopathy",[91],"2025-05-30","2021-06-01",[7937],"Transthyretin Amyloid Cardiopathy",[7922],{"trials":7940,"activeCount":102},[],{"trials":7942,"activeCount":102},[],{"trials":7944,"activeCount":102},[],{"intervention":7946,"totalTrials":265,"cells":7947},"Nesiritide",{"EARLY_PHASE1":7948,"PHASE1":7950,"PHASE2":7952,"PHASE3":7963,"PHASE4":7965,"NA":7967},{"trials":7949,"activeCount":102},[],{"trials":7951,"activeCount":102},[],{"trials":7953,"activeCount":102},[7954],{"nctId":7955,"briefTitle":7956,"status":108,"phases":7957,"primaryCompletion":7958,"completion":7958,"start":7544,"enrollment":7959,"conditions":7960,"interventions":7962},"NCT00119691","Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction",[91],"2005-11",34,[5044,7961],"Renal Insufficiency",[7946],{"trials":7964,"activeCount":102},[],{"trials":7966,"activeCount":102},[],{"trials":7968,"activeCount":102},[],{"intervention":7970,"totalTrials":265,"cells":7971},"Minocycline",{"EARLY_PHASE1":7972,"PHASE1":7974,"PHASE2":7976,"PHASE3":7986,"PHASE4":7988,"NA":7990},{"trials":7973,"activeCount":102},[],{"trials":7975,"activeCount":102},[],{"trials":7977,"activeCount":102},[7978],{"nctId":7979,"briefTitle":7980,"status":152,"phases":7981,"primaryCompletion":932,"completion":932,"start":7982,"enrollment":102,"conditions":7983,"interventions":7985},"NCT00401921","A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy",[91],"2006-10",[7984],"Carotid Stenosis",[7970],{"trials":7987,"activeCount":102},[],{"trials":7989,"activeCount":102},[],{"trials":7991,"activeCount":102},[],{"intervention":7993,"totalTrials":265,"cells":7994},"Cannabidiol 100 MG\u002FML [Epidiolex]",{"EARLY_PHASE1":7995,"PHASE1":7997,"PHASE2":7999,"PHASE3":8010,"PHASE4":8012,"NA":8014},{"trials":7996,"activeCount":102},[],{"trials":7998,"activeCount":102},[],{"trials":8000,"activeCount":102},[8001],{"nctId":8002,"briefTitle":8003,"status":108,"phases":8004,"primaryCompletion":8005,"completion":8005,"start":8006,"enrollment":364,"conditions":8007,"interventions":8009},"NCT04982029","Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder",[91],"2022-12-02","2022-04-14",[8008],"Opioid-use Disorder",[7993],{"trials":8011,"activeCount":102},[],{"trials":8013,"activeCount":102},[],{"trials":8015,"activeCount":102},[],{"intervention":8017,"totalTrials":265,"cells":8018},"Digital Fall Prevention",{"EARLY_PHASE1":8019,"PHASE1":8021,"PHASE2":8023,"PHASE3":8035,"PHASE4":8037,"NA":8039},{"trials":8020,"activeCount":102},[],{"trials":8022,"activeCount":102},[],{"trials":8024,"activeCount":102},[8025],{"nctId":8026,"briefTitle":8027,"status":108,"phases":8028,"primaryCompletion":8029,"completion":8030,"start":8031,"enrollment":113,"conditions":8032,"interventions":8034},"NCT05432674","Digital Fall Prevention Study",[90,91],"2023-05-25","2023-06-01","2022-06-30",[8033],"Fall",[8017],{"trials":8036,"activeCount":102},[],{"trials":8038,"activeCount":102},[],{"trials":8040,"activeCount":102},[],{"intervention":8042,"totalTrials":265,"cells":8043},"fasudil",{"EARLY_PHASE1":8044,"PHASE1":8046,"PHASE2":8048,"PHASE3":8059,"PHASE4":8061,"NA":8063},{"trials":8045,"activeCount":102},[],{"trials":8047,"activeCount":102},[],{"trials":8049,"activeCount":102},[8050],{"nctId":8051,"briefTitle":8052,"status":108,"phases":8053,"primaryCompletion":8054,"completion":8054,"start":8055,"enrollment":607,"conditions":8056,"interventions":8058},"NCT00120718","The Effect of Fasudil on Vascular Function in Humans",[91],"2007-01","2002-06",[471,8057],"Hypercholesterolemia",[8042],{"trials":8060,"activeCount":102},[],{"trials":8062,"activeCount":102},[],{"trials":8064,"activeCount":102},[],{"intervention":6345,"totalTrials":265,"cells":8066},{"EARLY_PHASE1":8067,"PHASE1":8069,"PHASE2":8071,"PHASE3":8077,"PHASE4":8079,"NA":8081},{"trials":8068,"activeCount":102},[],{"trials":8070,"activeCount":102},[],{"trials":8072,"activeCount":102},[8073],{"nctId":6334,"briefTitle":6335,"status":108,"phases":8074,"primaryCompletion":6337,"completion":6337,"start":6338,"conditions":8075,"interventions":8076},[91],[30,6340,6341,6342,978,6343],[6345,6346,6347,6348],{"trials":8078,"activeCount":102},[],{"trials":8080,"activeCount":102},[],{"trials":8082,"activeCount":102},[],{"intervention":6347,"totalTrials":265,"cells":8084},{"EARLY_PHASE1":8085,"PHASE1":8087,"PHASE2":8089,"PHASE3":8095,"PHASE4":8097,"NA":8099},{"trials":8086,"activeCount":102},[],{"trials":8088,"activeCount":102},[],{"trials":8090,"activeCount":102},[8091],{"nctId":6334,"briefTitle":6335,"status":108,"phases":8092,"primaryCompletion":6337,"completion":6337,"start":6338,"conditions":8093,"interventions":8094},[91],[30,6340,6341,6342,978,6343],[6345,6346,6347,6348],{"trials":8096,"activeCount":102},[],{"trials":8098,"activeCount":102},[],{"trials":8100,"activeCount":102},[],{"intervention":6348,"totalTrials":265,"cells":8102},{"EARLY_PHASE1":8103,"PHASE1":8105,"PHASE2":8107,"PHASE3":8113,"PHASE4":8115,"NA":8117},{"trials":8104,"activeCount":102},[],{"trials":8106,"activeCount":102},[],{"trials":8108,"activeCount":102},[8109],{"nctId":6334,"briefTitle":6335,"status":108,"phases":8110,"primaryCompletion":6337,"completion":6337,"start":6338,"conditions":8111,"interventions":8112},[91],[30,6340,6341,6342,978,6343],[6345,6346,6347,6348],{"trials":8114,"activeCount":102},[],{"trials":8116,"activeCount":102},[],{"trials":8118,"activeCount":102},[],{"intervention":8120,"totalTrials":265,"cells":8121},"Combination product of Atomoxetine and Oxybutynin",{"EARLY_PHASE1":8122,"PHASE1":8124,"PHASE2":8126,"PHASE3":8135,"PHASE4":8137,"NA":8139},{"trials":8123,"activeCount":102},[],{"trials":8125,"activeCount":102},[],{"trials":8127,"activeCount":102},[8128],{"nctId":8129,"briefTitle":8130,"status":108,"phases":8131,"primaryCompletion":8132,"completion":4834,"start":5042,"enrollment":1469,"conditions":8133,"interventions":8134},"NCT02908529","Atomoxetine and Oxybutynin in Obstructive Sleep Apnea",[90,91],"2017-12",[3243],[8120],{"trials":8136,"activeCount":102},[],{"trials":8138,"activeCount":102},[],{"trials":8140,"activeCount":102},[],{"intervention":8142,"totalTrials":265,"cells":8143},"DAW2020 oral",{"EARLY_PHASE1":8144,"PHASE1":8146,"PHASE2":8148,"PHASE3":8159,"PHASE4":8161,"NA":8163},{"trials":8145,"activeCount":102},[],{"trials":8147,"activeCount":102},[],{"trials":8149,"activeCount":102},[8150],{"nctId":8151,"briefTitle":8152,"status":436,"phases":8153,"primaryCompletion":8154,"completion":8155,"start":8156,"enrollment":34,"conditions":8157,"interventions":8158},"NCT04538755","DAW2020 on OSA Endotypic Traits",[90,91],"2024-05-15","2024-06-15","2020-11-15",[3243],[8142],{"trials":8160,"activeCount":102},[],{"trials":8162,"activeCount":102},[],{"trials":8164,"activeCount":102},[],{"intervention":7495,"totalTrials":265,"cells":8166},{"EARLY_PHASE1":8167,"PHASE1":8169,"PHASE2":8171,"PHASE3":8177,"PHASE4":8179,"NA":8181},{"trials":8168,"activeCount":102},[],{"trials":8170,"activeCount":102},[],{"trials":8172,"activeCount":102},[8173],{"nctId":7486,"briefTitle":7487,"status":108,"phases":8174,"primaryCompletion":7489,"completion":1267,"start":7490,"enrollment":7491,"conditions":8175,"interventions":8176},[91],[2739,7493],[7495,7467],{"trials":8178,"activeCount":102},[],{"trials":8180,"activeCount":102},[],{"trials":8182,"activeCount":102},[],{"intervention":8184,"totalTrials":265,"cells":8185},"LTM1201L",{"EARLY_PHASE1":8186,"PHASE1":8188,"PHASE2":8190,"PHASE3":8204,"PHASE4":8206,"NA":8208},{"trials":8187,"activeCount":102},[],{"trials":8189,"activeCount":102},[],{"trials":8191,"activeCount":102},[8192],{"nctId":8193,"briefTitle":8194,"status":108,"phases":8195,"primaryCompletion":8196,"completion":8197,"start":8198,"enrollment":1234,"conditions":8199,"interventions":8200},"NCT03640052","Pharmacological Activation of HMN for OSA",[90,91],"2019-09-30","2019-12-31","2018-10-30",[36],[8184,8201,8202,8203],"LTM1201LN","LTM1201LB","LTM1201LD",{"trials":8205,"activeCount":102},[],{"trials":8207,"activeCount":102},[],{"trials":8209,"activeCount":102},[],{"intervention":8201,"totalTrials":265,"cells":8211},{"EARLY_PHASE1":8212,"PHASE1":8214,"PHASE2":8216,"PHASE3":8222,"PHASE4":8224,"NA":8226},{"trials":8213,"activeCount":102},[],{"trials":8215,"activeCount":102},[],{"trials":8217,"activeCount":102},[8218],{"nctId":8193,"briefTitle":8194,"status":108,"phases":8219,"primaryCompletion":8196,"completion":8197,"start":8198,"enrollment":1234,"conditions":8220,"interventions":8221},[90,91],[36],[8184,8201,8202,8203],{"trials":8223,"activeCount":102},[],{"trials":8225,"activeCount":102},[],{"trials":8227,"activeCount":102},[],{"intervention":8202,"totalTrials":265,"cells":8229},{"EARLY_PHASE1":8230,"PHASE1":8232,"PHASE2":8234,"PHASE3":8240,"PHASE4":8242,"NA":8244},{"trials":8231,"activeCount":102},[],{"trials":8233,"activeCount":102},[],{"trials":8235,"activeCount":102},[8236],{"nctId":8193,"briefTitle":8194,"status":108,"phases":8237,"primaryCompletion":8196,"completion":8197,"start":8198,"enrollment":1234,"conditions":8238,"interventions":8239},[90,91],[36],[8184,8201,8202,8203],{"trials":8241,"activeCount":102},[],{"trials":8243,"activeCount":102},[],{"trials":8245,"activeCount":102},[],{"intervention":8203,"totalTrials":265,"cells":8247},{"EARLY_PHASE1":8248,"PHASE1":8250,"PHASE2":8252,"PHASE3":8258,"PHASE4":8260,"NA":8262},{"trials":8249,"activeCount":102},[],{"trials":8251,"activeCount":102},[],{"trials":8253,"activeCount":102},[8254],{"nctId":8193,"briefTitle":8194,"status":108,"phases":8255,"primaryCompletion":8196,"completion":8197,"start":8198,"enrollment":1234,"conditions":8256,"interventions":8257},[90,91],[36],[8184,8201,8202,8203],{"trials":8259,"activeCount":102},[],{"trials":8261,"activeCount":102},[],{"trials":8263,"activeCount":102},[],{"intervention":8265,"totalTrials":265,"cells":8266},"Mepolizumab",{"EARLY_PHASE1":8267,"PHASE1":8269,"PHASE2":8271,"PHASE3":8281,"PHASE4":8283,"NA":8285},{"trials":8268,"activeCount":102},[],{"trials":8270,"activeCount":102},[],{"trials":8272,"activeCount":102},[8273],{"nctId":8274,"briefTitle":8275,"status":108,"phases":8276,"primaryCompletion":4762,"completion":4762,"start":8277,"enrollment":98,"conditions":8278,"interventions":8280},"NCT00527566","Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome",[90,91],"2007-09",[8279],"Churg Strauss Syndrome",[8265],{"trials":8282,"activeCount":102},[],{"trials":8284,"activeCount":102},[],{"trials":8286,"activeCount":102},[],{"intervention":7681,"totalTrials":265,"cells":8288},{"EARLY_PHASE1":8289,"PHASE1":8291,"PHASE2":8293,"PHASE3":8299,"PHASE4":8301,"NA":8303},{"trials":8290,"activeCount":102},[],{"trials":8292,"activeCount":102},[],{"trials":8294,"activeCount":102},[8295],{"nctId":7675,"briefTitle":7676,"status":108,"phases":8296,"primaryCompletion":931,"completion":363,"start":975,"enrollment":216,"conditions":8297,"interventions":8298},[91],[7679],[7681,7666],{"trials":8300,"activeCount":102},[],{"trials":8302,"activeCount":102},[],{"trials":8304,"activeCount":102},[],{"intervention":8306,"totalTrials":265,"cells":8307},"Pyridostigmine Bromide",{"EARLY_PHASE1":8308,"PHASE1":8310,"PHASE2":8312,"PHASE3":8332,"PHASE4":8334,"NA":8336},{"trials":8309,"activeCount":102},[],{"trials":8311,"activeCount":102},[],{"trials":8313,"activeCount":102},[8314],{"nctId":8315,"briefTitle":8316,"status":108,"phases":8317,"primaryCompletion":8318,"completion":8319,"start":8320,"enrollment":5421,"conditions":8321,"interventions":8331},"NCT03674541","The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome",[91],"2021-12-05","2021-12-20","2020-01-14",[8322,8323,8324,8325,8326,8327,8328,8329,8330],"Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome","Chronic Fatigue Syndrome","Myalgic Encephalomyelitis","Exercise Intolerance","Dysautonomia","Low Ventricular Filling Pressures (Preload Failure)","Postural Orthostatic Tachycardia Syndrome","Orthostatic Hypotension","Fibromyalgia",[8306],{"trials":8333,"activeCount":102},[],{"trials":8335,"activeCount":102},[],{"trials":8337,"activeCount":102},[],{"intervention":8339,"totalTrials":265,"cells":8340},"Tranexamic Acid",{"EARLY_PHASE1":8341,"PHASE1":8343,"PHASE2":8345,"PHASE3":8355,"PHASE4":8357,"NA":8359},{"trials":8342,"activeCount":102},[],{"trials":8344,"activeCount":102},[],{"trials":8346,"activeCount":102},[8347],{"nctId":8348,"briefTitle":8349,"status":239,"phases":8350,"primaryCompletion":8351,"completion":8352,"start":974,"enrollment":607,"conditions":8353,"interventions":8354},"NCT02026297","Tranexamic Acid and Thromboelastography During Cesarean Delivery",[91],"2015-07","2020-02-21",[5639],[8339],{"trials":8356,"activeCount":102},[],{"trials":8358,"activeCount":102},[],{"trials":8360,"activeCount":102},[],{"intervention":8362,"totalTrials":265,"cells":8363},"Inotersen",{"EARLY_PHASE1":8364,"PHASE1":8366,"PHASE2":8368,"PHASE3":8378,"PHASE4":8380,"NA":8382},{"trials":8365,"activeCount":102},[],{"trials":8367,"activeCount":102},[],{"trials":8369,"activeCount":102},[8370],{"nctId":8371,"briefTitle":8372,"status":239,"phases":8373,"primaryCompletion":991,"completion":8374,"start":8375,"enrollment":1506,"conditions":8376,"interventions":8377},"NCT03702829","24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients",[91],"2022-01-15","2019-02-28",[7779],[8362],{"trials":8379,"activeCount":102},[],{"trials":8381,"activeCount":102},[],{"trials":8383,"activeCount":102},[],{"intervention":8385,"totalTrials":265,"cells":8386},"Danazol Pill",{"EARLY_PHASE1":8387,"PHASE1":8389,"PHASE2":8391,"PHASE3":8402,"PHASE4":8404,"NA":8406},{"trials":8388,"activeCount":102},[],{"trials":8390,"activeCount":102},[],{"trials":8392,"activeCount":102},[8393],{"nctId":8394,"briefTitle":8395,"status":152,"phases":8396,"primaryCompletion":8397,"completion":6316,"start":2311,"enrollment":102,"conditions":8398,"interventions":8401},"NCT04807309","PRETELL: PREvention of TELomere-related Complications After Lung Transplant",[90,91],"2021-11-20",[8399,8400],"Short Telomere Length","Lung Transplant",[8385],{"trials":8403,"activeCount":102},[],{"trials":8405,"activeCount":102},[],{"trials":8407,"activeCount":102},[],{"intervention":8409,"totalTrials":265,"cells":8410},"dual anti-platelet therapy",{"EARLY_PHASE1":8411,"PHASE1":8413,"PHASE2":8415,"PHASE3":8428,"PHASE4":8430,"NA":8432},{"trials":8412,"activeCount":102},[],{"trials":8414,"activeCount":102},[],{"trials":8416,"activeCount":102},[8417],{"nctId":8418,"briefTitle":8419,"status":108,"phases":8420,"primaryCompletion":8421,"completion":8421,"start":8422,"enrollment":364,"conditions":8423,"interventions":8427},"NCT05567562","Anti-Platelets in Chronic Obstructive Pulmonary Disease",[91],"2025-02-28","2024-03-27",[8424,8425,8426],"COPD","Emphysema","Emphysema or COPD",[8409],{"trials":8429,"activeCount":102},[],{"trials":8431,"activeCount":102},[],{"trials":8433,"activeCount":102},[],{"intervention":8435,"totalTrials":265,"cells":8436},"AD036",{"EARLY_PHASE1":8437,"PHASE1":8439,"PHASE2":8441,"PHASE3":8452,"PHASE4":8454,"NA":8456},{"trials":8438,"activeCount":102},[],{"trials":8440,"activeCount":102},[],{"trials":8442,"activeCount":102},[8443],{"nctId":8444,"briefTitle":8445,"status":108,"phases":8446,"primaryCompletion":8447,"completion":8447,"start":8448,"enrollment":4812,"conditions":8449,"interventions":8451},"NCT04611750","Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing",[91],"2022-01-18","2020-12-02",[8450],"Sleep Disordered Breathing",[8435],{"trials":8453,"activeCount":102},[],{"trials":8455,"activeCount":102},[],{"trials":8457,"activeCount":102},[],{"intervention":8459,"totalTrials":265,"cells":8460},"Borage Seed Oil and Echium Seed Oil",{"EARLY_PHASE1":8461,"PHASE1":8463,"PHASE2":8465,"PHASE3":8475,"PHASE4":8477,"NA":8479},{"trials":8462,"activeCount":102},[],{"trials":8464,"activeCount":102},[],{"trials":8466,"activeCount":102},[8467],{"nctId":8468,"briefTitle":8469,"status":108,"phases":8470,"primaryCompletion":8471,"completion":5485,"start":4004,"enrollment":5951,"conditions":8472,"interventions":8474},"NCT00806442","Treatment of Bronchial Asthma With Borage and Echium Seed Oils",[90,91],"2012-04",[8473],"Bronchial Asthma",[8459],{"trials":8476,"activeCount":102},[],{"trials":8478,"activeCount":102},[],{"trials":8480,"activeCount":102},[],{"intervention":8482,"totalTrials":265,"cells":8483},"Tauroursodeoxycholic Acid and Doxycycline",{"EARLY_PHASE1":8484,"PHASE1":8486,"PHASE2":8488,"PHASE3":8500,"PHASE4":8502,"NA":8504},{"trials":8485,"activeCount":102},[],{"trials":8487,"activeCount":102},[],{"trials":8489,"activeCount":102},[8490],{"nctId":8491,"briefTitle":8492,"status":108,"phases":8493,"primaryCompletion":8494,"completion":8494,"start":8495,"enrollment":167,"conditions":8496,"interventions":8499},"NCT01855360","Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy",[90,91],"2015-05-31","2013-06",[8497,8498],"Amyloidosis; Heart (Manifestation)","Senile Cardiac Amyloidosis",[8482],{"trials":8501,"activeCount":102},[],{"trials":8503,"activeCount":102},[],{"trials":8505,"activeCount":102},[],{"intervention":8507,"totalTrials":265,"cells":8508},"ICG Intervention",{"EARLY_PHASE1":8509,"PHASE1":8511,"PHASE2":8513,"PHASE3":8524,"PHASE4":8526,"NA":8528},{"trials":8510,"activeCount":102},[],{"trials":8512,"activeCount":102},[],{"trials":8514,"activeCount":102},[8515],{"nctId":8516,"briefTitle":8517,"status":108,"phases":8518,"primaryCompletion":8519,"completion":8519,"start":7481,"enrollment":1082,"conditions":8520,"interventions":8523},"NCT03097627","Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions",[90,91],"2016-10-28",[8521,8522],"Pulmonary Nodule, Solitary","Pulmonary Nodule, Multiple",[8507],{"trials":8525,"activeCount":102},[],{"trials":8527,"activeCount":102},[],{"trials":8529,"activeCount":102},[],{"intervention":8531,"totalTrials":265,"cells":8532},"Fluoxetine",{"EARLY_PHASE1":8533,"PHASE1":8535,"PHASE2":8537,"PHASE3":8548,"PHASE4":8550,"NA":8552},{"trials":8534,"activeCount":102},[],{"trials":8536,"activeCount":102},[],{"trials":8538,"activeCount":102},[8539],{"nctId":8540,"briefTitle":8541,"status":108,"phases":8542,"primaryCompletion":6307,"completion":6381,"start":8543,"enrollment":8544,"conditions":8545,"interventions":8547},"NCT00339079","Treatment of Hypochondriasis With CBT and\u002For SSRI",[90,91],"2006-06",195,[8546],"Hypochondriasis",[8531],{"trials":8549,"activeCount":102},[],{"trials":8551,"activeCount":102},[],{"trials":8553,"activeCount":102},[],{"intervention":8555,"totalTrials":265,"cells":8556},"Imatinib mesylate",{"EARLY_PHASE1":8557,"PHASE1":8559,"PHASE2":8561,"PHASE3":8571,"PHASE4":8573,"NA":8575},{"trials":8558,"activeCount":102},[],{"trials":8560,"activeCount":102},[],{"trials":8562,"activeCount":102},[8563],{"nctId":8564,"briefTitle":8565,"status":108,"phases":8566,"primaryCompletion":8567,"completion":227,"start":1716,"enrollment":8568,"conditions":8569,"interventions":8570},"NCT01097694","Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)",[91],"2015-08",176,[18],[8555],{"trials":8572,"activeCount":102},[],{"trials":8574,"activeCount":102},[],{"trials":8576,"activeCount":102},[],{"intervention":8578,"totalTrials":265,"cells":8579},"Captopril",{"EARLY_PHASE1":8580,"PHASE1":8582,"PHASE2":8584,"PHASE3":8592,"PHASE4":8594,"NA":8596},{"trials":8581,"activeCount":102},[],{"trials":8583,"activeCount":102},[],{"trials":8585,"activeCount":102},[8586],{"nctId":8587,"briefTitle":8588,"status":436,"phases":8589,"primaryCompletion":7865,"completion":7865,"start":6412,"enrollment":933,"conditions":8590,"interventions":8591},"NCT01626469","Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients",[90,91],[1368],[8578],{"trials":8593,"activeCount":102},[],{"trials":8595,"activeCount":102},[],{"trials":8597,"activeCount":102},[],{"intervention":8599,"totalTrials":265,"cells":8600},"DAW1033B2 oral",{"EARLY_PHASE1":8601,"PHASE1":8603,"PHASE2":8605,"PHASE3":8616,"PHASE4":8618,"NA":8620},{"trials":8602,"activeCount":102},[],{"trials":8604,"activeCount":102},[],{"trials":8606,"activeCount":102},[8607],{"nctId":8608,"briefTitle":8609,"status":108,"phases":8610,"primaryCompletion":8611,"completion":8612,"start":8613,"enrollment":942,"conditions":8614,"interventions":8615},"NCT03426631","DAW1033B2 in Obstructive Sleep Apnea",[90,91],"2019-10-01","2020-01-20","2017-09-15",[3243],[8599],{"trials":8617,"activeCount":102},[],{"trials":8619,"activeCount":102},[],{"trials":8621,"activeCount":102},[],{"intervention":8623,"totalTrials":265,"cells":8624},"Tiagabine",{"EARLY_PHASE1":8625,"PHASE1":8627,"PHASE2":8629,"PHASE3":8637,"PHASE4":8639,"NA":8641},{"trials":8626,"activeCount":102},[],{"trials":8628,"activeCount":102},[],{"trials":8630,"activeCount":102},[8631],{"nctId":8632,"briefTitle":8633,"status":108,"phases":8634,"primaryCompletion":5744,"completion":3612,"start":7650,"enrollment":1774,"conditions":8635,"interventions":8636},"NCT02387710","Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea",[91],[366],[8623],{"trials":8638,"activeCount":102},[],{"trials":8640,"activeCount":102},[],{"trials":8642,"activeCount":102},[],{"intervention":8644,"totalTrials":265,"cells":8645},"Povidine iodine nasal swabs",{"EARLY_PHASE1":8646,"PHASE1":8648,"PHASE2":8650,"PHASE3":8662,"PHASE4":8664,"NA":8666},{"trials":8647,"activeCount":102},[],{"trials":8649,"activeCount":102},[],{"trials":8651,"activeCount":102},[8652],{"nctId":8653,"briefTitle":8654,"status":436,"phases":8655,"primaryCompletion":8656,"completion":8657,"start":8658,"enrollment":531,"conditions":8659,"interventions":8661},"NCT04510402","Phase I\u002FII Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects",[90,91],"2021-02","2021-04","2020-08",[2314,8660],"Povidone Iodine Adverse Reaction",[8644],{"trials":8663,"activeCount":102},[],{"trials":8665,"activeCount":102},[],{"trials":8667,"activeCount":102},[],{"intervention":8669,"totalTrials":265,"cells":8670},"Cannabidiol 600mg",{"EARLY_PHASE1":8671,"PHASE1":8673,"PHASE2":8675,"PHASE3":8685,"PHASE4":8687,"NA":8689},{"trials":8672,"activeCount":102},[],{"trials":8674,"activeCount":102},[],{"trials":8676,"activeCount":102},[8677],{"nctId":8678,"briefTitle":8679,"status":108,"phases":8680,"primaryCompletion":8681,"completion":8681,"start":8682,"enrollment":3801,"conditions":8683,"interventions":8684},"NCT04192370","Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine",[91],"2021-12-30","2020-08-03",[8008],[8669],{"trials":8686,"activeCount":102},[],{"trials":8688,"activeCount":102},[],{"trials":8690,"activeCount":102},[],{"intervention":8692,"totalTrials":265,"cells":8693},"inhaled carbon monoxide",{"EARLY_PHASE1":8694,"PHASE1":8696,"PHASE2":8698,"PHASE3":8707,"PHASE4":8709,"NA":8711},{"trials":8695,"activeCount":102},[],{"trials":8697,"activeCount":102},[],{"trials":8699,"activeCount":102},[8700],{"nctId":8701,"briefTitle":8702,"status":108,"phases":8703,"primaryCompletion":5378,"completion":5311,"start":5312,"enrollment":6862,"conditions":8704,"interventions":8706},"NCT01214187","Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis",[91],[8705],"Idiopathic Pulmonary Fibrosis",[8692],{"trials":8708,"activeCount":102},[],{"trials":8710,"activeCount":102},[],{"trials":8712,"activeCount":102},[],{"intervention":8714,"totalTrials":265,"cells":8715},"Dexmedetomidine",{"EARLY_PHASE1":8716,"PHASE1":8718,"PHASE2":8720,"PHASE3":8729,"PHASE4":8731,"NA":8733},{"trials":8717,"activeCount":102},[],{"trials":8719,"activeCount":102},[],{"trials":8721,"activeCount":102},[8722],{"nctId":8723,"briefTitle":8724,"status":108,"phases":8725,"primaryCompletion":965,"completion":965,"start":7306,"enrollment":4812,"conditions":8726,"interventions":8728},"NCT00351299","Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium",[91],[8727,4865],"Delirium",[8714],{"trials":8730,"activeCount":102},[],{"trials":8732,"activeCount":102},[],{"trials":8734,"activeCount":102},[],{"intervention":8736,"totalTrials":265,"cells":8737},"BQ-123",{"EARLY_PHASE1":8738,"PHASE1":8740,"PHASE2":8742,"PHASE3":8753,"PHASE4":8755,"NA":8757},{"trials":8739,"activeCount":102},[],{"trials":8741,"activeCount":102},[],{"trials":8743,"activeCount":102},[8744],{"nctId":8745,"briefTitle":8746,"status":108,"phases":8747,"primaryCompletion":8748,"completion":4485,"start":8749,"enrollment":8750,"conditions":8751,"interventions":8752},"NCT00759408","The Role of Endothelin in Pulmonary Hypertension",[91],"2010-10","1999-02",38,[5356],[8736],{"trials":8754,"activeCount":102},[],{"trials":8756,"activeCount":102},[],{"trials":8758,"activeCount":102},[],{"intervention":8760,"totalTrials":265,"cells":8761},"Ifetroban",{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8766,"PHASE3":8778,"PHASE4":8780,"NA":8782},{"trials":8763,"activeCount":102},[],{"trials":8765,"activeCount":102},[],{"trials":8767,"activeCount":102},[8768],{"nctId":8769,"briefTitle":8770,"status":108,"phases":8771,"primaryCompletion":8772,"completion":8773,"start":8774,"enrollment":8750,"conditions":8775,"interventions":8777},"NCT03326063","Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban",[91],"2022-03-30","2023-04-15","2018-04-26",[260,261,8776,263],"Aspirin-exacerbated Respiratory Disease",[8760],{"trials":8779,"activeCount":102},[],{"trials":8781,"activeCount":102},[],{"trials":8783,"activeCount":102},[],{"intervention":8785,"totalTrials":265,"cells":8786},"DAW1033D oral",{"EARLY_PHASE1":8787,"PHASE1":8789,"PHASE2":8791,"PHASE3":8800,"PHASE4":8802,"NA":8804},{"trials":8788,"activeCount":102},[],{"trials":8790,"activeCount":102},[],{"trials":8792,"activeCount":102},[8793],{"nctId":8794,"briefTitle":8795,"status":108,"phases":8796,"primaryCompletion":8612,"completion":8612,"start":8797,"enrollment":1553,"conditions":8798,"interventions":8799},"NCT03383887","DAW1033D in Obstructive Sleep Apnea",[90,91],"2017-12-13",[3243],[8785],{"trials":8801,"activeCount":102},[],{"trials":8803,"activeCount":102},[],{"trials":8805,"activeCount":102},[],{"intervention":8807,"totalTrials":265,"cells":8808},"Pirfenidone",{"EARLY_PHASE1":8809,"PHASE1":8811,"PHASE2":8813,"PHASE3":8825,"PHASE4":8827,"NA":8829},{"trials":8810,"activeCount":102},[],{"trials":8812,"activeCount":102},[],{"trials":8814,"activeCount":102},[8815],{"nctId":8816,"briefTitle":8817,"status":108,"phases":8818,"primaryCompletion":8819,"completion":8819,"start":8820,"enrollment":8821,"conditions":8822,"interventions":8824},"NCT02808871","Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)",[91],"2021-04-07","2017-04-07",123,[8823],"Rheumatoid Arthritis Interstitial Lung Disease",[8807],{"trials":8826,"activeCount":102},[],{"trials":8828,"activeCount":102},[],{"trials":8830,"activeCount":102},[],{"intervention":8832,"totalTrials":265,"cells":8833},"Testosterone Undecanoate",{"EARLY_PHASE1":8834,"PHASE1":8836,"PHASE2":8838,"PHASE3":8851,"PHASE4":8853,"NA":8855},{"trials":8835,"activeCount":102},[],{"trials":8837,"activeCount":102},[],{"trials":8839,"activeCount":102},[8840],{"nctId":8841,"briefTitle":8842,"status":108,"phases":8843,"primaryCompletion":8844,"completion":8845,"start":8846,"enrollment":8847,"conditions":8848,"interventions":8850},"NCT03576001","Multimodality Intervention for Function and Metabolism in SCI",[91],"2025-01-15","2025-03-30","2019-08-23",84,[8849],"Spinal Cord Injuries",[8832],{"trials":8852,"activeCount":102},[],{"trials":8854,"activeCount":102},[],{"trials":8856,"activeCount":102},[],{"intervention":8858,"totalTrials":265,"cells":8859},"Fasudil Hydrochloride",{"EARLY_PHASE1":8860,"PHASE1":8862,"PHASE2":8864,"PHASE3":8874,"PHASE4":8876,"NA":8878},{"trials":8861,"activeCount":102},[],{"trials":8863,"activeCount":102},[],{"trials":8865,"activeCount":102},[8866],{"nctId":8867,"briefTitle":8868,"status":239,"phases":8869,"primaryCompletion":8870,"completion":8870,"start":8871,"enrollment":281,"conditions":8872,"interventions":8873},"NCT00670202","Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis",[91],"2011-01-20","2008-03-13",[7984],[8858],{"trials":8875,"activeCount":102},[],{"trials":8877,"activeCount":102},[],{"trials":8879,"activeCount":102},[],{"intervention":8881,"totalTrials":265,"cells":8882},"Dalfampridine",{"EARLY_PHASE1":8883,"PHASE1":8885,"PHASE2":8887,"PHASE3":8895,"PHASE4":8897,"NA":8899},{"trials":8884,"activeCount":102},[],{"trials":8886,"activeCount":102},[],{"trials":8888,"activeCount":102},[8889],{"nctId":8890,"briefTitle":8891,"status":108,"phases":8892,"primaryCompletion":5462,"completion":3612,"start":112,"enrollment":942,"conditions":8893,"interventions":8894},"NCT02656160","Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults",[91],[366],[8881],{"trials":8896,"activeCount":102},[],{"trials":8898,"activeCount":102},[],{"trials":8900,"activeCount":102},[],{"intervention":8902,"totalTrials":265,"cells":8903},"Sonazoid",{"EARLY_PHASE1":8904,"PHASE1":8906,"PHASE2":8908,"PHASE3":8920,"PHASE4":8922,"NA":8924},{"trials":8905,"activeCount":102},[],{"trials":8907,"activeCount":102},[],{"trials":8909,"activeCount":102},[8910],{"nctId":8911,"briefTitle":8912,"status":108,"phases":8913,"primaryCompletion":8914,"completion":8915,"start":8916,"enrollment":3801,"conditions":8917,"interventions":8919},"NCT02733029","Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection",[91],"2022-05-30","2023-02-01","2018-05-30",[8918],"Renal Transplant Rejection",[8902],{"trials":8921,"activeCount":102},[],{"trials":8923,"activeCount":102},[],{"trials":8925,"activeCount":102},[],{"intervention":8927,"totalTrials":265,"cells":8928},"installation of D. pteronyssinus allergens",{"EARLY_PHASE1":8929,"PHASE1":8931,"PHASE2":8933,"PHASE3":8942,"PHASE4":8944,"NA":8946},{"trials":8930,"activeCount":102},[],{"trials":8932,"activeCount":102},[],{"trials":8934,"activeCount":102},[8935],{"nctId":8936,"briefTitle":8937,"status":108,"phases":8938,"primaryCompletion":6675,"completion":6675,"start":363,"enrollment":8939,"conditions":8940,"interventions":8941},"NCT01691612","Role of the Isomerase Pin-1 in the Development and Treatment of Asthma",[91],14,[18],[8927],{"trials":8943,"activeCount":102},[],{"trials":8945,"activeCount":102},[],{"trials":8947,"activeCount":102},[],{"intervention":8949,"totalTrials":265,"cells":8950},"Riluzole",{"EARLY_PHASE1":8951,"PHASE1":8953,"PHASE2":8955,"PHASE3":8966,"PHASE4":8968,"NA":8970},{"trials":8952,"activeCount":102},[],{"trials":8954,"activeCount":102},[],{"trials":8956,"activeCount":102},[8957],{"nctId":8958,"briefTitle":8959,"status":239,"phases":8960,"primaryCompletion":8961,"completion":8961,"start":204,"enrollment":31,"conditions":8962,"interventions":8964},"NCT01703039","Riluzole Augmentation Pilot in Depression (RAPID) Trial",[91],"2018-06",[8963],"Major Depressive Disorder",[8949,8965],"Sertraline",{"trials":8967,"activeCount":102},[],{"trials":8969,"activeCount":102},[],{"trials":8971,"activeCount":102},[],{"intervention":8965,"totalTrials":265,"cells":8973},{"EARLY_PHASE1":8974,"PHASE1":8976,"PHASE2":8978,"PHASE3":8984,"PHASE4":8986,"NA":8988},{"trials":8975,"activeCount":102},[],{"trials":8977,"activeCount":102},[],{"trials":8979,"activeCount":102},[8980],{"nctId":8958,"briefTitle":8959,"status":239,"phases":8981,"primaryCompletion":8961,"completion":8961,"start":204,"enrollment":31,"conditions":8982,"interventions":8983},[91],[8963],[8949,8965],{"trials":8985,"activeCount":102},[],{"trials":8987,"activeCount":102},[],{"trials":8989,"activeCount":102},[],{"intervention":8991,"totalTrials":265,"cells":8992},"SAS0421a",{"EARLY_PHASE1":8993,"PHASE1":8995,"PHASE2":8997,"PHASE3":9009,"PHASE4":9011,"NA":9013},{"trials":8994,"activeCount":102},[],{"trials":8996,"activeCount":102},[],{"trials":8998,"activeCount":102},[8999],{"nctId":9000,"briefTitle":9001,"status":108,"phases":9002,"primaryCompletion":9003,"completion":9003,"start":9004,"enrollment":113,"conditions":9005,"interventions":9006},"NCT03892772","Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea",[90,91],"2021-07-03","2019-01-14",[245],[8991,9007,9008],"SAS0421b","SAS0421c",{"trials":9010,"activeCount":102},[],{"trials":9012,"activeCount":102},[],{"trials":9014,"activeCount":102},[],{"intervention":9007,"totalTrials":265,"cells":9016},{"EARLY_PHASE1":9017,"PHASE1":9019,"PHASE2":9021,"PHASE3":9027,"PHASE4":9029,"NA":9031},{"trials":9018,"activeCount":102},[],{"trials":9020,"activeCount":102},[],{"trials":9022,"activeCount":102},[9023],{"nctId":9000,"briefTitle":9001,"status":108,"phases":9024,"primaryCompletion":9003,"completion":9003,"start":9004,"enrollment":113,"conditions":9025,"interventions":9026},[90,91],[245],[8991,9007,9008],{"trials":9028,"activeCount":102},[],{"trials":9030,"activeCount":102},[],{"trials":9032,"activeCount":102},[],{"intervention":9008,"totalTrials":265,"cells":9034},{"EARLY_PHASE1":9035,"PHASE1":9037,"PHASE2":9039,"PHASE3":9045,"PHASE4":9047,"NA":9049},{"trials":9036,"activeCount":102},[],{"trials":9038,"activeCount":102},[],{"trials":9040,"activeCount":102},[9041],{"nctId":9000,"briefTitle":9001,"status":108,"phases":9042,"primaryCompletion":9003,"completion":9003,"start":9004,"enrollment":113,"conditions":9043,"interventions":9044},[90,91],[245],[8991,9007,9008],{"trials":9046,"activeCount":102},[],{"trials":9048,"activeCount":102},[],{"trials":9050,"activeCount":102},[],{"intervention":9052,"totalTrials":265,"cells":9053},"VM-202",{"EARLY_PHASE1":9054,"PHASE1":9056,"PHASE2":9058,"PHASE3":9069,"PHASE4":9071,"NA":9073},{"trials":9055,"activeCount":102},[],{"trials":9057,"activeCount":102},[],{"trials":9059,"activeCount":102},[9060],{"nctId":9061,"briefTitle":9062,"status":152,"phases":9063,"primaryCompletion":9064,"completion":9064,"start":9065,"enrollment":102,"conditions":9066,"interventions":9068},"NCT04087941","Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial",[91],"2022-12","2019-11",[9067],"Painful Diabetic Neuropathy",[9052],{"trials":9070,"activeCount":102},[],{"trials":9072,"activeCount":102},[],{"trials":9074,"activeCount":102},[],{"intervention":9076,"totalTrials":265,"cells":9077},"Atomoxetine 80 mg plus Oxybutynin 5 mg",{"EARLY_PHASE1":9078,"PHASE1":9080,"PHASE2":9082,"PHASE3":9092,"PHASE4":9094,"NA":9096},{"trials":9079,"activeCount":102},[],{"trials":9081,"activeCount":102},[],{"trials":9083,"activeCount":102},[9084],{"nctId":9085,"briefTitle":9086,"status":108,"phases":9087,"primaryCompletion":9088,"completion":9088,"start":61,"enrollment":25,"conditions":9089,"interventions":9090},"NCT05944965","Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea",[90,91],"2025-06-17",[1567],[9076,9091],"Atomoxetine 80 MG",{"trials":9093,"activeCount":102},[],{"trials":9095,"activeCount":102},[],{"trials":9097,"activeCount":102},[],{"intervention":9091,"totalTrials":265,"cells":9099},{"EARLY_PHASE1":9100,"PHASE1":9102,"PHASE2":9104,"PHASE3":9110,"PHASE4":9112,"NA":9114},{"trials":9101,"activeCount":102},[],{"trials":9103,"activeCount":102},[],{"trials":9105,"activeCount":102},[9106],{"nctId":9085,"briefTitle":9086,"status":108,"phases":9107,"primaryCompletion":9088,"completion":9088,"start":61,"enrollment":25,"conditions":9108,"interventions":9109},[90,91],[1567],[9076,9091],{"trials":9111,"activeCount":102},[],{"trials":9113,"activeCount":102},[],{"trials":9115,"activeCount":102},[],{"intervention":4476,"totalTrials":265,"cells":9117},{"EARLY_PHASE1":9118,"PHASE1":9120,"PHASE2":9122,"PHASE3":9128,"PHASE4":9130,"NA":9132},{"trials":9119,"activeCount":102},[],{"trials":9121,"activeCount":102},[],{"trials":9123,"activeCount":102},[9124],{"nctId":4470,"briefTitle":4471,"status":152,"phases":9125,"primaryCompletion":4473,"completion":4473,"start":2829,"enrollment":102,"conditions":9126,"interventions":9127},[91],[2638],[4442,4476],{"trials":9129,"activeCount":102},[],{"trials":9131,"activeCount":102},[],{"trials":9133,"activeCount":102},[],{"intervention":9135,"totalTrials":265,"cells":9136},"Stage 1 Active Methylenedioxymethamphetamine",{"EARLY_PHASE1":9137,"PHASE1":9139,"PHASE2":9141,"PHASE3":9153,"PHASE4":9155,"NA":9157},{"trials":9138,"activeCount":102},[],{"trials":9140,"activeCount":102},[],{"trials":9142,"activeCount":102},[9143],{"nctId":9144,"briefTitle":9145,"status":239,"phases":9146,"primaryCompletion":9147,"completion":6256,"start":468,"enrollment":281,"conditions":9148,"interventions":9150},"NCT00252174","MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer",[91],"2010-12",[9149,486],"Anxiety Disorder",[9135,9151,9152],"Stage 1 Low dose Methylenedioxymethamphetamine","Stage 2 Active Methylenedioxymethamphetamine",{"trials":9154,"activeCount":102},[],{"trials":9156,"activeCount":102},[],{"trials":9158,"activeCount":102},[],{"intervention":9151,"totalTrials":265,"cells":9160},{"EARLY_PHASE1":9161,"PHASE1":9163,"PHASE2":9165,"PHASE3":9171,"PHASE4":9173,"NA":9175},{"trials":9162,"activeCount":102},[],{"trials":9164,"activeCount":102},[],{"trials":9166,"activeCount":102},[9167],{"nctId":9144,"briefTitle":9145,"status":239,"phases":9168,"primaryCompletion":9147,"completion":6256,"start":468,"enrollment":281,"conditions":9169,"interventions":9170},[91],[9149,486],[9135,9151,9152],{"trials":9172,"activeCount":102},[],{"trials":9174,"activeCount":102},[],{"trials":9176,"activeCount":102},[],{"intervention":9152,"totalTrials":265,"cells":9178},{"EARLY_PHASE1":9179,"PHASE1":9181,"PHASE2":9183,"PHASE3":9189,"PHASE4":9191,"NA":9193},{"trials":9180,"activeCount":102},[],{"trials":9182,"activeCount":102},[],{"trials":9184,"activeCount":102},[9185],{"nctId":9144,"briefTitle":9145,"status":239,"phases":9186,"primaryCompletion":9147,"completion":6256,"start":468,"enrollment":281,"conditions":9187,"interventions":9188},[91],[9149,486],[9135,9151,9152],{"trials":9190,"activeCount":102},[],{"trials":9192,"activeCount":102},[],{"trials":9194,"activeCount":102},[],{"intervention":9196,"totalTrials":265,"cells":9197},"SAS2094AH and SAS2094BH",{"EARLY_PHASE1":9198,"PHASE1":9200,"PHASE2":9202,"PHASE3":9214,"PHASE4":9216,"NA":9218},{"trials":9199,"activeCount":102},[],{"trials":9201,"activeCount":102},[],{"trials":9203,"activeCount":102},[9204],{"nctId":9205,"briefTitle":9206,"status":108,"phases":9207,"primaryCompletion":9208,"completion":9208,"start":9209,"enrollment":25,"conditions":9210,"interventions":9212},"NCT03720353","Pharmacological Intervention for Symptomatic Snoring",[90,91],"2019-12-10","2018-12-17",[9211],"Snoring",[9196,9213],"SAS2094AL and SAS2094BL",{"trials":9215,"activeCount":102},[],{"trials":9217,"activeCount":102},[],{"trials":9219,"activeCount":102},[],{"intervention":9213,"totalTrials":265,"cells":9221},{"EARLY_PHASE1":9222,"PHASE1":9224,"PHASE2":9226,"PHASE3":9232,"PHASE4":9234,"NA":9236},{"trials":9223,"activeCount":102},[],{"trials":9225,"activeCount":102},[],{"trials":9227,"activeCount":102},[9228],{"nctId":9205,"briefTitle":9206,"status":108,"phases":9229,"primaryCompletion":9208,"completion":9208,"start":9209,"enrollment":25,"conditions":9230,"interventions":9231},[90,91],[9211],[9196,9213],{"trials":9233,"activeCount":102},[],{"trials":9235,"activeCount":102},[],{"trials":9237,"activeCount":102},[],{"intervention":7758,"totalTrials":265,"cells":9239},{"EARLY_PHASE1":9240,"PHASE1":9242,"PHASE2":9244,"PHASE3":9250,"PHASE4":9252,"NA":9254},{"trials":9241,"activeCount":102},[],{"trials":9243,"activeCount":102},[],{"trials":9245,"activeCount":102},[9246],{"nctId":7747,"briefTitle":7748,"status":108,"phases":9247,"primaryCompletion":7750,"completion":7750,"start":7751,"enrollment":2055,"conditions":9248,"interventions":9249},[91],[7753,7754],[7756,7155,7757,7758],{"trials":9251,"activeCount":102},[],{"trials":9253,"activeCount":102},[],{"trials":9255,"activeCount":102},[],{"intervention":9257,"totalTrials":265,"cells":9258},"Genetic Analysis for Genetic Risk Score for Tau.",{"EARLY_PHASE1":9259,"PHASE1":9261,"PHASE2":9263,"PHASE3":9274,"PHASE4":9276,"NA":9278},{"trials":9260,"activeCount":102},[],{"trials":9262,"activeCount":102},[],{"trials":9264,"activeCount":102},[9265],{"nctId":9266,"briefTitle":9267,"status":108,"phases":9268,"primaryCompletion":9269,"completion":9269,"start":9270,"enrollment":678,"conditions":9271,"interventions":9273},"NCT02191267","Tau Imaging of Chronic Traumatic Encephalopathy",[91],"2016-09-30","2015-01",[9272],"Chronic Traumatic Encephalopathy",[9257],{"trials":9275,"activeCount":102},[],{"trials":9277,"activeCount":102},[],{"trials":9279,"activeCount":102},[],{"intervention":9281,"totalTrials":265,"cells":9282},"Eculizumab",{"EARLY_PHASE1":9283,"PHASE1":9285,"PHASE2":9287,"PHASE3":9298,"PHASE4":9300,"NA":9302},{"trials":9284,"activeCount":102},[],{"trials":9286,"activeCount":102},[],{"trials":9288,"activeCount":102},[9289],{"nctId":9290,"briefTitle":9291,"status":239,"phases":9292,"primaryCompletion":7710,"completion":7710,"start":6190,"enrollment":1553,"conditions":9293,"interventions":9296},"NCT01895127","Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation",[91],[9294,9295],"Antibody-mediated Rejection","Humoral Rejection",[9281,9297],"Immunoglobulin",{"trials":9299,"activeCount":102},[],{"trials":9301,"activeCount":102},[],{"trials":9303,"activeCount":102},[],{"intervention":9297,"totalTrials":265,"cells":9305},{"EARLY_PHASE1":9306,"PHASE1":9308,"PHASE2":9310,"PHASE3":9316,"PHASE4":9318,"NA":9320},{"trials":9307,"activeCount":102},[],{"trials":9309,"activeCount":102},[],{"trials":9311,"activeCount":102},[9312],{"nctId":9290,"briefTitle":9291,"status":239,"phases":9313,"primaryCompletion":7710,"completion":7710,"start":6190,"enrollment":1553,"conditions":9314,"interventions":9315},[91],[9294,9295],[9281,9297],{"trials":9317,"activeCount":102},[],{"trials":9319,"activeCount":102},[],{"trials":9321,"activeCount":102},[],{"intervention":9323,"totalTrials":265,"cells":9324},"V158866",{"EARLY_PHASE1":9325,"PHASE1":9327,"PHASE2":9329,"PHASE3":9338,"PHASE4":9340,"NA":9342},{"trials":9326,"activeCount":102},[],{"trials":9328,"activeCount":102},[],{"trials":9330,"activeCount":102},[9331],{"nctId":9332,"briefTitle":9333,"status":108,"phases":9334,"primaryCompletion":8351,"completion":8351,"start":8495,"enrollment":2966,"conditions":9335,"interventions":9337},"NCT01748695","A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury",[91],[9336],"Neuropathic Pain Due to Spinal Cord Injury",[9323],{"trials":9339,"activeCount":102},[],{"trials":9341,"activeCount":102},[],{"trials":9343,"activeCount":102},[],{"intervention":9345,"totalTrials":281,"cells":9346},"Mepivacaine",{"EARLY_PHASE1":9347,"PHASE1":9349,"PHASE2":9369,"PHASE3":9371,"PHASE4":9373,"NA":9375},{"trials":9348,"activeCount":102},[],{"trials":9350,"activeCount":102},[9351,9361],{"nctId":9352,"briefTitle":9353,"status":108,"phases":9354,"primaryCompletion":9355,"completion":9355,"start":9356,"enrollment":167,"conditions":9357,"interventions":9360},"NCT06005480","Understanding Rebound Pain After Regional Anesthesia Resolution in Healthy Volunteers",[90],"2024-05-28","2023-09-28",[9358,9359,33],"Regional Anesthesia Morbidity","Pain, Acute",[9345],{"nctId":9362,"briefTitle":9363,"status":108,"phases":9364,"primaryCompletion":6513,"completion":6513,"start":9365,"enrollment":2312,"conditions":9366,"interventions":9368},"NCT04113954","Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers",[90],"2020-09-29",[9367,33],"Compartment Syndrome of Leg",[9345,9345],{"trials":9370,"activeCount":102},[],{"trials":9372,"activeCount":102},[],{"trials":9374,"activeCount":102},[],{"trials":9376,"activeCount":102},[],{"intervention":7536,"totalTrials":265,"cells":9378},{"EARLY_PHASE1":9379,"PHASE1":9381,"PHASE2":9387,"PHASE3":9389,"PHASE4":9391,"NA":9393},{"trials":9380,"activeCount":102},[],{"trials":9382,"activeCount":102},[9383],{"nctId":7527,"briefTitle":7528,"status":108,"phases":9384,"primaryCompletion":7530,"completion":7530,"start":7531,"enrollment":1774,"conditions":9385,"interventions":9386},[90],[7533,7534],[7536,7520],{"trials":9388,"activeCount":102},[],{"trials":9390,"activeCount":102},[],{"trials":9392,"activeCount":102},[],{"trials":9394,"activeCount":102},[],{"intervention":9396,"totalTrials":265,"cells":9397},"Sodium Zirconium Cyclosilicate Oral Product",{"EARLY_PHASE1":9398,"PHASE1":9400,"PHASE2":9410,"PHASE3":9412,"PHASE4":9414,"NA":9416},{"trials":9399,"activeCount":102},[],{"trials":9401,"activeCount":102},[9402],{"nctId":9403,"briefTitle":9404,"status":436,"phases":9405,"primaryCompletion":8374,"completion":8374,"start":9406,"enrollment":34,"conditions":9407,"interventions":9409},"NCT04727840","Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)",[90],"2021-03-15",[1787,9408],"Hyperkalemia",[9396],{"trials":9411,"activeCount":102},[],{"trials":9413,"activeCount":102},[],{"trials":9415,"activeCount":102},[],{"trials":9417,"activeCount":102},[],{"intervention":3146,"totalTrials":265,"cells":9419},{"EARLY_PHASE1":9420,"PHASE1":9422,"PHASE2":9428,"PHASE3":9430,"PHASE4":9432,"NA":9434},{"trials":9421,"activeCount":102},[],{"trials":9423,"activeCount":102},[9424],{"nctId":3137,"briefTitle":3138,"status":108,"phases":9425,"primaryCompletion":1079,"completion":3140,"start":1505,"enrollment":3141,"conditions":9426,"interventions":9427},[90],[3143],[3102,3145,3146,3147],{"trials":9429,"activeCount":102},[],{"trials":9431,"activeCount":102},[],{"trials":9433,"activeCount":102},[],{"trials":9435,"activeCount":102},[],{"intervention":3147,"totalTrials":265,"cells":9437},{"EARLY_PHASE1":9438,"PHASE1":9440,"PHASE2":9446,"PHASE3":9448,"PHASE4":9450,"NA":9452},{"trials":9439,"activeCount":102},[],{"trials":9441,"activeCount":102},[9442],{"nctId":3137,"briefTitle":3138,"status":108,"phases":9443,"primaryCompletion":1079,"completion":3140,"start":1505,"enrollment":3141,"conditions":9444,"interventions":9445},[90],[3143],[3102,3145,3146,3147],{"trials":9447,"activeCount":102},[],{"trials":9449,"activeCount":102},[],{"trials":9451,"activeCount":102},[],{"trials":9453,"activeCount":102},[],{"intervention":9455,"totalTrials":265,"cells":9456},"Inhaled Carbon Monoxide at 100ppm",{"EARLY_PHASE1":9457,"PHASE1":9459,"PHASE2":9469,"PHASE3":9471,"PHASE4":9473,"NA":9475},{"trials":9458,"activeCount":102},[],{"trials":9460,"activeCount":102},[9461],{"nctId":9462,"briefTitle":9463,"status":108,"phases":9464,"primaryCompletion":4511,"completion":4511,"start":5311,"enrollment":2917,"conditions":9465,"interventions":9467},"NCT02425579","Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)",[90],[9466],"Acute Respiratory Distress Syndrome (ARDS)",[9455,9468],"Inhaled Carbon Monoxide at 200ppm",{"trials":9470,"activeCount":102},[],{"trials":9472,"activeCount":102},[],{"trials":9474,"activeCount":102},[],{"trials":9476,"activeCount":102},[],{"intervention":9468,"totalTrials":265,"cells":9478},{"EARLY_PHASE1":9479,"PHASE1":9481,"PHASE2":9487,"PHASE3":9489,"PHASE4":9491,"NA":9493},{"trials":9480,"activeCount":102},[],{"trials":9482,"activeCount":102},[9483],{"nctId":9462,"briefTitle":9463,"status":108,"phases":9484,"primaryCompletion":4511,"completion":4511,"start":5311,"enrollment":2917,"conditions":9485,"interventions":9486},[90],[9466],[9455,9468],{"trials":9488,"activeCount":102},[],{"trials":9490,"activeCount":102},[],{"trials":9492,"activeCount":102},[],{"trials":9494,"activeCount":102},[],{"intervention":9496,"totalTrials":265,"cells":9497},"Buprenorphine",{"EARLY_PHASE1":9498,"PHASE1":9500,"PHASE2":9508,"PHASE3":9510,"PHASE4":9512,"NA":9514},{"trials":9499,"activeCount":102},[],{"trials":9501,"activeCount":102},[9502],{"nctId":9503,"briefTitle":9504,"status":108,"phases":9505,"primaryCompletion":2439,"completion":2439,"start":66,"enrollment":1774,"conditions":9506,"interventions":9507},"NCT06086275","Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder",[90],[1344],[9496],{"trials":9509,"activeCount":102},[],{"trials":9511,"activeCount":102},[],{"trials":9513,"activeCount":102},[],{"trials":9515,"activeCount":102},[],{"intervention":9517,"totalTrials":265,"cells":9518},"Azithromycin Oleogel",{"EARLY_PHASE1":9519,"PHASE1":9521,"PHASE2":9533,"PHASE3":9535,"PHASE4":9537,"NA":9539},{"trials":9520,"activeCount":102},[],{"trials":9522,"activeCount":102},[9523],{"nctId":9524,"briefTitle":9525,"status":108,"phases":9526,"primaryCompletion":9527,"completion":9527,"start":9528,"enrollment":1774,"conditions":9529,"interventions":9532},"NCT05796362","A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel",[90],"2025-11-25","2024-08-08",[7064,9530,9531],"Drug Effect","Clinical Infection",[9517],{"trials":9534,"activeCount":102},[],{"trials":9536,"activeCount":102},[],{"trials":9538,"activeCount":102},[],{"trials":9540,"activeCount":102},[],{"intervention":117,"totalTrials":265,"cells":9542},{"EARLY_PHASE1":9543,"PHASE1":9545,"PHASE2":9551,"PHASE3":9553,"PHASE4":9555,"NA":9557},{"trials":9544,"activeCount":102},[],{"trials":9546,"activeCount":102},[9547],{"nctId":106,"briefTitle":107,"status":108,"phases":9548,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":9549,"interventions":9550},[90],[115],[117,97],{"trials":9552,"activeCount":102},[],{"trials":9554,"activeCount":102},[],{"trials":9556,"activeCount":102},[],{"trials":9558,"activeCount":102},[],{"intervention":9560,"totalTrials":265,"cells":9561},"Protollin",{"EARLY_PHASE1":9562,"PHASE1":9564,"PHASE2":9576,"PHASE3":9578,"PHASE4":9580,"NA":9582},{"trials":9563,"activeCount":102},[],{"trials":9565,"activeCount":102},[9566],{"nctId":9567,"briefTitle":9568,"status":108,"phases":9569,"primaryCompletion":9570,"completion":9571,"start":9572,"enrollment":206,"conditions":9573,"interventions":9575},"NCT07187141","Nasal Protollin in Early Symptomatic Alzheimer's Disease",[90],"2022-09-22","2023-02-21","2021-11-18",[9574],"Alzheimer Disease (AD)",[9560],{"trials":9577,"activeCount":102},[],{"trials":9579,"activeCount":102},[],{"trials":9581,"activeCount":102},[],{"trials":9583,"activeCount":102},[],{"intervention":9585,"totalTrials":265,"cells":9586},"Oxycodone or morphine sulfate immediate release",{"EARLY_PHASE1":9587,"PHASE1":9589,"PHASE2":9600,"PHASE3":9602,"PHASE4":9604,"NA":9606},{"trials":9588,"activeCount":102},[],{"trials":9590,"activeCount":102},[9591],{"nctId":9592,"briefTitle":9593,"status":108,"phases":9594,"primaryCompletion":9595,"completion":1288,"start":9596,"enrollment":2793,"conditions":9597,"interventions":9599},"NCT02824276","Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain",[90],"2022-12-30","2017-01-06",[9598],"Low Back Pain",[9585],{"trials":9601,"activeCount":102},[],{"trials":9603,"activeCount":102},[],{"trials":9605,"activeCount":102},[],{"trials":9607,"activeCount":102},[],{"intervention":9609,"totalTrials":265,"cells":9610},"Hydroxocobalamin",{"EARLY_PHASE1":9611,"PHASE1":9613,"PHASE2":9623,"PHASE3":9625,"PHASE4":9627,"NA":9629},{"trials":9612,"activeCount":102},[],{"trials":9614,"activeCount":102},[9615],{"nctId":9616,"briefTitle":9617,"status":108,"phases":9618,"primaryCompletion":4739,"completion":4739,"start":9619,"enrollment":98,"conditions":9620,"interventions":9622},"NCT07469189","A Study on Hydroxocobalamin Given to Healthy Individual to Monitor Symptoms",[90],"2023-01-02",[9621],"Hydroxocobalamin Adverse Reaction",[9609],{"trials":9624,"activeCount":102},[],{"trials":9626,"activeCount":102},[],{"trials":9628,"activeCount":102},[],{"trials":9630,"activeCount":102},[],{"intervention":9632,"totalTrials":265,"cells":9633},"\"Sirolimus\" and \"Hydroxychloroquine\" 200 mg",{"EARLY_PHASE1":9634,"PHASE1":9636,"PHASE2":9646,"PHASE3":9648,"PHASE4":9650,"NA":9652},{"trials":9635,"activeCount":102},[],{"trials":9637,"activeCount":102},[9638],{"nctId":9639,"briefTitle":9640,"status":108,"phases":9641,"primaryCompletion":8567,"completion":8567,"start":9642,"enrollment":8939,"conditions":9643,"interventions":9644},"NCT01687179","Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis",[90],"2012-09",[2146],[9632,9645],"\"Sirolimus\" and \"Hydroxychloroquine\" 400 mg",{"trials":9647,"activeCount":102},[],{"trials":9649,"activeCount":102},[],{"trials":9651,"activeCount":102},[],{"trials":9653,"activeCount":102},[],{"intervention":9645,"totalTrials":265,"cells":9655},{"EARLY_PHASE1":9656,"PHASE1":9658,"PHASE2":9664,"PHASE3":9666,"PHASE4":9668,"NA":9670},{"trials":9657,"activeCount":102},[],{"trials":9659,"activeCount":102},[9660],{"nctId":9639,"briefTitle":9640,"status":108,"phases":9661,"primaryCompletion":8567,"completion":8567,"start":9642,"enrollment":8939,"conditions":9662,"interventions":9663},[90],[2146],[9632,9645],{"trials":9665,"activeCount":102},[],{"trials":9667,"activeCount":102},[],{"trials":9669,"activeCount":102},[],{"trials":9671,"activeCount":102},[],{"intervention":9673,"totalTrials":265,"cells":9674},"Inhaled Carbon Monoxide at CFK equation-determined personalized dose",{"EARLY_PHASE1":9675,"PHASE1":9677,"PHASE2":9688,"PHASE3":9690,"PHASE4":9692,"NA":9694},{"trials":9676,"activeCount":102},[],{"trials":9678,"activeCount":102},[9679],{"nctId":9680,"briefTitle":9681,"status":239,"phases":9682,"primaryCompletion":9683,"completion":9683,"start":9684,"enrollment":3730,"conditions":9685,"interventions":9687},"NCT04870125","Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)",[90],"2024-10-25","2023-12-06",[2399,9686],"Sepsis",[9673],{"trials":9689,"activeCount":102},[],{"trials":9691,"activeCount":102},[],{"trials":9693,"activeCount":102},[],{"trials":9695,"activeCount":102},[],{"intervention":9697,"totalTrials":265,"cells":9698},"Interleukin-2",{"EARLY_PHASE1":9699,"PHASE1":9701,"PHASE2":9712,"PHASE3":9714,"PHASE4":9716,"NA":9718},{"trials":9700,"activeCount":102},[],{"trials":9702,"activeCount":102},[9703],{"nctId":9704,"briefTitle":9705,"status":108,"phases":9706,"primaryCompletion":7687,"completion":9707,"start":9708,"enrollment":265,"conditions":9709,"interventions":9711},"NCT01853111","Withdrawal of Immunosuppression in Recipients of Face and Extremity Transplants",[90],"2020-03-10","2014-03-01",[9710],"Vascularized Composite Allotransplantation",[9697],{"trials":9713,"activeCount":102},[],{"trials":9715,"activeCount":102},[],{"trials":9717,"activeCount":102},[],{"trials":9719,"activeCount":102},[],{"intervention":9721,"totalTrials":265,"cells":9722},"PanChol",{"EARLY_PHASE1":9723,"PHASE1":9725,"PHASE2":9736,"PHASE3":9738,"PHASE4":9740,"NA":9742},{"trials":9724,"activeCount":102},[],{"trials":9726,"activeCount":102},[9727],{"nctId":9728,"briefTitle":9729,"status":436,"phases":9730,"primaryCompletion":5927,"completion":1288,"start":9731,"enrollment":4812,"conditions":9732,"interventions":9735},"NCT05657782","First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers",[90],"2022-12-12",[9733,9734],"Cholera","Cholera Vaccine Toxicity",[9721],{"trials":9737,"activeCount":102},[],{"trials":9739,"activeCount":102},[],{"trials":9741,"activeCount":102},[],{"trials":9743,"activeCount":102},[],{"intervention":9745,"totalTrials":265,"cells":9746},"Tolvaptan Oral",{"EARLY_PHASE1":9747,"PHASE1":9749,"PHASE2":9760,"PHASE3":9762,"PHASE4":9764,"NA":9766},{"trials":9748,"activeCount":102},[],{"trials":9750,"activeCount":102},[9751],{"nctId":9752,"briefTitle":9753,"status":108,"phases":9754,"primaryCompletion":9755,"completion":9756,"start":9757,"enrollment":678,"conditions":9758,"interventions":9759},"NCT03910231","The Role of Vasopressin Antagonism on Renal Sodium Handling",[90],"2014-09-30","2015-02-01","2012-02-01",[33],[9745],{"trials":9761,"activeCount":102},[],{"trials":9763,"activeCount":102},[],{"trials":9765,"activeCount":102},[],{"trials":9767,"activeCount":102},[],{"intervention":9769,"totalTrials":281,"cells":9770},"desferrioxamine",{"EARLY_PHASE1":9771,"PHASE1":9789,"PHASE2":9791,"PHASE3":9793,"PHASE4":9795,"NA":9797},{"trials":9772,"activeCount":102},[9773,9780],{"nctId":9774,"briefTitle":9775,"status":239,"phases":9776,"primaryCompletion":3140,"completion":8351,"start":9777,"enrollment":281,"conditions":9778,"interventions":9779},"NCT02216513","Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage",[89],"2014-09",[7725],[9769],{"nctId":9781,"briefTitle":9782,"status":108,"phases":9783,"primaryCompletion":4486,"completion":362,"start":9784,"enrollment":9785,"conditions":9786,"interventions":9788},"NCT01365104","Modulation of Cerebral Blood Flow Using Iron Chelators",[89],"2008-03",97,[3850,9787],"Problem of Aging",[9769],{"trials":9790,"activeCount":102},[],{"trials":9792,"activeCount":102},[],{"trials":9794,"activeCount":102},[],{"trials":9796,"activeCount":102},[],{"trials":9798,"activeCount":102},[],{"intervention":9800,"totalTrials":265,"cells":9801},"oral treprostinil",{"EARLY_PHASE1":9802,"PHASE1":9811,"PHASE2":9813,"PHASE3":9815,"PHASE4":9817,"NA":9819},{"trials":9803,"activeCount":102},[9804],{"nctId":9805,"briefTitle":9806,"status":108,"phases":9807,"primaryCompletion":991,"completion":991,"start":5462,"enrollment":2917,"conditions":9808,"interventions":9810},"NCT02583789","Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon",[89],[9809],"Raynaud's Phenomenon",[9800],{"trials":9812,"activeCount":102},[],{"trials":9814,"activeCount":102},[],{"trials":9816,"activeCount":102},[],{"trials":9818,"activeCount":102},[],{"trials":9820,"activeCount":102},[],{"intervention":9822,"totalTrials":265,"cells":9823},"Palmitoylethanolamide",{"EARLY_PHASE1":9824,"PHASE1":9832,"PHASE2":9834,"PHASE3":9836,"PHASE4":9838,"NA":9840},{"trials":9825,"activeCount":102},[9826],{"nctId":9827,"briefTitle":9828,"status":108,"phases":9829,"primaryCompletion":1268,"completion":1268,"start":2803,"enrollment":2917,"conditions":9830,"interventions":9831},"NCT05480072","Endocannabinoids, Stress, Craving And Pain Effects Study",[89],[1344],[9822],{"trials":9833,"activeCount":102},[],{"trials":9835,"activeCount":102},[],{"trials":9837,"activeCount":102},[],{"trials":9839,"activeCount":102},[],{"trials":9841,"activeCount":102},[],{"intervention":9843,"totalTrials":265,"cells":9844},"anti-mycoplasma hominis antibodies",{"EARLY_PHASE1":9845,"PHASE1":9860,"PHASE2":9862,"PHASE3":9864,"PHASE4":9866,"NA":9868},{"trials":9846,"activeCount":102},[9847],{"nctId":9848,"briefTitle":9849,"status":108,"phases":9850,"primaryCompletion":9851,"completion":9851,"start":9852,"enrollment":265,"conditions":9853,"interventions":9859},"NCT02508584","Personalized Immunotherapeutic for Antibiotic-resistant Infection",[89],"2019-06-12","2016-04-12",[9854,9855,9856,9857,9858],"Infection","Immune Deficiency","Hypogammaglobulinemia","Septic Arthritis","Mycoplasma Hominis",[9843],{"trials":9861,"activeCount":102},[],{"trials":9863,"activeCount":102},[],{"trials":9865,"activeCount":102},[],{"trials":9867,"activeCount":102},[],{"trials":9869,"activeCount":102},[],{"intervention":9871,"totalTrials":265,"cells":9872},"hyaluronidase injected intradermally",{"EARLY_PHASE1":9873,"PHASE1":9886,"PHASE2":9888,"PHASE3":9890,"PHASE4":9892,"NA":9894},{"trials":9874,"activeCount":102},[9875],{"nctId":9876,"briefTitle":9877,"status":152,"phases":9878,"primaryCompletion":6316,"completion":6316,"start":7490,"enrollment":102,"conditions":9879,"interventions":9885},"NCT04656704","Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease",[89],[9880,9881,9882,9883,9884],"Microstomia","Scleroderma","CREST Syndrome","Scleromyxedema","Morphea",[9871],{"trials":9887,"activeCount":102},[],{"trials":9889,"activeCount":102},[],{"trials":9891,"activeCount":102},[],{"trials":9893,"activeCount":102},[],{"trials":9895,"activeCount":102},[],{"intervention":9897,"totalTrials":265,"cells":9898},"Tildrakizumab Prefilled Syringe",{"EARLY_PHASE1":9899,"PHASE1":9909,"PHASE2":9911,"PHASE3":9913,"PHASE4":9915,"NA":9917},{"trials":9900,"activeCount":102},[9901],{"nctId":9902,"briefTitle":9903,"status":436,"phases":9904,"primaryCompletion":9905,"completion":1706,"start":913,"enrollment":206,"conditions":9906,"interventions":9908},"NCT04465292","The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid",[89],"2022-12-01",[9907],"Pemphigoid, Bullous",[9897],{"trials":9910,"activeCount":102},[],{"trials":9912,"activeCount":102},[],{"trials":9914,"activeCount":102},[],{"trials":9916,"activeCount":102},[],{"trials":9918,"activeCount":102},[],{"intervention":1627,"totalTrials":265,"cells":9920},{"EARLY_PHASE1":9921,"PHASE1":9927,"PHASE2":9929,"PHASE3":9931,"PHASE4":9933,"NA":9935},{"trials":9922,"activeCount":102},[9923],{"nctId":1615,"briefTitle":1616,"status":108,"phases":9924,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":1620,"conditions":9925,"interventions":9926},[89],[1622,1623,1624,1625],[1610,1627],{"trials":9928,"activeCount":102},[],{"trials":9930,"activeCount":102},[],{"trials":9932,"activeCount":102},[],{"trials":9934,"activeCount":102},[],{"trials":9936,"activeCount":102},[],{"intervention":9938,"totalTrials":265,"cells":9939},"Immunosuppressive Agents",{"EARLY_PHASE1":9940,"PHASE1":9951,"PHASE2":9953,"PHASE3":9955,"PHASE4":9957,"NA":9959},{"trials":9941,"activeCount":102},[9942],{"nctId":9943,"briefTitle":9944,"status":436,"phases":9945,"primaryCompletion":9946,"completion":9946,"start":9947,"enrollment":98,"conditions":9948,"interventions":9950},"NCT02416674","Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects",[89],"2025-02","2015-03-01",[9949],"Abdominal Wall Defect",[9938],{"trials":9952,"activeCount":102},[],{"trials":9954,"activeCount":102},[],{"trials":9956,"activeCount":102},[],{"trials":9958,"activeCount":102},[],{"trials":9960,"activeCount":102},[],{"intervention":9962,"totalTrials":265,"cells":9963},"Midazolam and Fentanyl",{"EARLY_PHASE1":9964,"PHASE1":9976,"PHASE2":9978,"PHASE3":9980,"PHASE4":9982,"NA":9984},{"trials":9965,"activeCount":102},[9966],{"nctId":9967,"briefTitle":9968,"status":108,"phases":9969,"primaryCompletion":9970,"completion":9970,"start":9971,"enrollment":9972,"conditions":9973,"interventions":9975},"NCT05579509","Personalizing Preprocedural Sedation for Regional Anesthesia",[89],"2024-05-24","2022-10-22",82,[9974],"Catastrophizing Pain",[9962],{"trials":9977,"activeCount":102},[],{"trials":9979,"activeCount":102},[],{"trials":9981,"activeCount":102},[],{"trials":9983,"activeCount":102},[],{"trials":9985,"activeCount":102},[],{"intervention":9987,"totalTrials":265,"cells":9988},"Lovaza",{"EARLY_PHASE1":9989,"PHASE1":10002,"PHASE2":10004,"PHASE3":10006,"PHASE4":10008,"NA":10010},{"trials":9990,"activeCount":102},[9991],{"nctId":9992,"briefTitle":9993,"status":108,"phases":9994,"primaryCompletion":178,"completion":9995,"start":9996,"enrollment":1620,"conditions":9997,"interventions":10001},"NCT04308889","Pro-Resolving Mediators in Acute Inflammation in Humans",[89],"2022-02-22","2018-07-02",[9998,9999,10000],"Inflammation; Skin","Resolution","Blister",[9987],{"trials":10003,"activeCount":102},[],{"trials":10005,"activeCount":102},[],{"trials":10007,"activeCount":102},[],{"trials":10009,"activeCount":102},[],{"trials":10011,"activeCount":102},[],{"intervention":10013,"totalTrials":265,"cells":10014},"Tasimelteon",{"EARLY_PHASE1":10015,"PHASE1":10024,"PHASE2":10026,"PHASE3":10028,"PHASE4":10030,"NA":10032},{"trials":10016,"activeCount":102},[10017],{"nctId":10018,"briefTitle":10019,"status":239,"phases":10020,"primaryCompletion":61,"completion":61,"start":56,"enrollment":34,"conditions":10021,"interventions":10023},"NCT05922995","The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)",[89],[10022],"REM Behavior Disorder",[10013],{"trials":10025,"activeCount":102},[],{"trials":10027,"activeCount":102},[],{"trials":10029,"activeCount":102},[],{"trials":10031,"activeCount":102},[],{"trials":10033,"activeCount":102},[],{"intervention":10035,"totalTrials":265,"cells":10036},"endothelial progenitor cell",{"EARLY_PHASE1":10037,"PHASE1":10048,"PHASE2":10050,"PHASE3":10052,"PHASE4":10054,"NA":10056},{"trials":10038,"activeCount":102},[10039],{"nctId":10040,"briefTitle":10041,"status":436,"phases":10042,"primaryCompletion":2031,"completion":10043,"start":10044,"enrollment":98,"conditions":10045,"interventions":10047},"NCT04187625","Cell-based Therapy for the Treatment of Kidney Disease",[89],"2025-05-01","2023-01-01",[10046],"Kidney Diseases",[10035],{"trials":10049,"activeCount":102},[],{"trials":10051,"activeCount":102},[],{"trials":10053,"activeCount":102},[],{"trials":10055,"activeCount":102},[],{"trials":10057,"activeCount":102},[],{"intervention":10059,"totalTrials":265,"cells":10060},"IL-2",{"EARLY_PHASE1":10061,"PHASE1":10074,"PHASE2":10076,"PHASE3":10078,"PHASE4":10080,"NA":10082},{"trials":10062,"activeCount":102},[10063],{"nctId":10064,"briefTitle":10065,"status":239,"phases":10066,"primaryCompletion":3877,"completion":3877,"start":10067,"enrollment":281,"conditions":10068,"interventions":10073},"NCT03241719","Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA",[89],"2017-10-17",[10069,10070,10071,10072,9949],"Amputation, Traumatic","Amputation;Traumatic;Old","Face Injury","Face; Deformity",[10059],{"trials":10075,"activeCount":102},[],{"trials":10077,"activeCount":102},[],{"trials":10079,"activeCount":102},[],{"trials":10081,"activeCount":102},[],{"trials":10083,"activeCount":102},[],{"intervention":10085,"totalTrials":265,"cells":10086},"Sodium Oxybate Oral Solution [Xyrem]",{"EARLY_PHASE1":10087,"PHASE1":10098,"PHASE2":10100,"PHASE3":10102,"PHASE4":10104,"NA":10106},{"trials":10088,"activeCount":102},[10089],{"nctId":10090,"briefTitle":10091,"status":152,"phases":10092,"primaryCompletion":913,"completion":913,"start":7865,"enrollment":102,"conditions":10093,"interventions":10097},"NCT03626727","Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia",[89],[10094,10095,10096],"Hypersomnia","Narcolepsy","Traumatic Brain Injury",[10085],{"trials":10099,"activeCount":102},[],{"trials":10101,"activeCount":102},[],{"trials":10103,"activeCount":102},[],{"trials":10105,"activeCount":102},[],{"trials":10107,"activeCount":102},[],{"intervention":3823,"totalTrials":243,"cells":10109},{"EARLY_PHASE1":10110,"PHASE1":10112,"PHASE2":10114,"PHASE3":10116,"PHASE4":10118,"NA":10120},{"trials":10111,"activeCount":102},[],{"trials":10113,"activeCount":102},[],{"trials":10115,"activeCount":102},[],{"trials":10117,"activeCount":102},[],{"trials":10119,"activeCount":102},[],{"trials":10121,"activeCount":102},[10122,10126,10133,10137,10144,10151,10155,10159,10166],{"nctId":3816,"briefTitle":3817,"status":108,"phases":10123,"primaryCompletion":3711,"completion":3711,"start":913,"enrollment":3819,"conditions":10124,"interventions":10125},[],[3821],[3823,3800],{"nctId":10127,"briefTitle":10128,"status":108,"phases":10129,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":10130,"conditions":10131,"interventions":10132},"NCT04736719","Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data",[],19002,[485],[3853,3823],{"nctId":3825,"briefTitle":3826,"status":108,"phases":10134,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":3829,"conditions":10135,"interventions":10136},[],[485],[3800,3823],{"nctId":10138,"briefTitle":10139,"status":108,"phases":10140,"primaryCompletion":3711,"completion":3711,"start":913,"enrollment":10141,"conditions":10142,"interventions":10143},"NCT04593030","Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data",[],220518,[3821],[3823,3853],{"nctId":10145,"briefTitle":10146,"status":108,"phases":10147,"primaryCompletion":3711,"completion":3711,"start":7490,"enrollment":10148,"conditions":10149,"interventions":10150},"NCT04593043","Replication of the RELY Anticoagulant Trial in Healthcare Claims Data",[],78140,[3821],[3823,3852],{"nctId":3842,"briefTitle":3843,"status":436,"phases":10152,"primaryCompletion":2208,"completion":2208,"start":3845,"enrollment":3846,"conditions":10153,"interventions":10154},[],[3821,3848,3849,3850],[3823,3852,3800,3853,3854],{"nctId":3865,"briefTitle":3866,"status":108,"phases":10156,"primaryCompletion":3693,"completion":3693,"start":3868,"enrollment":3869,"conditions":10157,"interventions":10158},[],[3871],[3800,3823],{"nctId":10160,"briefTitle":10161,"status":108,"phases":10162,"primaryCompletion":4485,"completion":4485,"start":8054,"enrollment":10163,"conditions":10164,"interventions":10165},"NCT00401414","Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information",[94],344,[3871,4007,3821],[3823],{"nctId":10167,"briefTitle":10168,"status":108,"phases":10169,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":10170,"conditions":10171,"interventions":10172},"NCT04735523","Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data",[],5350,[485],[3852,3823],{"intervention":7155,"totalTrials":3730,"cells":10174},{"EARLY_PHASE1":10175,"PHASE1":10177,"PHASE2":10179,"PHASE3":10185,"PHASE4":10195,"NA":10197},{"trials":10176,"activeCount":102},[],{"trials":10178,"activeCount":102},[],{"trials":10180,"activeCount":102},[10181],{"nctId":7747,"briefTitle":7748,"status":108,"phases":10182,"primaryCompletion":7750,"completion":7750,"start":7751,"enrollment":2055,"conditions":10183,"interventions":10184},[91],[7753,7754],[7756,7155,7757,7758],{"trials":10186,"activeCount":102},[10187,10191],{"nctId":6352,"briefTitle":6353,"status":108,"phases":10188,"primaryCompletion":6355,"completion":6356,"start":6357,"enrollment":6358,"conditions":10189,"interventions":10190},[92],[30,6360,6341,6342,978,6343,6361],[6363,6325],{"nctId":7147,"briefTitle":7148,"status":108,"phases":10192,"primaryCompletion":7150,"completion":7151,"start":7152,"conditions":10193,"interventions":10194},[92],[30,6341,6342,6343],[7155,7136],{"trials":10196,"activeCount":102},[],{"trials":10198,"activeCount":102},[10199,10206],{"nctId":10200,"briefTitle":10201,"status":108,"phases":10202,"primaryCompletion":10203,"completion":10203,"start":3612,"enrollment":167,"conditions":10204,"interventions":10205},"NCT02824523","Role of Inflammatory Mediators in AERD",[],"2021-05-01",[261],[7155],{"nctId":10207,"briefTitle":10208,"status":108,"phases":10209,"primaryCompletion":4762,"completion":4762,"start":10210,"enrollment":1082,"conditions":10211,"interventions":10212},"NCT00898222","Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects",[94],"2009-05",[33],[7155],{"intervention":3853,"totalTrials":3730,"cells":10214},{"EARLY_PHASE1":10215,"PHASE1":10217,"PHASE2":10219,"PHASE3":10221,"PHASE4":10223,"NA":10225},{"trials":10216,"activeCount":102},[],{"trials":10218,"activeCount":102},[],{"trials":10220,"activeCount":102},[],{"trials":10222,"activeCount":102},[],{"trials":10224,"activeCount":102},[],{"trials":10226,"activeCount":102},[10227,10231,10235,10239,10243],{"nctId":10127,"briefTitle":10128,"status":108,"phases":10228,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":10130,"conditions":10229,"interventions":10230},[],[485],[3853,3823],{"nctId":10138,"briefTitle":10139,"status":108,"phases":10232,"primaryCompletion":3711,"completion":3711,"start":913,"enrollment":10141,"conditions":10233,"interventions":10234},[],[3821],[3823,3853],{"nctId":3842,"briefTitle":3843,"status":436,"phases":10236,"primaryCompletion":2208,"completion":2208,"start":3845,"enrollment":3846,"conditions":10237,"interventions":10238},[],[3821,3848,3849,3850],[3823,3852,3800,3853,3854],{"nctId":3856,"briefTitle":3857,"status":108,"phases":10240,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":3861,"conditions":10241,"interventions":10242},[],[3821],[3800,3853],{"nctId":3883,"briefTitle":3884,"status":108,"phases":10244,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":3886,"conditions":10245,"interventions":10246},[],[485,3871,3888],[3800,3853],{"intervention":4515,"totalTrials":1082,"cells":10248},{"EARLY_PHASE1":10249,"PHASE1":10251,"PHASE2":10253,"PHASE3":10255,"PHASE4":10257,"NA":10267},{"trials":10250,"activeCount":102},[],{"trials":10252,"activeCount":102},[],{"trials":10254,"activeCount":102},[],{"trials":10256,"activeCount":102},[],{"trials":10258,"activeCount":102},[10259,10263],{"nctId":4508,"briefTitle":4509,"status":152,"phases":10260,"primaryCompletion":4511,"completion":4511,"start":4512,"enrollment":102,"conditions":10261,"interventions":10262},[93],[3681],[4515,4495],{"nctId":5038,"briefTitle":5039,"status":239,"phases":10264,"primaryCompletion":5041,"completion":5041,"start":5042,"enrollment":1082,"conditions":10265,"interventions":10266},[93],[5044],[5025,5046,4515],{"trials":10268,"activeCount":102},[10269,10279],{"nctId":10270,"briefTitle":10271,"status":436,"phases":10272,"primaryCompletion":2208,"completion":2208,"start":10273,"enrollment":10274,"conditions":10275,"interventions":10277},"NCT04743063","Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty",[],"2021-01-14",40000,[10276,3848],"Heart Failure, Systolic",[4515,10278],"Angiotensin II Receptor Blockers",{"nctId":10280,"briefTitle":10281,"status":108,"phases":10282,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":10283,"conditions":10284,"interventions":10285},"NCT04736433","Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.",[],6066,[24],[10286,10287],"ACE inhibitor","Sacubitril\u002FValsartan",{"intervention":10289,"totalTrials":1082,"cells":10290},"Spironolactone",{"EARLY_PHASE1":10291,"PHASE1":10293,"PHASE2":10295,"PHASE3":10297,"PHASE4":10299,"NA":10317},{"trials":10292,"activeCount":102},[],{"trials":10294,"activeCount":102},[],{"trials":10296,"activeCount":102},[],{"trials":10298,"activeCount":102},[],{"trials":10300,"activeCount":102},[10301,10308],{"nctId":10302,"briefTitle":10303,"status":108,"phases":10304,"primaryCompletion":9527,"completion":9527,"start":10305,"enrollment":1415,"conditions":10306,"interventions":10307},"NCT03429946","Hypoglycemia and Autonomic Nervous System Function-B",[93],"2013-07-17",[230,33],[10289],{"nctId":10309,"briefTitle":10310,"status":152,"phases":10311,"primaryCompletion":10312,"completion":10312,"start":10313,"enrollment":102,"conditions":10314,"interventions":10316},"NCT01855334","L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD",[93],"2018-07","2013-09",[10315,298],"End Stage Renal Disease",[10289],{"trials":10318,"activeCount":102},[10319,10328],{"nctId":10320,"briefTitle":10321,"status":108,"phases":10322,"primaryCompletion":155,"completion":10323,"start":4487,"enrollment":128,"conditions":10324,"interventions":10326},"NCT00865124","Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease",[94],"2014-05",[1368,10325],"Vascular Disease",[10289,10327],"Hydrochlorothiazide + potassium",{"nctId":10329,"briefTitle":10330,"status":108,"phases":10331,"primaryCompletion":155,"completion":7305,"start":4728,"enrollment":8750,"conditions":10332,"interventions":10333},"NCT01406015","Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications",[94],[21,3011],[10289],{"intervention":10335,"totalTrials":1082,"cells":10336},"Salmeterol",{"EARLY_PHASE1":10337,"PHASE1":10339,"PHASE2":10341,"PHASE3":10343,"PHASE4":10355,"NA":10357},{"trials":10338,"activeCount":102},[],{"trials":10340,"activeCount":102},[],{"trials":10342,"activeCount":102},[],{"trials":10344,"activeCount":102},[10345],{"nctId":10346,"briefTitle":10347,"status":108,"phases":10348,"primaryCompletion":5193,"completion":5193,"start":10349,"enrollment":10350,"conditions":10351,"interventions":10352},"NCT01290874","Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)",[92],"2011-03-30",1070,[18],[10353,10335,10354],"Tiotropium","Formoterol",{"trials":10356,"activeCount":102},[],{"trials":10358,"activeCount":102},[10359,10366,10376],{"nctId":10360,"briefTitle":10361,"status":108,"phases":10362,"primaryCompletion":6307,"completion":6947,"start":7543,"enrollment":678,"conditions":10363,"interventions":10364},"NCT00595361","How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment",[94],[18],[10365],"salmeterol",{"nctId":10367,"briefTitle":10368,"status":239,"phases":10369,"primaryCompletion":932,"completion":1715,"start":6054,"enrollment":10370,"conditions":10371,"interventions":10372},"NCT00706446","The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations",[94],255,[18],[10373,10335,10354,10374,10375],"tiotropium bromide","Fluticasone propionate","budesonide",{"nctId":10377,"briefTitle":10378,"status":108,"phases":10379,"primaryCompletion":10380,"completion":10380,"start":3828,"enrollment":10381,"conditions":10382,"interventions":10383},"NCT05083429","Replication of the POET-COPD Trial in Healthcare Claims Data",[],"2021-08-09",8716,[7844],[10335,10353],{"intervention":10385,"totalTrials":1082,"cells":10386},"Abatacept",{"EARLY_PHASE1":10387,"PHASE1":10389,"PHASE2":10400,"PHASE3":10402,"PHASE4":10404,"NA":10406},{"trials":10388,"activeCount":102},[],{"trials":10390,"activeCount":102},[10391],{"nctId":10392,"briefTitle":10393,"status":436,"phases":10394,"primaryCompletion":10395,"completion":10396,"start":9270,"enrollment":98,"conditions":10397,"interventions":10399},"NCT02281058","Open-label Pilot Study of Abatacept for the Treatment of Vitiligo",[90],"2017-11","2018-05",[10398],"Vitiligo",[10385],{"trials":10401,"activeCount":102},[],{"trials":10403,"activeCount":102},[],{"trials":10405,"activeCount":102},[],{"trials":10407,"activeCount":102},[10408,10417,10425],{"nctId":10409,"briefTitle":10410,"status":108,"phases":10411,"primaryCompletion":3627,"completion":3627,"start":10412,"enrollment":10413,"conditions":10414,"interventions":10415},"NCT04529876","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept",[],"2020-08-17",29464,[3631],[10416,10385],"Tofacitinib",{"nctId":10418,"briefTitle":10419,"status":108,"phases":10420,"primaryCompletion":3627,"completion":3627,"start":10412,"enrollment":10421,"conditions":10422,"interventions":10423},"NCT04529863","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept",[],30432,[3631],[10424,10385],"Tocilizumab",{"nctId":10426,"briefTitle":10427,"status":108,"phases":10428,"primaryCompletion":3627,"completion":3627,"start":10412,"enrollment":10429,"conditions":10430,"interventions":10431},"NCT04529902","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept",[],63013,[3631],[10432,10385],"Tumor Necrosis Factor Inhibitors",{"intervention":3716,"totalTrials":197,"cells":10434},{"EARLY_PHASE1":10435,"PHASE1":10437,"PHASE2":10439,"PHASE3":10441,"PHASE4":10443,"NA":10445},{"trials":10436,"activeCount":102},[],{"trials":10438,"activeCount":102},[],{"trials":10440,"activeCount":102},[],{"trials":10442,"activeCount":102},[],{"trials":10444,"activeCount":102},[],{"trials":10446,"activeCount":102},[10447,10455,10459],{"nctId":10448,"briefTitle":10449,"status":108,"phases":10450,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":10451,"conditions":10452,"interventions":10453},"NCT03936023","Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims",[],182126,[27],[10454,3716],"Saxagliptin",{"nctId":3708,"briefTitle":3709,"status":108,"phases":10456,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3713,"conditions":10457,"interventions":10458},[],[27],[1283,3716],{"nctId":10460,"briefTitle":10461,"status":108,"phases":10462,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":10463,"conditions":10464,"interventions":10465},"NCT03936036","Replication of the CARMELINA Diabetes Trial in Healthcare Claims",[],101830,[27],[10466,3716],"Linagliptin",{"intervention":10416,"totalTrials":197,"cells":10468},{"EARLY_PHASE1":10469,"PHASE1":10471,"PHASE2":10473,"PHASE3":10475,"PHASE4":10477,"NA":10479},{"trials":10470,"activeCount":102},[],{"trials":10472,"activeCount":102},[],{"trials":10474,"activeCount":102},[],{"trials":10476,"activeCount":102},[],{"trials":10478,"activeCount":102},[],{"trials":10480,"activeCount":102},[10481,10491,10495],{"nctId":10482,"briefTitle":10483,"status":108,"phases":10484,"primaryCompletion":991,"completion":10485,"start":10486,"enrollment":10487,"conditions":10488,"interventions":10489},"NCT04798287","Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints",[],"2022-05-16","2021-03-10",105711,[3631],[10416,10490],"TNF Inhibitor",{"nctId":10409,"briefTitle":10410,"status":108,"phases":10492,"primaryCompletion":3627,"completion":3627,"start":10412,"enrollment":10413,"conditions":10493,"interventions":10494},[],[3631],[10416,10385],{"nctId":10496,"briefTitle":10497,"status":108,"phases":10498,"primaryCompletion":8681,"completion":8681,"start":10499,"enrollment":10487,"conditions":10500,"interventions":10501},"NCT04772248","Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints",[],"2021-02-22",[3631],[10416,10490],{"intervention":10503,"totalTrials":197,"cells":10504},"Naltrexone",{"EARLY_PHASE1":10505,"PHASE1":10507,"PHASE2":10509,"PHASE3":10528,"PHASE4":10530,"NA":10532},{"trials":10506,"activeCount":102},[],{"trials":10508,"activeCount":102},[],{"trials":10510,"activeCount":102},[10511,10520],{"nctId":10512,"briefTitle":10513,"status":152,"phases":10514,"primaryCompletion":10515,"completion":10515,"start":3041,"enrollment":102,"conditions":10516,"interventions":10519},"NCT04115020","Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis",[91],"2020-01-07",[10517,3615,10518],"Osteoarthritis","Arthritis, Psoriatic",[10503],{"nctId":10521,"briefTitle":10522,"status":108,"phases":10523,"primaryCompletion":1457,"completion":1457,"start":10524,"enrollment":1620,"conditions":10525,"interventions":10527},"NCT07132177","Targeted Naltrexone to Support Individuals Participating in Dry January",[91],"2025-11-03",[10526],"Alcohol Misuse",[10503],{"trials":10529,"activeCount":102},[],{"trials":10531,"activeCount":102},[],{"trials":10533,"activeCount":102},[10534],{"nctId":10535,"briefTitle":10536,"status":108,"phases":10537,"primaryCompletion":4485,"completion":4485,"start":8054,"enrollment":10538,"conditions":10539,"interventions":10542},"NCT00675961","Effectiveness of Alcohol Interventions Among Tuberculosis (TB) Patients in Tomsk Oblast, Russia",[94],400,[10540,10541],"Tuberculosis","Alcohol Use Disorders",[10503],{"intervention":4744,"totalTrials":197,"cells":10544},{"EARLY_PHASE1":10545,"PHASE1":10547,"PHASE2":10549,"PHASE3":10551,"PHASE4":10553,"NA":10559},{"trials":10546,"activeCount":102},[],{"trials":10548,"activeCount":102},[],{"trials":10550,"activeCount":102},[],{"trials":10552,"activeCount":102},[],{"trials":10554,"activeCount":102},[10555],{"nctId":4736,"briefTitle":4737,"status":436,"phases":10556,"primaryCompletion":4739,"completion":4739,"start":4740,"enrollment":296,"conditions":10557,"interventions":10558},[93],[4742,1590],[4744,4745,4712],{"trials":10560,"activeCount":102},[10561,10570],{"nctId":10562,"briefTitle":10563,"status":239,"phases":10564,"primaryCompletion":8197,"completion":8197,"start":10565,"enrollment":31,"conditions":10566,"interventions":10567},"NCT02277782","Intrathecal Hydromorphone for Labor Analgesia",[94],"2015-09-01",[5976],[10568,10569,4744],"Hydromorphone","Hyperbaric bupivacaine",{"nctId":10571,"briefTitle":10572,"status":108,"phases":10573,"primaryCompletion":10574,"completion":10574,"start":974,"enrollment":1553,"conditions":10575,"interventions":10577},"NCT02419547","Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia",[94],"2015-04-26",[10576],"Ventricular Tachycardia",[10578,4744,10579,10580],"Versed","Propofol","Sevoflurane",{"intervention":3618,"totalTrials":197,"cells":10582},{"EARLY_PHASE1":10583,"PHASE1":10585,"PHASE2":10587,"PHASE3":10589,"PHASE4":10597,"NA":10603},{"trials":10584,"activeCount":102},[],{"trials":10586,"activeCount":102},[],{"trials":10588,"activeCount":102},[],{"trials":10590,"activeCount":102},[10591],{"nctId":10592,"briefTitle":10593,"status":108,"phases":10594,"primaryCompletion":8471,"completion":4486,"start":932,"enrollment":678,"conditions":10595,"interventions":10596},"NCT01132118","Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis",[92],[3631,3011],[3618],{"trials":10598,"activeCount":102},[10599],{"nctId":3608,"briefTitle":3609,"status":108,"phases":10600,"primaryCompletion":3611,"completion":3611,"start":3612,"enrollment":3613,"conditions":10601,"interventions":10602},[93],[3615],[3115,3617,3618,3619,3620],{"trials":10604,"activeCount":102},[10605],{"nctId":3624,"briefTitle":3625,"status":108,"phases":10606,"primaryCompletion":3627,"completion":3627,"start":3628,"enrollment":3629,"conditions":10607,"interventions":10608},[],[3631],[3115,3618],{"intervention":10610,"totalTrials":197,"cells":10611},"eszopiclone",{"EARLY_PHASE1":10612,"PHASE1":10622,"PHASE2":10624,"PHASE3":10626,"PHASE4":10628,"NA":10630},{"trials":10613,"activeCount":102},[10614],{"nctId":10615,"briefTitle":10616,"status":108,"phases":10617,"primaryCompletion":4762,"completion":10618,"start":1504,"enrollment":258,"conditions":10619,"interventions":10620},"NCT01102270","The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome",[89],"2010-05",[36],[10621],"Eszopiclone",{"trials":10623,"activeCount":102},[],{"trials":10625,"activeCount":102},[],{"trials":10627,"activeCount":102},[],{"trials":10629,"activeCount":102},[],{"trials":10631,"activeCount":102},[10632,10640],{"nctId":10633,"briefTitle":10634,"status":108,"phases":10635,"primaryCompletion":10636,"completion":975,"start":214,"enrollment":34,"conditions":10637,"interventions":10639},"NCT00555750","Sleep Loss and Mechanisms of Impaired Glucose Metabolism",[94],"2008-07",[10638],"Primary Insomnia",[10610],{"nctId":10641,"briefTitle":10642,"status":108,"phases":10643,"primaryCompletion":5266,"completion":6167,"start":10210,"enrollment":933,"conditions":10644,"interventions":10646},"NCT00900159","Effects of Daytime Eszopiclone Administration in Shift Workers",[94],[10645],"Shift-Work Sleep Disorder",[10610],{"intervention":3938,"totalTrials":197,"cells":10648},{"EARLY_PHASE1":10649,"PHASE1":10651,"PHASE2":10653,"PHASE3":10655,"PHASE4":10657,"NA":10667},{"trials":10650,"activeCount":102},[],{"trials":10652,"activeCount":102},[],{"trials":10654,"activeCount":102},[],{"trials":10656,"activeCount":102},[],{"trials":10658,"activeCount":102},[10659],{"nctId":10660,"briefTitle":10661,"status":436,"phases":10662,"primaryCompletion":10663,"completion":10663,"start":10664,"enrollment":167,"conditions":10665,"interventions":10666},"NCT06438146","LIROH - Liraglutide for Obesity in HIV",[93],"2025-05","2024-05-02",[21,4695],[3938],{"trials":10668,"activeCount":102},[10669,10678],{"nctId":10670,"briefTitle":10671,"status":108,"phases":10672,"primaryCompletion":10673,"completion":10673,"start":10674,"enrollment":10675,"conditions":10676,"interventions":10677},"NCT05162183","Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data",[],"2021-09-01","2019-09-01",3474,[27],[3673,3938],{"nctId":3932,"briefTitle":3933,"status":108,"phases":10679,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3935,"conditions":10680,"interventions":10681},[],[27],[3938,408],{"intervention":3852,"totalTrials":197,"cells":10683},{"EARLY_PHASE1":10684,"PHASE1":10686,"PHASE2":10688,"PHASE3":10690,"PHASE4":10692,"NA":10694},{"trials":10685,"activeCount":102},[],{"trials":10687,"activeCount":102},[],{"trials":10689,"activeCount":102},[],{"trials":10691,"activeCount":102},[],{"trials":10693,"activeCount":102},[],{"trials":10695,"activeCount":102},[10696,10700,10704],{"nctId":10145,"briefTitle":10146,"status":108,"phases":10697,"primaryCompletion":3711,"completion":3711,"start":7490,"enrollment":10148,"conditions":10698,"interventions":10699},[],[3821],[3823,3852],{"nctId":3842,"briefTitle":3843,"status":436,"phases":10701,"primaryCompletion":2208,"completion":2208,"start":3845,"enrollment":3846,"conditions":10702,"interventions":10703},[],[3821,3848,3849,3850],[3823,3852,3800,3853,3854],{"nctId":10167,"briefTitle":10168,"status":108,"phases":10705,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":10170,"conditions":10706,"interventions":10707},[],[485],[3852,3823],{"intervention":10353,"totalTrials":197,"cells":10709},{"EARLY_PHASE1":10710,"PHASE1":10712,"PHASE2":10714,"PHASE3":10716,"PHASE4":10722,"NA":10724},{"trials":10711,"activeCount":102},[],{"trials":10713,"activeCount":102},[],{"trials":10715,"activeCount":102},[],{"trials":10717,"activeCount":102},[10718],{"nctId":10346,"briefTitle":10347,"status":108,"phases":10719,"primaryCompletion":5193,"completion":5193,"start":10349,"enrollment":10350,"conditions":10720,"interventions":10721},[92],[18],[10353,10335,10354],{"trials":10723,"activeCount":102},[],{"trials":10725,"activeCount":102},[10726,10730],{"nctId":10377,"briefTitle":10378,"status":108,"phases":10727,"primaryCompletion":10380,"completion":10380,"start":3828,"enrollment":10381,"conditions":10728,"interventions":10729},[],[7844],[10335,10353],{"nctId":10731,"briefTitle":10732,"status":108,"phases":10733,"primaryCompletion":2143,"completion":2143,"start":3828,"enrollment":10734,"conditions":10735,"interventions":10736},"NCT05179512","Replication of the INSPIRE Trial in Healthcare Claims Data",[],98278,[7844],[10353,10737],"salmeterol-fluticasone",{"intervention":10454,"totalTrials":281,"cells":10739},{"EARLY_PHASE1":10740,"PHASE1":10742,"PHASE2":10744,"PHASE3":10746,"PHASE4":10748,"NA":10757},{"trials":10741,"activeCount":102},[],{"trials":10743,"activeCount":102},[],{"trials":10745,"activeCount":102},[],{"trials":10747,"activeCount":102},[],{"trials":10749,"activeCount":102},[10750],{"nctId":10751,"briefTitle":10752,"status":108,"phases":10753,"primaryCompletion":10754,"completion":10754,"start":974,"enrollment":651,"conditions":10755,"interventions":10756},"NCT02182895","Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient",[93],"2017-02",[218],[10454],{"trials":10758,"activeCount":102},[10759],{"nctId":10448,"briefTitle":10449,"status":108,"phases":10760,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":10451,"conditions":10761,"interventions":10762},[],[27],[10454,3716],{"intervention":10764,"totalTrials":281,"cells":10765},"Ramipril",{"EARLY_PHASE1":10766,"PHASE1":10768,"PHASE2":10770,"PHASE3":10776,"PHASE4":10778,"NA":10780},{"trials":10767,"activeCount":102},[],{"trials":10769,"activeCount":102},[],{"trials":10771,"activeCount":102},[10772],{"nctId":7747,"briefTitle":7748,"status":108,"phases":10773,"primaryCompletion":7750,"completion":7750,"start":7751,"enrollment":2055,"conditions":10774,"interventions":10775},[91],[7753,7754],[7756,7155,7757,7758],{"trials":10777,"activeCount":102},[],{"trials":10779,"activeCount":102},[],{"trials":10781,"activeCount":102},[10782],{"nctId":10783,"briefTitle":10784,"status":108,"phases":10785,"primaryCompletion":10786,"completion":10786,"start":3712,"enrollment":10787,"conditions":10788,"interventions":10789},"NCT04354350","Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data",[],"2021-02-08",63744,[15],[10764,10790],"Telmisartan",{"intervention":10790,"totalTrials":281,"cells":10792},{"EARLY_PHASE1":10793,"PHASE1":10795,"PHASE2":10797,"PHASE3":10799,"PHASE4":10801,"NA":10803},{"trials":10794,"activeCount":102},[],{"trials":10796,"activeCount":102},[],{"trials":10798,"activeCount":102},[],{"trials":10800,"activeCount":102},[],{"trials":10802,"activeCount":102},[],{"trials":10804,"activeCount":102},[10805,10809],{"nctId":10783,"briefTitle":10784,"status":108,"phases":10806,"primaryCompletion":10786,"completion":10786,"start":3712,"enrollment":10787,"conditions":10807,"interventions":10808},[],[15],[10764,10790],{"nctId":10810,"briefTitle":10811,"status":108,"phases":10812,"primaryCompletion":10786,"completion":10786,"start":3712,"enrollment":10813,"conditions":10814,"interventions":10815},"NCT04354376","Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data",[],40048,[15],[10816,10790],"Loop diuretics, thiazides, dihydropyridines",{"intervention":6562,"totalTrials":281,"cells":10818},{"EARLY_PHASE1":10819,"PHASE1":10821,"PHASE2":10823,"PHASE3":10825,"PHASE4":10831,"NA":10833},{"trials":10820,"activeCount":102},[],{"trials":10822,"activeCount":102},[],{"trials":10824,"activeCount":102},[],{"trials":10826,"activeCount":102},[10827],{"nctId":6556,"briefTitle":6557,"status":239,"phases":10828,"primaryCompletion":205,"completion":205,"start":4005,"enrollment":113,"conditions":10829,"interventions":10830},[92],[6560],[6562,6545],{"trials":10832,"activeCount":102},[],{"trials":10834,"activeCount":102},[10835],{"nctId":10571,"briefTitle":10572,"status":108,"phases":10836,"primaryCompletion":10574,"completion":10574,"start":974,"enrollment":1553,"conditions":10837,"interventions":10838},[94],[10576],[10578,4744,10579,10580],{"intervention":10490,"totalTrials":281,"cells":10840},{"EARLY_PHASE1":10841,"PHASE1":10843,"PHASE2":10845,"PHASE3":10847,"PHASE4":10849,"NA":10851},{"trials":10842,"activeCount":102},[],{"trials":10844,"activeCount":102},[],{"trials":10846,"activeCount":102},[],{"trials":10848,"activeCount":102},[],{"trials":10850,"activeCount":102},[],{"trials":10852,"activeCount":102},[10853,10857],{"nctId":10482,"briefTitle":10483,"status":108,"phases":10854,"primaryCompletion":991,"completion":10485,"start":10486,"enrollment":10487,"conditions":10855,"interventions":10856},[],[3631],[10416,10490],{"nctId":10496,"briefTitle":10497,"status":108,"phases":10858,"primaryCompletion":8681,"completion":8681,"start":10499,"enrollment":10487,"conditions":10859,"interventions":10860},[],[3631],[10416,10490],{"intervention":10862,"totalTrials":281,"cells":10863},"Ticagrelor 90mg",{"EARLY_PHASE1":10864,"PHASE1":10866,"PHASE2":10868,"PHASE3":10870,"PHASE4":10872,"NA":10874},{"trials":10865,"activeCount":102},[],{"trials":10867,"activeCount":102},[],{"trials":10869,"activeCount":102},[],{"trials":10871,"activeCount":102},[],{"trials":10873,"activeCount":102},[],{"trials":10875,"activeCount":102},[10876,10886],{"nctId":10877,"briefTitle":10878,"status":108,"phases":10879,"primaryCompletion":3711,"completion":3711,"start":10880,"enrollment":10881,"conditions":10882,"interventions":10884},"NCT04237935","Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data",[],"2019-09-22",27960,[10883],"Antiplatelet",[10862,10885],"Clopidogrel 75mg",{"nctId":10887,"briefTitle":10888,"status":108,"phases":10889,"primaryCompletion":10890,"completion":10890,"start":3868,"enrollment":10891,"conditions":10892,"interventions":10894},"NCT05086081","Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data",[],"2021-09-10",28389,[10893],"Acute Coronary Syndrome",[10862,10895],"Prasugrel 10mg",{"intervention":10885,"totalTrials":281,"cells":10897},{"EARLY_PHASE1":10898,"PHASE1":10900,"PHASE2":10902,"PHASE3":10904,"PHASE4":10906,"NA":10908},{"trials":10899,"activeCount":102},[],{"trials":10901,"activeCount":102},[],{"trials":10903,"activeCount":102},[],{"trials":10905,"activeCount":102},[],{"trials":10907,"activeCount":102},[],{"trials":10909,"activeCount":102},[10910,10914],{"nctId":10877,"briefTitle":10878,"status":108,"phases":10911,"primaryCompletion":3711,"completion":3711,"start":10880,"enrollment":10881,"conditions":10912,"interventions":10913},[],[10883],[10862,10885],{"nctId":10915,"briefTitle":10916,"status":108,"phases":10917,"primaryCompletion":3711,"completion":3711,"start":10880,"enrollment":10918,"conditions":10919,"interventions":10920},"NCT04237922","Replication of the TRITON-TIMI Antiplatelet Trial in Healthcare Claims Data",[],43864,[10883],[10895,10885],{"intervention":3972,"totalTrials":281,"cells":10922},{"EARLY_PHASE1":10923,"PHASE1":10925,"PHASE2":10927,"PHASE3":10929,"PHASE4":10931,"NA":10933},{"trials":10924,"activeCount":102},[],{"trials":10926,"activeCount":102},[],{"trials":10928,"activeCount":102},[],{"trials":10930,"activeCount":102},[],{"trials":10932,"activeCount":102},[],{"trials":10934,"activeCount":102},[10935,10939],{"nctId":3963,"briefTitle":3964,"status":108,"phases":10936,"primaryCompletion":3966,"completion":3966,"start":3967,"enrollment":3968,"conditions":10937,"interventions":10938},[94],[3850,3970],[3972,1053],{"nctId":10940,"briefTitle":10941,"status":108,"phases":10942,"primaryCompletion":41,"completion":9946,"start":955,"enrollment":956,"conditions":10943,"interventions":10946},"NCT01351805","Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain",[94],[10944,10945,5549,10517,3631],"Autoimmune Diseases","Systemic Inflammatory Process",[10947],"Fish Oil",{"intervention":3699,"totalTrials":281,"cells":10949},{"EARLY_PHASE1":10950,"PHASE1":10952,"PHASE2":10954,"PHASE3":10956,"PHASE4":10958,"NA":10960},{"trials":10951,"activeCount":102},[],{"trials":10953,"activeCount":102},[],{"trials":10955,"activeCount":102},[],{"trials":10957,"activeCount":102},[],{"trials":10959,"activeCount":102},[],{"trials":10961,"activeCount":102},[10962,10966],{"nctId":3905,"briefTitle":3906,"status":108,"phases":10963,"primaryCompletion":3711,"completion":3711,"start":3791,"enrollment":3908,"conditions":10964,"interventions":10965},[],[27],[3699,408],{"nctId":3690,"briefTitle":3691,"status":108,"phases":10967,"primaryCompletion":3693,"completion":3693,"start":3694,"enrollment":3695,"conditions":10968,"interventions":10969},[],[3697],[3699,1283],{"intervention":10971,"totalTrials":281,"cells":10972},"Calcitriol",{"EARLY_PHASE1":10973,"PHASE1":10975,"PHASE2":10977,"PHASE3":10987,"PHASE4":10989,"NA":10991},{"trials":10974,"activeCount":102},[],{"trials":10976,"activeCount":102},[],{"trials":10978,"activeCount":102},[10979],{"nctId":10980,"briefTitle":10981,"status":108,"phases":10982,"primaryCompletion":6411,"completion":6411,"start":6676,"enrollment":10983,"conditions":10984,"interventions":10986},"NCT01689441","Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis",[91],67,[10985],"Severe Sepsis or Septic Shock",[10971],{"trials":10988,"activeCount":102},[],{"trials":10990,"activeCount":102},[],{"trials":10992,"activeCount":102},[10993],{"nctId":10994,"briefTitle":10995,"status":108,"phases":10996,"primaryCompletion":6790,"completion":6790,"start":9642,"enrollment":1708,"conditions":10997,"interventions":10998},"NCT01635062","The VALIDATE-D Study",[94],[1258,21],[10971],{"intervention":11000,"totalTrials":281,"cells":11001},"New use of semaglutide",{"EARLY_PHASE1":11002,"PHASE1":11004,"PHASE2":11006,"PHASE3":11008,"PHASE4":11010,"NA":11012},{"trials":11003,"activeCount":102},[],{"trials":11005,"activeCount":102},[],{"trials":11007,"activeCount":102},[],{"trials":11009,"activeCount":102},[],{"trials":11011,"activeCount":102},[],{"trials":11013,"activeCount":102},[11014,11023],{"nctId":11015,"briefTitle":11016,"status":108,"phases":11017,"primaryCompletion":11018,"completion":11018,"start":892,"enrollment":11019,"conditions":11020,"interventions":11021},"NCT05577728","Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data",[],"2022-10-31",2316,[885],[11000,11022],"New initiation of \"standard of care\"",{"nctId":11024,"briefTitle":11025,"status":108,"phases":11026,"primaryCompletion":11027,"completion":11027,"start":3652,"enrollment":11028,"conditions":11029,"interventions":11030},"NCT06659744","Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims",[],"2025-03-06",158310,[885],[11000,11031],"New initiation of sitagliptin",{"intervention":10895,"totalTrials":281,"cells":11033},{"EARLY_PHASE1":11034,"PHASE1":11036,"PHASE2":11038,"PHASE3":11040,"PHASE4":11042,"NA":11044},{"trials":11035,"activeCount":102},[],{"trials":11037,"activeCount":102},[],{"trials":11039,"activeCount":102},[],{"trials":11041,"activeCount":102},[],{"trials":11043,"activeCount":102},[],{"trials":11045,"activeCount":102},[11046,11050],{"nctId":10915,"briefTitle":10916,"status":108,"phases":11047,"primaryCompletion":3711,"completion":3711,"start":10880,"enrollment":10918,"conditions":11048,"interventions":11049},[],[10883],[10895,10885],{"nctId":10887,"briefTitle":10888,"status":108,"phases":11051,"primaryCompletion":10890,"completion":10890,"start":3868,"enrollment":10891,"conditions":11052,"interventions":11053},[],[10893],[10862,10895],{"intervention":6750,"totalTrials":281,"cells":11055},{"EARLY_PHASE1":11056,"PHASE1":11058,"PHASE2":11060,"PHASE3":11062,"PHASE4":11068,"NA":11070},{"trials":11057,"activeCount":102},[],{"trials":11059,"activeCount":102},[],{"trials":11061,"activeCount":102},[],{"trials":11063,"activeCount":102},[11064],{"nctId":6741,"briefTitle":6742,"status":108,"phases":11065,"primaryCompletion":6675,"completion":3140,"start":6256,"enrollment":6744,"conditions":11066,"interventions":11067},[92],[6746,6747,6748,1280,21],[6730,6750,6751],{"trials":11069,"activeCount":102},[],{"trials":11071,"activeCount":102},[11072],{"nctId":11073,"briefTitle":11074,"status":108,"phases":11075,"primaryCompletion":11076,"completion":1357,"start":11077,"enrollment":11078,"conditions":11079,"interventions":11081},"NCT04746989","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol",[],"2023-07-17","2021-02-01",294878,[11080],"Gout",[6750,6751],{"intervention":6751,"totalTrials":281,"cells":11083},{"EARLY_PHASE1":11084,"PHASE1":11086,"PHASE2":11088,"PHASE3":11090,"PHASE4":11096,"NA":11098},{"trials":11085,"activeCount":102},[],{"trials":11087,"activeCount":102},[],{"trials":11089,"activeCount":102},[],{"trials":11091,"activeCount":102},[11092],{"nctId":6741,"briefTitle":6742,"status":108,"phases":11093,"primaryCompletion":6675,"completion":3140,"start":6256,"enrollment":6744,"conditions":11094,"interventions":11095},[92],[6746,6747,6748,1280,21],[6730,6750,6751],{"trials":11097,"activeCount":102},[],{"trials":11099,"activeCount":102},[11100],{"nctId":11073,"briefTitle":11074,"status":108,"phases":11101,"primaryCompletion":11076,"completion":1357,"start":11077,"enrollment":11078,"conditions":11102,"interventions":11103},[],[11080],[6750,6751],{"intervention":3673,"totalTrials":281,"cells":11105},{"EARLY_PHASE1":11106,"PHASE1":11108,"PHASE2":11110,"PHASE3":11112,"PHASE4":11114,"NA":11116},{"trials":11107,"activeCount":102},[],{"trials":11109,"activeCount":102},[],{"trials":11111,"activeCount":102},[],{"trials":11113,"activeCount":102},[],{"trials":11115,"activeCount":102},[],{"trials":11117,"activeCount":102},[11118,11122],{"nctId":3667,"briefTitle":3668,"status":108,"phases":11119,"primaryCompletion":401,"completion":401,"start":2712,"enrollment":3670,"conditions":11120,"interventions":11121},[],[27],[1283,3673],{"nctId":10670,"briefTitle":10671,"status":108,"phases":11123,"primaryCompletion":10673,"completion":10673,"start":10674,"enrollment":10675,"conditions":11124,"interventions":11125},[],[27],[3673,3938],{"intervention":133,"totalTrials":281,"cells":11127},{"EARLY_PHASE1":11128,"PHASE1":11130,"PHASE2":11132,"PHASE3":11134,"PHASE4":11140,"NA":11142},{"trials":11129,"activeCount":102},[],{"trials":11131,"activeCount":102},[],{"trials":11133,"activeCount":102},[],{"trials":11135,"activeCount":102},[11136],{"nctId":123,"briefTitle":124,"status":108,"phases":11137,"primaryCompletion":126,"completion":127,"start":112,"enrollment":128,"conditions":11138,"interventions":11139},[91,92],[130],[132,133,134],{"trials":11141,"activeCount":102},[],{"trials":11143,"activeCount":102},[11144],{"nctId":11145,"briefTitle":11146,"status":108,"phases":11147,"primaryCompletion":1356,"completion":1357,"start":126,"enrollment":11148,"conditions":11149,"interventions":11150},"NCT05125237","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene",[],155963,[15],[11151,11152],"Amiloride","Triamterene",{"intervention":11154,"totalTrials":281,"cells":11155},"Genomic Sequencing",{"EARLY_PHASE1":11156,"PHASE1":11158,"PHASE2":11160,"PHASE3":11162,"PHASE4":11164,"NA":11166},{"trials":11157,"activeCount":102},[],{"trials":11159,"activeCount":102},[],{"trials":11161,"activeCount":102},[],{"trials":11163,"activeCount":102},[],{"trials":11165,"activeCount":102},[],{"trials":11167,"activeCount":102},[11168,11177],{"nctId":11169,"briefTitle":11170,"status":108,"phases":11171,"primaryCompletion":7934,"completion":7934,"start":11172,"enrollment":16,"conditions":11173,"interventions":11176},"NCT04196374","Return of Genomic Results and Aggregate Penetrance in Population-Based Cohorts",[94],"2021-06-09",[11174,11175],"Seemingly Healthy","Genetic Predisposition to Disease",[11154],{"nctId":11178,"briefTitle":11179,"status":108,"phases":11180,"primaryCompletion":11181,"completion":11182,"start":6675,"enrollment":11183,"conditions":11184,"interventions":11186},"NCT02422511","Genomic Sequencing for Childhood Risk and Newborn Illness",[94],"2020-04","2021-08-05",1205,[11185,11175],"Hereditary Disease",[11187],"Genomic sequencing",{"intervention":11189,"totalTrials":281,"cells":11190},"Ramelteon",{"EARLY_PHASE1":11191,"PHASE1":11193,"PHASE2":11195,"PHASE3":11197,"PHASE4":11199,"NA":11209},{"trials":11192,"activeCount":102},[],{"trials":11194,"activeCount":102},[],{"trials":11196,"activeCount":102},[],{"trials":11198,"activeCount":102},[],{"trials":11200,"activeCount":102},[11201],{"nctId":11202,"briefTitle":11203,"status":152,"phases":11204,"primaryCompletion":8197,"completion":8197,"start":11205,"enrollment":102,"conditions":11206,"interventions":11208},"NCT03165695","Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults",[93],"2019-12-01",[11207],"Delirium in Old Age",[11189],{"trials":11210,"activeCount":102},[11211],{"nctId":11212,"briefTitle":11213,"status":108,"phases":11214,"primaryCompletion":1503,"completion":1503,"start":4645,"enrollment":1553,"conditions":11215,"interventions":11216},"NCT00595075","Ramelteon for a Nap Prior to a Night Shift",[94],[33],[11189],{"intervention":10424,"totalTrials":281,"cells":11218},{"EARLY_PHASE1":11219,"PHASE1":11221,"PHASE2":11223,"PHASE3":11231,"PHASE4":11233,"NA":11235},{"trials":11220,"activeCount":102},[],{"trials":11222,"activeCount":102},[],{"trials":11224,"activeCount":102},[11225],{"nctId":11226,"briefTitle":11227,"status":239,"phases":11228,"primaryCompletion":3033,"completion":3033,"start":7710,"enrollment":197,"conditions":11229,"interventions":11230},"NCT02660528","Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder",[91],[8963],[10424],{"trials":11232,"activeCount":102},[],{"trials":11234,"activeCount":102},[],{"trials":11236,"activeCount":102},[11237],{"nctId":10418,"briefTitle":10419,"status":108,"phases":11238,"primaryCompletion":3627,"completion":3627,"start":10412,"enrollment":10421,"conditions":11239,"interventions":11240},[],[3631],[10424,10385],{"intervention":4779,"totalTrials":281,"cells":11242},{"EARLY_PHASE1":11243,"PHASE1":11245,"PHASE2":11247,"PHASE3":11249,"PHASE4":11251,"NA":11257},{"trials":11244,"activeCount":102},[],{"trials":11246,"activeCount":102},[],{"trials":11248,"activeCount":102},[],{"trials":11250,"activeCount":102},[],{"trials":11252,"activeCount":102},[11253],{"nctId":4771,"briefTitle":4772,"status":108,"phases":11254,"primaryCompletion":4774,"completion":4775,"start":4776,"enrollment":28,"conditions":11255,"interventions":11256},[93],[3631],[4779,4780,3970,4781],{"trials":11258,"activeCount":102},[11259],{"nctId":11260,"briefTitle":11261,"status":108,"phases":11262,"primaryCompletion":3693,"completion":3693,"start":11263,"enrollment":11264,"conditions":11265,"interventions":11267},"NCT04879420","Replication of the VERO Osteoporosis Trial in Healthcare Claims Data",[],"2020-10-29",12757,[11266],"Osteoporosis",[4779,11268],"Risedronate",{"intervention":11270,"totalTrials":281,"cells":11271},"Modafinil",{"EARLY_PHASE1":11272,"PHASE1":11274,"PHASE2":11276,"PHASE3":11278,"PHASE4":11288,"NA":11290},{"trials":11273,"activeCount":102},[],{"trials":11275,"activeCount":102},[],{"trials":11277,"activeCount":102},[],{"trials":11279,"activeCount":102},[11280],{"nctId":11281,"briefTitle":11282,"status":152,"phases":11283,"primaryCompletion":8351,"completion":6789,"start":11284,"enrollment":102,"conditions":11285,"interventions":11287},"NCT02028260","Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill",[92],"2014-01",[8727,11286],"Respiratory Failure",[11270],{"trials":11289,"activeCount":102},[],{"trials":11291,"activeCount":102},[11292],{"nctId":11293,"briefTitle":11294,"status":108,"phases":11295,"primaryCompletion":11296,"completion":11296,"start":11297,"enrollment":34,"conditions":11298,"interventions":11301},"NCT00895570","The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction",[94],"2007-04","2005-01",[11299,11300],"Sleep Restriction","Impaired Glucose Metabolism",[11302],"modafinil",{"intervention":11304,"totalTrials":281,"cells":11305},"Montelukast",{"EARLY_PHASE1":11306,"PHASE1":11308,"PHASE2":11310,"PHASE3":11312,"PHASE4":11321,"NA":11323},{"trials":11307,"activeCount":102},[],{"trials":11309,"activeCount":102},[],{"trials":11311,"activeCount":102},[],{"trials":11313,"activeCount":102},[11314],{"nctId":11315,"briefTitle":11316,"status":108,"phases":11317,"completion":11318,"start":7544,"enrollment":2055,"conditions":11319,"interventions":11320},"NCT00116324","Predicting the Response to Montelukast by Genetic Variation in Asthmatics",[92],"2006-12",[18],[11304],{"trials":11322,"activeCount":102},[],{"trials":11324,"activeCount":102},[11325],{"nctId":11326,"briefTitle":11327,"status":108,"phases":11328,"primaryCompletion":1356,"completion":1357,"start":11329,"enrollment":11330,"conditions":11331,"interventions":11332},"NCT05457855","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone",[],"2022-02-01",51533,[18],[11304,11333],"Fluticasone",{"intervention":11031,"totalTrials":281,"cells":11335},{"EARLY_PHASE1":11336,"PHASE1":11338,"PHASE2":11340,"PHASE3":11342,"PHASE4":11344,"NA":11346},{"trials":11337,"activeCount":102},[],{"trials":11339,"activeCount":102},[],{"trials":11341,"activeCount":102},[],{"trials":11343,"activeCount":102},[],{"trials":11345,"activeCount":102},[],{"trials":11347,"activeCount":102},[11348,11356],{"nctId":11349,"briefTitle":11350,"status":108,"phases":11351,"primaryCompletion":11027,"completion":11027,"start":3652,"enrollment":11352,"conditions":11353,"interventions":11354},"NCT06659679","Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims",[],26126,[885],[11355,11031],"New use of oral semaglutide",{"nctId":11024,"briefTitle":11025,"status":108,"phases":11357,"primaryCompletion":11027,"completion":11027,"start":3652,"enrollment":11028,"conditions":11358,"interventions":11359},[],[885],[11000,11031],{"intervention":10354,"totalTrials":281,"cells":11361},{"EARLY_PHASE1":11362,"PHASE1":11364,"PHASE2":11366,"PHASE3":11368,"PHASE4":11374,"NA":11376},{"trials":11363,"activeCount":102},[],{"trials":11365,"activeCount":102},[],{"trials":11367,"activeCount":102},[],{"trials":11369,"activeCount":102},[11370],{"nctId":10346,"briefTitle":10347,"status":108,"phases":11371,"primaryCompletion":5193,"completion":5193,"start":10349,"enrollment":10350,"conditions":11372,"interventions":11373},[92],[18],[10353,10335,10354],{"trials":11375,"activeCount":102},[],{"trials":11377,"activeCount":102},[11378],{"nctId":10367,"briefTitle":10368,"status":239,"phases":11379,"primaryCompletion":932,"completion":1715,"start":6054,"enrollment":10370,"conditions":11380,"interventions":11381},[94],[18],[10373,10335,10354,10374,10375],{"intervention":10375,"totalTrials":281,"cells":11383},{"EARLY_PHASE1":11384,"PHASE1":11386,"PHASE2":11388,"PHASE3":11390,"PHASE4":11392,"NA":11394},{"trials":11385,"activeCount":102},[],{"trials":11387,"activeCount":102},[],{"trials":11389,"activeCount":102},[],{"trials":11391,"activeCount":102},[],{"trials":11393,"activeCount":102},[],{"trials":11395,"activeCount":102},[11396,11400],{"nctId":10367,"briefTitle":10368,"status":239,"phases":11397,"primaryCompletion":932,"completion":1715,"start":6054,"enrollment":10370,"conditions":11398,"interventions":11399},[94],[18],[10373,10335,10354,10374,10375],{"nctId":11401,"briefTitle":11402,"status":108,"phases":11403,"primaryCompletion":3693,"completion":3693,"start":11263,"enrollment":11404,"conditions":11405,"interventions":11406},"NCT04892732","Replication of the D58 Asthma Trial in Healthcare Claims Data",[],66581,[18],[11407,11408],"Budesonide","Budesonide-Formoterol",{"intervention":222,"totalTrials":281,"cells":11410},{"EARLY_PHASE1":11411,"PHASE1":11413,"PHASE2":11415,"PHASE3":11417,"PHASE4":11419,"NA":11421},{"trials":11412,"activeCount":102},[],{"trials":11414,"activeCount":102},[],{"trials":11416,"activeCount":102},[],{"trials":11418,"activeCount":102},[],{"trials":11420,"activeCount":102},[],{"trials":11422,"activeCount":102},[11423,11431],{"nctId":11424,"briefTitle":11425,"status":108,"phases":11426,"primaryCompletion":1356,"completion":1357,"start":126,"enrollment":11427,"conditions":11428,"interventions":11429},"NCT05125224","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide",[],163720,[15],[11430,222],"Dihydropyridine calcium channel blocker",{"nctId":211,"briefTitle":212,"status":108,"phases":11432,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":11433,"interventions":11434},[94],[218,219,220],[132,222],{"intervention":939,"totalTrials":281,"cells":11436},{"EARLY_PHASE1":11437,"PHASE1":11439,"PHASE2":11441,"PHASE3":11443,"PHASE4":11445,"NA":11456},{"trials":11438,"activeCount":102},[],{"trials":11440,"activeCount":102},[],{"trials":11442,"activeCount":102},[],{"trials":11444,"activeCount":102},[],{"trials":11446,"activeCount":102},[11447],{"nctId":11448,"briefTitle":11449,"status":239,"phases":11450,"primaryCompletion":1600,"completion":1600,"start":11451,"enrollment":98,"conditions":11452,"interventions":11455},"NCT01437943","Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients",[93],"2010-04",[11453,11454],"Kidney Disease","Kidney Failure, Chronic",[939],{"trials":11457,"activeCount":102},[11458],{"nctId":928,"briefTitle":929,"status":239,"phases":11459,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":11460,"interventions":11461},[94],[935,936,937],[939,940,183],{"intervention":11463,"totalTrials":265,"cells":11464},"Fluticasone Furoate-Vilanterol Trifenatate",{"EARLY_PHASE1":11465,"PHASE1":11467,"PHASE2":11469,"PHASE3":11471,"PHASE4":11473,"NA":11475},{"trials":11466,"activeCount":102},[],{"trials":11468,"activeCount":102},[],{"trials":11470,"activeCount":102},[],{"trials":11472,"activeCount":102},[],{"trials":11474,"activeCount":102},[],{"trials":11476,"activeCount":102},[11477],{"nctId":11478,"briefTitle":11479,"status":108,"phases":11480,"primaryCompletion":3878,"completion":3878,"start":3694,"enrollment":11481,"conditions":11482,"interventions":11483},"NCT05062304","Replication of the IMPACT COPD Trial in Healthcare Claims Data",[],17281,[8424],[11463,11484],"Furoate-umeclidinium-vilanterol",{"intervention":11484,"totalTrials":265,"cells":11486},{"EARLY_PHASE1":11487,"PHASE1":11489,"PHASE2":11491,"PHASE3":11493,"PHASE4":11495,"NA":11497},{"trials":11488,"activeCount":102},[],{"trials":11490,"activeCount":102},[],{"trials":11492,"activeCount":102},[],{"trials":11494,"activeCount":102},[],{"trials":11496,"activeCount":102},[],{"trials":11498,"activeCount":102},[11499],{"nctId":11478,"briefTitle":11479,"status":108,"phases":11500,"primaryCompletion":3878,"completion":3878,"start":3694,"enrollment":11481,"conditions":11501,"interventions":11502},[],[8424],[11463,11484],{"intervention":11504,"totalTrials":265,"cells":11505},"L-N^G monomethyl arginine",{"EARLY_PHASE1":11506,"PHASE1":11508,"PHASE2":11510,"PHASE3":11512,"PHASE4":11514,"NA":11516},{"trials":11507,"activeCount":102},[],{"trials":11509,"activeCount":102},[],{"trials":11511,"activeCount":102},[],{"trials":11513,"activeCount":102},[],{"trials":11515,"activeCount":102},[],{"trials":11517,"activeCount":102},[11518],{"nctId":11519,"briefTitle":11520,"status":108,"phases":11521,"primaryCompletion":5745,"completion":5745,"start":5267,"enrollment":1620,"conditions":11522,"interventions":11524},"NCT00759707","Endothelial Function in Lower Extremity Bypass Grafts",[94],[11523],"Peripheral Arterial Disease",[11504],{"intervention":11526,"totalTrials":265,"cells":11527},"Ergocalciferol",{"EARLY_PHASE1":11528,"PHASE1":11530,"PHASE2":11532,"PHASE3":11534,"PHASE4":11536,"NA":11538},{"trials":11529,"activeCount":102},[],{"trials":11531,"activeCount":102},[],{"trials":11533,"activeCount":102},[],{"trials":11535,"activeCount":102},[],{"trials":11537,"activeCount":102},[],{"trials":11539,"activeCount":102},[11540],{"nctId":11541,"briefTitle":11542,"status":239,"phases":11543,"primaryCompletion":11544,"completion":11544,"start":11545,"enrollment":1774,"conditions":11546,"interventions":11549},"NCT00535158","Vitamin D 2 to Dialysis Patients",[],"2009-06-01","2008-06-01",[11453,11547,1811,11548],"Muscle Weakness","Fractures, Bone",[11526],{"intervention":887,"totalTrials":265,"cells":11551},{"EARLY_PHASE1":11552,"PHASE1":11554,"PHASE2":11556,"PHASE3":11558,"PHASE4":11560,"NA":11562},{"trials":11553,"activeCount":102},[],{"trials":11555,"activeCount":102},[],{"trials":11557,"activeCount":102},[],{"trials":11559,"activeCount":102},[],{"trials":11561,"activeCount":102},[],{"trials":11563,"activeCount":102},[11564],{"nctId":878,"briefTitle":879,"status":436,"phases":11565,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":11566,"interventions":11567},[],[885],[392,887],{"intervention":10568,"totalTrials":265,"cells":11569},{"EARLY_PHASE1":11570,"PHASE1":11572,"PHASE2":11574,"PHASE3":11576,"PHASE4":11578,"NA":11580},{"trials":11571,"activeCount":102},[],{"trials":11573,"activeCount":102},[],{"trials":11575,"activeCount":102},[],{"trials":11577,"activeCount":102},[],{"trials":11579,"activeCount":102},[],{"trials":11581,"activeCount":102},[11582],{"nctId":10562,"briefTitle":10563,"status":239,"phases":11583,"primaryCompletion":8197,"completion":8197,"start":10565,"enrollment":31,"conditions":11584,"interventions":11585},[94],[5976],[10568,10569,4744],{"intervention":10569,"totalTrials":265,"cells":11587},{"EARLY_PHASE1":11588,"PHASE1":11590,"PHASE2":11592,"PHASE3":11594,"PHASE4":11596,"NA":11598},{"trials":11589,"activeCount":102},[],{"trials":11591,"activeCount":102},[],{"trials":11593,"activeCount":102},[],{"trials":11595,"activeCount":102},[],{"trials":11597,"activeCount":102},[],{"trials":11599,"activeCount":102},[11600],{"nctId":10562,"briefTitle":10563,"status":239,"phases":11601,"primaryCompletion":8197,"completion":8197,"start":10565,"enrollment":31,"conditions":11602,"interventions":11603},[94],[5976],[10568,10569,4744],{"intervention":11605,"totalTrials":265,"cells":11606},"Certolizumab",{"EARLY_PHASE1":11607,"PHASE1":11609,"PHASE2":11611,"PHASE3":11613,"PHASE4":11615,"NA":11617},{"trials":11608,"activeCount":102},[],{"trials":11610,"activeCount":102},[],{"trials":11612,"activeCount":102},[],{"trials":11614,"activeCount":102},[],{"trials":11616,"activeCount":102},[],{"trials":11618,"activeCount":102},[11619],{"nctId":11620,"briefTitle":11621,"status":108,"phases":11622,"primaryCompletion":11623,"completion":11624,"start":11625,"enrollment":11626,"conditions":11627,"interventions":11628},"NCT02714881","Lipids, Inflammation, and CV Risk in RA",[],"2020-12-14","2022-12-21","2016-10-17",74,[3631,958],[11605],{"intervention":3918,"totalTrials":265,"cells":11630},{"EARLY_PHASE1":11631,"PHASE1":11633,"PHASE2":11635,"PHASE3":11637,"PHASE4":11639,"NA":11641},{"trials":11632,"activeCount":102},[],{"trials":11634,"activeCount":102},[],{"trials":11636,"activeCount":102},[],{"trials":11638,"activeCount":102},[],{"trials":11640,"activeCount":102},[],{"trials":11642,"activeCount":102},[11643],{"nctId":3912,"briefTitle":3913,"status":108,"phases":11644,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3915,"conditions":11645,"interventions":11646},[],[27],[3918,408],{"intervention":11648,"totalTrials":265,"cells":11649},"Next generation sequencing",{"EARLY_PHASE1":11650,"PHASE1":11652,"PHASE2":11654,"PHASE3":11656,"PHASE4":11658,"NA":11660},{"trials":11651,"activeCount":102},[],{"trials":11653,"activeCount":102},[],{"trials":11655,"activeCount":102},[],{"trials":11657,"activeCount":102},[],{"trials":11659,"activeCount":102},[],{"trials":11661,"activeCount":102},[11662],{"nctId":11663,"briefTitle":11664,"status":108,"phases":11665,"primaryCompletion":11666,"completion":11666,"start":6411,"enrollment":11667,"conditions":11668,"interventions":11670},"NCT02118818","RhEumatiC Heart diseAse Genetics",[],"2024-07",245,[11669],"Rheumatic Heart Disease",[11648],{"intervention":11022,"totalTrials":265,"cells":11672},{"EARLY_PHASE1":11673,"PHASE1":11675,"PHASE2":11677,"PHASE3":11679,"PHASE4":11681,"NA":11683},{"trials":11674,"activeCount":102},[],{"trials":11676,"activeCount":102},[],{"trials":11678,"activeCount":102},[],{"trials":11680,"activeCount":102},[],{"trials":11682,"activeCount":102},[],{"trials":11684,"activeCount":102},[11685],{"nctId":11015,"briefTitle":11016,"status":108,"phases":11686,"primaryCompletion":11018,"completion":11018,"start":892,"enrollment":11019,"conditions":11687,"interventions":11688},[],[885],[11000,11022],{"intervention":11690,"totalTrials":265,"cells":11691},"Dexmedetomidine Hydrochloride",{"EARLY_PHASE1":11692,"PHASE1":11694,"PHASE2":11696,"PHASE3":11698,"PHASE4":11700,"NA":11702},{"trials":11693,"activeCount":102},[],{"trials":11695,"activeCount":102},[],{"trials":11697,"activeCount":102},[],{"trials":11699,"activeCount":102},[],{"trials":11701,"activeCount":102},[],{"trials":11703,"activeCount":102},[11704],{"nctId":11705,"briefTitle":11706,"status":108,"phases":11707,"primaryCompletion":11708,"completion":11709,"start":5353,"enrollment":296,"conditions":11710,"interventions":11714},"NCT06502002","Dexmedetomidine Infusion and Postoperative Lung Aeration After Thoracic Surgery",[94],"2025-11-13","2025-11-15",[11711,11712,11713],"Surgery-Complications","Respiratory Complication","Lung Injury, Acute",[11690],{"intervention":11716,"totalTrials":265,"cells":11717},"Formoterol fumarate 10 mcg",{"EARLY_PHASE1":11718,"PHASE1":11720,"PHASE2":11722,"PHASE3":11724,"PHASE4":11726,"NA":11728},{"trials":11719,"activeCount":102},[],{"trials":11721,"activeCount":102},[],{"trials":11723,"activeCount":102},[],{"trials":11725,"activeCount":102},[],{"trials":11727,"activeCount":102},[],{"trials":11729,"activeCount":102},[11730],{"nctId":11731,"briefTitle":11732,"status":108,"phases":11733,"primaryCompletion":3693,"completion":3693,"start":11263,"enrollment":11734,"conditions":11735,"interventions":11736},"NCT04892758","Replication of the P04334 Asthma Trial in Healthcare Claims Data",[],10288,[18],[11716,11737],"Mometasone furoate\u002Fformoterol fumarate combination MDI 200\u002F10 mcg BID",{"intervention":11737,"totalTrials":265,"cells":11739},{"EARLY_PHASE1":11740,"PHASE1":11742,"PHASE2":11744,"PHASE3":11746,"PHASE4":11748,"NA":11750},{"trials":11741,"activeCount":102},[],{"trials":11743,"activeCount":102},[],{"trials":11745,"activeCount":102},[],{"trials":11747,"activeCount":102},[],{"trials":11749,"activeCount":102},[],{"trials":11751,"activeCount":102},[11752],{"nctId":11731,"briefTitle":11732,"status":108,"phases":11753,"primaryCompletion":3693,"completion":3693,"start":11263,"enrollment":11734,"conditions":11754,"interventions":11755},[],[18],[11716,11737],{"intervention":11757,"totalTrials":265,"cells":11758},"Low Dose Melatonin",{"EARLY_PHASE1":11759,"PHASE1":11761,"PHASE2":11763,"PHASE3":11765,"PHASE4":11767,"NA":11769},{"trials":11760,"activeCount":102},[],{"trials":11762,"activeCount":102},[],{"trials":11764,"activeCount":102},[],{"trials":11766,"activeCount":102},[],{"trials":11768,"activeCount":102},[],{"trials":11770,"activeCount":102},[11771],{"nctId":11772,"briefTitle":11773,"status":108,"phases":11774,"primaryCompletion":155,"completion":155,"start":7260,"enrollment":2312,"conditions":11775,"interventions":11779},"NCT00950885","Melatonin Treatment for Induced Transient Insomnia",[94],[11776,11777,11778],"Delayed Sleep Phase Disorder","Jet-lag","Shift-work Disorder",[11757,11780],"High Dose Melatonin",{"intervention":11780,"totalTrials":265,"cells":11782},{"EARLY_PHASE1":11783,"PHASE1":11785,"PHASE2":11787,"PHASE3":11789,"PHASE4":11791,"NA":11793},{"trials":11784,"activeCount":102},[],{"trials":11786,"activeCount":102},[],{"trials":11788,"activeCount":102},[],{"trials":11790,"activeCount":102},[],{"trials":11792,"activeCount":102},[],{"trials":11794,"activeCount":102},[11795],{"nctId":11772,"briefTitle":11773,"status":108,"phases":11796,"primaryCompletion":155,"completion":155,"start":7260,"enrollment":2312,"conditions":11797,"interventions":11798},[94],[11776,11777,11778],[11757,11780],{"intervention":11800,"totalTrials":265,"cells":11801},"Anticipatory dose increase of levothyroxine",{"EARLY_PHASE1":11802,"PHASE1":11804,"PHASE2":11806,"PHASE3":11808,"PHASE4":11810,"NA":11812},{"trials":11803,"activeCount":102},[],{"trials":11805,"activeCount":102},[],{"trials":11807,"activeCount":102},[],{"trials":11809,"activeCount":102},[],{"trials":11811,"activeCount":102},[],{"trials":11813,"activeCount":102},[11814],{"nctId":11815,"briefTitle":11816,"status":108,"phases":11817,"primaryCompletion":955,"completion":955,"start":6337,"enrollment":16,"conditions":11818,"interventions":11820},"NCT00230802","Thyroid Hormone Dose Adjustment in Pregnancy",[94],[5976,11819],"Hypothyroidism",[11800,11821,11821],"levothyroxine",{"intervention":11821,"totalTrials":265,"cells":11823},{"EARLY_PHASE1":11824,"PHASE1":11826,"PHASE2":11828,"PHASE3":11830,"PHASE4":11832,"NA":11834},{"trials":11825,"activeCount":102},[],{"trials":11827,"activeCount":102},[],{"trials":11829,"activeCount":102},[],{"trials":11831,"activeCount":102},[],{"trials":11833,"activeCount":102},[],{"trials":11835,"activeCount":102},[11836],{"nctId":11815,"briefTitle":11816,"status":108,"phases":11837,"primaryCompletion":955,"completion":955,"start":6337,"enrollment":16,"conditions":11838,"interventions":11839},[94],[5976,11819],[11800,11821,11821],{"intervention":11841,"totalTrials":265,"cells":11842},"Inspired oxygen",{"EARLY_PHASE1":11843,"PHASE1":11845,"PHASE2":11847,"PHASE3":11849,"PHASE4":11851,"NA":11853},{"trials":11844,"activeCount":102},[],{"trials":11846,"activeCount":102},[],{"trials":11848,"activeCount":102},[],{"trials":11850,"activeCount":102},[],{"trials":11852,"activeCount":102},[],{"trials":11854,"activeCount":102},[11855],{"nctId":11856,"briefTitle":11857,"status":108,"phases":11858,"primaryCompletion":3612,"completion":3612,"start":1002,"enrollment":6791,"conditions":11859,"interventions":11860},"NCT01751971","Estimating Apnea Phenotypes From Polysomnography: Oxygen",[94],[245],[11841],{"intervention":896,"totalTrials":265,"cells":11862},{"EARLY_PHASE1":11863,"PHASE1":11865,"PHASE2":11867,"PHASE3":11869,"PHASE4":11871,"NA":11873},{"trials":11864,"activeCount":102},[],{"trials":11866,"activeCount":102},[],{"trials":11868,"activeCount":102},[],{"trials":11870,"activeCount":102},[],{"trials":11872,"activeCount":102},[],{"trials":11874,"activeCount":102},[11875],{"nctId":889,"briefTitle":890,"status":436,"phases":11876,"primaryCompletion":71,"completion":71,"start":892,"enrollment":893,"conditions":11877,"interventions":11878},[],[885],[896,392,897,898,899],{"intervention":897,"totalTrials":265,"cells":11880},{"EARLY_PHASE1":11881,"PHASE1":11883,"PHASE2":11885,"PHASE3":11887,"PHASE4":11889,"NA":11891},{"trials":11882,"activeCount":102},[],{"trials":11884,"activeCount":102},[],{"trials":11886,"activeCount":102},[],{"trials":11888,"activeCount":102},[],{"trials":11890,"activeCount":102},[],{"trials":11892,"activeCount":102},[11893],{"nctId":889,"briefTitle":890,"status":436,"phases":11894,"primaryCompletion":71,"completion":71,"start":892,"enrollment":893,"conditions":11895,"interventions":11896},[],[885],[896,392,897,898,899],{"intervention":898,"totalTrials":265,"cells":11898},{"EARLY_PHASE1":11899,"PHASE1":11901,"PHASE2":11903,"PHASE3":11905,"PHASE4":11907,"NA":11909},{"trials":11900,"activeCount":102},[],{"trials":11902,"activeCount":102},[],{"trials":11904,"activeCount":102},[],{"trials":11906,"activeCount":102},[],{"trials":11908,"activeCount":102},[],{"trials":11910,"activeCount":102},[11911],{"nctId":889,"briefTitle":890,"status":436,"phases":11912,"primaryCompletion":71,"completion":71,"start":892,"enrollment":893,"conditions":11913,"interventions":11914},[],[885],[896,392,897,898,899],{"intervention":899,"totalTrials":265,"cells":11916},{"EARLY_PHASE1":11917,"PHASE1":11919,"PHASE2":11921,"PHASE3":11923,"PHASE4":11925,"NA":11927},{"trials":11918,"activeCount":102},[],{"trials":11920,"activeCount":102},[],{"trials":11922,"activeCount":102},[],{"trials":11924,"activeCount":102},[],{"trials":11926,"activeCount":102},[],{"trials":11928,"activeCount":102},[11929],{"nctId":889,"briefTitle":890,"status":436,"phases":11930,"primaryCompletion":71,"completion":71,"start":892,"enrollment":893,"conditions":11931,"interventions":11932},[],[885],[896,392,897,898,899],{"intervention":11934,"totalTrials":265,"cells":11935},"Nebivolol",{"EARLY_PHASE1":11936,"PHASE1":11938,"PHASE2":11940,"PHASE3":11942,"PHASE4":11944,"NA":11946},{"trials":11937,"activeCount":102},[],{"trials":11939,"activeCount":102},[],{"trials":11941,"activeCount":102},[],{"trials":11943,"activeCount":102},[],{"trials":11945,"activeCount":102},[],{"trials":11947,"activeCount":102},[11948],{"nctId":11949,"briefTitle":11950,"status":239,"phases":11951,"primaryCompletion":5193,"completion":5193,"start":11952,"enrollment":1553,"conditions":11953,"interventions":11955},"NCT01441570","The Impact of Nebivolol Versus Metoprolol on Quality of Life",[94],"2012-02",[11954,15],"Transplant; Failure, Kidney",[11934,11956],"Metoprolol succinate",{"intervention":11956,"totalTrials":265,"cells":11958},{"EARLY_PHASE1":11959,"PHASE1":11961,"PHASE2":11963,"PHASE3":11965,"PHASE4":11967,"NA":11969},{"trials":11960,"activeCount":102},[],{"trials":11962,"activeCount":102},[],{"trials":11964,"activeCount":102},[],{"trials":11966,"activeCount":102},[],{"trials":11968,"activeCount":102},[],{"trials":11970,"activeCount":102},[11971],{"nctId":11949,"briefTitle":11950,"status":239,"phases":11972,"primaryCompletion":5193,"completion":5193,"start":11952,"enrollment":1553,"conditions":11973,"interventions":11974},[94],[11954,15],[11934,11956],{"intervention":11976,"totalTrials":265,"cells":11977},"Ozanimod",{"EARLY_PHASE1":11978,"PHASE1":11980,"PHASE2":11982,"PHASE3":11984,"PHASE4":11986,"NA":11988},{"trials":11979,"activeCount":102},[],{"trials":11981,"activeCount":102},[],{"trials":11983,"activeCount":102},[],{"trials":11985,"activeCount":102},[],{"trials":11987,"activeCount":102},[],{"trials":11989,"activeCount":102},[11990],{"nctId":11991,"briefTitle":11992,"status":239,"phases":11993,"primaryCompletion":11994,"completion":11994,"start":5571,"enrollment":28,"conditions":11995,"interventions":11997},"NCT05319093","Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients",[],"2024-07-23",[11996,723],"Fatigue",[11976],{"intervention":11999,"totalTrials":265,"cells":12000},"Ocrelizumab",{"EARLY_PHASE1":12001,"PHASE1":12003,"PHASE2":12005,"PHASE3":12007,"PHASE4":12009,"NA":12011},{"trials":12002,"activeCount":102},[],{"trials":12004,"activeCount":102},[],{"trials":12006,"activeCount":102},[],{"trials":12008,"activeCount":102},[],{"trials":12010,"activeCount":102},[],{"trials":12012,"activeCount":102},[12013],{"nctId":12014,"briefTitle":12015,"status":108,"phases":12016,"primaryCompletion":333,"completion":333,"start":9572,"enrollment":12017,"conditions":12018,"interventions":12019},"NCT05131984","Ocrelizumab Access by Socio-Economic Status",[],800,[723],[11999],{"intervention":11152,"totalTrials":265,"cells":12021},{"EARLY_PHASE1":12022,"PHASE1":12024,"PHASE2":12026,"PHASE3":12028,"PHASE4":12030,"NA":12032},{"trials":12023,"activeCount":102},[],{"trials":12025,"activeCount":102},[],{"trials":12027,"activeCount":102},[],{"trials":12029,"activeCount":102},[],{"trials":12031,"activeCount":102},[],{"trials":12033,"activeCount":102},[12034],{"nctId":11145,"briefTitle":11146,"status":108,"phases":12035,"primaryCompletion":1356,"completion":1357,"start":126,"enrollment":11148,"conditions":12036,"interventions":12037},[],[15],[11151,11152],{"intervention":12039,"totalTrials":265,"cells":12040},"18F-PBR06",{"EARLY_PHASE1":12041,"PHASE1":12043,"PHASE2":12045,"PHASE3":12047,"PHASE4":12049,"NA":12051},{"trials":12042,"activeCount":102},[],{"trials":12044,"activeCount":102},[],{"trials":12046,"activeCount":102},[],{"trials":12048,"activeCount":102},[],{"trials":12050,"activeCount":102},[],{"trials":12052,"activeCount":102},[12053],{"nctId":12054,"briefTitle":12055,"status":436,"phases":12056,"primaryCompletion":12057,"completion":2965,"start":12058,"enrollment":531,"conditions":12059,"interventions":12065},"NCT05486806","Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders",[],"2024-09-15","2023-03-01",[12060,12061,12062,12063,12064],"Neurodegenerative Diseases","sca3","MSA - Multiple System Atrophy","Ataxia","Synucleinopathies",[12039],{"intervention":12067,"totalTrials":265,"cells":12068},"Lisinopril",{"EARLY_PHASE1":12069,"PHASE1":12071,"PHASE2":12073,"PHASE3":12075,"PHASE4":12077,"NA":12079},{"trials":12070,"activeCount":102},[],{"trials":12072,"activeCount":102},[],{"trials":12074,"activeCount":102},[],{"trials":12076,"activeCount":102},[],{"trials":12078,"activeCount":102},[],{"trials":12080,"activeCount":102},[12081],{"nctId":12082,"briefTitle":12083,"status":108,"phases":12084,"primaryCompletion":227,"completion":7842,"start":965,"enrollment":1708,"conditions":12085,"interventions":12087},"NCT01691781","The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study",[94],[12086],"Hyperparathyroidism",[12067],{"intervention":10816,"totalTrials":265,"cells":12089},{"EARLY_PHASE1":12090,"PHASE1":12092,"PHASE2":12094,"PHASE3":12096,"PHASE4":12098,"NA":12100},{"trials":12091,"activeCount":102},[],{"trials":12093,"activeCount":102},[],{"trials":12095,"activeCount":102},[],{"trials":12097,"activeCount":102},[],{"trials":12099,"activeCount":102},[],{"trials":12101,"activeCount":102},[12102],{"nctId":10810,"briefTitle":10811,"status":108,"phases":12103,"primaryCompletion":10786,"completion":10786,"start":3712,"enrollment":10813,"conditions":12104,"interventions":12105},[],[15],[10816,10790],{"intervention":12107,"totalTrials":265,"cells":12108},"aminolevulinic acid HCl",{"EARLY_PHASE1":12109,"PHASE1":12111,"PHASE2":12113,"PHASE3":12115,"PHASE4":12117,"NA":12119},{"trials":12110,"activeCount":102},[],{"trials":12112,"activeCount":102},[],{"trials":12114,"activeCount":102},[],{"trials":12116,"activeCount":102},[],{"trials":12118,"activeCount":102},[],{"trials":12120,"activeCount":102},[12121],{"nctId":12122,"briefTitle":12123,"status":152,"phases":12124,"primaryCompletion":1048,"completion":9064,"start":1047,"enrollment":102,"conditions":12125,"interventions":12128},"NCT02867722","Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States",[94],[12126,12127],"Actinic Keratosis","Non-melanoma Skin Cancer",[12107],{"intervention":12130,"totalTrials":265,"cells":12131},"Tissue Plasminogen Activator",{"EARLY_PHASE1":12132,"PHASE1":12134,"PHASE2":12136,"PHASE3":12138,"PHASE4":12140,"NA":12142},{"trials":12133,"activeCount":102},[],{"trials":12135,"activeCount":102},[],{"trials":12137,"activeCount":102},[],{"trials":12139,"activeCount":102},[],{"trials":12141,"activeCount":102},[],{"trials":12143,"activeCount":102},[12144],{"nctId":12145,"briefTitle":12146,"status":12147,"phases":12148,"primaryCompletion":1232,"completion":12149,"start":2310,"enrollment":607,"conditions":12150,"interventions":12153},"NCT06310018","Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE","SUSPENDED",[],"2028-12-31",[3871,12151,12152],"Right Ventricular Dysfunction","Right Ventricular Failure",[12130],{"intervention":12155,"totalTrials":265,"cells":12156},"Propranolol or Carvedilol",{"EARLY_PHASE1":12157,"PHASE1":12159,"PHASE2":12161,"PHASE3":12163,"PHASE4":12165,"NA":12167},{"trials":12158,"activeCount":102},[],{"trials":12160,"activeCount":102},[],{"trials":12162,"activeCount":102},[],{"trials":12164,"activeCount":102},[],{"trials":12166,"activeCount":102},[],{"trials":12168,"activeCount":102},[12169],{"nctId":12170,"briefTitle":12171,"status":108,"phases":12172,"primaryCompletion":10044,"completion":1357,"start":46,"enrollment":12173,"conditions":12174,"interventions":12175},"NCT05794997","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol\u002FCarvedilol Versus Atenolol\u002FBisoprolol\u002FSotalol",[],817337,[15],[12155,12176],"Atenolol, Bisoprolol or Sotalol",{"intervention":12176,"totalTrials":265,"cells":12178},{"EARLY_PHASE1":12179,"PHASE1":12181,"PHASE2":12183,"PHASE3":12185,"PHASE4":12187,"NA":12189},{"trials":12180,"activeCount":102},[],{"trials":12182,"activeCount":102},[],{"trials":12184,"activeCount":102},[],{"trials":12186,"activeCount":102},[],{"trials":12188,"activeCount":102},[],{"trials":12190,"activeCount":102},[12191],{"nctId":12170,"briefTitle":12171,"status":108,"phases":12192,"primaryCompletion":10044,"completion":1357,"start":46,"enrollment":12173,"conditions":12193,"interventions":12194},[],[15],[12155,12176],{"intervention":10278,"totalTrials":265,"cells":12196},{"EARLY_PHASE1":12197,"PHASE1":12199,"PHASE2":12201,"PHASE3":12203,"PHASE4":12205,"NA":12207},{"trials":12198,"activeCount":102},[],{"trials":12200,"activeCount":102},[],{"trials":12202,"activeCount":102},[],{"trials":12204,"activeCount":102},[],{"trials":12206,"activeCount":102},[],{"trials":12208,"activeCount":102},[12209],{"nctId":10270,"briefTitle":10271,"status":436,"phases":12210,"primaryCompletion":2208,"completion":2208,"start":10273,"enrollment":10274,"conditions":12211,"interventions":12212},[],[10276,3848],[4515,10278],{"intervention":12214,"totalTrials":265,"cells":12215},"Pentoxifylline",{"EARLY_PHASE1":12216,"PHASE1":12218,"PHASE2":12220,"PHASE3":12222,"PHASE4":12224,"NA":12226},{"trials":12217,"activeCount":102},[],{"trials":12219,"activeCount":102},[],{"trials":12221,"activeCount":102},[],{"trials":12223,"activeCount":102},[],{"trials":12225,"activeCount":102},[],{"trials":12227,"activeCount":102},[12228],{"nctId":12229,"briefTitle":12230,"status":108,"phases":12231,"primaryCompletion":1356,"completion":1357,"start":2803,"enrollment":12232,"conditions":12233,"interventions":12234},"NCT05635370","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol",[],10398,[5195],[12214,12235],"Cilostazol",{"intervention":12235,"totalTrials":265,"cells":12237},{"EARLY_PHASE1":12238,"PHASE1":12240,"PHASE2":12242,"PHASE3":12244,"PHASE4":12246,"NA":12248},{"trials":12239,"activeCount":102},[],{"trials":12241,"activeCount":102},[],{"trials":12243,"activeCount":102},[],{"trials":12245,"activeCount":102},[],{"trials":12247,"activeCount":102},[],{"trials":12249,"activeCount":102},[12250],{"nctId":12229,"briefTitle":12230,"status":108,"phases":12251,"primaryCompletion":1356,"completion":1357,"start":2803,"enrollment":12232,"conditions":12252,"interventions":12253},[],[5195],[12214,12235],{"intervention":12255,"totalTrials":265,"cells":12256},"Initiation of abemaciclib plus letrozole\u002Fanastrozole",{"EARLY_PHASE1":12257,"PHASE1":12259,"PHASE2":12261,"PHASE3":12263,"PHASE4":12265,"NA":12267},{"trials":12258,"activeCount":102},[],{"trials":12260,"activeCount":102},[],{"trials":12262,"activeCount":102},[],{"trials":12264,"activeCount":102},[],{"trials":12266,"activeCount":102},[],{"trials":12268,"activeCount":102},[12269],{"nctId":12270,"briefTitle":12271,"status":108,"phases":12272,"primaryCompletion":428,"completion":428,"start":10524,"enrollment":12273,"conditions":12274,"interventions":12276},"NCT07225790","Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases",[],3883,[12275],"Advanced Breast Cancer",[12255,12277],"Initiation of letrozole\u002Fanastrozole",{"intervention":12277,"totalTrials":265,"cells":12279},{"EARLY_PHASE1":12280,"PHASE1":12282,"PHASE2":12284,"PHASE3":12286,"PHASE4":12288,"NA":12290},{"trials":12281,"activeCount":102},[],{"trials":12283,"activeCount":102},[],{"trials":12285,"activeCount":102},[],{"trials":12287,"activeCount":102},[],{"trials":12289,"activeCount":102},[],{"trials":12291,"activeCount":102},[12292],{"nctId":12270,"briefTitle":12271,"status":108,"phases":12293,"primaryCompletion":428,"completion":428,"start":10524,"enrollment":12273,"conditions":12294,"interventions":12295},[],[12275],[12255,12277],{"intervention":12297,"totalTrials":265,"cells":12298},"Sedative",{"EARLY_PHASE1":12299,"PHASE1":12301,"PHASE2":12303,"PHASE3":12305,"PHASE4":12307,"NA":12309},{"trials":12300,"activeCount":102},[],{"trials":12302,"activeCount":102},[],{"trials":12304,"activeCount":102},[],{"trials":12306,"activeCount":102},[],{"trials":12308,"activeCount":102},[],{"trials":12310,"activeCount":102},[12311],{"nctId":12312,"briefTitle":12313,"status":108,"phases":12314,"primaryCompletion":362,"completion":362,"start":5485,"enrollment":1469,"conditions":12315,"interventions":12316},"NCT01633827","Combination Therapy to Treat Sleep Apnea",[94],[366],[12297],{"intervention":12318,"totalTrials":265,"cells":12319},"Genome Sequencing",{"EARLY_PHASE1":12320,"PHASE1":12322,"PHASE2":12324,"PHASE3":12326,"PHASE4":12328,"NA":12330},{"trials":12321,"activeCount":102},[],{"trials":12323,"activeCount":102},[],{"trials":12325,"activeCount":102},[],{"trials":12327,"activeCount":102},[],{"trials":12329,"activeCount":102},[],{"trials":12331,"activeCount":102},[12332],{"nctId":12333,"briefTitle":12334,"status":108,"phases":12335,"primaryCompletion":4329,"completion":4329,"start":11624,"enrollment":2700,"conditions":12336,"interventions":12338},"NCT05161169","Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants",[94],[11175,12337],"Hereditary Diseases",[12318],{"intervention":11355,"totalTrials":265,"cells":12340},{"EARLY_PHASE1":12341,"PHASE1":12343,"PHASE2":12345,"PHASE3":12347,"PHASE4":12349,"NA":12351},{"trials":12342,"activeCount":102},[],{"trials":12344,"activeCount":102},[],{"trials":12346,"activeCount":102},[],{"trials":12348,"activeCount":102},[],{"trials":12350,"activeCount":102},[],{"trials":12352,"activeCount":102},[12353],{"nctId":11349,"briefTitle":11350,"status":108,"phases":12354,"primaryCompletion":11027,"completion":11027,"start":3652,"enrollment":11352,"conditions":12355,"interventions":12356},[],[885],[11355,11031],{"intervention":12358,"totalTrials":265,"cells":12359},"Irbesartan",{"EARLY_PHASE1":12360,"PHASE1":12362,"PHASE2":12364,"PHASE3":12366,"PHASE4":12368,"NA":12370},{"trials":12361,"activeCount":102},[],{"trials":12363,"activeCount":102},[],{"trials":12365,"activeCount":102},[],{"trials":12367,"activeCount":102},[],{"trials":12369,"activeCount":102},[],{"trials":12371,"activeCount":102},[12372],{"nctId":12373,"briefTitle":12374,"status":12147,"phases":12375,"primaryCompletion":7530,"completion":12376,"start":6412,"enrollment":2055,"conditions":12377,"interventions":12380},"NCT01519297","Preeclampsia: A Marker for Future Cardiovascular Risk in Women",[94],"2019-07",[12378,12379],"Preeclampsia","Pregnancy Induced Hypertension",[12358],{"intervention":12382,"totalTrials":265,"cells":12383},"Biktarvy Pill",{"EARLY_PHASE1":12384,"PHASE1":12386,"PHASE2":12388,"PHASE3":12390,"PHASE4":12392,"NA":12394},{"trials":12385,"activeCount":102},[],{"trials":12387,"activeCount":102},[],{"trials":12389,"activeCount":102},[],{"trials":12391,"activeCount":102},[],{"trials":12393,"activeCount":102},[],{"trials":12395,"activeCount":102},[12396],{"nctId":12397,"briefTitle":12398,"status":152,"phases":12399,"primaryCompletion":12400,"completion":12401,"start":12057,"enrollment":102,"conditions":12402,"interventions":12406},"NCT06465862","Development of a Silica Microparticle Taggant System to Measure ART Adherence",[94],"2024-12-30","2025-04-15",[12403,12404,12405],"Hiv","Medication Adherence","Compliance, Medication",[12382],{"intervention":12408,"totalTrials":265,"cells":12409},"2% Lidocaine",{"EARLY_PHASE1":12410,"PHASE1":12412,"PHASE2":12414,"PHASE3":12416,"PHASE4":12418,"NA":12420},{"trials":12411,"activeCount":102},[],{"trials":12413,"activeCount":102},[],{"trials":12415,"activeCount":102},[],{"trials":12417,"activeCount":102},[],{"trials":12419,"activeCount":102},[],{"trials":12421,"activeCount":102},[12422],{"nctId":12423,"briefTitle":12424,"status":108,"phases":12425,"primaryCompletion":7650,"completion":3140,"start":12426,"enrollment":607,"conditions":12427,"interventions":12429},"NCT02084706","Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection",[94],"2014-03",[12428],"Trigger Finger",[12408,12430],"Triamcinolone",{"intervention":12430,"totalTrials":265,"cells":12432},{"EARLY_PHASE1":12433,"PHASE1":12435,"PHASE2":12437,"PHASE3":12439,"PHASE4":12441,"NA":12443},{"trials":12434,"activeCount":102},[],{"trials":12436,"activeCount":102},[],{"trials":12438,"activeCount":102},[],{"trials":12440,"activeCount":102},[],{"trials":12442,"activeCount":102},[],{"trials":12444,"activeCount":102},[12445],{"nctId":12423,"briefTitle":12424,"status":108,"phases":12446,"primaryCompletion":7650,"completion":3140,"start":12426,"enrollment":607,"conditions":12447,"interventions":12448},[94],[12428],[12408,12430],{"intervention":12450,"totalTrials":265,"cells":12451},"Bupivacaine",{"EARLY_PHASE1":12452,"PHASE1":12454,"PHASE2":12456,"PHASE3":12458,"PHASE4":12460,"NA":12462},{"trials":12453,"activeCount":102},[],{"trials":12455,"activeCount":102},[],{"trials":12457,"activeCount":102},[],{"trials":12459,"activeCount":102},[],{"trials":12461,"activeCount":102},[],{"trials":12463,"activeCount":102},[12464],{"nctId":12465,"briefTitle":12466,"status":108,"phases":12467,"primaryCompletion":12468,"completion":12469,"start":12470,"enrollment":531,"conditions":12471,"interventions":12473},"NCT02420951","Local Injection of Local Anesthetic 24 Hours After Knee Replacement Surgery May Decrease Pain for Several More Hours",[94],"2016-03-22","2016-12-09","2015-10-05",[12472,1811],"Arthroplasty, Knee",[12450],{"intervention":12475,"totalTrials":265,"cells":12476},"albuterol",{"EARLY_PHASE1":12477,"PHASE1":12479,"PHASE2":12481,"PHASE3":12483,"PHASE4":12485,"NA":12487},{"trials":12478,"activeCount":102},[],{"trials":12480,"activeCount":102},[],{"trials":12482,"activeCount":102},[],{"trials":12484,"activeCount":102},[],{"trials":12486,"activeCount":102},[],{"trials":12488,"activeCount":102},[12489],{"nctId":12490,"briefTitle":12491,"status":108,"phases":12492,"primaryCompletion":1504,"completion":1504,"start":11297,"enrollment":7307,"conditions":12493,"interventions":12495},"NCT01143688","Characterization of Placebo Responses in Stable Asthma",[94],[12494],"Asthma Placebo Effects",[12475],{"intervention":12497,"totalTrials":265,"cells":12498},"New use of osimertinib",{"EARLY_PHASE1":12499,"PHASE1":12501,"PHASE2":12503,"PHASE3":12505,"PHASE4":12507,"NA":12509},{"trials":12500,"activeCount":102},[],{"trials":12502,"activeCount":102},[],{"trials":12504,"activeCount":102},[],{"trials":12506,"activeCount":102},[],{"trials":12508,"activeCount":102},[],{"trials":12510,"activeCount":102},[12511],{"nctId":12512,"briefTitle":12513,"status":108,"phases":12514,"primaryCompletion":4398,"completion":4398,"start":12515,"enrollment":12516,"conditions":12517,"interventions":12519},"NCT06675695","Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases",[],"2024-10-30",4864,[12518],"Non Small Cell Lung Cancer",[12497,12520],"New use of erlotinib or gefitinib",{"intervention":12520,"totalTrials":265,"cells":12522},{"EARLY_PHASE1":12523,"PHASE1":12525,"PHASE2":12527,"PHASE3":12529,"PHASE4":12531,"NA":12533},{"trials":12524,"activeCount":102},[],{"trials":12526,"activeCount":102},[],{"trials":12528,"activeCount":102},[],{"trials":12530,"activeCount":102},[],{"trials":12532,"activeCount":102},[],{"trials":12534,"activeCount":102},[12535],{"nctId":12512,"briefTitle":12513,"status":108,"phases":12536,"primaryCompletion":4398,"completion":4398,"start":12515,"enrollment":12516,"conditions":12537,"interventions":12538},[],[12518],[12497,12520],{"intervention":12540,"totalTrials":265,"cells":12541},"Degarelix",{"EARLY_PHASE1":12542,"PHASE1":12544,"PHASE2":12546,"PHASE3":12548,"PHASE4":12550,"NA":12552},{"trials":12543,"activeCount":102},[],{"trials":12545,"activeCount":102},[],{"trials":12547,"activeCount":102},[],{"trials":12549,"activeCount":102},[],{"trials":12551,"activeCount":102},[],{"trials":12553,"activeCount":102},[12554],{"nctId":12555,"briefTitle":12556,"status":108,"phases":12557,"primaryCompletion":401,"completion":401,"start":12558,"enrollment":12559,"conditions":12560,"interventions":12561},"NCT04897958","Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data",[],"2019-09-21",14417,[747],[12540,12562],"Leuprolide",{"intervention":12562,"totalTrials":265,"cells":12564},{"EARLY_PHASE1":12565,"PHASE1":12567,"PHASE2":12569,"PHASE3":12571,"PHASE4":12573,"NA":12575},{"trials":12566,"activeCount":102},[],{"trials":12568,"activeCount":102},[],{"trials":12570,"activeCount":102},[],{"trials":12572,"activeCount":102},[],{"trials":12574,"activeCount":102},[],{"trials":12576,"activeCount":102},[12577],{"nctId":12555,"briefTitle":12556,"status":108,"phases":12578,"primaryCompletion":401,"completion":401,"start":12558,"enrollment":12559,"conditions":12579,"interventions":12580},[],[747],[12540,12562],{"intervention":12582,"totalTrials":265,"cells":12583},"IV Lidocaine",{"EARLY_PHASE1":12584,"PHASE1":12586,"PHASE2":12588,"PHASE3":12590,"PHASE4":12592,"NA":12594},{"trials":12585,"activeCount":102},[],{"trials":12587,"activeCount":102},[],{"trials":12589,"activeCount":102},[],{"trials":12591,"activeCount":102},[],{"trials":12593,"activeCount":102},[],{"trials":12595,"activeCount":102},[12596],{"nctId":12597,"briefTitle":12598,"status":108,"phases":12599,"primaryCompletion":5744,"completion":5744,"start":9147,"enrollment":34,"conditions":12600,"interventions":12602},"NCT01968694","Effects of Intravenous Lidocaine on Endometriosis Pain",[94],[12601],"Endometriosis",[12582,12603],"IV diphenhydramine",{"intervention":12603,"totalTrials":265,"cells":12605},{"EARLY_PHASE1":12606,"PHASE1":12608,"PHASE2":12610,"PHASE3":12612,"PHASE4":12614,"NA":12616},{"trials":12607,"activeCount":102},[],{"trials":12609,"activeCount":102},[],{"trials":12611,"activeCount":102},[],{"trials":12613,"activeCount":102},[],{"trials":12615,"activeCount":102},[],{"trials":12617,"activeCount":102},[12618],{"nctId":12597,"briefTitle":12598,"status":108,"phases":12619,"primaryCompletion":5744,"completion":5744,"start":9147,"enrollment":34,"conditions":12620,"interventions":12621},[94],[12601],[12582,12603],{"intervention":10373,"totalTrials":265,"cells":12623},{"EARLY_PHASE1":12624,"PHASE1":12626,"PHASE2":12628,"PHASE3":12630,"PHASE4":12632,"NA":12634},{"trials":12625,"activeCount":102},[],{"trials":12627,"activeCount":102},[],{"trials":12629,"activeCount":102},[],{"trials":12631,"activeCount":102},[],{"trials":12633,"activeCount":102},[],{"trials":12635,"activeCount":102},[12636],{"nctId":10367,"briefTitle":10368,"status":239,"phases":12637,"primaryCompletion":932,"completion":1715,"start":6054,"enrollment":10370,"conditions":12638,"interventions":12639},[94],[18],[10373,10335,10354,10374,10375],{"intervention":10374,"totalTrials":265,"cells":12641},{"EARLY_PHASE1":12642,"PHASE1":12644,"PHASE2":12646,"PHASE3":12648,"PHASE4":12650,"NA":12652},{"trials":12643,"activeCount":102},[],{"trials":12645,"activeCount":102},[],{"trials":12647,"activeCount":102},[],{"trials":12649,"activeCount":102},[],{"trials":12651,"activeCount":102},[],{"trials":12653,"activeCount":102},[12654],{"nctId":10367,"briefTitle":10368,"status":239,"phases":12655,"primaryCompletion":932,"completion":1715,"start":6054,"enrollment":10370,"conditions":12656,"interventions":12657},[94],[18],[10373,10335,10354,10374,10375],{"intervention":3854,"totalTrials":265,"cells":12659},{"EARLY_PHASE1":12660,"PHASE1":12662,"PHASE2":12664,"PHASE3":12666,"PHASE4":12668,"NA":12670},{"trials":12661,"activeCount":102},[],{"trials":12663,"activeCount":102},[],{"trials":12665,"activeCount":102},[],{"trials":12667,"activeCount":102},[],{"trials":12669,"activeCount":102},[],{"trials":12671,"activeCount":102},[12672],{"nctId":3842,"briefTitle":3843,"status":436,"phases":12673,"primaryCompletion":2208,"completion":2208,"start":3845,"enrollment":3846,"conditions":12674,"interventions":12675},[],[3821,3848,3849,3850],[3823,3852,3800,3853,3854],{"intervention":12677,"totalTrials":265,"cells":12678},"Salbutamol",{"EARLY_PHASE1":12679,"PHASE1":12681,"PHASE2":12683,"PHASE3":12685,"PHASE4":12687,"NA":12689},{"trials":12680,"activeCount":102},[],{"trials":12682,"activeCount":102},[],{"trials":12684,"activeCount":102},[],{"trials":12686,"activeCount":102},[],{"trials":12688,"activeCount":102},[],{"trials":12690,"activeCount":102},[12691],{"nctId":12692,"briefTitle":12693,"status":108,"phases":12694,"primaryCompletion":12695,"completion":1357,"start":11077,"enrollment":12696,"conditions":12697,"interventions":12698},"NCT05457868","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists",[],"2022-07-30",124117,[7844],[12677,12699],"LAMA",{"intervention":12699,"totalTrials":265,"cells":12701},{"EARLY_PHASE1":12702,"PHASE1":12704,"PHASE2":12706,"PHASE3":12708,"PHASE4":12710,"NA":12712},{"trials":12703,"activeCount":102},[],{"trials":12705,"activeCount":102},[],{"trials":12707,"activeCount":102},[],{"trials":12709,"activeCount":102},[],{"trials":12711,"activeCount":102},[],{"trials":12713,"activeCount":102},[12714],{"nctId":12692,"briefTitle":12693,"status":108,"phases":12715,"primaryCompletion":12695,"completion":1357,"start":11077,"enrollment":12696,"conditions":12716,"interventions":12717},[],[7844],[12677,12699],{"intervention":11333,"totalTrials":265,"cells":12719},{"EARLY_PHASE1":12720,"PHASE1":12722,"PHASE2":12724,"PHASE3":12726,"PHASE4":12728,"NA":12730},{"trials":12721,"activeCount":102},[],{"trials":12723,"activeCount":102},[],{"trials":12725,"activeCount":102},[],{"trials":12727,"activeCount":102},[],{"trials":12729,"activeCount":102},[],{"trials":12731,"activeCount":102},[12732],{"nctId":11326,"briefTitle":11327,"status":108,"phases":12733,"primaryCompletion":1356,"completion":1357,"start":11329,"enrollment":11330,"conditions":12734,"interventions":12735},[],[18],[11304,11333],{"intervention":12737,"totalTrials":265,"cells":12738},"Rebif",{"EARLY_PHASE1":12739,"PHASE1":12741,"PHASE2":12743,"PHASE3":12745,"PHASE4":12747,"NA":12749},{"trials":12740,"activeCount":102},[],{"trials":12742,"activeCount":102},[],{"trials":12744,"activeCount":102},[],{"trials":12746,"activeCount":102},[],{"trials":12748,"activeCount":102},[],{"trials":12750,"activeCount":102},[12751],{"nctId":12752,"briefTitle":12753,"status":152,"phases":12754,"primaryCompletion":6790,"completion":5461,"start":6675,"enrollment":102,"conditions":12755,"interventions":12756},"NCT02419638","Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS",[],[723],[12737,12757],"Tecifdera",{"intervention":12757,"totalTrials":265,"cells":12759},{"EARLY_PHASE1":12760,"PHASE1":12762,"PHASE2":12764,"PHASE3":12766,"PHASE4":12768,"NA":12770},{"trials":12761,"activeCount":102},[],{"trials":12763,"activeCount":102},[],{"trials":12765,"activeCount":102},[],{"trials":12767,"activeCount":102},[],{"trials":12769,"activeCount":102},[],{"trials":12771,"activeCount":102},[12772],{"nctId":12752,"briefTitle":12753,"status":152,"phases":12773,"primaryCompletion":6790,"completion":5461,"start":6675,"enrollment":102,"conditions":12774,"interventions":12775},[],[723],[12737,12757],{"intervention":11430,"totalTrials":265,"cells":12777},{"EARLY_PHASE1":12778,"PHASE1":12780,"PHASE2":12782,"PHASE3":12784,"PHASE4":12786,"NA":12788},{"trials":12779,"activeCount":102},[],{"trials":12781,"activeCount":102},[],{"trials":12783,"activeCount":102},[],{"trials":12785,"activeCount":102},[],{"trials":12787,"activeCount":102},[],{"trials":12789,"activeCount":102},[12790],{"nctId":11424,"briefTitle":11425,"status":108,"phases":12791,"primaryCompletion":1356,"completion":1357,"start":126,"enrollment":11427,"conditions":12792,"interventions":12793},[],[15],[11430,222],{"intervention":12795,"totalTrials":265,"cells":12796},"cefazolin or vancomycin",{"EARLY_PHASE1":12797,"PHASE1":12799,"PHASE2":12801,"PHASE3":12803,"PHASE4":12805,"NA":12807},{"trials":12798,"activeCount":102},[],{"trials":12800,"activeCount":102},[],{"trials":12802,"activeCount":102},[],{"trials":12804,"activeCount":102},[],{"trials":12806,"activeCount":102},[],{"trials":12808,"activeCount":102},[12809],{"nctId":12810,"briefTitle":12811,"status":108,"phases":12812,"primaryCompletion":1601,"completion":1601,"start":9784,"enrollment":12813,"conditions":12814,"interventions":12816},"NCT00818766","Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy",[94],251,[12815],"Antibiotic Prophylaxis",[12795],{"intervention":12818,"totalTrials":265,"cells":12819},"Chlorhexidine-alcohol group",{"EARLY_PHASE1":12820,"PHASE1":12822,"PHASE2":12824,"PHASE3":12826,"PHASE4":12828,"NA":12830},{"trials":12821,"activeCount":102},[],{"trials":12823,"activeCount":102},[],{"trials":12825,"activeCount":102},[],{"trials":12827,"activeCount":102},[],{"trials":12829,"activeCount":102},[],{"trials":12831,"activeCount":102},[12832],{"nctId":12833,"briefTitle":12834,"status":152,"phases":12835,"primaryCompletion":10754,"completion":10754,"start":3140,"enrollment":102,"conditions":12836,"interventions":12838},"NCT02027324","Prevention of Surgical Site Infection After Cesarean Delivery",[94],[12837],"Surgical Site Infection",[12818,12839],"Povidone-Iodine Group",{"intervention":12839,"totalTrials":265,"cells":12841},{"EARLY_PHASE1":12842,"PHASE1":12844,"PHASE2":12846,"PHASE3":12848,"PHASE4":12850,"NA":12852},{"trials":12843,"activeCount":102},[],{"trials":12845,"activeCount":102},[],{"trials":12847,"activeCount":102},[],{"trials":12849,"activeCount":102},[],{"trials":12851,"activeCount":102},[],{"trials":12853,"activeCount":102},[12854],{"nctId":12833,"briefTitle":12834,"status":152,"phases":12855,"primaryCompletion":10754,"completion":10754,"start":3140,"enrollment":102,"conditions":12856,"interventions":12857},[94],[12837],[12818,12839],{"intervention":10327,"totalTrials":265,"cells":12859},{"EARLY_PHASE1":12860,"PHASE1":12862,"PHASE2":12864,"PHASE3":12866,"PHASE4":12868,"NA":12870},{"trials":12861,"activeCount":102},[],{"trials":12863,"activeCount":102},[],{"trials":12865,"activeCount":102},[],{"trials":12867,"activeCount":102},[],{"trials":12869,"activeCount":102},[],{"trials":12871,"activeCount":102},[12872],{"nctId":10320,"briefTitle":10321,"status":108,"phases":12873,"primaryCompletion":155,"completion":10323,"start":4487,"enrollment":128,"conditions":12874,"interventions":12875},[94],[1368,10325],[10289,10327],{"intervention":12877,"totalTrials":265,"cells":12878},"CEE pill",{"EARLY_PHASE1":12879,"PHASE1":12881,"PHASE2":12883,"PHASE3":12885,"PHASE4":12887,"NA":12889},{"trials":12880,"activeCount":102},[],{"trials":12882,"activeCount":102},[],{"trials":12884,"activeCount":102},[],{"trials":12886,"activeCount":102},[],{"trials":12888,"activeCount":102},[],{"trials":12890,"activeCount":102},[12891],{"nctId":12892,"briefTitle":12893,"status":108,"phases":12894,"primaryCompletion":7305,"completion":7305,"start":6382,"enrollment":12895,"conditions":12896,"interventions":12899},"NCT02524561","KEEPS Mammographic Density And Breast Health Ancillary Study",[94],517,[12897,12898],"Mammographic Density","Abnormal Mammogram",[12877,12900,12901],"Estradiol patch","Active Progesterone",{"intervention":12900,"totalTrials":265,"cells":12903},{"EARLY_PHASE1":12904,"PHASE1":12906,"PHASE2":12908,"PHASE3":12910,"PHASE4":12912,"NA":12914},{"trials":12905,"activeCount":102},[],{"trials":12907,"activeCount":102},[],{"trials":12909,"activeCount":102},[],{"trials":12911,"activeCount":102},[],{"trials":12913,"activeCount":102},[],{"trials":12915,"activeCount":102},[12916],{"nctId":12892,"briefTitle":12893,"status":108,"phases":12917,"primaryCompletion":7305,"completion":7305,"start":6382,"enrollment":12895,"conditions":12918,"interventions":12919},[94],[12897,12898],[12877,12900,12901],{"intervention":12901,"totalTrials":265,"cells":12921},{"EARLY_PHASE1":12922,"PHASE1":12924,"PHASE2":12926,"PHASE3":12928,"PHASE4":12930,"NA":12932},{"trials":12923,"activeCount":102},[],{"trials":12925,"activeCount":102},[],{"trials":12927,"activeCount":102},[],{"trials":12929,"activeCount":102},[],{"trials":12931,"activeCount":102},[],{"trials":12933,"activeCount":102},[12934],{"nctId":12892,"briefTitle":12893,"status":108,"phases":12935,"primaryCompletion":7305,"completion":7305,"start":6382,"enrollment":12895,"conditions":12936,"interventions":12937},[94],[12897,12898],[12877,12900,12901],{"intervention":12939,"totalTrials":265,"cells":12940},"Optison",{"EARLY_PHASE1":12941,"PHASE1":12943,"PHASE2":12945,"PHASE3":12947,"PHASE4":12949,"NA":12951},{"trials":12942,"activeCount":102},[],{"trials":12944,"activeCount":102},[],{"trials":12946,"activeCount":102},[],{"trials":12948,"activeCount":102},[],{"trials":12950,"activeCount":102},[],{"trials":12952,"activeCount":102},[12953],{"nctId":12954,"briefTitle":12955,"status":239,"phases":12956,"primaryCompletion":111,"completion":111,"start":9270,"enrollment":98,"conditions":12957,"interventions":12959},"NCT02300870","Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection",[],[12958],"Heart Transplantation",[12939],{"intervention":12961,"totalTrials":265,"cells":12962},"15N-Thymidine, 2H-Water",{"EARLY_PHASE1":12963,"PHASE1":12965,"PHASE2":12967,"PHASE3":12969,"PHASE4":12971,"NA":12973},{"trials":12964,"activeCount":102},[],{"trials":12966,"activeCount":102},[],{"trials":12968,"activeCount":102},[],{"trials":12970,"activeCount":102},[],{"trials":12972,"activeCount":102},[],{"trials":12974,"activeCount":102},[12975],{"nctId":12976,"briefTitle":12977,"status":108,"phases":12978,"primaryCompletion":7842,"completion":12979,"start":9147,"enrollment":34,"conditions":12980,"interventions":12981},"NCT01257997","Quantification of Human Adipogenesis",[],"2017-01",[33],[12961],{"intervention":12983,"totalTrials":265,"cells":12984},"Initiation of tirzepatide",{"EARLY_PHASE1":12985,"PHASE1":12987,"PHASE2":12989,"PHASE3":12991,"PHASE4":12993,"NA":12995},{"trials":12986,"activeCount":102},[],{"trials":12988,"activeCount":102},[],{"trials":12990,"activeCount":102},[],{"trials":12992,"activeCount":102},[],{"trials":12994,"activeCount":102},[],{"trials":12996,"activeCount":102},[12997],{"nctId":12998,"briefTitle":12999,"status":108,"phases":13000,"primaryCompletion":677,"completion":677,"start":13001,"enrollment":13002,"conditions":13003,"interventions":13006},"NCT07203677","Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)",[],"2025-09-19",49065,[13004,13005],"Type2 Diabetes Mellitus","Atherosclerotic Cardiovascular Disease",[12983,13007],"Initiation of sitagliptin",{"intervention":13007,"totalTrials":265,"cells":13009},{"EARLY_PHASE1":13010,"PHASE1":13012,"PHASE2":13014,"PHASE3":13016,"PHASE4":13018,"NA":13020},{"trials":13011,"activeCount":102},[],{"trials":13013,"activeCount":102},[],{"trials":13015,"activeCount":102},[],{"trials":13017,"activeCount":102},[],{"trials":13019,"activeCount":102},[],{"trials":13021,"activeCount":102},[13022],{"nctId":12998,"briefTitle":12999,"status":108,"phases":13023,"primaryCompletion":677,"completion":677,"start":13001,"enrollment":13002,"conditions":13024,"interventions":13025},[],[13004,13005],[12983,13007],{"intervention":13027,"totalTrials":265,"cells":13028},"Lower dialysate sodium",{"EARLY_PHASE1":13029,"PHASE1":13031,"PHASE2":13033,"PHASE3":13035,"PHASE4":13037,"NA":13039},{"trials":13030,"activeCount":102},[],{"trials":13032,"activeCount":102},[],{"trials":13034,"activeCount":102},[],{"trials":13036,"activeCount":102},[],{"trials":13038,"activeCount":102},[],{"trials":13040,"activeCount":102},[13041],{"nctId":13042,"briefTitle":13043,"status":108,"phases":13044,"primaryCompletion":881,"completion":3860,"start":13045,"enrollment":13046,"conditions":13047,"interventions":13048},"NCT02145260","Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients",[94],"2014-07-01",144,[6504],[13027,13049],"Higher dialysate sodium",{"intervention":13049,"totalTrials":265,"cells":13051},{"EARLY_PHASE1":13052,"PHASE1":13054,"PHASE2":13056,"PHASE3":13058,"PHASE4":13060,"NA":13062},{"trials":13053,"activeCount":102},[],{"trials":13055,"activeCount":102},[],{"trials":13057,"activeCount":102},[],{"trials":13059,"activeCount":102},[],{"trials":13061,"activeCount":102},[],{"trials":13063,"activeCount":102},[13064],{"nctId":13042,"briefTitle":13043,"status":108,"phases":13065,"primaryCompletion":881,"completion":3860,"start":13045,"enrollment":13046,"conditions":13066,"interventions":13067},[94],[6504],[13027,13049],{"intervention":13069,"totalTrials":265,"cells":13070},"Initiation of palbociclib plus letrozole",{"EARLY_PHASE1":13071,"PHASE1":13073,"PHASE2":13075,"PHASE3":13077,"PHASE4":13079,"NA":13081},{"trials":13072,"activeCount":102},[],{"trials":13074,"activeCount":102},[],{"trials":13076,"activeCount":102},[],{"trials":13078,"activeCount":102},[],{"trials":13080,"activeCount":102},[],{"trials":13082,"activeCount":102},[13083],{"nctId":13084,"briefTitle":13085,"status":108,"phases":13086,"primaryCompletion":1098,"completion":1098,"start":13087,"enrollment":13088,"conditions":13089,"interventions":13090},"NCT07178743","Emulation of the PALOMA-2 Trial",[],"2025-07-14",6097,[12275],[13069,13091],"Initiation of letrozole",{"intervention":13091,"totalTrials":265,"cells":13093},{"EARLY_PHASE1":13094,"PHASE1":13096,"PHASE2":13098,"PHASE3":13100,"PHASE4":13102,"NA":13104},{"trials":13095,"activeCount":102},[],{"trials":13097,"activeCount":102},[],{"trials":13099,"activeCount":102},[],{"trials":13101,"activeCount":102},[],{"trials":13103,"activeCount":102},[],{"trials":13105,"activeCount":102},[13106],{"nctId":13084,"briefTitle":13085,"status":108,"phases":13107,"primaryCompletion":1098,"completion":1098,"start":13087,"enrollment":13088,"conditions":13108,"interventions":13109},[],[12275],[13069,13091],{"intervention":13111,"totalTrials":265,"cells":13112},"Dabigatran: extended treatment",{"EARLY_PHASE1":13113,"PHASE1":13115,"PHASE2":13117,"PHASE3":13119,"PHASE4":13121,"NA":13123},{"trials":13114,"activeCount":102},[],{"trials":13116,"activeCount":102},[],{"trials":13118,"activeCount":102},[],{"trials":13120,"activeCount":102},[],{"trials":13122,"activeCount":102},[],{"trials":13124,"activeCount":102},[13125],{"nctId":13126,"briefTitle":13127,"status":436,"phases":13128,"primaryCompletion":13129,"completion":13129,"start":4451,"enrollment":13130,"conditions":13131,"interventions":13133},"NCT03271450","The DARE Warfarin CER Study",[],"2021-10-30",416000,[13132,3871],"Deep Venous Thrombosis",[13111,13111,13111,13134,13134,13134,13135,13135,13135,13136,13136,13136,13137,13137,13137],"Apixaban: extended treatment","Rivaroxaban: extended treatment","Edoxaban: extended treatment","Warfarin: extended treatment",{"intervention":13134,"totalTrials":265,"cells":13139},{"EARLY_PHASE1":13140,"PHASE1":13142,"PHASE2":13144,"PHASE3":13146,"PHASE4":13148,"NA":13150},{"trials":13141,"activeCount":102},[],{"trials":13143,"activeCount":102},[],{"trials":13145,"activeCount":102},[],{"trials":13147,"activeCount":102},[],{"trials":13149,"activeCount":102},[],{"trials":13151,"activeCount":102},[13152],{"nctId":13126,"briefTitle":13127,"status":436,"phases":13153,"primaryCompletion":13129,"completion":13129,"start":4451,"enrollment":13130,"conditions":13154,"interventions":13155},[],[13132,3871],[13111,13111,13111,13134,13134,13134,13135,13135,13135,13136,13136,13136,13137,13137,13137],{"intervention":13135,"totalTrials":265,"cells":13157},{"EARLY_PHASE1":13158,"PHASE1":13160,"PHASE2":13162,"PHASE3":13164,"PHASE4":13166,"NA":13168},{"trials":13159,"activeCount":102},[],{"trials":13161,"activeCount":102},[],{"trials":13163,"activeCount":102},[],{"trials":13165,"activeCount":102},[],{"trials":13167,"activeCount":102},[],{"trials":13169,"activeCount":102},[13170],{"nctId":13126,"briefTitle":13127,"status":436,"phases":13171,"primaryCompletion":13129,"completion":13129,"start":4451,"enrollment":13130,"conditions":13172,"interventions":13173},[],[13132,3871],[13111,13111,13111,13134,13134,13134,13135,13135,13135,13136,13136,13136,13137,13137,13137],{"intervention":13136,"totalTrials":265,"cells":13175},{"EARLY_PHASE1":13176,"PHASE1":13178,"PHASE2":13180,"PHASE3":13182,"PHASE4":13184,"NA":13186},{"trials":13177,"activeCount":102},[],{"trials":13179,"activeCount":102},[],{"trials":13181,"activeCount":102},[],{"trials":13183,"activeCount":102},[],{"trials":13185,"activeCount":102},[],{"trials":13187,"activeCount":102},[13188],{"nctId":13126,"briefTitle":13127,"status":436,"phases":13189,"primaryCompletion":13129,"completion":13129,"start":4451,"enrollment":13130,"conditions":13190,"interventions":13191},[],[13132,3871],[13111,13111,13111,13134,13134,13134,13135,13135,13135,13136,13136,13136,13137,13137,13137],{"intervention":13137,"totalTrials":265,"cells":13193},{"EARLY_PHASE1":13194,"PHASE1":13196,"PHASE2":13198,"PHASE3":13200,"PHASE4":13202,"NA":13204},{"trials":13195,"activeCount":102},[],{"trials":13197,"activeCount":102},[],{"trials":13199,"activeCount":102},[],{"trials":13201,"activeCount":102},[],{"trials":13203,"activeCount":102},[],{"trials":13205,"activeCount":102},[13206],{"nctId":13126,"briefTitle":13127,"status":436,"phases":13207,"primaryCompletion":13129,"completion":13129,"start":4451,"enrollment":13130,"conditions":13208,"interventions":13209},[],[13132,3871],[13111,13111,13111,13134,13134,13134,13135,13135,13135,13136,13136,13136,13137,13137,13137],{"intervention":11268,"totalTrials":265,"cells":13211},{"EARLY_PHASE1":13212,"PHASE1":13214,"PHASE2":13216,"PHASE3":13218,"PHASE4":13220,"NA":13222},{"trials":13213,"activeCount":102},[],{"trials":13215,"activeCount":102},[],{"trials":13217,"activeCount":102},[],{"trials":13219,"activeCount":102},[],{"trials":13221,"activeCount":102},[],{"trials":13223,"activeCount":102},[13224],{"nctId":11260,"briefTitle":11261,"status":108,"phases":13225,"primaryCompletion":3693,"completion":3693,"start":11263,"enrollment":11264,"conditions":13226,"interventions":13227},[],[11266],[4779,11268],{"intervention":13229,"totalTrials":265,"cells":13230},"Whole exome sequencing",{"EARLY_PHASE1":13231,"PHASE1":13233,"PHASE2":13235,"PHASE3":13237,"PHASE4":13239,"NA":13241},{"trials":13232,"activeCount":102},[],{"trials":13234,"activeCount":102},[],{"trials":13236,"activeCount":102},[],{"trials":13238,"activeCount":102},[],{"trials":13240,"activeCount":102},[],{"trials":13242,"activeCount":102},[13243],{"nctId":13244,"briefTitle":13245,"status":108,"phases":13246,"primaryCompletion":13247,"completion":13248,"start":13249,"enrollment":13250,"conditions":13251,"interventions":13253},"NCT03276637","Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force",[94],"2019-06-22","2020-01-11","2017-08-23",105,[13252,11175],"Healthy Adults",[13229],{"intervention":13255,"totalTrials":265,"cells":13256},"Drug",{"EARLY_PHASE1":13257,"PHASE1":13259,"PHASE2":13261,"PHASE3":13263,"PHASE4":13265,"NA":13267},{"trials":13258,"activeCount":102},[],{"trials":13260,"activeCount":102},[],{"trials":13262,"activeCount":102},[],{"trials":13264,"activeCount":102},[],{"trials":13266,"activeCount":102},[],{"trials":13268,"activeCount":102},[13269],{"nctId":13270,"briefTitle":13271,"status":108,"phases":13272,"primaryCompletion":11296,"completion":11296,"start":13273,"enrollment":4452,"conditions":13274,"interventions":13276},"NCT00115583","The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries",[94],"1998-11",[13275],"Atherosclerosis, Coronary",[13255],{"intervention":13278,"totalTrials":265,"cells":13279},"trimethoprim-sulfamethoxazole",{"EARLY_PHASE1":13280,"PHASE1":13282,"PHASE2":13284,"PHASE3":13286,"PHASE4":13288,"NA":13290},{"trials":13281,"activeCount":102},[],{"trials":13283,"activeCount":102},[],{"trials":13285,"activeCount":102},[],{"trials":13287,"activeCount":102},[],{"trials":13289,"activeCount":102},[],{"trials":13291,"activeCount":102},[13292],{"nctId":13293,"briefTitle":13294,"status":108,"phases":13295,"primaryCompletion":6412,"completion":6412,"start":4811,"enrollment":13296,"conditions":13297,"interventions":13299},"NCT00676130","Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients",[94],153,[13298],"Cellulitis",[13278,13300],"Cephalexin",{"intervention":13300,"totalTrials":265,"cells":13302},{"EARLY_PHASE1":13303,"PHASE1":13305,"PHASE2":13307,"PHASE3":13309,"PHASE4":13311,"NA":13313},{"trials":13304,"activeCount":102},[],{"trials":13306,"activeCount":102},[],{"trials":13308,"activeCount":102},[],{"trials":13310,"activeCount":102},[],{"trials":13312,"activeCount":102},[],{"trials":13314,"activeCount":102},[13315],{"nctId":13293,"briefTitle":13294,"status":108,"phases":13316,"primaryCompletion":6412,"completion":6412,"start":4811,"enrollment":13296,"conditions":13317,"interventions":13318},[94],[13298],[13278,13300],{"intervention":13320,"totalTrials":265,"cells":13321},"Lisinopril, Atenolol",{"EARLY_PHASE1":13322,"PHASE1":13324,"PHASE2":13326,"PHASE3":13328,"PHASE4":13330,"NA":13332},{"trials":13323,"activeCount":102},[],{"trials":13325,"activeCount":102},[],{"trials":13327,"activeCount":102},[],{"trials":13329,"activeCount":102},[],{"trials":13331,"activeCount":102},[],{"trials":13333,"activeCount":102},[13334],{"nctId":13335,"briefTitle":13336,"status":152,"phases":13337,"primaryCompletion":13338,"completion":13338,"start":8054,"enrollment":102,"conditions":13339,"interventions":13340},"NCT01009944","Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study",[94],"2019-03-19",[15],[13320],{"intervention":13342,"totalTrials":265,"cells":13343},"Cosyntropin",{"EARLY_PHASE1":13344,"PHASE1":13346,"PHASE2":13348,"PHASE3":13350,"PHASE4":13352,"NA":13354},{"trials":13345,"activeCount":102},[],{"trials":13347,"activeCount":102},[],{"trials":13349,"activeCount":102},[],{"trials":13351,"activeCount":102},[],{"trials":13353,"activeCount":102},[],{"trials":13355,"activeCount":102},[13356],{"nctId":13357,"briefTitle":13358,"status":108,"phases":13359,"primaryCompletion":13360,"completion":13361,"start":5311,"enrollment":113,"conditions":13362,"interventions":13366},"NCT02339506","Stress and the Nervous System",[94],"2016-10","2020-11",[13363,13364,13365],"Autonomic Nervous System","Baroreflex","Stress, Physiological",[13342],{"intervention":10578,"totalTrials":265,"cells":13368},{"EARLY_PHASE1":13369,"PHASE1":13371,"PHASE2":13373,"PHASE3":13375,"PHASE4":13377,"NA":13379},{"trials":13370,"activeCount":102},[],{"trials":13372,"activeCount":102},[],{"trials":13374,"activeCount":102},[],{"trials":13376,"activeCount":102},[],{"trials":13378,"activeCount":102},[],{"trials":13380,"activeCount":102},[13381],{"nctId":10571,"briefTitle":10572,"status":108,"phases":13382,"primaryCompletion":10574,"completion":10574,"start":974,"enrollment":1553,"conditions":13383,"interventions":13384},[94],[10576],[10578,4744,10579,10580],{"intervention":10580,"totalTrials":265,"cells":13386},{"EARLY_PHASE1":13387,"PHASE1":13389,"PHASE2":13391,"PHASE3":13393,"PHASE4":13395,"NA":13397},{"trials":13388,"activeCount":102},[],{"trials":13390,"activeCount":102},[],{"trials":13392,"activeCount":102},[],{"trials":13394,"activeCount":102},[],{"trials":13396,"activeCount":102},[],{"trials":13398,"activeCount":102},[13399],{"nctId":10571,"briefTitle":10572,"status":108,"phases":13400,"primaryCompletion":10574,"completion":10574,"start":974,"enrollment":1553,"conditions":13401,"interventions":13402},[94],[10576],[10578,4744,10579,10580],{"intervention":13404,"totalTrials":265,"cells":13405},"Extended Release Nicotinic Acid",{"EARLY_PHASE1":13406,"PHASE1":13408,"PHASE2":13410,"PHASE3":13412,"PHASE4":13414,"NA":13416},{"trials":13407,"activeCount":102},[],{"trials":13409,"activeCount":102},[],{"trials":13411,"activeCount":102},[],{"trials":13413,"activeCount":102},[],{"trials":13415,"activeCount":102},[],{"trials":13417,"activeCount":102},[13418],{"nctId":13419,"briefTitle":13420,"status":239,"phases":13421,"primaryCompletion":362,"completion":362,"start":955,"enrollment":1469,"conditions":13422,"interventions":13424},"NCT01159054","Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid",[94],[13423,958,471,2614],"Dialysis",[13404],{"intervention":10466,"totalTrials":265,"cells":13426},{"EARLY_PHASE1":13427,"PHASE1":13429,"PHASE2":13431,"PHASE3":13433,"PHASE4":13435,"NA":13437},{"trials":13428,"activeCount":102},[],{"trials":13430,"activeCount":102},[],{"trials":13432,"activeCount":102},[],{"trials":13434,"activeCount":102},[],{"trials":13436,"activeCount":102},[],{"trials":13438,"activeCount":102},[13439],{"nctId":10460,"briefTitle":10461,"status":108,"phases":13440,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":10463,"conditions":13441,"interventions":13442},[],[27],[10466,3716],{"intervention":2715,"totalTrials":265,"cells":13444},{"EARLY_PHASE1":13445,"PHASE1":13447,"PHASE2":13449,"PHASE3":13451,"PHASE4":13453,"NA":13455},{"trials":13446,"activeCount":102},[],{"trials":13448,"activeCount":102},[],{"trials":13450,"activeCount":102},[],{"trials":13452,"activeCount":102},[],{"trials":13454,"activeCount":102},[],{"trials":13456,"activeCount":102},[13457],{"nctId":2708,"briefTitle":2709,"status":436,"phases":13458,"primaryCompletion":2711,"completion":2711,"start":2712,"enrollment":883,"conditions":13459,"interventions":13460},[],[885],[2715,2670],{"intervention":13462,"totalTrials":265,"cells":13463},"Anastrozole",{"EARLY_PHASE1":13464,"PHASE1":13466,"PHASE2":13468,"PHASE3":13470,"PHASE4":13472,"NA":13474},{"trials":13465,"activeCount":102},[],{"trials":13467,"activeCount":102},[],{"trials":13469,"activeCount":102},[],{"trials":13471,"activeCount":102},[],{"trials":13473,"activeCount":102},[],{"trials":13475,"activeCount":102},[13476],{"nctId":13477,"briefTitle":13478,"status":108,"phases":13479,"primaryCompletion":4739,"completion":1357,"start":2803,"enrollment":13480,"conditions":13481,"interventions":13482},"NCT05635357","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane\u002FLetrozole",[],16989,[2471],[13462,13483],"Exemestane\u002FLetrozole",{"intervention":13483,"totalTrials":265,"cells":13485},{"EARLY_PHASE1":13486,"PHASE1":13488,"PHASE2":13490,"PHASE3":13492,"PHASE4":13494,"NA":13496},{"trials":13487,"activeCount":102},[],{"trials":13489,"activeCount":102},[],{"trials":13491,"activeCount":102},[],{"trials":13493,"activeCount":102},[],{"trials":13495,"activeCount":102},[],{"trials":13497,"activeCount":102},[13498],{"nctId":13477,"briefTitle":13478,"status":108,"phases":13499,"primaryCompletion":4739,"completion":1357,"start":2803,"enrollment":13480,"conditions":13500,"interventions":13501},[],[2471],[13462,13483],{"intervention":13503,"totalTrials":265,"cells":13504},"Nitrous Oxide",{"EARLY_PHASE1":13505,"PHASE1":13507,"PHASE2":13509,"PHASE3":13511,"PHASE4":13513,"NA":13515},{"trials":13506,"activeCount":102},[],{"trials":13508,"activeCount":102},[],{"trials":13510,"activeCount":102},[],{"trials":13512,"activeCount":102},[],{"trials":13514,"activeCount":102},[],{"trials":13516,"activeCount":102},[13517],{"nctId":13518,"briefTitle":13519,"status":152,"phases":13520,"primaryCompletion":4612,"completion":4612,"start":13521,"enrollment":102,"conditions":13522,"interventions":13523},"NCT04813874","Nitrous Oxide and Neuraxial Labor Analgesia Use on Maternal Fetal Outcomes",[],"2016-07-01",[5976],[13503],{"intervention":13525,"totalTrials":265,"cells":13526},"Sevelamer Carbonate",{"EARLY_PHASE1":13527,"PHASE1":13529,"PHASE2":13531,"PHASE3":13533,"PHASE4":13535,"NA":13537},{"trials":13528,"activeCount":102},[],{"trials":13530,"activeCount":102},[],{"trials":13532,"activeCount":102},[],{"trials":13534,"activeCount":102},[],{"trials":13536,"activeCount":102},[],{"trials":13538,"activeCount":102},[13539],{"nctId":13540,"briefTitle":13541,"status":239,"phases":13542,"primaryCompletion":13543,"completion":13543,"start":13544,"enrollment":933,"conditions":13545,"interventions":13547},"NCT01238588","The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan",[94],"2016-04-08","2011-06-10",[13423,958,471,2614,13546],"Hyperphosphatemia",[13525],{"intervention":10286,"totalTrials":265,"cells":13549},{"EARLY_PHASE1":13550,"PHASE1":13552,"PHASE2":13554,"PHASE3":13556,"PHASE4":13558,"NA":13560},{"trials":13551,"activeCount":102},[],{"trials":13553,"activeCount":102},[],{"trials":13555,"activeCount":102},[],{"trials":13557,"activeCount":102},[],{"trials":13559,"activeCount":102},[],{"trials":13561,"activeCount":102},[13562],{"nctId":10280,"briefTitle":10281,"status":108,"phases":13563,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":10283,"conditions":13564,"interventions":13565},[],[24],[10286,10287],{"intervention":13567,"totalTrials":265,"cells":13568},"Raloxifene",{"EARLY_PHASE1":13569,"PHASE1":13571,"PHASE2":13573,"PHASE3":13575,"PHASE4":13577,"NA":13579},{"trials":13570,"activeCount":102},[],{"trials":13572,"activeCount":102},[],{"trials":13574,"activeCount":102},[],{"trials":13576,"activeCount":102},[],{"trials":13578,"activeCount":102},[],{"trials":13580,"activeCount":102},[13581],{"nctId":13582,"briefTitle":13583,"status":108,"phases":13584,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":13585,"conditions":13586,"interventions":13587},"NCT04736693","Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data",[],18028,[11266],[13567,13588],"Zoledronic Acid",{"intervention":13588,"totalTrials":265,"cells":13590},{"EARLY_PHASE1":13591,"PHASE1":13593,"PHASE2":13595,"PHASE3":13597,"PHASE4":13599,"NA":13601},{"trials":13592,"activeCount":102},[],{"trials":13594,"activeCount":102},[],{"trials":13596,"activeCount":102},[],{"trials":13598,"activeCount":102},[],{"trials":13600,"activeCount":102},[],{"trials":13602,"activeCount":102},[13603],{"nctId":13582,"briefTitle":13583,"status":108,"phases":13604,"primaryCompletion":3711,"completion":3711,"start":3828,"enrollment":13585,"conditions":13605,"interventions":13606},[],[11266],[13567,13588],{"intervention":10737,"totalTrials":265,"cells":13608},{"EARLY_PHASE1":13609,"PHASE1":13611,"PHASE2":13613,"PHASE3":13615,"PHASE4":13617,"NA":13619},{"trials":13610,"activeCount":102},[],{"trials":13612,"activeCount":102},[],{"trials":13614,"activeCount":102},[],{"trials":13616,"activeCount":102},[],{"trials":13618,"activeCount":102},[],{"trials":13620,"activeCount":102},[13621],{"nctId":10731,"briefTitle":10732,"status":108,"phases":13622,"primaryCompletion":2143,"completion":2143,"start":3828,"enrollment":10734,"conditions":13623,"interventions":13624},[],[7844],[10353,10737],{"intervention":940,"totalTrials":265,"cells":13626},{"EARLY_PHASE1":13627,"PHASE1":13629,"PHASE2":13631,"PHASE3":13633,"PHASE4":13635,"NA":13637},{"trials":13628,"activeCount":102},[],{"trials":13630,"activeCount":102},[],{"trials":13632,"activeCount":102},[],{"trials":13634,"activeCount":102},[],{"trials":13636,"activeCount":102},[],{"trials":13638,"activeCount":102},[13639],{"nctId":928,"briefTitle":929,"status":239,"phases":13640,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":13641,"interventions":13642},[94],[935,936,937],[939,940,183],{"intervention":13644,"totalTrials":265,"cells":13645},"PDE5 inhibitor",{"EARLY_PHASE1":13646,"PHASE1":13648,"PHASE2":13650,"PHASE3":13652,"PHASE4":13654,"NA":13656},{"trials":13647,"activeCount":102},[],{"trials":13649,"activeCount":102},[],{"trials":13651,"activeCount":102},[],{"trials":13653,"activeCount":102},[],{"trials":13655,"activeCount":102},[],{"trials":13657,"activeCount":102},[13658],{"nctId":13659,"briefTitle":13660,"status":108,"phases":13661,"primaryCompletion":13662,"completion":13663,"start":10673,"enrollment":13664,"conditions":13665,"interventions":13666},"NCT05039086","Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5",[],"2021-09-30","2022-10-04",13021,[5681],[13644,13667],"Endothelin Receptor Antagonists",{"intervention":13667,"totalTrials":265,"cells":13669},{"EARLY_PHASE1":13670,"PHASE1":13672,"PHASE2":13674,"PHASE3":13676,"PHASE4":13678,"NA":13680},{"trials":13671,"activeCount":102},[],{"trials":13673,"activeCount":102},[],{"trials":13675,"activeCount":102},[],{"trials":13677,"activeCount":102},[],{"trials":13679,"activeCount":102},[],{"trials":13681,"activeCount":102},[13682],{"nctId":13659,"briefTitle":13660,"status":108,"phases":13683,"primaryCompletion":13662,"completion":13663,"start":10673,"enrollment":13664,"conditions":13684,"interventions":13685},[],[5681],[13644,13667],{"intervention":13687,"totalTrials":265,"cells":13688},"intra-articular corticosteroid",{"EARLY_PHASE1":13689,"PHASE1":13691,"PHASE2":13693,"PHASE3":13695,"PHASE4":13697,"NA":13699},{"trials":13690,"activeCount":102},[],{"trials":13692,"activeCount":102},[],{"trials":13694,"activeCount":102},[],{"trials":13696,"activeCount":102},[],{"trials":13698,"activeCount":102},[],{"trials":13700,"activeCount":102},[13701],{"nctId":13702,"briefTitle":13703,"status":436,"phases":13704,"primaryCompletion":991,"completion":6316,"start":11205,"enrollment":607,"conditions":13705,"interventions":13707},"NCT04329884","Use of Cooled Radiofrequency for the Treatment of Hip Pain Associated With Hip OA Compared to Intra-articular Steroid Injections",[94],[13706],"Osteoarthritis, Hip",[13687],{"intervention":11408,"totalTrials":265,"cells":13709},{"EARLY_PHASE1":13710,"PHASE1":13712,"PHASE2":13714,"PHASE3":13716,"PHASE4":13718,"NA":13720},{"trials":13711,"activeCount":102},[],{"trials":13713,"activeCount":102},[],{"trials":13715,"activeCount":102},[],{"trials":13717,"activeCount":102},[],{"trials":13719,"activeCount":102},[],{"trials":13721,"activeCount":102},[13722],{"nctId":11401,"briefTitle":11402,"status":108,"phases":13723,"primaryCompletion":3693,"completion":3693,"start":11263,"enrollment":11404,"conditions":13724,"interventions":13725},[],[18],[11407,11408],{"intervention":13727,"totalTrials":265,"cells":13728},"Fondaparinux",{"EARLY_PHASE1":13729,"PHASE1":13731,"PHASE2":13733,"PHASE3":13735,"PHASE4":13737,"NA":13739},{"trials":13730,"activeCount":102},[],{"trials":13732,"activeCount":102},[],{"trials":13734,"activeCount":102},[],{"trials":13736,"activeCount":102},[],{"trials":13738,"activeCount":102},[],{"trials":13740,"activeCount":102},[13741],{"nctId":13742,"briefTitle":13743,"status":108,"phases":13744,"completion":13745,"start":5267,"enrollment":678,"conditions":13746,"interventions":13747},"NCT00413504","Fondaparinux as Monotherapy for DVT and\u002For Pulmonary Embolism",[94],"2007-07",[4007,3871],[13727],{"intervention":10432,"totalTrials":265,"cells":13749},{"EARLY_PHASE1":13750,"PHASE1":13752,"PHASE2":13754,"PHASE3":13756,"PHASE4":13758,"NA":13760},{"trials":13751,"activeCount":102},[],{"trials":13753,"activeCount":102},[],{"trials":13755,"activeCount":102},[],{"trials":13757,"activeCount":102},[],{"trials":13759,"activeCount":102},[],{"trials":13761,"activeCount":102},[13762],{"nctId":10426,"briefTitle":10427,"status":108,"phases":13763,"primaryCompletion":3627,"completion":3627,"start":10412,"enrollment":10429,"conditions":13764,"interventions":13765},[],[3631],[10432,10385],{"intervention":13767,"totalTrials":265,"cells":13768},"Vitamin B12",{"EARLY_PHASE1":13769,"PHASE1":13771,"PHASE2":13773,"PHASE3":13775,"PHASE4":13777,"NA":13779},{"trials":13770,"activeCount":102},[],{"trials":13772,"activeCount":102},[],{"trials":13774,"activeCount":102},[],{"trials":13776,"activeCount":102},[],{"trials":13778,"activeCount":102},[],{"trials":13780,"activeCount":102},[13781],{"nctId":13782,"briefTitle":13783,"status":108,"phases":13784,"primaryCompletion":4645,"completion":7543,"start":13785,"enrollment":98,"conditions":13786,"interventions":13788},"NCT00120484","Effects of Vitamin B12 on the Body's Internal Clock",[94],"2005-04",[13787],"Sleep Disorders, Circadian Rhythm",[13767]]